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Abstract
Current approaches to selecting new chemotherapies are inadequate. In vitro tissue 
culture models ignore the tumour microenviroment whilst murine models do not 
mimic human cancers. The aim of this thesis was to develop an isolated, perfused and 
oxygenated human liver tumour model to investigate the short term effects of 
chemotherapeutic agents used in the treatment of liver cancer.
Expression of drug resistance transporter proteins was evaluated in hepatocellular 
carcinoma (HCC) and colorectal carcinoma (CRC) cell lines and did not correlate 
with drug resistance. P-glycoprotein (P-gp), when present, failed to demonstrate 
significant function. The comet assay demonstrated tumour DNA damage with 
chemotherapy and DNA-adduct repair with cisplatin.
An orthotopic model of human liver cancer in nude mice evaluated the topographic 
distribution of cisplatin DNA-adducts by the comet assay in vivo. This was correlated 
with the presence of tumour proliferation, hypoxia, vascularity and P-gp expression 
determined by immunohistochemistry. Rates of repair of DNA-adducts were both 
quantitatively and qualitatively different from in vitro data, and superficial tumour 
cells were more efficient at repair in comparison with deep cells.
An isolated, dual perfused liver cancer model was then developed in both the rat and 
human. In both models livers remained viable whilst on the perfusion circuit. 
Differences were observed in the timing of maximal DNA damage between drugs,
and DNA damage was dose dependent. Chemotherapy induced greater tumour DNA 
damage in superficial as compared to deep portions of the cancers.
This thesis has investigated the chemoresistance of liver cancers and developed a 
unique methodology for investigating human liver cancers using an ex vivo perfusion 
model. New insight into early DNA damage with chemotherapy has been 
demonstrated but more importantly the scientific basis established for a new approach 
to refining conventional therapies or evaluating new biological cancer therapies.
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CHAPTER I
INTRODUCTION
Chapter I: Introduction
I. INTRODUCTION 
1.1 Colorectal cancer (CRC) hepatic metastases
1.1.1 Incidence of colorectal cancer
In industrialised countries, colorectal cancer (CRC) is the third most common 
malignancy after lung and prostate cancer in men, and breast cancer in women. In 
Europe there were approximately 170,000 new cases in 1990 and over 90,000 deaths 
due to the disease (Esteve et al, 1993). It is a disease predominantly of older people, 
though it may occur at any age. Less than 5% of patients are under the age of 40 and 
more than half are over the age of 60, with a peak incidence between 70-80 years of 
age. There is no noticeable sex difference. High rates of CRC are characteristic of 
North America, the UK, New Zealand and Northern and Western Europe (Vogel and 
McPherson, 1989). The age standardised annual incidence rates in these countries are 
10-32 per 100,000 population. The lowest rates are found in Asia, Latin America and 
Africa (< 10 per 100,000 annually), although regional differences in CRC incidence 
occur within each country.
Surgery is currently the first line treatment for CRC, although surgical cure is not 
possible in approximately 40% of patients owing to advanced stages of the disease 
(Gordon et al, 1993). If diagnosed at an early stage, CRC has an excellent prognosis 
following surgical resection. The 5-year survival rate for patients with tumours 
involving only the mucosa or submucosa is in excess of 90% (Cohen et al, 1993). For 
more advanced stages, adjuvant chemotherapy following curative resection has been 
shown to improve survival rates in patients with Dukes B2 or C disease. Five-year 
survival rates of 89% and 65-69% respectively have been reported (Anonymous, 
1995a; Francini et al, 1994; Moertel et al, 1995). Following potentially curative
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surgery, 10-25% of patients subsequently develop local recurrence. Although 
recurrent disease can often be resected, ultimately dissemination of disease makes 
cure impossible.
The liver is the first organ reached by venous blood draining from the gastrointestinal 
tract and hence cancer cells via haematogenous spread have a high likelihood of 
lodging within the liver sinusoids. In one series of 1314 patients with advanced colon 
carcinoma, 77% had hepatic metastases (Bengtsson et al, 1981). In addition, at 
laparotomy for primary colon resection, 25% of patients demonstrate synchronous 
liver metastases (Bengmark and Hafstrom, 1969), and 20-30% develop metachronous 
liver metastases on follow up (Huylesk et al, 1989; Niederhuber and Ensminger,
1983).
1.1.2 Pathogenesis of CRC
Most CRC’s develop through the sequence from normal colonic epithelium, to 
hyperplasia, to small adenoma, to intermediate adenoma, to dysplastic adenoma on to 
a carcinoma in situ (Bresailer and Kim, 1993). Adenomas are classified by 
histological architecture as tubular, tubulovillous and villous. Villous change is 
associated with a higher malignant potential, as are large adenomas (25% are > 1 cm 
in diameter) and high-grade epithelial dysplasia (severe dysplasia is found in 5-10% 
of adenomatous polyps). About 5% of adenomatous polyps are estimated to become 
malignant usually over a 5-10 year time course.
Relative risk factors of CRC include environmental factors, such as a diet low in fibre, 
folate and vegetables and high in alcohol, fat and red meat. A sedentary occupation
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and cigarette smoking are also associated. The recognition of the genetic component 
of CRC continues to grow. There are two main inherited predisposition syndromes: 
Familial Adenomatous Polyposis (FAP) and Hereditary Non-Polyposis Colorectal 
Cancer (HNPCC), whilst the remaining cases are the result of sporadic colorectal 
cancer.
1.1.2.1 Familial Adenomatous Polyposis (FAP)
FAP is an autosomal dominant disorder in which multiple adenomatous polyps 
develop in the colon during the second and third decades of life. Individually each 
polyp has little risk of malignant transformation. However, the numbers are so great 
that the risk of CRC is almost 100% by 40 years of age (Cawkwell and Quirke, 1996). 
The gene that causes FAP (the adenomatous polyposis coli [APC] gene) encodes a 
300 kDa cytoplasmic protein and most of the mutations seen, result via loss of 
expression or truncation of the protein. Although the precise function of the wild-type 
APC gene product has yet to be characterised it does bind to (3-catenin, which in turn 
binds cadherins and suggests a role in cell to cell interactions, adhesion and metastasis 
(Kemler, 1993). Clinical studies have also been done of phenotypes of specific 
mutations. Families that do not demonstrate congenital hypertrophy of the retinal 
pigment as a clinical marker of FAP, have a mutation 5* to exon 9 of the APC gene 
(Olschwang et al, 1993). Less severe forms of FAP are associated with mutations of 
the extreme ends of the gene. By contrast, profuse FAP has been localised to exon 15, 
codons 1255-1467 (Nagase et al, 1992).
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1.1.2.2 Hereditary Non-Polyposis Colorectal Cancer (HNPCC)
HNPCC is also an autosomal dominant disorder, which accounts for up to 6% of CRC 
cases. It is associated with other tumours including endometrium, ovary and 
hepatobiliary tract, usually involving the right side of the colon and produces poorly 
differentiated mucinous tumours, which are invasive. The gene responsible for 60% of 
HNPCC cases is human Mut S Homolog (I1MSH2) (Fishel et al, 1993). The other 
genes that have been identified are hMLHl (3p), hPMSl (2q) and hPMS2 (7p) which 
account for 30%, 5% and 5% of cases respectively (Bronner et al, 1994; Nicolaides et 
al, 1994). All these genes encode enzymes involved in DNA surveillance; if any are 
defective, mismatched bases in replication are not repaired and genome-wide 
mutations follow.
Mutated mismatch repair genes produce microsatellite instability, short-repeat DNA 
sequences that are susceptible to mispairing during replication, which creates DNA 
loops. Normally these loops are repaired, with dysfunctional repair genes, however, 
they are undetected and new alleles occur. Evidence suggests that mismatch repair 
deficits cause cancer by inhibition of growth of colonic epithelium by the tumour 
growth factor p family and direct induction of apoptotic cell death, with the tumour 
growth factor p receptor (RII) acting as a tumour-suppressor gene in colon cells. 
Inactivation of RII mutations is present in more than 90% of patients with 
microsatellite instability (Grady et al, 1997).
1.1.2.3 Sporadic CRC
A multistep model for the genetic events in the progression of sporadic CRC has been 
proposed (Vogelstein et al, 1988). CRC occurs mainly in the elderly, which is
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consistent with the theory that a cell must accumulate a combination of 4 or 5 defects, 
involving mutational activation of oncogenes and inactivation of tumour suppressor 
genes, to undergo full malignant transformation. If one or more of these defects are 
present at birth, fewer further mutations are required to complete transformation and 
CRC appears earlier. The most studied genetic changes in sporadic CRC are shown in 
Table 1.1.
1.1.3 Natural history of CRC metastases
Reported survival with untreated liver metastases from CRC varies. Most patients die 
within 2 years of diagnosis, Palmer and colleagues (Palmer et al, 1989) reported a 
mean survival of 12 months in untreated patients, whereas other groups have shown a 
median survival of only 4.5 months in patients discovered to have synchronous liver 
metastases at the time of primary surgery (Moertel and Reitemeyar, 1969). An 
analysis of 484 untreated patients by Stangl et al (Stangl et al, 1994), showed a 
median survival of 7.5 months from time of diagnosis. Six factors proved to be 
independently significant for survival, (i) Percentage liver volume replaced by tumour 
(LVRT), was the most important single factor (< 25% confirmed a clear outcome 
advantage and all patients with a LVRT of > 25% died within 3 years); (ii) the 
number of metastases, and unilateral versus bilateral distribution of metastases exerted 
a highly significant influence on survival; followed by (iii) grade of primary tumour; 
(iv) presence of extrahepatic disease and mesenteric lymph node involvement; (v) 
carcinomoembryonic antigen (CEA) (< 39) and (vi) age (< 59).
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Genetic
modification
Position Frequency Molecular function Postulated stage 
in adenoma to 
carcinoma 
sequence
Oncogenes
K-Ras Chromosome 12 40% Mutant ras-p21 is stable 
in active signal 
transmitting state, 
allowing cell 
proliferation and loss of 
adhesion
Intermediate, 
small to large 
adenoma
MYC Low Induces cell 
proliferation
N/K
Tumour- 
suppressor genes
APC Chromosome 5 >60% Mutant protein binds 
Wt, causing loss of 
adhesion and possible 
transformation
Early adenoma 
formation
MCC (mutated in 
CRC)
Chromosome 5 60% N/K N/K
p53 Chromosome 17 75% Mutation prevents 
apoptosis and GI arrest 
(disallowing DNA 
repair)
Late, adenoma to 
carcinoma
DCC (deleted in 
CRC)
Chromosome 18 30% Loss of WT causes loss 
of normal adhesion
Intermediate, 
small to large 
adenoma and 
adenoma to 
carcinoma
NFI GAP Chromosome 17 14% Loss of WT allows 
increase in the active 
GTP-bound ras-p21
Intermediate
Metastasis genes
NM23 Low N/K Very late, 
metastases
Hypomethylation Across genome N/K Allows overexpression 
of oncogenes
Early, adenoma 
formation
Table 1.1. Most commonly studied genetic changes in sporadic colorectal cancer. 
N/K = not known; WT = wild-type; GI = gastrointestinal; CRC = colorectal cancer.
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1.1.4 Treatment of CRC hepatic metastases
1.1.4.1 Surgical resection
Surgical resection for isolated hepatic metastases from CRC has gained acceptance as 
a safe and potentially curative treatment. Several studies have demonstrated that 
resection of as much of 80% of the liver can be performed with an associated surgical 
mortality rate of < 5% (Gayowski et al, 1994; Scheele et al, 1995). Reported 5-year 
survival rates after curative resection of hepatic metastases range from 25 to 35% 
(Fong et al, 1997; Gayowski et al, 1994; Rosen et al, 1992; Scheele et al, 1995), and a 
further 10% survive between 5 and 9 years, despite relapse with irresectable cancer, 
thereby indicating substantial palliation (Scheele et al, 1990). Approximately 50% of 
all patients with CRC present at some stage with hepatic metastases, and around 20- 
25% eventually become candidates for liver resection. Thus only a small fraction (< 
12.5%) of all patients with CRC may benefit from surgical resection. Advances in 
imaging and surgical techniques now permit earlier detection of metastases and 
improved perioperative survival. Current data confirm a multifactorial determinant of 
long term outcome following hepatic resection, including patient demographics, 
primary tumour factors, presentation of metastatic disease and surgical findings.
1.1.4.1.1 Patient demographics
It is clear from many reports that age has no impact on survival (Cady et al, 1992; 
Fong et al, 1999). Gender has had a prognostic importance in only one study by Holm 
et al (Holm et al, 1989), who found a significant survival advantage for women 
undergoing liver resection compared with men.
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1.1.4.1.2 Primary tumour characteristics
The site of the primary CRC does not seem to have prognostic significance (Cady et 
al, 1998; Fong et al, 1999). Tumour grade (ploidy or differentiation) has been shown 
to be a statistically significant prognostic indicator (Cady et al, 1992), although a 
subsequent study conflicted with this observation (Cady et al, 1998). However, it was 
suggested that the small sample size in the original study accounted for the 
discrepancy. Other authors have also shown no prognostic predictive value (Fong et 
al, 1999; McEntee et al, 1992). The predictive value of Dukes staging has been 
conflicting. Dukes B colon cancer has been shown to have significantly better 5-year 
survival rates (35%), compared to patients with Dukes C colon cancer (28%) (Hughes 
et al, 1989). These findings have also been reported by other groups’ (Adson and van 
Heerden, 1980; Finan et al, 1985; Fong et al, 1999; Hughes et al, 1989). In contrast, 
many other studies have found no correlation between the stage of the primary 
tumour, the presence or absence of mesenteric lymph nodes and survival, after 
resection of liver metastases (Cady et al, 1992; Nakamura et al, 1992).
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1.1.4.1.3 Synchronous versus metachronous lesions
In 25% of patients with CRC, liver metastases are present when the primary lesion is 
diagnosed (Bengmark and Hafstrom, 1969). According to a review of the literature by 
Ballantyre and Quinn (Ballantyne and Quin, 1993), 5-year post resection survival 
among 433 patients with synchronous lesions was 27%. This was only slightly worse 
than the 31% 5-year post treatment survival in 555 patients with metachronous 
lesions. However, Hughes et al (Hughes et al, 1989) found a disease free interval of 
more than 1 year from the initial colorectal resection, which conferred a survival 
advantage over patients with either synchronous lesions or a shorter disease free 
interval (40% vs 24 % and 28% respectively, P < 0.05). Presentation of liver 
metastases with a disease free interval of < 12 months has also been found to be 
predictive of an adverse outcome by other groups (Fong et al, 1999). It should be 
noted, however, that even when the presentation of liver tumours is synchronous or 
within 12 months of primary resection, the 5-year survival rate was still 30%.
1.1.4.1.4 Pathological features of liver tumours
Historically, increasing numbers of liver metastases were thought to be associated 
with a poor prognosis, with solitary lesions being significantly more favourable. It has 
become apparent, however, that survival after removal of 3 lesions is similar to that 
seen after resection of a solitary lesion. Cady et al (Cady et al, 1998), noted that no 
patient with more than 3 metastatic lesions was alive after 4 years, and there was no 
difference in disease free survival in patients with either 1, 2 or 3 lesions. This is in 
agreement with several other published studies that set 3 lesions as the cut off for 
considering surgery (Gayowski et al, 1994; Hughes et al, 1989; McEntee et al, 1992). 
Coboum et al (Coboum et al, 1987), stressed the importance of distinguishing true
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multiple metastases from solitary lesions with satellites. They noted a 33% 5-year 
survival in patients with satellite lesions, compared to 0% 3-year survival with true 
multiple lesions. Although the number of hepatic metastases resected is of prognostic 
significance, it seems to be unimportant whether the lesions are bilobar or unilobar, as 
long as removal with adequate residual hepatic function can be achieved (Cady et al, 
1992; Hughes et al, 1989). However, Fong et al (Fong et al, 1999) found bilobar 
disease to be a predictor of adverse outcome, the 5-year survival rate was 29% and 
thus sufficiently favourable to justify the risks of resection if it was the only positive 
predictor of outcome.
The size of liver metastases is also thought to be predictive of outcome. Nakamura et 
al (Nakamura et al, 1992), reported 100% 5-year survival in patients with tumours less 
than 3 cm, compared to a 38% 3-year survival in patients with larger lesions. 
Similarly Fong et al (Fong et al, 1999), found that if the size of the largest tumour was 
> 5 cm this was an independent predictor of adverse outcome. Despite this the 5-year 
survival rate was 40% with tumours > 5 cm, and thus sufficiently favourable to justify 
surgery.
1.1.4.1.5 Carcinoembryonic antigen (CEA)
CEA is used as a marker for recurrent disease following resection of primary CRC 
(Martin et al, 1993). Recurrence is not always associated with an elevated CEA, and 
thus a low CEA does not eliminate the presence of metastases (Verdi et al, 1993). In a 
report by Cady et al, a CEA level > 200 ng/ml was one of the most significant 
preoperative indicators of poor prognosis after hepatic resection. No patient with a 
CEA level > 200 ng/ml had a disease free survival of greater than 5 years, whereas the
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5-year disease free survival for patients with a CEA level < 5 ng/ml was > 50% (Cady 
et al, 1992). A subsequent study confirmed this with no long-term disease free 
survivors in patients with CEA levels > 200 ng/ml (Cady et al, 1998). Similarly Fong 
et al (Fong et al. 1999), reported that a CEA level > 200 ng/ml was predictive of 
adverse outcome, but even so the 5-year actuarial survival rate with a CEA level > 
200 ng/ml was 24%. Of the 85 patients with this preoperative level 12 survived 
beyond 5 years.
1.1.4.1.6 Surgical margins
The most important prognostic factor in many studies is the presence or absence of 
adequate resection margins. In a number of studies no patient with positive margins 
was disease free after 20 months, and 5-year survival was poor (0-18%) (Cady et al, 
1992; Hughes et al, 1989; Hughes et al, 1986). Five-year survival in patients with 
margins of < 1 cm varied from 18-26% compared with 44-50% reported in patients 
with margins > 1 cm (Cady et al, 1992; Hughes et al, 1989; Hughes et al, 1986).
1.1.4.1.7 Extrahepatic disease and lymph node metastases
Extrahepatic disease (lung lesions or contiguous spread) is not a contraindication to 
resection, if the entire tumour can be removed surgically. Survival however is 
significantly poorer in this group. Fong et al (Fong et al, 1999), reported an 18% 5- 
year actuarial survival rate in 88 patients who underwent simultaneous resection for 
both hepatic and extrahepatic metastases. Positive coeliac or hepatic lymph nodes are 
generally considered a contraindication to surgical resection. Results of patients with 
lymph node metastases have been universally poor with no long-term survivors 
reported in one study (Adson et al, 1984). A systematic review recently analysed 15
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series that provided data on 145 node-positive patients (Rodgers and McCall, 2000). 
Five patients were reported to have survived 5 years after liver resection: 1 was 
diseases free, 2 had recurrent disease, and 2 had undescribed disease status. However, 
5 studies involving 83 patients specified a formal lymph node dissection as part of the 
surgical procedure, and 4 of the 5 node-positive 5-year survivors were in these 
studies. The authors of the review concluded that there are few 5-year survivors after 
liver resection, with or without lymph node dissection, for CRC hepatic metastases 
involving the hepatic lymph nodes.
1.1.4.1.8 Repeat resection of recurrent hepatic CRC metastases
In patients who develop recurrent disease, the recurrence is limited to the liver in 40- 
60% (Hughes et al, 1986). Hepatic recurrence after liver resection is still an 
uncommon indication for further resection, being performed in only 7-10% of patients 
undergoing initial resection (Griffith et al, 1990; Stone et al, 1990). Early reports 
indicated that the survival rate was lower after repeat resection than after initial 
resection for CRC metastases. A multi-institutional study on 170 patients from the 
Repeat Hepatic Resection Registry 1994 (Repat Hepatic Resection Registry, 1994), 
showed 3- and 5-year actuarial survival rates of 37 and 26% respectively. This 
suggests that the results of repeat resection are no different from those of initial 
hepatectomy.
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1.1.4.2 Chemotherapy
1.1.4.2.1 Systemic chemotherapy
Only the role of chemotherapy in advanced CRC will be discussed in detail in this 
section. As far as neoadjuvant chemotherapy is concerned for primarily unresectable 
hepatic metastases, there have only been a limited number of non-randomised 
retrospective studies and case reports, that have described down-staging to 
resectability using chemotherapy. Elias et al (Elias et al, 1995), reported 14 patients (9 
with CRC metastases) who became resectable after 6 or more courses of intra-arterial 
chemotherapy with 5-Fluorouracil (5-FU), combined with epirubicin or mitomycin C. 
These patients represented only 6% of the total number of patients treated for 
unresectable liver tumours. Three patients had the volume of the future remnant liver 
increased by preoperative portal vein embolisation. Five of the nine patients were 
alive at 5 years.
Bismuth et al (Bismuth et al, 1996), also described 53 patients who underwent 
neoadjuvant chemotherapy with systemic 5-FU, leucovorin (LV) and oxaliplatin. 
They represented 16% of the total number of patients treated for unresectable liver 
tumours. Mean duration of preoperative chemotherapy was 8 months and a number of 
other techniques were used to increase resectability rates, including portal vein 
embolisation (5 patients) and two stage hepatectomy (5 patients). A 5-year survival 
rate of 40% may have been influenced by repeat hepatectomy in 15 patients (28%) 
and resection of pulmonary metastases in 10 (19%) of the patients. The same group 
then reported the follow-up of 701 patients with CRC liver metastases, who were 
evaluated for liver resection and deemed unresectable. Following chemotherapy with 
5-FU, LV and oxaliplatin, 95 patients (13.6%) subsequently underwent a potentially
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curative liver resection. The acturarial 5-year survival in this group was 34% (Adam 
et al, 2001). In a smaller group, comprising 42 patients with unresectable liver only 
CRC metastases, Alberts et al (Alberts et al, 2005) reported a 60% response rate with 
the same regime, allowing surgical resection in 17 patients (40%).
Following hepatectomy for liver metastases 60-70% of patients develop recurrent 
disease, usually in the liver, indicating a possible role for post operative adjuvant 
chemotherapy. Early trials of systemic chemotherapy after liver resection for CRC 
metastases failed to demonstrate any benefit in terms of survival (Donato et al, 1994). 
Although no prospective randomised study has evaluated the role of adjuvant 
systemic chemotherapy in patients subjected to potentially curative liver resection, the 
role of adjuvant intra-arterial (IA) chemotherapy has been addressed. Initial results 
were encouraging (Curley et al, 1993) (Nonami et al, 1997), however, a large 
randomised study of resection alone vs resection plus hepatic arterial 5-FU performed 
by the German Cooperative on Liver Metastases was closed prematurely after the 
interim analysis showed a lower survival in the treatment group (Lorenz et al, 1998). 
One year later, two large prospective randomised studies renewed interest in adjuvant 
IA chemotherapy. In the first, 109 patients having undergone resection of up to 3 
CRC liver metastases were randomised between no adjuvant treatment vs hepatic 
arterial floxuridine (5-fluoro-2’deoxyuridine; FUDR) plus systemic continuous 
infusion of 5-FU. Although the recurrence-free survival at 3 years was significantly 
higher with chemotherapy, an overall survival benefit was not demonstrated (Kemeny 
et al, 1999a). The second study compared hepatic artery FUDR and dexamethasone 
plus systemic 5-FU vs systemic 5-FU alone. Results from the analysis of 156 
randomised patients showed an improvement of the overall survival at two years with
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the combination of IA and systemic chemotherapy (86% vs 72%, respectively, P < 
0.05) (Kemeny et al, 1999b).
The role of chemotherapy in the management of patients with advanced CRC has 
been well established in 3 trials comparing chemotherapy plus best supportive care to 
best supportive care alone. These trials are summarised in Table 1.2.
Trial Randomisation Patient
No.
Results (median survival)
Nordic Primary expectancy 
vs
MTX 250 mg/m2, 5-FU500 mg/m2 (3+23 
hours),LV 15 mg po x3 days
183 9 months
vs (P < 0.02) 
14 months
Scheithauer
e ta l
Best Supportive Care 
vs
5-FU 550 mg/m2/day, LV 200 mg/m2/day 
+ Cisplatin 20 mg/m2/day Dl-4 4 weekly
40 5 months
vs (P = 0.006) 
11 months
Allen- 
Mersh et al
Best Supportive Care 
vs
Hepatic artery infusional fluoxuridine 0.2 
mg/kg/day, heparin 5000 u/day for 14 
days, 4 weekly
100 226 days
vs (P = 0.03) 
405 days
Table 1.2. Critical trials of chemotherapy versus best supportive care in patients with 
metastatic CRC.
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In the Nordic study, patients with asymptomatic advanced disease were randomised to 
receive either chemotherapy (methotrexate [MTX], 5-FU, and LV) or primary 
expectancy. Five months post randomisation 57% of the patients in the primary 
expectancy arm had developed symptoms and crossed over to receive chemotherapy 
(Anonymous, 1992a). The median overall survival (OS) and progression free survival 
(PFS) were significantly better for the patients treated initially with chemotherapy 
(OS: 14 months and 9 months respectively, P < 0.02; PFS: 8 months and 3 months 
respectively, P < 0.001). Scheithauer et al, randomised 40 patients with metastatic 
CRC, to receive either chemotherapy (LV, 5-FU, and cisplatin) or best supportive care 
(Scheithauer et al, 1993). Both median survival and median time to disease 
progression were improved in the patients who received chemotherapy (P = 0.006 and 
P = 0.008 respectively). In the third study, the role of hepatic artery infusion of FUDR 
was established in 100 patients with unresectable liver metastases secondary to CRC 
(Allen-Mersh et al, 1994). Patients were randomised to hepatic artery infusion of 
chemotherapy or best supportive care. The median survival of the patients receiving 
chemotherapy was significantly longer than the best supportive care patients (405 
days and 226 days P = 0.03).
These trials clearly demonstrate a survival advantage from the use of palliative 
chemotherapy in patients with advanced CRC. In addition, the Nordic study confirms 
a benefit from the early use of chemotherapy for metastatic disease, rather than 
delaying treatment until the onset of symptoms.
5-FU is itself inactive and requires intracellular conversion to form active metabolites. 
Its major active metabolite is 5-fluorodeoxyuridine monophosphate (5-FdUMP),
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which inhibits thymidylate synthase (TS), the key enzyme in the biosynthesis of 
deoxythymidine monophosphate, essential for DNA synthesis. Although the affinity 
of 5-FdUMP for TS is approximately 1000-fold higher than that of the natural 
substrate, deoxyuridine monophosphate, effective inhibition resulting in 
deoxythymidine triphosphate depletion requires formation of the ternary complex of 
TS, 5-FdUMP and the folate co-factor 5,10-methylene-tetrahydrofolate. Hence, cell 
killing by 5-FU only occurs when the cell contains adequate levels of LV. 5-FU is 
also converted to 5-fluorouridine triphosphate (5-FUTP) and 5- fluorodeoxyuridine 
triphosphate (5-FdUTP) which are incorporated directly into RNA and DNA 
respectively, resulting in the production of DNA single-strand breaks.
Single agent response rates for bolus 5-FU of around 20-35% quoted in the 1980s are 
probably misleading. Large phase III trials published since 1995 quote objective 
response rates below 20% and median progression-free survival under 6 months 
(Anonymous, 1995b; Labianca et al, 1997). Modulation with LV, which acts by 
increasing intracellular levels of reduced folates, thus enhancing the formation and 
retention of the 5-FdUMP/TS complex, has improved response rates in the order of 2- 
fold. A meta analysis of 9 trials comparing 5-FU alone to 5-FU plus LV in over 1500 
patients, showed a significantly higher response rate in the 5-FU/LV group compared 
to the 5-FU alone group (23% vs 11%, odds ratio 0.45, P < 10'7). There was no 
difference in the median survival times (11.5 and 11 months respectively). The large 
number of patients who did not respond to treatment in both groups, and cross-overs 
from 5-FU alone to 5-FU/LV were thought to be plausible explanations for the lack of 
a survival difference (Anonymous, 1992b).
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The response rates of 5-FU can be improved not only by modulation, but also by 
different scheduling of administration. The mechanism by which 5-FU exerts its 
cytotoxic effect depends on the dose schedule, bolus injections of high doses exert 
cytotoxic activity predominantly via inhibition of RNA whilst prolonged exposure to 
low doses acts mainly via inhibition of TS. A meta analysis comparing protracted 
venous infusion 5-FU to bolus 5-FU showed significantly higher response rates and 
median survival in the continuous 5-FU arm (response rates: 22% vs 14% 
respectively, P = 0.0002; median survival 12.1 months vs 11.3 months respectively, P 
= 0.04) (Anonymous, 1998a). Toxicity was also significantly reduced in the 
continuous infusion arm.
The de Gramont regimen is commonly used in France and the United Kingdom. This 
regime combines bolus and infusional administration of 5-FU with LV (LV 200
9 9mg/m /day as a 2-hour infusion, 5-FU 400 mg/m /day bolus and a 22-hour infusion of
' j
600 mg/m /day for two consecutive days every 2 weeks). This regime was compared 
in a randomised study to the Mayo NCCTG regime (LV 20 mg/m2 and 5-FU 425 
mg/m days 1-5 repeated every 4 weeks) (de Gramont et al, 1997a). Four hundred and 
forty eight patients were randomised. The overall response rate for the monthly 
treatment was 14.5% and for the bimonthly treatment 32.6%, (P = 0.0004). 
Progression free survival was also significantly longer in the bimonthly group (27.6 
weeks vs 22 weeks, P = 0.001). Median survival was longer with the bimonthly 
regime although this did not reach statistical significance (62 weeks vs 56.8 weeks, P 
= 0.067).
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An additional variation in administration of 5-FU and other drugs utilises the 
circadian variation in the activity of enzymes. Cell division in normal tissues, unlike 
that in malignant tumours, tends to ‘sleep’ at night. Circadian modulation of drugs 
therefore offers the possibility of decreased toxicity and increased dose intensity. Levi 
et al, published a randomised study in patients with chemonaive metastatic CRC 
comparing constant rate or chronomodulated oxaliplatin, 5-FU and LV (Levi et al, 
1997). The study was terminated early as there were significantly higher response 
rates in the chronomodulated treatment arm and a correspondingly lower rate of 
toxicity. Mitomycin C has also been used as a single agent in the management of 
metastatic CRC with response rates of 0-33% being reported (Petrelli and Mittelman,
1984). The combination of protracted venous infusion (PVI) 5-FU and mitomycin C 
has been shown to have significantly improved response rates and disease free 
survival compared to PVI 5-FU alone (response rates: 54% and 38% respectively; 
disease free survival 7.9 months and 5.4 months respectively) (Ross et al, 1997). The 
same group explored the effect of dose intensification by circadian timing of 5-FU in 
this combination. Three hundred and twenty patients with advanced CRC were
•y
randomised to receive either PVI 5-FU 300 mg/m daily or circadian-timed infusion 
(CTI) of 5-FU, beginning at 600 mg/m2 and subsequently reduced to 450 mg/m2. Both 
groups received mitomycin-C at a dose of 7 mg/m2 given every 6 weeks. The overall 
response rate for the PVI 5-FU group was 38%, compared with 30.3% for the CTI 
group (P = 0.176). There was no statistically significant difference in terms of disease- 
free survival (8 months vs 9.9 months; P = 0.131) or OS (15.8 months vs 16.3 months; 
P = 0.275) between the treatment groups. This study thus confirmed the high response 
rate and overall survival figures for the combination of PVI 5-FU and mitomycin C in
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CRC, but failed to support previous evidence for improved response or survival with 
dose intensification by circadian timing of 5-FU (Price et al, 2004).
1.1.4.2.2 New systemic treatment options for advanced CRC
Irinotecan (CPT11) is a semisynthetic water-soluble camptothecan. Its mechanism of 
action is via inhibition of the nuclear enzyme DNA topoisomerase (topo) I. Topo I 
allows relaxation of supercoiled double strand (ds) DNA to occur so that transcription 
and translation can proceed. Inhibition of the enzyme results in an accumulation of 
single strand (ss) DNA breaks in the cell with resultant cell death. CRC cells are 
known to have levels of topo 14-16 times higher than those of normal tissues 
(Giovanella et al, 1989). Irinotecan has been shown to be an active drug in CRC. 
Following publication of a randomised trial comparing irinotecan and best supportive 
care to best supportive care alone, which showed a clear survival benefit in the 
irinotecan group (36% vs 14% at 1 year), it is now established as an effective second 
line agent in 5-FU resistant disease (Cunningham et al, 1998).
Raltitrexed (Tomudex) is a direct and specific TS inhibitor. It is incorporated into the 
cell via the reduced folate membrane carrier system. Once raltitrexed is intracellular, 
it is polyglutamated to more potent forms. This has two benefits, firstly it extends the 
intracellular retention of the drug and secondly it prolongs TS inhibition. 
Consequently, it can be administered as a single dose 3 weekly. Studies to date show 
that raltitrexed has comparable response rates to a 5-FU/LV combination and in 2 out 
of 3 phase III trials, a similar survival time (Cunningham et al, 1996; Kerr, 1997). 
This, combined with the fact that raltitrexed has a simple dose schedule represents an 
advance in the management of CRC. Currently trials are underway looking at the role
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of raltitrexed in combination with 5-FU, oxaliplatin and irinotecan, and in addition its 
role in the adjuvant setting is also being assessed.
Oxaliplatin is a third generation platinum (pt) compound whose major toxicities are 
peripheral sensory neuropathy and nausea. As a single agent, response rates in 
patients with 5-FU resistant disease are 10% (Levi et al, 1993; Machover et al, 1996), 
and for those receiving first line treatment 25% (Diaz-Rubio et al, 1996). Synergy 
between oxaliplatin and 5-FU has been demonstrated both preclinically and clinically. 
De Gramont et al, demonstrated this phenomenon in 46 patients who had progressed 
on 5-FU/LV for metastatic disease or who had relapsed within 6 months of adjuvant 
treatment, by proceeding with the same schedule of 5-FU/LV on progression of 
disease, with the addition of oxaliplatin (de Gramont et al, 1995; Garufi et al, 1995). 
Rather than the expected response rate of 10%, the observed response rate in this trial 
was 46%. Two large Phase III trials have assessed the role of oxaliplatin in addition to 
5-FU and LV as first line treatment for advanced CRC. In one, 420 patients were 
randomised to receive a regime of LV and 5-FU bolus plus a 24 hour infusion on 2 
consecutive days every 2 weeks plus or minus 85 mg/m oxaliplatin on D1 every 2 
weeks. The median PFS was superior in the Oxaliplatin arm (39.6 weeks vs 27.8 
weeks, P = 0.0001). An interim analysis was performed on 200 patients and response 
rates of 57% for oxaliplatin/5-FU/LV vs 26% for 5-FU/LV alone, were observed (de 
Gramont et al, 1997b). The second study assessed the role of oxaliplatin in addition to 
chronomodulated 5-FU/LV. Two hundred patients were randomised to receive 
chronomodulated 5-FU (700 mg/m /day x5) and LV (300 mg/m /day x5) with peaks 
at 04:00am, with or without oxaliplatin (125 mg/m2 Dl). The median PFS was 7.9 
months in the oxaliplatin arm and 4.3 months in the control arm (P = 0.05). There was
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no significant difference in the median OS between the arms (17.6 months oxaliplatin;
19.4 months control; P = 0.82) (Giachetti et al, 1997). An analysis of the use of 
second line chemotherapy and surgery for metastases in the two arms showed that the 
incidence of both of these modalities of treatment was more frequently employed in 
the control group. This may account for the lack of a significant survival benefit in the 
oxaliplatin arm (Giacchetti et al, 1998).
1.1.4.2.3 Intra-arterial hepatic chemotherapy for isolated liver metastases
Surgical excision should be considered in all patients with metastatic disease isolated 
to the liver. However, approximately 75-80% of patients have disease that is 
unresectable. Intra-arterial chemotherapy is based on the principle that CRC 
metastases derive most of their blood supply from the hepatic artery (once the lesion 
is approximately 1 mm), lower drug doses are required, lower toxicity is produced 
(because the liver eliminates 80% of the infused drug), and higher concentrations of 
drug in tumour tissues are achieved. FUDR has a higher concentration than 5-FU, 
when given via the hepatic artery (Ensminger and Gyves, 1983).
Phase II trials of intra-arterial hepatic chemotherapy using 5-FU and external pumps 
gave encouraging results with response rates between 30-80%. With the development 
of implantable pumps and the use of FUDR, response rates in the order of 30-60% 
have been reported (Dworkin and Allen-Mersh, 1991; Kemeny et al, 1990). Five 
randomised trials have been published comparing hepatic arterial infusion of 
chemotherapy with intravenous chemotherapy (FUDR via hepatic artery, FUDR 
intravenously or 5-FU bolus regimes intravenously). Two further trials compared 
hepatic arterial chemotherapy with no treatment. The majority of these trials
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confirmed improved response rates with chemotherapy administered via the hepatic 
artery. However, the impact on survival was not consistently established in the 
individual trials. A meta analysis was therefore reported using data from the 654 
patients included in these seven trials (Anonymous, 1996). For the 5 trials (391 
patients) comparing intra-arterial hepatic with intravenous chemotherapy response 
rates of 41% vs 14% were reported and this improvement, in favour of hepatic artery 
chemotherapy, was highly statistically significant, (P < 10'10). This translated into a 
median survival of 16 months vs 12.2 months in the two groups respectively which 
was not statistically significant (P = 0.14). A survival benefit for hepatic arterial 
chemotherapy was clearly demonstrated in the two trials in which the control arm was 
best supportive care. However, there are problems in interpreting these results, 
namely that the systemic treatment arm involves fluoropyrimidine treatment alone, 
without biochemical modulation, which is not the standard systemic treatment for 
metastatic CRC. Another potential influencing factor on the results is that in some of 
the trials there was a crossover from intravenous to intra-arterial hepatic 
chemotherapy and this may have had some bearing on the lack of survival benefit, 
despite improved response rates.
A major concern associated with hepatic artery infusional chemotherapy is its 
potential toxicity. Whilst this route of administration reduces the systemic toxicity 
associated with the fluoropyrimidines, it is associated with an increased risk of 
chemical hepatitis and sclerosing cholangitis, duodenal ulceration and hepatic artery 
thrombosis (Rougier et al, 1992). In an attempt to overcome these problems, short 
infusions of 5-FU have been used with some success.
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These results demonstrate a possible role for intra-arterial hepatic chemotherapy in 
patients with unresectable isolated liver metastases. Future developments are being 
focused on the combined modality of intra-arterial hepatic and systemic 
chemotherapy, but the results of randomised trials are awaited to establish if this 
approach is superior to either treatment alone.
1.1.4.3 Direct ablation
Several interstitial ablative techniques have shown promising results as an alternative 
to systemic chemotherapy in the palliative treatment of CRC liver metastases. 
Cryoablation is the use of low temperatures to achieve cellular destruction. Most 
published series of CRC liver metastases treated by cryoablation have a short follow 
up, with only 5 studies following patients for more than 24 months (Ravikumar et al, 
1991a; Ravikumar et al, 1991b; Dilley et al, 1993; Weaver et al, 1998; Ruers et al, 
2001). Although it is difficult to infer valid long-term results, 2-year survival rates of 
up to 62% have been reported. Median survival times following cryoablation are 
generally greater than 24 months (range 8-30 months) (Seifert et al, 1998). With a 
median follow up of 14-30 months, the percentage of patients that are alive and 
disease free ranges from 10-50%.
Thermal ablative techniques use heat to destroy tissue through coagulative necrosis, 
which is irreversible if the temperature reaches 60-100°C. Several sources have been 
used to generate heat including radiofrequency ablation (RFA), which employs a 
high-frequency alternating current (350-500 KHz) that produces ionic agitation and 
results in frictional heat. Solbiati et al reported an overall survival of 100, 94 and 89% 
at 6, 12 and 18 months respectively in a series of 29 patients with 44 liver metastases
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of different origins (22 patients with CRC). The disease-free survival rate was 50% at 
12 months (Solbiati et al, 1997). Although experience is still limited, interstitial laser 
photocoagulation, whereby light at optical or near-infrared wavelengths scatters 
within tissue and is converted into heat, has reports of local tumour control rates 
ranging from 40-75%. Nolsoe et al used the Nd YAG laser in 11 patients with 16 
CRC liver metastases and achieved complete necrosis in 12 of 16 tumours (Nolsoe et 
al, 1993). Mean diameter of the tumours was 2.4 cm, compared with 3.4 cm for 
tumours that were not completely destroyed. Finally, microwave ablation (MA) uses 
alternating ultrahigh-speed (2450 MHz) waves to induce rotation of water molecules 
and thus generate heat. Shibata et al recently randomised 30 patients with multiple 
espectable CRC liver metastases to either resection (16 patients) or intraoperative 
MA (14 patients); the mean disease-free survival time was 11.3 and 13.3 months 
respectively, with estimated 1, 2 and 3-year survival rates of 69, 56 and 23% for 
surgery, and of 71, 57 and 14% for MA respectively (Shibata et al, 2000). This 
suggests palliative benefit as with the other forms of local ablation.
1.1.4.4 Biological therapy
1.1.4.4.1 Immunotherapy
A number of tumour associated antigens have been identified on CRC cells: CEA, 
Cathepsin B, 17-1, Cal9-9 and TAG-72. Monoclonal antibodies (mAb) targeting 
these antigens result in antibody dependent cell-mediated cytotoxicity (ADCC). 
Monoclonal antibody 17-1A is a murine IgG class 2A immunoglobulin that detects 
tumour-associated antigen CO 17-1 A. Trials have been performed using mAb 17-1A 
in patients with advanced CRC. They have reported response rates in the order of 5% 
but this has not been statistically significant (Mellstedt et al, 1991; Wadler, 1991).
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However, Riethmuller et al have shown a 30% reduction in mortality with mAb being 
used in the adjuvant setting for patients with Dukes C CRC (Riethmuller et al, 1998), 
although these results have not been reproduced by other groups. Other mAb are 
currently being investigated in advanced and adjuvant trials.
1.1.4.4.2 Cytokines
Cytokines with potential antitumour activity include Interleukin -  2 (IL-2), Interferon 
alpha (IFNa), Interferon beta (IFNP), and Tumour Necrosis Factor (TNF). Cytokines 
are produced by lymphocytes in response to antigenic recognition by T cells. They 
induce an immune reaction, which can lead to rejection of cancer cells. The use of IL- 
2 and IFNa, P or % alone or in combination have not been shown to be effective in the 
management of advanced disease and in addition to this they are associated with 
significant toxicity.
There is convincing in vitro data suggesting biomodulation of 5- FU with IFN (Chu et 
al, 1990; Wadler and Schwartz, 1990). Additionally, in vitro the modulation of 5-FU 
by LV plus IFN has been shown to be synergistic (Houghton et al, 1991). Randomised 
trials have been performed to assess the role of IFN as a lone modulator of 5-FU 
(Anonymous, 1995b; Greco et al, 1996) or in addition to LV (Kohne et al, 1998; 
Seymour et al, 1996). None of these trials have demonstrated any benefits from the 
clinical use of IFN in this situation.
1.1.4.4.3 Gene therapy
Gene therapy involves the insertion of genes into cells with the intent of correcting an 
inborn genetic error or creating a new cellular function. The molecular basis of CRC
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is being extensively investigated and much is known about the numerous genes 
involved in the carcinogenesis in this disease. Gene therapy does not necessarily 
constitute the replacement of a mutated gene; there are a number of different 
approaches:
• Enzyme or prodrug systems (gene directed enzyme prodrug therapy -  GDEPT). In 
this situation the transferred gene converts a non-toxic prodrug to an active 
cytotoxic agent. This can be a tumour specific action if the gene or prodrug is 
targeted to the tumour cells.
• Tumour suppressor gene replacement with wild type p53.
• Immune gene therapy e.g. a polynucleotide tumour vaccine of CEA cDNA.
Phase I and II clinical trials have been conducted using a variety of genes. Results 
have shown that, although gene therapy is well tolerated and has low toxicity, the 
clinical benefit is marginal (Havlik et al, 2002). Gene therapy as a definitive treatment 
for liver metastases remains limited, but it may be useful as an adjuvant treatment in 
combination with radiotherapy, chemotherapy and surgery to achieve disease-free 
survival.
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1.2 Hepatocellular carcinoma
1.2.1 Epidemiology
Hepatocellular carcinoma (HCC) is the seventh commonest malignant neoplasm 
world-wide in men and the ninth in women. It is responsible for more than 4% of all 
cancer cases and is the third commonest cause of death from cancer throughout the 
world (315,000 deaths per year). It has an estimated annual incidence between
250.000 and over 1 million cases world-wide (Wands and Blum, 1991). HCC is more 
frequent in men than women with ratios between 3:1 to 8:1 reported. There are world­
wide differences in incidence due to various aetiological factors prevalent in different 
geographical regions.
In Africa, HCC is frequently observed in Mozambique, Nigeria and South Africa, 
whereas in the Asiatic continent, China, Taiwan and Korea carry the highest 
incidence. In these countries the incidence ranges between 20 and 150 cases per
100.000 per year (Rustgi, 1987). In Western countries the rate is 10 times lower but 
progressively increasing. In the United States the incidence of histologically proven 
HCC increased from 1.4 per 100,000 population for the period from 1976-1980 to 2.4 
per 100,000 for the period from 1991-1995 (El-Serag and Mason, 1999).
1.2.2 Risk factors
The two main aetiological factors for HCC are cirrhosis and viral hepatitis. Although 
cirrhosis is considered a major risk factor, it is not an absolute prerequisite for the 
development of HCC as shown by the occurrence of HCC’s both in non-cirrhotic 
chronic liver diseases and in apparently normal liver. Numerous epidemiological and
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experimental evidence indicates that HCC is of multifactorial aetiology. The relative 
roles of risk factors in HCC vary considerably among populations (Table 1.3).
Prevalence (%)
Risk Factor South
Africa
China and 
Taiwan
Japan USA Southern
Europe
Hepatitis B 
virus
50 60-90 20 15 5-10
Hepatitis C 
virus
30 30 70 30-60 60-80
Alcohol <10 <10 <10 <15 15-30
Table 1.3. Prevalence of risk factors in HCC patients: geographical differences.
1.2.2.1 Cirrhosis
Cirrhosis is a premalignant condition, irrespective of the aetiology, secondary to 
nodular hyperplasia progressing to carcinoma. About 70-90% of HCCs develop on a 
background of cirrhosis whilst 20% of patients who die of cirrhosis are noted to have 
HCC at autopsy (Okuda, 1992). Non alcoholic cirrhosis is more frequently associated 
with HCC than alcoholic cirrhosis. In patients with cirrhosis, the annual incidence of 
HCC is 2-7% (Liaw et al, 1986; Okuda et al, 1982).
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1.2.2.2 Hepatitis B Virus
Hepatitis B virus (HBV) is an enveloped virus with a compact incomplete ds DNA 
genome. Chronic infection tends to occur after perinatal infection by a carrier mother, 
infections in very young children and in 10-15% of acute HBV infection in adults. 
World-wide chronic HBV infection correlates with the frequency of HCC, for 
example in Taiwan the carrier rate for HbsAg in the general population is 10%, but 
80% in individuals with HCC (Tong et al, 1971). In a prospective study following 
over 20,000 Chinese males the risk of developing HCC in HbsAg carriers was 100 
times that of HbsAg negative males (Beesley RP, 1987). The carriers at the highest 
risk of developing HCC are those with actively replicating infection (HbeAg positive) 
and those with cirrhosis.
The mechanism by which HBV contributes to hepatocarcinogenesis can be either 
direct or indirect. A direct mechanism is viral genome integration into the host 
chromosomal DNA (often at multiple sites). This either causes or contributes to 
genomic instability secondary to point mutation, inversion, translocation and deletion 
(Brechot et al, 1980). HBV integration can trigger large cellular deletions in cellular 
DNA (Rogler et al, 1985) resulting in the loss of tumour suppressor genes. Some viral 
gene products, such as HBX protein, activate transcription and may increase the 
expression of growth regulating genes involved in the malignant transformation of 
hepatocytes. As an indirect mechanism, persistent HBV infection (but not HBV itself) 
predisposes the hepatocyte to genetic changes resulting from other causes. The virus 
continuously replicates and causes recurrent episodes of hepatitis. The liver responds 
to persistent inflammation with continuous regeneration and fibrosis that eventually 
results in cirrhosis.
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1.2.2.3 Hepatitis C Virus
Hepatitis C virus (HCV) is an RNA virus and may be more important than HBV in 
the aetiology of HCC. In most epidemiological studies, HCV has been diagnosed by 
the presence of antibodies to the virus, which unlike antibodies to Hepatitis A and B 
virus are not protective. There is a 4-fold higher incidence of HCC with the presence 
of anti HCV antibodies than among HBV carriers, this is particularly important in 
Japan, Italy and Spain and the United States (Sherlock S and Dooley J, 1993). 
Evidence suggests that the relationship between viral acquisition and the development 
of HCC is prolonged, taking approximately 30 years, with chronic active hepatitis 
occurring during the first 10 years, and cirrhosis after 20 years (Kijosawa K et al, 
1990).
Eighty percent of anti-HCV positive (HbsAg negative) HCC patients have cirrhosis 
(Hasan et al, 1990), whilst HCC develops in 18% of patients with HCV associated 
cirrhosis within 2 years, and in 75% of patients within 15 years (Foster et al, 1997). 
The presence of both HCV and HBV increases the risk of HCC, as does the use of 
alcohol.
The mechanism by which HCV contributes to hepatocarcinogenesis in unknown. As 
an RNA virus, without the enzyme reverse transcriptase, there is no mechanism for it 
to be incorporated into the host DNA, nor is there any evidence to indicate the 
activation of protooncogenes or inactivation of tumour suppressor genes. Continuous 
viral replication with associated inflammation and hepatocyte cell death appears to 
contribute to HCV related hepatocarcinogenesis.
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1.2.2.4 Miscellaneous factors
Aflatoxins probably increase the risk of HCC. These are produced by the fungi 
Aspergillus flavium and parasitium and are divided into two chemical groups, 
aflatoxin Bi (AFB1) and its derivatives and aflatoxin Gi and its series. AFB1 
contaminates foods such as com, groundnuts, rice and sorghum in tropical areas. 
AFB1 is a potent hepatocarcinogen in experimental animals being converted to its 
reactive 2,3-oxide by liver microsomes and subsequently trapped as an RNA adduct. 
This AFB1 epoxide reacts with the guanine residues of the DNA molecule forming a 
covalent bond. It causes a specific mutation, transversion of guanine to thymine in 
codon 249 of the p53 tumour suppressor gene. A linear relationship between the risk 
of HCC and AFB1 content in diet has been established (Yeh et al, 1989).
Alcohol is a risk factor for HCC, particularly in older age groups. In London, where 
the incidence of HBV infection is low, HCC was seen in 30% of alcoholics with 
cirrhosis, compared with 4% of non-alcoholics with cirrhosis (Lee, 1966). The 10- 
year cumulative occurrence of HCC in patients with alcoholic cirrhosis is 18.5% 
(Yamauchi et al, 1993). Several mechanisms have been postulated to explain the role 
of alcohol in promoting the development of HCC: direct hepatocellular injury, 
activation of chemical carcinogens via the induction of the microsomal P450- 
dependent biotransformation system, suppression of the immune system and reduced 
activity of the enzymes involved in the repair of carcinogen-mediated DNA 
alkylation.
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In HbsAg negative patient’s cigarette smoking is a dose dependent risk factor for 
HCC (Kaklamani et al, 1991). Case controlled studies in developed countries show a 
2 to 5-fold increased risk of HCC with oral contraceptive use (Schlesselman, 1995). 
Other disease processes which have a high incidence of HCC include autoimmune 
chronic active hepatitis, Wilson’s disease, haemochromatosis, type I glycogen storage 
disease and porphyria cutanea tarda. HCC may also complicate immunosuppressive 
therapy following organ transplantation and clonorchiasis, shistosomiasis and 
membranous obstruction of the inferior vena cava are important factors in some 
endemic areas.
1.2.3 Natural history of HCC
The natural history of HCC is variable. Most patients die within 3-6 months after the 
onset of symptoms (Paraskevopoulos, 1994), but 3-year survivals of 50% have been 
reported (Llovet et al, 1999a). The progression of HCC depends largely on the size 
and number of tumours, growth rate, together with histological grade and the degree 
of cirrhotic changes. In 73 untreated patients with Child’s A cirrhosis and a single 
HCC smaller than 5 cm in diameter, the 3-year survival was 26%, compared with 
13% for 43 patients with Child’s B cirrhosis (Livraghi et al, 1995). Approximately 
20% of all nodules less than 1 cm in diameter when first detected already show 
microscopic signs of intrahepatic metastases, the number of tumours showing 
microscopic metastases increases with increasing tumour size and reaches 80% for 
nodules larger than 3 cm (Ebara et al, 1986).
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1.2.4 Treatment of HCC
1.2.4.1 Surgical resection
Surgical resection appears to be the only potential curative treatment for HCC. 
Advances in diagnostic imaging techniques and the introduction and popularisation of 
ultrasound guided fine needle biopsy have led to the early detection of smaller HCC’s. 
Despite this, only 5-15% of HCC patients are suitable for surgical resection due to the 
presence of cirrhosis, anatomically unresectable disease or extrahepatic and vascular 
spread. Resectability in cirrhotic patients is also limited by diminished functional 
reserve of the cirrhotic liver, with the associated risks of intraoperative bleeding and 
postoperative liver failure. In the absence of cirrhosis hepatic resection for HCC can 
be undertaken with low morbidity and mortality rates (Iwatsuki and Starzl, 1988; 
Nagomey et al, 1989), and are associated with 5-year survival of over 30% (Farmer et 
al, 1994; Zibari et al, 1998), and as high as 68% in one study (Nagasue et al, 1986).
The surgical approach in patients with cirrhosis is less clearly defined. European and 
Japanese centers using highly selective criteria have reported 5-year survival rates of 
60-70% (Bruix et al, 1996; Llovet et al, 1999b). In Western countries, where liver 
cancer typically develops in the setting of well established cirrhosis, fewer than 5% of 
HCC patients meet these criteria and even in carefully selected patients the rate of 
tumour recurrence is 50% after 3 years (Anonymous, 1994; Llovet et al, 1999b).
As previously mentioned most HCCs develop on a background of cirrhosis and are 
frequently multifocal (Bhattacharya et al, 1997). The underlying cirrhosis poses a 
constant threat of de novo emergence of HCC after resection of the original tumour. 
HCCs that appear in the liver remnant could result from incomplete removal of
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tumour, pre-existing intrahepatic metastases or undetected synchronous tumours. Less 
than 27% of recurrences occur near the resection site, suggesting that incomplete 
removal of the tumour is responsible for only a minority (Chen et al, 1994). An early 
recurrence of multiple lesions probably represents undetected synchronous lesions 
(Chen et al, 1994). Late recurrence (3-6 years after resection) is unlikely to be due to 
the presence of occult intrahepatic metastases but to non-synchronous mutlifocal 
tumourigenesis (Ouchi et al, 1993).
Most hepatologists now favour orthotopic liver transplantation (OLT) as the preferred 
option for early HCC. In one study 34 patients underwent liver resection and 30 
patients had OLT for HCC with cirrhosis (Gugenheim et al, 1997). After resection 
there was a 5-year survival of 13% and 5-year recurrence of 92.6%, with the diameter 
of nodules being a predictive factor for outcome. In the transplanted group, 5-year 
survival was 32.6%, 5-year recurrence 40.9% and the predictive factor for outcome 
was the number of nodules. Two groups of patients were identified, those with large 
HCC (> 5 cm and/or > 3 nodules) and those with small HCC (< 5 cm and < 3 
nodules). It was concluded that OLT was the best treatment for small HCC because of 
the lower recurrence rate (11% vs 82.6%) but both treatments had a high recurrence 
rate in large HCCs (72.3% resection, 100% transplantation) (Gugenheim et al, 1997). 
OLT removes the entire process and can be applied to patients with end-stage liver 
disease. Recent data have shown that the restriction of OLT to patients with single 
tumours less than 5 cm or with 3 nodules, each less than 3 cm, will result in 5-year 
survival rates of approximately 70% (Bismuth et al, 1999; Llovet et al, 1998).
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1.2.4.2 Chemotherapy
1.2.4.2.1 Systemic chemotherapy
The majority of patients with HCC present at an inoperable stage. There have been 
few randomised-controlled trials of systemic chemotherapy, and as such, its use tends 
to be limited to study groups. Many of these studies have enrolled patients with poor 
prognostic factors (impaired liver function, ascites, jaundice) thus it is not surprising 
that reported response rates are less than 20%, with a median survival of 2-6 months 
(Colleoni et al, 1994; Falkson et al, 1978; Nerenstone et al, 1988).
The first chemotherapeutic agent used was 5-FU (Brennan M et al, 1964; Nerenstone 
et al, 1988), which produced response rates of 0-10% and a median survival of 3-5 
months. Combination with high dose folinic acid did not show any improvement in 
outcome (Zaniboni et al, 1988). Doxorubicin has been commonly used, but the 
objective response rate from 13 published trials was < 20% and the median survival 
only 4 months (Nerenstone et al, 1988). Other active single agents include 4’- 
epidoxorubicin (Hochster et al, 1985) -  response rate 17% and cisplatin (Falkson et al. 
) -  response rate 17%. Combination regimens have been more promising, such as the 
combination of systemic cisplatin, doxorubicin, 5-FU and IFNa in patients with 
advanced unresectable HCC (Leung et al, 1999) producing a 26% partial response rate 
in 13 patients. Four of 9 patients who underwent surgical resection after partial 
response revealed no visible tumour cells on histological examination. There was 
however significant toxicity (2 treatment related deaths due to neutropenic sepsis). 
Other cytotoxic drugs used have included mitomycin, vinblastine, fludarabine and 
doxifluridine. None of these agents either alone or in combination have produced a
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significant improvement in survival. In addition, toxicity and multidrug resistance 
have proved to be major problems.
1.2.4.2.2 Intra-arterial chemotherapy
Intra-arterial chemotherapy is based on the principles that HCCs derive most of their 
blood supply from the hepatic artery, lower drug doses are required, lower toxicity is 
produced and a higher concentration of drug in tumour tissues is achieved compared 
with systemic chemotherapy (Chen et al, 1994). Fluorouracil and anthracyclines have 
been used, the latter producing response rates of up to 42% (Doci et al, 1988). When 
used in combination with floxuridine, LV and cisplatin, Patt et al reported a 64% 
response rate to the anthracycline doxorubicin, but with significant toxicity (3 
treatment related deaths) (Patt et al.,1994). Other drugs used include mitomycin C, 
cisplatin and mitoxantrone, yielding response rates of 50%, 55% and 25% 
respectively (Kinami et al, 1985; Onohara et al, 1988; Shepherd et al, 1987).
1.2.4.2.3 Transcatheter arterial chemoembolisation (TACE)
Transcatheter arterial chemoembolisation (TACE) is a combination of chemotherapy 
and arterial embolisation that has both selective ischaemic and chemotherapeutic 
effects on HCC. It can be used only in the absence of major portal vein thrombosis. 
As there is no standard protocol, a large number of combinations have been used. 
Ryder et al reported a > 50% reduction in tumour size in 10 of 18 patients with small 
tumours (< 4 cm) and a response in 5 of 49 patients with large or multifocal tumours, 
using doxorubicin and lipiodol (Ryder et al, 1996). Survival ranged between 3 days 
and 4 years with a median survival of 36 weeks. Despite encouraging figures for small 
tumours, several randomised trials have shown no significant improvement in survival
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with TACE treatment over best supportive care (1-year survival 24% and 31% 
respectively) (Pelletier et al, 1990), (1-year survival 62% and 43.3% respectively) 
(Anonymous, 1995c).
1.2.4.3 Direct ablation
Cryoablation has reported 2-year survival rates of 30-63% (Crews et al, 1997; Adam 
et al, 1997; Wong et al, 1998) and REA survival rates of 94, 86, 68 and 40% at 1, 2, 3 
and 5 years respectively (Rossi et al, 1996). Percutaneous ethanol injection, however, 
is still considered to be the most effective form of direct ablative therapy for HCC. It 
is suitable for HCCs less than 3 cm in size and fewer than 3 in number. Absolute 
alcohol induces cellular dehydration, coagulative necrosis and vascular thrombosis, 
causing destruction of the tumour cells. Though 3 year survival rates of 55-70% have 
been reported, more than half of these patients develop recurrent tumour within 2 
years (Castells et al, 1993; Isobe et al, 1994).
1.2.4.4 Hormonal therapy
The use of hormonal agents, in particular tamoxifen, is a convenient treatment 
modality for advanced HCC. Results, however, from small randomised trials on 
tamoxifen in the treatment of HCC are conflicting. Some prospective randomised 
studies have demonstrated significant prolongation of survival in the tamoxifen group 
with 1 year survival of 35-49% compared to 0-9% in the control group (Farinati et al, 
1992; Martinez et al, 1994). However, randomised controlled studies showed that 
tamoxifen is not effective in prolonging survival in patients with cirrhosis and HCC 
(Anonymous, 1998b).
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1.2.4.5 Immunotherapy
Immunologically active agents should theoretically be of use in the treatment of HCC, 
as the activity of lymphokine-activated killer (LAK) cells is often reduced in HCC 
patients (Son et al, 1982). Interferons, proteins produced by cells in response to viral 
infection and foreign antigens, play a role in viral reproduction and have 
immunomodulatory and antiproliferative effects on tumour cells. IFNa has been used 
as a single agent to treat advanced HCC and produced a response rate of 31.4% and a 
small improvement in survival (Lai et al, 1993). It has also been used in combination 
with doxorubicin to little effect (Kardinal et al, 1993) and with 5-FU with a 
documented response rate of 18% (Patt et al, 1993). More recently the combination of 
cisplatin, doxorubicn, 5-FU and IFNa given systemically produced a 26% partial 
response (Leung et al, 1999). Whilst combined therapy consisting of intra-arterial 
cisplatin infusion and systemic IFNa showed a partial response and 1 year survival 
significantly higher than a comparative group that received intra-arterial cisplatin only 
(33% vs 14%, P < 0.05 and 27% vs 9%, P < 0.05) (Chung et al, 2000). Other 
strategies have included the use of IFNa, IFNp, LAK, interleukins and antibodies 
against a-fetoprotein and ferritin, all with no significant improvement in survival.
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1.3 Chemotherapy -  classes of anticancer drugs
The first use of drugs in cancer therapy stemmed from the observation of the 
myelosuppressive effects of sulphur mustard in men exposed to mustard gas during 
the First World War. This led to the use of nitrogen mustard and related compounds in 
the treatment of leukaemia and lymphoma (Priestman, 1989). The nitrogen mustards 
are thus the oldest effective cancer chemotherapeutics, many members of this group 
still remain in clinical use. Cytotoxic drugs can be classified according to their 
mechanism of action and biochemistry. The three main categories of anticancer agents 
are the alkylating agents, natural products and antimetabolites (Table 1.4).
Drug Family Examples
I Alkylating agents
Nitrogen mustards eg melphalan, mechlorethamine 
hydrochloride, chlorambucil
Cisplatin
II Natural products
Vinca alkaloids eg vincristine, etoposide
Anthracyclines eg doxorubicin
Non-anthracycline antibiotics eg actinomycin
III Antimetabolites Methotrexate, 5-fluorouracil
Table 1.4. Examples of the three main categories of anticancer agents.
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1.3.1 Cisplatin and alkylating agents
Cisplatin and classical alkylating agents such as the nitrogen mustards are agents 
commonly used in the treatment of solid tumours eg. cisplatin in testicular and 
ovarian malignancies (Reed and Kohn, 1990) and haematological malignancies eg 
melphalan for acute and chronic leukaemia (Colvin and Chabner , 1990). They act by 
binding covalently to DNA, and as they possess two functional groups can form 
mono- and diadducts, the former modifying only a single base, the latter including 
intra- and interstrand crosslinks (Lawley and Phillips, 1996) (Figure 1.1).
CH3 Cl Cl
I * \  /  *
N  * Pt 
c ic h 2c h 2/  c h 2c h 2ci h 3n  NH;
Mechlorethamine Cisplatin
Figure 1.1. Structures of the nitrogen mustard mechlorethamine (HN2) and cisplatin. 
Functional groups are marked*.
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Intrastrand crosslinks are formed by the drug binding to two nucleotides within the 
same strand of the DNA double helix, whilst interstrand crosslinks (ICLs) involve 
drugs binding to a nucleotide in each of the two DNA strands.
Cisplatin binds preferentially to the N7 atom of guanine (G) and to a lesser extent the 
N7 atom of adenine (A) residues. Cisplatin forms a variety of DNA adducts, the most 
prevalent (> 90%) of which is the 1,2 intrastrand crosslink. Other platinum DNA 
adducts include monofunctional 1,3 and longer range intrastrand, interstrand and 
protein DNA crosslinks (Figure 1.2). Because of their abundance and their ability to 
block DNA synthesis (Heiger-Bemays et al, 1990; Pinto and Lippard, 1985), 
intrastrand diadducts are considered to be the primary cytotoxic lesions caused by 
most platinum compounds. However, some studies have suggested that ICLs may also 
play a role in determining the cytotoxicity of platinum compounds (Fram et al, 1990; 
Osmak, 1992).
1,2-d(GpG) intrastrand crosslink TCTAGGCCTTCT
AGATCCGGAAGA
1,2-d(ApG) intrastrand crosslink TCTTAGTTCTCT
AGAATCAAGAGA
l,3-d(GpTpG) intrastrand crosslink TCTGTGCACTCT
AGACACGTGAGA
d(GpC)d(GpC) interstrand crosslink TCCTTGCTCTCC
AGGAACGAGAGG
Figure 1.2. Schematic representation of cisplatin adducts. The platinated nucleosides 
are underlined.
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The nitrogen mustard mechlorethamine (HN2) also binds preferentially to N G. 
Although the majority of adducts are monoadducts, a total of 4-7% of the lesions are 
GZG ICLs, and these are thought to be the primary cytotoxic lesions (Chaney and 
Sancar, 1996).
The mechanism by which intra- and interstrand crosslinks induce cytotoxicity are 
unknown, however both block DNA polymerase I, preventing DNA synthesis and cell 
division. ICLs appear to be more cytotoxic because they are more difficult to process, 
and attempts to repair or replicate past such damage leads to highly cytotoxic ds 
breaks (Chaney and Sancar, 1996; Vock et al, 1998).
1.3.2 Natural products
The natural products include the vinca alkaloids, such as vincristine which exert their 
effects by binding to tubulin and thus inhibiting spindle formation and blocking 
mitosis. Etoposide, a semisynthetic derivative of podophylotoxin, produces ds DNA 
breaks by interacting with DNA and the enzyme topoisomerase (topo) II. This enzyme 
produces temporary enzyme associated DNA strand interruptions in ds DNA, to allow 
the relaxation of supercoiled DNA during replication. The presence of etoposide 
results in stabilisation of topo II induced DNA cleavable complexes, with production 
of ds breaks and a subsequent cascade of effects that culminate in cell death (Takano 
et al, 1992).
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1.3.3 Anti-metabolites
5-FU was first synthesised in 1957 and has been the major cytotoxic agent used in the 
management of CRC since. 5-FU itself is inactive and requires intracellular 
conversion to form active metabolites. Its 3 major active metabolites are:
1. 5-fluorodeoxyuridylate (5-FdUMP), which inhibits thymidylate synthase (TS), the 
rate limiting step of DNA synthesis.
2. 5-fluorouridine triphosphate (5-FUTP), which incorporates into RNA and causes 
alteration in its processing.
3. 5-fluorodeoxyuridine triphosphate (5-FdUTP), which incorporates into DNA 
instead of deoxythymidine triphosphate (DTTP), the usual substrate for DNA 
polymerase.
5-FU degradation is rate limited by the enzyme dihydropyrimidine dehydrogenase 
(DPD), within 24 hours of a bolus injection up to 80% of the drug is metabolised.
1.4 Drug resistance
The objective of cancer treatment is to eradicate all cancer cells. The functional cell 
kill hypothesis states that a given drug concentration applied for a defined time period 
will kill a constant fraction of the cell population. Thus, the concentration, number 
and frequency of drug treatments are vital. Toxicity also has to be considered, 
therefore time intervals between cycles of treatment are designed to allow normal cell 
populations, in particular bone marrow, time to recover before repetition of therapy 
(Kaufmen and Chabner , 1996).
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A chemotherapeutic agent that is effective in cell culture and animal models, although 
frequently applied successfully in human leukaemia and lymphoma, is often 
unsuccessful in eliminating solid tumours in adults. Heterogeneity in drug delivery 
and distribution; heterogeneity of the tumour microenviromental characteristics such 
as interstitial pH, partial pressure of oxygen (pC>2) and cell proliferation; and intrinsic 
or acquired drug resistance by the cancer cells themselves often means some tumour 
cells receive sublethal drug concentrations with subsequent treatment failure.
1.4.1 Heterogeneity of drug delivery and distribution
The efficacy of chemotherapy is limited by its inability to reach target cells in vivo in 
adequate quantities (Jain, 1996). A solid tumour in vivo consists of cancer cells, which 
often occupy < 50% of the total volume, and two extracellular components: vascular, 
occupying 1-10% of the total volume and interstitial, composed primarily of an 
abundant collagen rich matrix that surrounds cancer cells and separates them from the 
vasculature. Since no blood-borne molecules can reach cancer cells without passing 
through these compartments, there are therefore at least three physiological barriers to 
delivery (i) heterogeneous blood supply and blood flow in tumours, (ii) heterogeneous 
permeability of tumour vessels, and (iii) physico-chemical properties and 
hypertension of the interstitium.
1.4.1.1 Heterogeneous blood supply
In normal organs blood vessels are arranged in a predictable fashion and supply blood 
to cells areas of the constituent tissue. Although tumour vessels originate from well- 
organised host vessels, they are disorganised in their growth, structure and function. 
Consequently, some areas of the tumour may be hypervascular whereas others may be
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hypo- or avascular (Jain, 1996). Furthermore, secondary to the irregular vasculature, 
there is often noticeable slowing of blood flow, exacerbated by the high viscosity of 
blood within tumours. Thus tumour blood flow tends to be spatially and temporally 
heterogeneous contributing a specific barrier to drug delivery.
Normal hepatic vasculature consists of flow into liver sinusoids as a singular 
confluence of arterial and venous blood. Structurally, the sinusoid is classified as a 
discontinuous capillary with endothelial gaps and no basement membrane (Martinez- 
Hemandez and Martinez, 1991). The vascularity of experimental liver metastases is 
dependent on size and growth of the tumours and appears to be a continually changing 
phenomenon. Ackerman et al, found that small tumours (< 1 mm) had no evidence of 
newly developed circulation, whilst tumours between 1-2 mm in diameter had 
neovascularisation encircling the tumour derived from either the arterial or portal 
circulation or from both. Tumours between 3-7 mm had well developed arterial 
circulations, whilst larger tumours ranging from 7-33 mm in size, developed a wide 
variety of vascular patterns ranging from predominantly arterial to predominantly 
portal as well as a combination of both (Ackerman, 1974). Lin et al performed an 
autopsy study on a total of 13 human livers with 101 metastases measuring < 1 cm in 
diameter (Lin et al, 1984). Of these 83 were injected with microfil via both the hepatic 
artery and portal vein, exclusive perfusion via the hepatic artery was seen in 12 
tumours, no tumour had exclusive perfusion via the portal vein, the remaining 71 had 
a combination of both. With increasing size, the number of tumour vessels decreased 
in the centre of the tumour.
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Angiographic studies have led to the classification of hepatic metastases according to 
their degree of vascularity. Kim et al, found that vascularity of hepatic metastases 
from CRC in 21 patients was the same or less than that of surrounding hepatic tissue 
(Grade I) in 38% of cases, slightly greater (Grade II) in 48% and much greater (Grade 
III) in 14% (Kim et al, 1977). Survival prolongation after devascularisation and IA 
chemotherapy was directly proportional to vascularity, with a median survival being 
4, 10.5 and 11 months for Grades I, II and III respectively. They suggested that the 
portal vein may be more important than the hepatic artery in hypovascular tumours, 
indeed Honjo et al reported a good response following portal vein ligation in the 
treatment of hepatic tumours of various origins (Honjo et al, 1975).
The sinusoids of normally functioning liver acini change as cirrhosis is established 
and the microvasculature becomes composed of vessels resembling systemic 
capillaries. Similarly HCC shows a diffuse uniform pattern of capillarisation 
(Haratake and Scheuer, 1990). Small HCCs (< 3 cm) are surrounded by a vascular 
plexus consisting of hepatic arterial and portal venous branches that feed into tumour 
capillaries (Kita et al, 1991). Although portal blood supply to HCCs has been noted in 
a number of studies (Saitoh et al, 1994; Taniguchi et al, 1993), HCC blood supply is 
mainly arterial. Borderline nodules (regenerative nodules with focal areas of change 
suggesting HCC) have a dual portal and hepatic arterial supply. There is progressively 
more arterial supply in small HCCs (<2.5 cm) compared with borderline nodules 
(Tanaka et al, 1992), and in higher-grade HCCs compared to well-differentiated 
HCCs and borderline lesions (Matsui et al, 1991).
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Arterialisation in HCCs is usually accompanied by hypervascularity (increased blood 
flow compared to adjacent liver tissue). Reduction of portal flow appears to precede 
the increase in arterial flow, and early, well-differentiated HCCs may be hypo- or 
isovascular (Takayasu et al, 1986). Hypervascularity is usually present in higher- 
grade tumours greater than 2 cm in diameter, and establishing this condition from the 
low-flow state takes approximately a year (Ikeda et al, 1993). Since diagnostic 
arteriography relies on this aspect of HCC vascularity, its sensitivity depends on the 
size of the tumour. Arteriography is ineffective in tumours less than 1 cm in diameter; 
tumours 3 to 5 cm in diameter are detected with a sensitivity of 82 to 89%; and almost 
all larger tumours can be identified (Pavone et al, 1992).
1.4.1.2 Heterogenous permeability of tumour vessels
One of the major barriers to drug delivery is the tumour microvessel wall. In general, 
vascular permeability is much higher in tumours that in host tissues. However, the 
permeability of the wall to molecules is heterogeneous in tumours, in some regions 
tumour vessels are nearly impermeable whilst other regions are much more leaky than 
normal vessels (Yuan et al, 1994). The large pores in the vascular endothelium (Yuan 
et al, 1995) and discontinuity in the basement membrane (Bosman et al, 1985), 
presumably cause the leakiness of tumour vessels. These physiological properties of a 
tumour depend on its local environment. Tumours that are grown in a subcutaneous 
microenvironment have a tumour-dependent functional pore cut-off size ranging from 
200 nm to 1.2 pm, which is dramatically reduced when the tumour is grown in a 
cranial microenvironment (Hobbs et al, 1998). In addition to size selectivity, the 
transvascular transport is influenced by the charge of molecules. Dellian et al, have 
demonstrated that positively charged molecules extravasate faster in solid tumours
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compared to similar sized compounds with neutral or negative charges (Dellian et al, 
2000).
1.4.1.3 Physico-chemical properties and hypertension of interstitium
The interstitial compartment presents a third barrier. The movement of molecules and 
particles depends on their size, charge and conformation and the physico-chemical 
properties of the interstitium. Movement through this compartment occurs by 
diffusion and convection. Unlike diffusion, which is unaffected by pressure gradients, 
convection is governed by them: fluid flows from areas of high pressure to areas of 
low pressure, carrying molecules with it. Small molecules such as oxygen and 
conventional chemotherapeutic agents (with a MW < 2000) migrate mainly by 
diffusion, whilst large molecules (with a MW > 5000), move mainly by convection. 
Diffusion coefficient (D) decreases with increasing MW of drug (D~MW'n, n > 1). 
Thus, high MW drugs penetrate the interstitium slowly (Jain, 1999). The net transport 
of small molecules by diffusion may be further retarded as a result of binding to 
relatively large molecules that move at a much slower speed (Morrison et al, 1991).
The extracellular matrix (ECM) contributes to the drug resistance of a solid tumour. 
Tumour and stromal cells produce and assemble a matrix of collagens, proteoglycans 
(eg glycosaminoglycans [GAG]), and other molecules that hinder the transport of 
molecules. In normal tissues, resistance to water and solute transport is attributed to 
the amount of hydrophilic ground substance, predominantly GAG (Auckland and 
Nicalaynes, 1981; Comper and Laurent, 1978). Tumour tissue, however, possesses 
unique characteristics with extensive synthesis of ECM (Ronnov-Jessen et al, 1996), 
which leads to substantial differences in composition and assembly compared with the
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host tissue. Recently, functional properties of ECM have been found to be correlated 
with total tissue content of collagen rather than GAG as previously thought (Netti et 
al, 2000). An extended collagen network was observed in the more penetration- 
resistant tumours studied.
Solid tumours also exhibit interstitial hypertension. In normal tissues, the pressure is 
approximately 0 mmHg, but in solid tumours it is uniformly higher, except at the 
periphery where it remains close to normal (Jain, 1996). A lack of functional 
lymphatics is a key contributor to interstitial hypertension. This has two effects: it 
reduces convection across the wall of tumour vessels and leads to steep pressure 
gradients from the tumour periphery to the surrounding host tissue. These gradients 
cause tumours to lose interstitial fluid, and along with it, therapeutic drugs, into the 
surrounding tissue.
1.4.2 Heterogeneity of tumour microenviromental characteristics
For chemotherapy to be successful it must be effective in the in vivo 
microenvironment. By the time a tumour has reached a detectable size, the cancer 
cells and their local microenvironments often become heterogeneous. Many 
microenviromental changes are the result of inefficient vascular function within the 
tumour, with subsequent gradients of critical metabolites such as oxygen (O2), 
glucose, lactate and H+ ions. Because of the selective pressure of the heterogeneous 
environments and the instability of the malignant genome, new and diverse cell 
phenotypes emerge with diverse responses to chemotherapeutic agents (Sutherland, 
1988). Tumour growth is characterised by a phase of exponential cell proliferation 
followed by a phase of decreased growth rate associated with an increase in
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nonproliferating (quiescent) cells and necrotic cells. Proliferating cells are usually 
located adjacent to functional blood vessels, whilst quiescent and necrotic cells are 
located at progressively greater radial distances from the vessels. The fraction of stem 
cells in human tumours is variable, but usually small (< 1%). These stem cells are 
targets for therapy, and from these cells resistant variants can emerge. Cloned stem 
cell lines from the same tumour often express a variety of cytotoxic sensitivities 
(Weichselbaum et al, 1986) (Figure 1.3).
Oj.^lucosc.growth 
/  factors
Variable blood flow
Figure 1.3. Factors contributing to the development of heterogeneous 
microenvironments and cells.
P, proliferating cells; Q, quiescent cells; N, necrotic cells; P-gp, P-glycoprotein.
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Oxygen and pH are key microenviromental factors in the development and growth of 
tumours including their response to chemotherapy, their levels affecting tumour cell 
metabolism, glucose and O2 consumption rates and tumour cell proliferation and 
viability (Casciari et al, 1992; Vaupel et al, 1989). Hypoxia can stimulate 
angiogenesis (Shweiki et al, 1992) as well as induce tumour cell apoptosis (Shimizu et 
al, 1996), thereby affecting tumour growth. The selective microenviromental 
characteristics displayed by tumours, such as interstitial acidity or hypoxia, can be 
either advantageous or unfavourable for cancer treatment depending on which 
modality is considered. The situation is even further complicated by intra- and 
intertumour variations in interstitial pH and pC>2 . Hypoxic tumour cells are well 
known to be radiation resistant (Hockel et al, 1993). During chemotherapy, hypoxia 
can either aid cytotoxicity such as in the case of bioreductive drugs (Chaplin and 
Acker, 1987) and alkylating agent’s (Skarsgard et al, 1995), or inhibit cytotoxicity, as 
with bleomycin or actinomycin D (Teicher et al, 1981). Similarly, acidic pH 
potentiates the cytotoxicity of alkylating agents (Jahde et al, 1989) and weak acids 
(Gerweck and Seetharaman, 1996) and decreases the cytotoxicity of other 
chemotherapeutic drugs (ie. adriamycin and bleomycin) (Wike-Hooley et al, 1984).
1.4.3 Intrinsic and acquired drug resistance
At a cellular level, CRC and HCC are often intrinsically resistant to multiple 
chemotherapeutic agent’s (Kaufmen and Chabner, 1996; Nerenstone et al, 1988). 
Frequently they respond to initial treatment but acquire chemoresistance. A classic 
example occurs during the treatment of CRC with 5-FU in which first line treatment 
usually gives a 23% response rate, but second line therapy only achieves 7% response. 
The mechanism of resistance to this antimetabolite is known to be increased levels of
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TS enzyme, the drug target, and 7-dihydrofoloate reductase, which is involved in 
metabolising the drug (Cole and Tannock, 2004).
The mechanisms of drug resistance are not fully understood. Undoubtedly, most 
resistant tumours have acquired a number of overlapping mechanisms for avoiding the 
toxic effects of chemotherapy. The most widely accepted hypothesis for development 
of acquired drug resistance is that cancer cells accumulate random spontaneous 
mutations and positive selection of these resistant cells carries clinical drug resistance 
(Kaufmen and Chabner, 1996).
It has long been recognised that simultaneous resistance to many seemingly 
structurally and functionally unrelated compounds can occur. These drugs are 
predominantly natural, or semisynthetic lipophilic, relatively large, heterogenous 
molecules including the vinca alkaloids (vincristine and vinblatine), 
epipodophyllotoxins (etoposide and teniposide), anthracyclines (doxorubicin and 
daunomycin), colchicine and taxols. Such cells are referred to as displaying a 
multidrug resistant phenotype (MDR) (Gottesman and Pastan, 1993). The term MDR 
covers a number of different mechanisms, including interference with the apoptotic 
pathway -  such as inactivation of p53, expression of energy-dependent pump 
systems-such as P-glycoprotein (P-gp) or multidrug resistance associated protein 
(MRP), alteration in topos, or a combination of these (Figure 1.4).
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D rug efflux by MRP1
Figure 1.4. Summary of the major mechanisms of multidrug resistance.
1.4.3.1 P-glycoprotein (P-gp)
The best characterised form of drug resistance to date, usually referred to as classical 
MDR, is that mediated by the MDR-1 gene. The protein product of MDR-1 is P-gp 
which belongs to a super family of adenosine triphosphate (ATP)-binding cassette 
(ABC) transport proteins (Gottesman et al, 1996). As a result of P-gp expression, 
tumour cells exhibit an increased efflux of many cytotoxic agents with subsequent 
reduced intracellular accumulation resulting in insufficient drug levels for adequate 
anti tumour activity to occur (Kiehntopf et al, 1994).
There are two MDR genes identified in humans MDR-1 and MDR-2, and three in 
mice. Only the product of MDR-1 (P-gp) is associated with drug resistance (Cole and 
Tannock, 2004). P-gp is a cell surface glycoprotein of 170 kDa, which is located 
primarily in the plasma membrane. The molecule consists of two homologous 
transmembrane domains connected by a short joining section. Each domain consists
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of three pairs of membrane-spanning a-helical segments, with the N- and C-termini 
on the cytoplasmic side of the membrane and three extracellular and two intracellular 
loops per domain (Figure 1.5).
Lumen
Y l  n o n
coo
Cytoplasm
Figure 1.5. Proposed structure of P-gp.
Although there is considerable evidence that P-gp is involved in removal of 
chemotherapeutic drugs from the cell, the exact mechanism by which this occurs is 
unknown. The most prevailing hypothesis is that P-gp functions as a pore-forming 
protein, which acts in an energy dependent manner to export compounds. The 
identification of ATPase activity associated with P-gp provides a mechanism by 
which energy may be transduced for active drug efflux. This hypothesis, however, 
leaves a number of aspects not fully explained, such as the broad substrate specificity 
observed for P-gp, and the inability to correlate the initial rate of transport with the P- 
gp concentration. It has also been proposed that P-gp acts as a ‘hydrophobic vacuum 
cleaner’ by removal of compounds directly from the plasma membrane before they 
reach the cytosol (Gottesman et al, 1996). Under this model the primary determinant 
of substrate specificity would be the ability of a compound to interact with the lipid
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bilayer and the secondary determinant would be its ability to interact with the binding 
site of the transporter. This is consistent with the observation that substrates for P-gp 
are lipophilic and that the major determinant of a particular substrate to be transported 
by P-gp is its relative hydrophobicity. Photoaffinity labelling, mutational analysis and 
inhibitor studies indicate that transport of compounds by P-gp occurs through a single 
barrel of the transporter (Figure 1.6).
Direct correlation has been found between the content of P-gp in the cell membrane 
and the degree of resistance to the selecting drug, with high levels found in 
chemoresistant CRC and HCC’s (Cole and Tannock, 2004). P-gp overexpression in 
human tumour cells results in resistance to antracyclines, such as doxorubicin, to 
epipodophyllotoxins, such as etoposide, and to vinca alkaloids, taxoids, topotecan, 
and actinomycin D, but not to many of the other clinically important drugs, such as 
alkylating agents, cisplatin, methotrexate (MTX), and purine and pyrimidine 
analogues. Kiehntopf et al, reported a hammerhead ribozyme specifically recognising 
and cleaving the MDR-1 mRNA (Kiehntopf et al, 1994). Liposome-mediated transfer 
of the ribozymes into MDR cell lines resulted in significantly reduced expression of 
the MDR-1 gene, and reversed the multidrug resistance phenotype, restoring 
sensitivity to cytotoxics. Many drugs including verapamil (vpm), quinine, cyclosporin 
A and its non-immunosupressive analogue PSC-833, inhibit P-gp mediated drug 
efflux in cancer cell lines (Ford and Hait, 1990; Gottesman and Pastan, 1993). These 
chemosensitising agents act as competitive inhibitors and correct accumulation 
defects thus restoring drug sensitivity in MDR cell lines.
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Figure 1.6. Schematic diagram of the proposed structure of P-gp, which functions as 
an energy-dependent drug efflux pump.
1.4.3.2 Multidrug resistance associated protein (MRP)
The MRPs are also members of the ABC superfamily of transport proteins. The MRP 
gene has been mapped to chromosome 16 at band p 13.13-13.12, and is amplified 
relatively frequently in drug-selected human cell lines that over-express MRP mRNA. 
MRP is now known to be one of six genes that make up a family of multi-specific 
organic anion transporters (MOAT) (Lee et al, 1998). MRP1 now designates the 
original 190 kDa glycoprotein MRP, while both MRP2 (canalicular MOAT 
[cMOAT]) and MRP3 (MOAT-D) have been cloned and transfected into drug 
sensitive cells resulting in resistance to cisplatin, anthracyclines, etoposide, MTX; and 
vinca alkaloids, etoposide and MTX respectively (Ross, 2000). MRP1 is located at the 
basolateral side of epithelial cells and is believed to have an unusual arrangement of 
the membrane domains with five additional transmembrane domains at the N- 
terminus (Figure 1.7).
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Figure 1.7. Proposed structure of MRP 1.
It produces a similar range of resistance to that of P-gp, except to mitoxantrone 
(Futscher et al, 1994).
MRP transport relies on the presence of glutathione (GSH) with drug substrates being 
transported as either GSH conjugates or co-transported with GSH. Depletion of GSH 
with buthionine sulfoxamine (BSO) sensitises MRP over expressing cells to drugs that 
are transported by MRP (Lautier et al, 1996 ).
1.4.3.3 Lung resistance related protein (LRP)
A further protein, found in many MDR cells not overproducing P-gp, is LRP (Scheper 
et al, 1993 ), which has been identified as the human vault protein (Scheffer et al, 
1995). Vaults are novel cellular organelles, broadly distributed and highly conserved 
among diverse erythropoeitic cells. They localise to nuclear pore complexes, thus are 
involved with intracellular transport (Figure 1.8).
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Figure 1.8. Hypothetical role of LRP in drug-resistance. LRP/vaults may mediate 
nucleocytoplasmic and vesicular transport of drugs. Through exocytotoxic vesicles 
the drugs would be extruded from the cell.
ER = endoplasmic reticulum.
The overexpression of LRP alone in transfected drug sensitive cells does not result in 
drug resistance (Scheffer et al, 1995), as this does not increase the number of 
intracellular vaults. The overexpression of vaults results in sequestration of 
therapeutic drugs within the vaults, preventing interaction with their targets. 
Conflicting reports exist as to the significance of overexpression of LRP in prognosis 
of haematological malignancies.
1.4.3.4 Atypical multidrug resistance (at-MDR)
At-MDR refers to cells with altered topo II activity (Beck, 1990). At-MDR cells show 
cross-resistance to topo II poisons and “pure” at-MDR cells are not resistant to vinca 
alkaloids, they have no change in P-gp expression or in drug accumulation, but show 
altered topo II activity by quantitative or qualitative means. Topo II alterations are 
complex, and numerous facets of the mechanisms involved remain unexplained
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(Danks et al, 1993; Perrin et al, 1998). The main mechanisms of resistance are 
reduction in topo II protein expression and activity, both having the effect of limiting 
the target available to the drug thus limiting damage within the cell.
1.4.3.5 Mechanisms of DNA-drug adduct resistance
Mechanisms of cisplatin and nitrogen mustard resistance have been postulated to be 
associated with several different cellular changes including:
1.4.3.5.1 Reduced intracellular accumulation
The development of cisplatin resistance has been associated with decreases in 
intracellular accumulation. When decreases are observed they are usually modest, 
even if the level of resistance is high. To date, the search for a specific cisplatin 
membrane transport system has been inconclusive. Andrews and Howell (Andrews 
and Howell, 1990), noted that uptake was not saturable up to the solubility limit of 
cisplatin (3.3 mM), thus even if a transport system does exist it is either a low affinity 
site or very abundant.
1.4.3.5.2 Increased drug inactivation by intracellular thiols
Intracellular non-protein sulfhydryl GSH has multiple functions in catalysis, transport 
and reductive phenomena. Moreover, it reacts with toxic endogenous and exogenous 
substances, including free radicals and chemotherapeutic agents. These functions are 
important in drug resistance with agents such as nitrogen mustards (Arrick and 
Nathan, 1984) and cisplatin (Ishikawa and Ali-Osman, 1993).
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Figure 1.9. Simplified scheme of the glutathione synthesis pathway and conjugation 
of glutathione to drugs catalysed by glutathione-S-transferase.
GSH is a tripeptide of glycine, glutamic acid and cysteine which is synthetised 
intracellularly by two ATP-dependent catalytic reactions, involving y- 
glutamylcysteine synthase (y-GCS) and glutathione synthase. The rate-limiting step of 
GSH synthesis is catalysed by y-GCS and is feedback inhibited by GSH (Figure 1.9).
As a potent nucleophile, GSH reacts with alkylating agents and evidence exists that 
the resulting GSH-S conjugate is then eliminated from the cell by an ATP-dependent 
GSH-S conjugate export pump (Ishikawa and Ali-Osman, 1993). GSH may protect 
cells by intercepting alkylating agents before they interact with DNA, certainly 
acquired resistance to alkylating agents is often accompanied by an elevation in GSH. 
Melphalan-resistant leukaemia cells have a 2 to 4-fold higher level of GSH than their 
sensitive parental cells (Somfai-Relle et al, 1984), whilst Ozols and his colleagues 
have demonstrated that ovarian cancer cell lines resistant to adriamycin, cisplatin and
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other various alkylating agents have increased GSH levels (Behrens et al, 1987; Green 
et al, 1984; Rogan et al, 1984). Furthermore, lowering GSH levels by treatment with 
the y-GCS inhibitor, BSO, can potentiate the activity of melphalan (Ozols et al, 1987) 
and cisplatin (Meijer et al, 1992). However, cisplatin is not invariably affected by 
BSO, suggesting there are other cellular mechanisms of resistance (Andrews et al, 
1985).
1.4.3.5.3 Enhanced repair of DNA-drug adducts
DNA repair encompasses the molecular reactions that eliminate damaged or 
mismatched nucleotides from DNA. Five broad categories of DNA repair mechanisms 
exist:
1) Direct repair, using specific enzymes such as 0 6-methylguanine-DNA methyl 
transferase (MGMT), to repair specific but directly reversible types of damage. 
The chemical bond linking the base to a substituent is broken leaving the base in 
situ in the DNA strand (Sancar, 1996).
2) Base excision repair, the single damaged nucleotide is removed in two steps. First, 
the modified base is released by a glycosylase, this cleaves the glycosylic bond 
linking the deoxyribose to the base, then the abasic sugar is released by a pair of 
apurinic or apyrimidinic (AP) endonucleases.
3) Nucleotide excision repair (NER), most DNA damage is repaired by the NER 
system which recognises DNA adducts induced by numerous chemical treatments 
(Wood, 1996). This mechanism, now well characterised, is known to consist of 
two distinct major steps: (i) the incision reaction involving damage recognition 
and excision of the damaged oligonucleotide or base, and (ii) repair synthesis of 
new DNA using the complementary strand as a template and its subsequent
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ligation to restore strand continuity (Ma et al. 1995; Sancar, 1996; Wood, 1996). 
Human genetic defects in NER have been found in association with xeroderma 
pigmentosum (XP), Cockayne’s syndrome (CS) and Trichothiodystrophy (TTD) 
(Ma et al, 1995; Sancar, 1996). In each of these diseases, several complementation 
groups have been defined from XPA to XPG, from TTD1 to TTD3, and CSA and 
CSB. These have been assigned to 11 complementation groups and so far have 
allowed the cloning of 6 human NER genes. Another class of laboratory-induced 
mammalian UV-sensitive NER-deficient mutants has been obtained from cultured 
rodent cells (Collins, 1993). These have been designated as excision repair cross­
complementing genes (ERCC). Each of these genes and their corresponding 
proteins have been the subject of numerous studies aimed at describing NER at a 
molecular level (Sancar, 1996; Wood, 1995), this can be summarised as follows 
(Figure 1.10):
(i) The NER mechanism is initiated by XPA, which binds to the damaged site. 
XPE was also proposed as a protein involved in the recognition step. 
However, several studies have shown that XPE is not essential for this step 
(Sancar, 1996). The binding of XPA facilitates entry of the replication 
protein A (RPA) and forms a complex with it.
(ii) This complex then recruits transcription factor IIH (TFIIH) and 
ERCC1/XPF complexes.
(iii) The helicase activity of XPB and XPD contained in the TFIIH locally 
unwinds DNA. The structural modification(s) of DNA induced by this 
unwinding facilitates the 5' incision made by the ERCC1/XPF. Similarly, 
XPA/TFIIH recruits XPG which makes the 3' incision.
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(iv) Repair synthesis is then carried out by the pol-5 and/or -s which requires 
proliferating cell nuclear antigen (PCNA) and replication factor C (RF-C) 
to form a DNA synthesis complex as in DNA replication.
(v) Finally, the repair patch is sealed by a ligase, most likely ligase I.
X P A
X P E ?
X P C
E R C C 1 / X P F
XPI)
D N A  L igase  I
Figure 1.10. Model for human NER.
XPA-E, xeroderma pigmentosum A-E; RPA, replication protein A; TFIIH, 
transcription factor IIH; ERCC, excision repair cross-complementing gene; RF-C, 
replication factor C; PCNA, proliferating cell nuclear antigen.
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4) Mismatch repair, this process detects and repairs mismatches in base pairing that 
disobey Watson-Crick rules, as occurs during recombination and replication 
events (Modrich, 1994). An ATP-dependent multisubunit nuclease removes the 
mismatch in the form of a mononucleotide. The resulting ss gap is filled by DNA 
polymerase 8 or £ and closed by DNA ligase. The mismatch repair process was 
not thought to be involved in repair of DNA-drug adducts, however one 
compartment was found to bind to cisplatin intrastrand crosslinks (Duckett et al. 
1996), implicating it in the repair of the lesion. Subsequently, it has been found 
this is due to the mechanism repairing mismatch lesions, rather than cisplatin 
adducts, that have occurred during replicative bypass (DNA replication occurring 
around cisplatin adducts without their removal) (Yamada et al. 1997) (Figure 
1 . 1 1 ).
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Figure 1.11. Proposed model for the contribution of mismatch repair activity to 
cisplatin cytotoxicity. DNA replication past cisplatin adduct results in imperfect base 
pairing. This anomaly is recognised by the hMutLa/hMutSa mismatch repair complex. 
Attempted mismatch repair fails because it is directed at the daughter strand. Thus, the 
newly synthesised strand is removed, and the lesion on the parental remains unexcised. 
The continued action of these futile replication/repair cycles results in the formation of 
gaps or strand breaks, which lead to cell death. An inability to initiate mismatch 
correction would be beneficial to the cell, because these futile repair attempts would be 
avoided.
93
Chapter I: Introduction
5) Recombinational repair, this poorly understood mechanism is required for 
rejoining DNA ds breaks whilst preserving DNA fidelity. Double strand breaks 
can either be repaired with no check on integrity of the DNA code (non- 
homologous end joining), or be repaired accurately using information contained in 
homologous regions on another chromosome or sister chromatid for reference 
(homologous recombination) (Takata et al. 1998).
Many pt-resistant cell lines appear to have enhanced repair activity based on the rate 
of disappearance of pt-adducts (Masuda et al, 1990; Parker et al, 1991), and the rate of 
disappearance of ICLs (Chen G et al, 1992; Zhen et al, 1992). The pathway is capable 
of repairing both pt-monoadducts and pt-intrastrand diadducts in vitro, with a 
preference for the repair of monoadducts compared with intrastrand diadducts (Page 
et al, 1990; Szymkowski et al, 1992). The repair of pt-ICLs represents a specific 
challenge for DNA repair mechanisms. ICLs are large lesions, and as such are 
substrates for the NER mechanism. As both strands of DNA are damaged, however, 
NER alone cannot perform the process because excision of both strands would be 
required. At present, evidence points to a mechanism combining components of NER 
and homologous recombination. In rodent cells studied in vitro, this process has been 
shown to require the XPF-ERCC1 complex a heterodimer involved in NER 
(Thompson, 1996).
Since ICLs appear to be the major cytotoxic lesions for nitrogen mustards, it is logical 
that the NER and recombination pathways should be critical in repair of cytotoxic 
nitrogen mustard lesions. Cells lacking XPF-ERCC1 are hypersensitive to HN2 (Hoy 
et al, 1985) and several pt-resistant cell lines characterised by an increase in the rate
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of pt-adduct removal also show partial cross-resistance to melphalan and other 
nitrogen mustards (Kelland et al, 1992). Taken together these data suggest enhanced 
NER and/or recombination in resistance to nitrogen mustards has a role.
1.4.3.5.4 Increased platinum-DNA damage tolerance
Enhanced replicative bypass, defined as the ability of the replication complex of a cell 
to synthesise DNA past the site of DNA damage, has been suggested to have a 
potential role in cisplatin resistance (Mamenta et al, 1994), leading to increased DNA 
damage tolerance. Defects in mismatch repair are associated with cisplatin resistance 
(Fink et al, 1996). In an intact mismatch repair system futile cycles of translesion 
synthesis past cisplatin-DNA adducts followed by removal of the newly synthesised 
DNA eventually leads to cell death. Thus, an inability to initiate mismatch correction 
would be beneficial to the cell, because futile repair attempts would be avoided 
(Figurel.il). Five genes encode proteins required for mismatch repair, of these 
defects in hMLHl or hMLH6 result in 1.5 to 4.8-fold increased cisplatin resistance 
and 2.5 to 6-fold increased replicative bypass of cisplatin adducts (Vaisman et al, 
1998).
1.5 Models to study the effect of chemotherapy
Recent insights and discoveries in cancer biology have dramatically increased 
knowledge of this disease. The knowledge gained in the existence of tumour 
suppressor genes, critical genes and proteins involved in tumourogenesis and 
progression has led to a number of new strategies being developed to systemically 
treat metastatic disease. The resulting agents include monoclonal antibodies,
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cytokines, antisense oligonucleotides and gene-specific targeted therapeutics (Brown 
et al, 2000). These strategies have been shown to produce a potent effect on cancer 
cells in vitro and in some in vivo tumour models, however, clinical results to date have 
been disappointing. For any therapy to be successful it must first reach target cells in 
vivo in optimal quantities and second, be effective in the in vivo microenvironment of 
the malignant phenotype (Jain, 1996).
1.5.1 In vitro models
Traditionally, the effect of chemotherapeutic agents is gained through the study of 
standard two dimensional monolayer cultures in vitro. Cells in tissue culture 
incubated with an agent in a well-controlled homogenous environment, however, are 
not adequate to describe damage produced in cells exposed in a solid environment. 
One approach to studying the biology of tumour micro-regions is to culture cancer 
cells in the form of three-dimensional multicell spheroids that simulate 
micrometastases or intervascular micro-regions of larger tumours (Olive et al, 1997). 
This tumour model is intermediate in complexity between standard two-dimensional 
monolayer cultures and tumours in vivo. Spheroids grown from tumour cell lines or 
directly from primary tumour specimens, show growth kinetics similar to tumours in 
vivo. As growth progresses, the number of cells that are proliferating decreases, and 
the proportion of non-proliferating (quiescent) cells increases. When cells become 
deprived of O2 , glucose, and other substrates, and when toxic metabolic waste 
products accumulate, there are steep gradients in these metabolites, and cell death and 
necrosis occurs in the centres of the spheroids. Over small distances of approximately 
10-20 cell diameters (equivalent to the radial distance from small blood vessels in 
tumours) significant differences in cell microenvironment develop. Generally, most of
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the proliferating cells in spheroids are located in the outer 3-5 cell layers. The 
quiescent cells are located more centrally and include a significant proportion of cells 
that are reproductively viable when removed from these environments. These cells 
can be recruited to repopulate the proliferating compartment. Sub-populations of cells 
from the peripheral or central regions of the spheroids can be isolated to study their 
biological properties and response to therapeutic agents. Major differences in 
sensitivity to drugs attributable to effects on accessibility and uptake as well as local 
microenvironments have been demonstrated in tumour cells grown as spheroids 
(Olive et al, 1997).
1.5.2 In vivo models
The National Cancer Institute (NCI) using three mouse tumours, a leukaemia, a 
sarcoma and a carcinoma created the first animal models (Gura, 1997). Agents that 
were effective against the mouse tumours, however, failed when used against 
equivalent human tumours. To overcome this, xenograft models were developed using 
implanted human tumours in Severe Combined Immunodeficiency (SCID) mice. 
Although these indicate the contribution of local microenvironment to chemotherapy 
distribution and response, they do not behave like naturally occurring human tumours. 
Often drugs effective in xenografts are ineffective in humans, whilst effective drugs 
are often missed. The NCI recently tested 12 chemotherapeutic agents currently used 
clinically against 48 human cancer xenografts, 30 of the tumours did not respond 
significantly (ie. > 50% reduction in tumour size) to any of the agents (Gura, 1997).
In order to create better models of cancer development in humans, similar genetic 
alterations (ie. activation of cancer promoting oncogenes or deletion of tumour
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suppressor genes) have been produced in mice, with the intention of producing 
tumours that behave like human tumours. Results to date have been mixed. In humans 
the deletion of the retinoblastoma (RB) tumour suppressor gene produces cancer of 
the retina, and loss of the BRCA1 gene causes human breast and ovarian cancer. 
Similar gene alterations in mice lead to pituitary gland tumours and no tumours 
respectively (Gura, 1997).
The above models usually rely on measuring changes in tumour size and survival 
secondary to chemotherapy. Drug concentration or gene expression is usually 
measured with techniques that have no spatial resolution to analyse the physico­
chemical or physiological barriers that lead to heterogeneous drug delivery and 
cytotoxic effects in solid tumours, or require tumour removal thus missing the 
temporal dynamics. To obtain detailed insight into blood flow and distribution of 
drugs in a tumour, various modified versions of “window” techniques have been 
utilised (Jain, 1996). Tumour cells are implanted in either the ear of a rabbit, or the 
brain or dorsal skin of a rodent and covered with a glass cover slip, the resulting 
tumour grows against the glass and can be observed directly. The use of in vivo 
microscopy has been used to provide information on angiogenesis and blood flow 
(Jain et al, 1998; Leunig et al, 1992), vascular permeability (Yuan et al, 1996) and 
interstitial pH and pC>2 (Helmlinger et al, 1997) continuously and non-invasively.
In situ perfused solid tumour preparations were originally developed in rodents to 
study primarily rodent tumours by Gullino in 1961. Essentially each cancerous mass 
is connected to the circulatory system by a single artery and single vein, providing 
control over physiological, biochemical and pharmacological composition of the
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arterial input and easy access to the venous output. This allows studies of transport 
and metabolism in solid tumours. This model has been adapted to the nude mouse 
allowing perfusion of human tumour xenografts implanted in ovarian fat pads 
(Kristjansen et al, 1994). It has been used to study tumour uptake of anthracyclines 
and subsequent clearance in human colon adenocarcinomas (Heijn et al, 1999), and 
the relationship between tumour physiology and the pharmokinetics of gemcitabine in 
human small cell cancer (Kristjansen et al, 1996).
1.5.3 Mathematical models
Biodistribution studies are expensive and difficult to carry out in humans, but such 
data can be easily obtained in rodents. Mathematical modelling uses physiological 
parameters such as organ volumes, blood flow rates and vascular permeabilities, the 
so-called compartments (organs) are connected anatomically. Such a physiologically 
based pharmokinetic model can be used for scaling up data from mice to humans. 
Baxter et al, devised a model for the biodistribution of mouse anti-bodies against CEA 
(Baxter et al, 1995). The model was found to be useful for optimisation of treatment 
parameters, such as dose and time interval for injections, binding affinities and choice 
of molecular carrier when tested with data obtained in human patients.
1.5.4 Methods to obtain data from human tumours
Drug resistance is considered to be the major obstacle to success in cancer 
chemotherapy, thus considerable effort has been made to identify tumours likely to 
be, or to become, resistant to the chemotherapy protocol of choice (Bellamy, 1992).
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1.5.4.1 In vitro assays
Generally, such ‘chemosensitivity testing’ relies on comparative or quantitative 
estimates of cell growth in tissue culture, in the presence of a range of test 
concentrations of drugs of choice. The practical problems of processing tumour 
biopsies, waiting for assay results and planning therapy based on their results make 
most of these approaches difficult to use (Von Hoff, 1990). In addition, other 
considerations include whether a single biopsy is representative, whether response in 
vitro reflects that in situ and whether ‘averaging’ for the biopsied cell population 
overlooks small but resistant subpopulations.
1.5.4.2 The comet assay (The single-cell gel electrophoresis technique)
Unlike other approaches, the comet assay is single cell based and therefore provides 
information not only on the overall response of the sample (the mean or median 
response), but also on the heterogeneity inherent within each specimen thus indicating 
the presence of unusually resistant subpopulations (Olive et al, 1990; Olive et al, 
1993). Multiple samples can be taken throughout therapy, and as only a few thousand 
cells are required, the assay can be performed with tumour cells obtained from 
procedures as minimally invasive as fine needle aspirate (FNA) biopsies. Olive et al, 
have quantified the hypoxic fraction in human breast cancers receiving radiotherapy 
using FNA biopsies only (Olive et al, 1993). The reduced sample size, however, 
potentially limits its representativeness. As the assay can be modified to detect DNA 
ss breaks, ds breaks and cross-links, it is applicable to a wide variety of chemotherapy 
agents (Fairbaim et al, 1995).
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Hypoxic cells in solid tumours are resistant to killing by ionising radiation and some 
forms of chemotherapy. The use of the comet assay to detect hypoxic cells, is based 
on the fact that ionising radiation produces three times more DNA strand breaks in 
aerobic than hypoxic cells. Although subject to some limitations, intratumour 
oxygenation, modification of hypoxia by various means, and rates of re-oxygenation 
after treatment are important properties of solid tumours that can be addressed in 
specific patient populations using this method (Olive et al, 1993). Studies using the 
comet assay with multicell tumour spheroids and murine tumours, indicate that the 
extent of DNA damage caused by chemotherapeutic agents correlates with eventual 
tumour cell kill (Olive et al, 1996). Furthermore, tumour cells that have lost the ability 
to undergo rapid apoptosis are typically more resistant to killing by ionising radiation 
and other DNA damaging agents. The comet assay is able to detect apoptopic cells 
based on the appearance of the cell following lysis and electrophoresis. Apoptosis 
results in extensive fragmentation of DNA, thus most of the DNA is able to migrate. 
The appearance of apoptopic and necrotic cells are often similar using this method, 
however, titration with a DNA cross-linking agent can provide information on 
fragment size that can be useful in distinguishing between the two.
Up to 90% of solid tumour may be quiescent, and thus are resistant to anti-metabolites 
and mitotic spindle poisons. Measurement of the proportion of non-cycling cells in 
samples from solid tumours is possible by a brief in vitro exposure of tumour cells to 
the topo II inhibitor, etoposide. DNA breaks are produced by etoposide in 
proliferating cells, but not in quiescent cells (Olive and Banath, 1992).
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1.5.5 Ex vivo isolated organ perfusion systems
The isolated perfused rat liver (IPRL) has been used for over 100 years to explore the 
physiology and pathophysiology of the liver (Miller, 1972). Its popularity is due to the 
fact that, in contrast to in vivo models, it allows repeated sampling of the perfusate 
and liver, permits easy exposure of the liver to different concentrations of test 
substances and is amenable to alterations in temperature that would not be tolerated in 
vivo. Furthermore, experiments can be done independent of the influence of other 
organ systems, plasma constituents and neural-hormonal effects. In contrast to the 
other in vitro models, hepatic architecture, cell polarity and bile flow are preserved in 
the IPRL. Normothermic extracorporeal perfusion of porcine livers have recently been 
shown to preserve liver function between 4 to 24 h and can reverse up to 1 h of warm 
ischaemic injury (Schon et al, 1993; St Peter et al, 2002).
Although chemotherapy has not been applied, primary human colorectal carcinomas 
have been perfused ex vivo in order to determine the geometric flow resistance (1-2 
orders of magnitude higher than that observed in normal tissues) and microvascular 
network architecture of human tumours (Less et al, 1997). In addition, isolated 
perfused ex-vivo whole cirrhotic and normal human livers have been used to study 
hepatic micro-circulation and drug elimination (Villeneuve et al, 1990; Villeneuve et 
al, 1996a). More recently MDR1 gene expression in pulmonary sarcoma metastases 
has been examined after acute in situ exposure (via isolated lung perfusion) to 
cytotoxic chemotherapy (Abolhoda et al, 1999).
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Research Aims
To develop an isolated, perfused and oxygenated human liver tumour model to
investigate the short term effects of chemotherapeutic agents used in the treatment of
liver cancer by:
1. Assessing in vitro intrinsic drug resistance in HCC and CRC cell lines using first 
FACScan analysis to determine the expression of MDR related transporter 
proteins and P-gp function when present, second an enzymatic recycling 
procedure to evaluate the contribution of GSH and third the comet assay to 
examine the role of enhanced DNA repair.
2. Establishing an orthotopic model of human liver cancer in nude mice to evaluate 
the topographic distribution of cisplatin DNA-adducts by the comet assay in vivo, 
and correlating this with tumour proliferation, hypoxia, vascularity and P-gp 
expression determined using immunohistochemistry.
3. Creating an intrahepatic xenograft of human CRC in nude rats and developing an 
isolated dual-perfused rat liver model to assess the spatial and temporal pattern of 
drug induced DNA damage using the comet assay.
4. Developing an isolated, perfused and oxygenated human liver tumour model using 
liver specimens obtained from patients undergoing hemihepatectomy for either 
HCC or CRC and studying the spatial and temporal pattern of drug induced DNA 
damage using the comet assay.
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II. MATERIALS AND METHODS
2.1 Introduction
To assess in vitro intrinsic drug resistance in HCC and CRC cell lines, the 
Sulforhodamine B (SRB) assay provided a rapid and sensitive method for measuring 
drug-induced cytotoxicity in attached cell cultures. To examine the contribution of 
MDR related transporter proteins to drug resistance, fluorescence-activated cell 
scanner (FACScan) analysis enabled simultaneous quantitative determination of P-gp, 
MRP1 and LRP protein expression, quantitative assessment of active P-gp drug 
efflux, and the effect of known modulators of P-gp function. The comet assay allowed 
assessment of cytotoxic induced DNA damage on only a few thousand cells, thus it 
could be applied to both in vitro tumour cells, and cells obtained from procedures as 
minimally invasive as fine-needle aspirate (FNA) biopsies in vivo. As the assay could 
be modified to detect DNA single-strand breaks, double-strand breaks and crosslinks, 
it was applicable to a wide variety of chemotherapy agents.
2.2 Reagents and solutions
The details of the reagents and solutions used in the experiments are listed in 
Appendix 2.1. Most of the stock solutions used in this study were prepared according 
to the manufacturers’ instructions, unless otherwise stated. The materials used in each 
experiment, whether cell culture or molecular biology techniques, were carefully 
selected to conform to standard laboratory safety procedures. The processes of 
cleansing or sterilisation either before or after in vitro or in vivo experiments were 
strictly adhered to according to the manufacturers’ instructions and/or the local 
laboratory codes of practice.
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2.3 Drugs
The details of the drugs used in the experiments are listed in Appendix 2.2. All 
aqueous stock solutions were prepared using ddtbO. Multiple aliquots were stored 
between 15-25°C, with the exception of vincristine (stored between 2-8°C) and 
mechlorethamine (nitrogen mustard, [HN2]) (stored at -20°C), to provide uniform 
samples for initial tests as well as retests, if required. Melphalan stock solution was 
prepared from freeze dried powder immediately prior to use due to its instability 
whilst stored. Drug solutions were prepared immediately prior to use by diluting the 
stock solution with serum-free Minimum Essential Medium, MEM (Gibco BRL, Life 
Technology, Paisley) to the required concentrations. Unused solutions and discarded 
supernatants were disposed of into alkali solution to inactivate any residual material.
2.4 Cell lines and cell culture
The human hepatic adenocarcinoma cell lines used were; HepG2, established from a 
15-year-old Caucasian male; C3A, a clonal derivative of HepG2; SKHep-1, derived 
from ascitic fluid in a 52-year-old Caucasian male; Hep3B, derived from an 8-year- 
old Negro male and PLC/PRF/5. The human colonic adenocarcinoma cell lines used 
were; SW620, established from a lymph node of a 51-year-old Caucasian male; HT- 
29, isolated from a primary tumour in a 44-year old Caucasian female; CAC02, 
isolated from a primary tumour in a 72-year-old Caucasian male and WIDR derived 
from a primary rectosigmoid adenocarcinoma of a 78-year-old female. All cell lines 
were purchased from the European Collection of Cell Cultures, Salisbury, Wiltshire, 
UK. The human T-lymphoid multidrug resistant cell line, CEM/VLB100, used as a P- 
gp positive control, was a gift from K.Ganeshaguru, Royal Free Hospital and 
University College School of Medicine, London, UK. Hep-G2, SKHep-1, Hep3B,
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CAC02 and WIDR were cultured in EMEM (EBSS) with 2 mM L-glutamine and 1% 
non-essential amino acids (NEAA), C3A had 1 mM NaP added to the above. 
PLC/PRF/5 and CEM/VLBioo were cultured in Dulbeccos Modified Eagle Medium 
(DMEM) and 2 mM L-glutamine, SW620 in L-15 and 2mM L-glutamine and HT-29 
in McCoy’s 5a with 2 mM L-glutamine. All culture medium was supplemented with 
10% heat-inactivated foetal calf serum (FCS), penicillin and streptomycin. All culture 
medium and reagents were obtained from Gibco-BRL, Life Technologies, UK.
To maintain healthy and contamination-free cultures, all procedures were carried out 
in a Class II laminar flow cabinet and all materials were sterile. Adherent cells were 
grown as monolayers in an atmosphere of 5% CO2 in a 39°C humidified incubator and 
grown to confluence in plastic tissue culture flasks (Falcon, Becton Dickinson). 
Exhausted media, due to cell metabolism and spontaneous degradation of constituents 
needed to be changed periodically to ensure optimum growing conditions. Cells had 
to be subcultured into new flasks when they had either covered the surface available 
for growth or depleted the nutrients in the medium. Prior to subculturing, the medium 
was removed and cells washed once with Ca2+/Mg2+-free phosphate buffered saline 
(PBS). Cells were then detached from culture flasks using trypsin (0.05% w/v)-5 mM 
EDTA (Gibco-BRL, Life Technologies) solution, resuspended in fresh medium 
containing 10% FCS, and spun at 1500 g for 5 min. The supernatant was removed and 
the cells were resuspended in fresh medium. The appropriate volume of cells was 
replated in new tissue culture flasks containing fresh medium. Cell counts were 
performed using an Improved Neubauer haemocytometer and an inverted microscope. 
For storage, cells were trypsinised, pelleted and resuspended at approximately 5 x 106 
cells/ml in FCS containing 10% v/v dimethylsulphoxide (AnalaR, BDH), the presence
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of which prevented the formation of damaging ice crystals. One-millilitre aliquots 
were transferred to 1.5 ml Nunc cryotubes which were then frozen slowly and stored 
immersed in liquid nitrogen (-196°C). Recovery of cells from liquid nitrogen storage 
was performed by rapid thawing in a 37°C water bath. Thawed cells were washed in 
10 ml of medium, harvested by centrifugation and were then transferred to 25 cm2 
flasks containing fresh culture medium.
2.4.1 Indirect Indicator test for Mycoplasma contamination
Cells were regularly screened for Mycoplasma contamination. Briefly, a 9 x 35 mm 
glass coverslip (Chance Propper, Scientific Lab Supplies Ltd) was placed into a 
Leighton tube (a tissue culture test tube with a flat bottom, Nunc). Four ml of 
DMEM/10% FCS was added and inoculated with 2 x 104 NIH 3T3 cells/tube, the cap 
was left loose and placed in a 39°C dry gassing incubator with 10% CO2 . After 24 h 
the tube was inoculated with 0.5 ml of supernatant from the culture to be tested. It was 
ensured the culture medium from the cells to be tested did not contain additives that 
would inhibit 3T3 growth, or antibiotics that might interfere with mycoplasma 
growth. Similarly, the medium was not harvested immediately after subculturing cells, 
or within 7 days of thawing as this potentially reduced mycoplasma load. The tubes 
were then incubated for a further 4 days or until confluent. The medium was then 
aspirated, the tubes washed with PBS and fixed for 5 min with absolute methanol, and 
then washed a further two times with PBS. Five pg/ml of Hoechst 22358 dissolved in 
PBS was added for 10 min, removed, and the tubes washed twice with PBS. The 
coverslip was removed and placed cell surface upwards on a glass microscope slide, a 
drop of PBS added and a further 22 x 50 mm glass coverslip was used to cover the 
original coverslip. The slide was then examined with a fluorescence microscope using
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x 40 objective and UV illumination. Control cells showed intense blue-white staining 
of nuclei only, while cells growing mycoplasma were in addition covered in a fine 
‘lawn’ of speckles. On one occasion three of the cell lines were positive and 
successfully treated with ciprofloxacin (20 pg/ml), Bayer, Germany.
2.5 Sulforhodamine B Assay
The growth characteristics for each cell line, including doubling times, required 
specific inoculation densities and cytotoxicity of chemotherapeutic drugs, were 
determined using the Sulforhodamine B (SRB) assay (Skehan et al, 1990). The SRB 
assay allows quantification of total cellular protein in each well of 96-well plates 
containing cells under investigation. To stain the plates, the supernatant medium was 
first flicked off. The cells were fixed with 100 pi of 30% (w/v) trichloroacetic acid for 
20 min at 4°C, washed five times with tap water, then stained by adding 100 pi of 
0.4% (w/v) SRB in 1% acetic acid and leaving for 20 min at room temperature. The 
plates were then washed five times with 1 % acetic acid to remove any free stain, and 
left to dry. Once dry, protein bound dye was solubilised by adding 100 pi of 10 mM 
Tris buffer (pH 10.5) to each well and placing on a plate agitator for 20 min. 
Absorbance was determined by reading at 540 nm with a Titertek Multiskan 
MCC/340 colorimeter (Labsystems, Finland).
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2.6 Flow cytometry (fluorescence-activated cell scanner [FACScanB analysis
2.6.1 P-gp, MRP and LRP
P-gp, MRP1 and LRP protein expression was measured by labelling freshly 
trypsinised exponentially growing cells with the monoclonal antibodies MRK16 (TCS 
Biologicals Ltd, Botoloph Clay don, Buckingham, UK), MRPm6 and LRP56 (both 
Bradsure Biologicals Ltd, Loughborough, Leicestershire, UK), respectively, and anti­
mouse IgG-FITC (DAKO, Dakopatts, Denmark) second antibody. Briefly, 1 x 106 
cells were used for each antibody, the cells for MRP1 and LRP expression were 
permeabilised with permeabilisation reagents A (fixation medium) and B 
(permeabilisation medium) (An Der Grub, Kaumberg, Austria). Cells were 
resuspended in 0.5 ml 10 % albumin in PBS and incubated at 37°C for 10 min. The 
relevant antibodies were then added to each cell group (MRK16, MRPm6 and LRP56, 
and control mouse antibodies IgG2a, IgG2b and IgGl for the control P-gp, MRP and 
LRP respectively) and incubated at 4°C for P-gp and 0°C for MRP1 and LRP. After 
washing twice with PBS, anti-mouse IgG-FITC was added to each tube and incubated 
for a further 45 min at the above temperatures. Ten thousand events were analysed on 
a FACScan flow cytometer. (Becton Dickson, Oxford, UK), equipped with a 15 mW 
argon laser. Fluorescence emission (488 nm excitation) was collected after passing 
through band pass filters (530 nm for FITC). Analyses were performed using Lysis II 
software (Becton Dickinson, Oxford). Values were expressed as median fluorescence 
index (MFI) relative to control i.e. the ratio of median antibody fluorescence/median 
control antibody fluorescence.
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2.6.2 P-gp function
P-gp function was determined using 3,3’-diethyloxacarbocyanine iodide (DiOC2), a 
fluorescent substrate for P-gp (Leith et al, 1995). Briefly, cells were incubated with 
DiOC2 with and without verapamil (vpm) (10 pM) or PSC833 (1 pM) for 30 min for 
substrate uptake. All tubes were washed with ice cold PBS and duplicate tubes 
incubated for a further 90 min. All tubes were further washed with ice cold PBS and 
10,000 events were analysed on a FACScan flow cytometer. Values were expressed 
as Mean Fluorescence Index (MFI), ie ratio of median fluorescence in the presence of 
modulation to median fluorescence with absence of modulation.
2.7 Western blot analysis
The mouse monoclonal anti-P-gp antibody, C219 (Chemicon International Inc., 
Temecula CA) was used for Western Blot analysis. Cells (3 x 107) were mixed with 
150 pi protein lysis solution (1 ml lysis buffer, 25 pi aprotinin, 1 pi p mercapto- 
ethanol, 30 pi VBF and 1 pi PMSF), incubated for 30 min at 0°C and centrifuged at 
14000 rpm for a further 30 min. Protein concentration in the supernatant was 
measured using a standard absorbance assay (Bio-Rad Laboratories, Hemel 
Hempstead, UK). The supernatant was treated at 100°C for 5 min, and 20 pg of 
protein was electrophoresed on an 8-16% Tris-Glycine Gel in a minigel apparatus 
(Bio-Rad Laboratories, Hemel Hempstead, UK), transferred onto a 0.2 pm 
nitrocellulose membrane, and blocked with 5% nonfat dry milk in TBS at 4°C 
overnight. The monoclonal mouse anti-Pgp antibody, C-219, was hybridised to the 
membrane at 4°C for 1 h and washed x 3 in 1% nonfat dry milk-TBS-0.5% Tween. 
The secondary antibody, a goat antimouse IgG horseradish peroxidase conjugate was 
added at 1:2000 dilution in TBS for 30 min at room temperature, rinsed x 3 in TBS-
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Tween, once with TBS and exposed to a chemiluminescent horseradish peroxidase 
substrate (ECL: Amersham Corp). Autoradiographs were digitally scanned, and the 
densities of specific bands were quantified using IP Lab Gel densitometry software 
(Molecular Dynamics, Amersham Biosciences UK Limited).
2.8 Intracellular glutathione (GSH) determination
All the following reagents were purchased from Sigma-Aldrich, UK and stored at 
4°C: glutathione (reduced form) (GSSG), glutathione reductase (type IV from bakers 
yeast), 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB), DL-buthionine-(S,R)- 
sulfoxamine (BSO), 5-sulfosalicylic acid and 0-NADPH (tetrasodium salt, type I). 
Three working solutions were made up in stock buffer (125 mM Na-phosphate, 6.3 
mM EDTA (pH 7.5)). Reaction mixture I: 0.3 mM NADPH; reaction mixture II: 6.0 
mM DTNB; reaction mixture III: 50 units glutathione reductase/ml. Cell lysis solution 
was made up with 0.6% 5-sulphosalicylic acid in distilled deionised water and 10 mM 
BSO made up in sterile PBS and added to cell culture medium to give a final 
concentration of 50 pM. All solutions were stored at 4°C and not kept for more than 
one week, apart from NADPH which was made up fresh immediately before each 
experiment. Standards were prepared by making up a 1 mM solution of GSSG in 
stock buffer and serially diluting to give a series of samples ranging from 6.25-150 
pM. Two hundred pi aliquots of the solutions were assayed as described below. Cells 
were grown either in normal culture medium, or in medium containing 50 pM BSO 
for 24 h. Cell extracts were prepared by harvesting 1 x 106 cells and washing twice 
with cold PBS, then lysing with 1 ml 0.6% sulfosalicylic acid followed by a 10- 
minute incubation at 4°C. Two hundred pi of the supernatant was obtained for assay 
following centrifugation (270 G for 5-min at 4°C).
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The total glutathione (GSH) content of the standards and the experimental cell lysates 
were determined by an enzymatic assay. Briefly, 700 pi of solution I, 100 pi of 
solution II and 200 pi of the GSH sample or experimental cell lysate were mixed in a 
cuvette (1 cm light path) and equilibrated to 30°C in an oven. Ten pi of solution III 
was added to the warm solution and the absorbance at 412 nm monitored continuously 
on a spectrophotometer until it exceeded 2.0. The DTNB is reduced to a yellow 
chromophore in the presence of GSH (Figure 2.1.A). For samples containing more 
than approximately 0.5 pi GSH, the rate of DTNB reduction was linear throughout. 
For samples containing less, the rate was taken from the linear portion of the data. The 
GSH content of the experimental cell lysates was determined by comparison of the 
rate observed to the standard curve generated with the known amounts of GSH 
(Figure 2.1.B). All experiments were performed in triplicate.
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Figure 2.1.A. Enzymatic reaction in which the rate of reduction of DTNB to a yellow 
chromophore in the presence of GSH is dependent on the concentration of glutathione 
in the original reaction mixture. B. Standard curve derived from measurements of 
colour development following addition of GSH standards.
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2.9 The comet assay
The single cell gel electrophoresis (comet) assay has been used to detect DNA 
damage in individual cells (Ostling and Johanson, 1984), particularly single strand 
breaks. The technique has been successfully applied to detect DNA repair deficiencies 
in human fibroblasts (Alapetite et al, 1996), and recently a modification has been 
described enabling interstrand DNA crosslinks to be measured in individual cells 
(Hartley et al, 1999; Spanswick et al, 1999). Cells are embedded in an agarose film on 
a glass slide, lysed, the DNA denatured and electrophoresed. Intact DNA remains in 
super-coiled bundles, which have virtually no electrophoretic mobility. Damage 
resulting in strand-breaks and fragmentation (such as the cytotoxic agent etoposide) 
allows the DNA to uncoil and stream away from the nucleus when subjected to 
electrophoresis, resulting in a ‘comet’ image as in Figure 2.2.
Unt rea t ed  Cont rol I r radiated Cont rol
% D N A  Tai l
Length
Figure 2.2. Representation of Comet Image.
115
Chapter II: Materials and Methods
Figure 2.3. Samples Comet Assays Images. Samples (a) and (b) are untreated 
controls. Sample (a) is un-irradiated, whereas sample (b) has received 10 Gy in X- 
rays. Samples (c) and (d) are 24 h post cisplatin treatment (100 pM, 1 h). Sample 
(c) is un-irradiated, whereas (d) has received 10 Gy in X-rays.
The head of the comet represents the intact DNA, which has remained static, the tail 
consisting of the loops and small fragments that have migrated during electrophoresis. 
The modification of the assay introduces a standard dose of X-rays prior to 
electrophoresis, which induces a random but constant level of strand breakage, 
resulting in comet formation when electrophoresed. Pre-treament with a crosslinking 
agent causes the DNA fragments to be bound together, reducing their electrophoretic 
mobility and therefore the extent of the comet tail, as demonstrated in Figure 2.3. 
Untreated control cells are shown in (a). In (b) cells have received 10 Gy in X-rays, 
the DNA damage resulting in comet formation. Samples (c) and (d) are both drug
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treated, (c) being un-irradiated, whereas (d) has received 10 Gy. The shorter the comet 
tail in (d) compared to (b) is due to the presence of interstrand crosslinks (ICL). The 
reduction in the extent of the comet tail, as compared to an untreated control, gives a 
measure of the quantity of ICLs present. Following these changes as time after drug 
exposure progresses enables repair of the ICLs to be measured, the comet tail 
increasing as the crosslinks are removed. A detailed description of the assay follows. 
Sufficient slides to perform the assay were prepared by pipetting onto the centre 1 ml 
of molten 1% Type-IA Agarose solution (40°C). A glass coverslip was placed on top, 
and then removed once the agarose had cooled and solidified. The slides were then 
left to dry overnight. The cell line to be investigated was harvested as previously 
described. After centrifugation, the cells were resuspended in MEM supplemented 
with 2 mM glutamine and 0.5% FCS (0.5% FCS MEM) in order to prevent cell 
division during the time course of the assay. After a cell count was performed, 6-well 
plates were seeded with 0.5-1 x 105 cells in 3 ml 0.5% FCS MEM per well, allowing 
sufficient wells for controls and treated samples. The plates were incubated under 
standard conditions over night to allow cell attachment to occur. After incubation, the 
plates were removed and all medium aspirated from the well to be treated. Drug 
solutions were prepared at the required concentrations by diluting the stock solution 
with serum-free MEM. These are added to the wells (recording the dose and time each 
well is exposed), and the plates incubated at 37°C for 1 h. Control wells received 
serum-free MEM alone. After the 1 h treatment, the drug solutions were aspirated and 
3 ml of 0.5% FCS MEM replaced in each well. The plates were returned to incubate 
under standard conditions for the required post-treatment interval. All subsequent 
steps, until electrophoresis had been completed, were performed on ice and with the 
samples protected from light wherever possible, to minimise light-induced DNA
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damage or cellular DNA repair. After the appropriate post-treatment interval, the 
treated cells were harvested as previously described. Alternatively cells obtained by 
fine needle aspiration (FNA) in the in vitro mice and isolated perfused rat and human 
liver experiments were simply defrosted. After centrifugation, the cell pellets were 
resuspended at 2.5 x 104 cells in 1 ml of serum-free MEM, in 1.75 ml Eppendorf™ 
tubes. Samples treated with cross-linking agents, plus one control, were subjected to 
10 Gy X-irradiation. The second control remained un-irradiated. For samples treated 
with agents whose mode of cytotoxicity was the production of single strand breaks, 
irradiation was omitted. A 24-well plate was placed on ice. The 1 ml cell sample was 
placed in a well, to which 2 ml of a molten 1% Type-VII Agarose solution (no 
warmer than 40°C). After mixing, duplicate slides were prepared by pipetting 1 ml 
into the centres of two pre-coated slides. A coverslip was placed on top, and then 
removed once the gel had solidified. The slides were then covered with ice-cold lysis 
buffer [2.5 M NaCl, 100 mM EDTA, 100 mM Tris HC1 (pH 10.5-11.5), 1% TritonX- 
100] for 1 h. After lysis, the slides were washed for 1 h using four changes of distilled 
water. Slides were arranged lengthwise in an electrophoresis tank (Flowgen 
Instruments, Lichfield, Staffs) and submerged in alkali buffer [50 mM NaOH, 1 mM 
EDTA (pH 12-12.5)] for 45 min. Slides were then electrophoresed for 25 min at 18 V 
(0.6 V/cm), 250 mA, then removed and washed with neutralisation buffer [0.5 M Tris 
HC1 (pH 7.5)] for 10 min, followed by a PBS wash for a further 10 min. To stain the 
slides, after leaving to air-dry overnight, they were rehydrated with distilled water for 
30 min, flooded with 2.5 pg/ml propidium iodide for 20-30 min and destained for a 
further 30 min in water. Slides were dried and stored until visualisation. Images were 
visualised using a NIKON inverted microscope DIAPHOT model TMD, with high 
pressure mercury light source and a 580 nm dichromic mirror, 510-560 nm excitation
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filter, and 590 barrier filter at x 20 magnification. Images were captured using an on­
line CCD camera and analysed using Komet assay software (Kinetic Imaging). The 
Komet Assay software captures individual comet images and measures the comet 
intensity, as demonstrated in Figure 2.4. By subtracting background levels from the 
portion of the captured image to be analysed (the ‘cell’), the program determines the 
extent of the comet. The shape of the comets’ head is assumed to be symmetrical, the 
extent of its’ right border being determined by producing a mirror image of the left 
border about the peak value. Once the head is determined, all the residual DNA is 
allocated to the tail. Proportions of DNA in the comet head and tail, and the centres of 
mass of DNA in the head and tail, are then calculated from areas under each 
respective line.
119
Chapter II: Materials and Methods
Analysis | Comet Options | Camera Settings | Calibration | 
Analysis
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Figure 2.4. Screen Shot of Komet Assay software analysing a comet image.
Having determined the centres of mass of the comet head and tail, the distance 
between the centres of mass, ‘(F, is measured (Figure 2.5).
Centre of mass of head DNA
Centre of mass of tail DNA
Figure 2.5. Centres of mass of comet head and tail DNA.
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This enables the tail moment (TM) to be calculated, (which represents the most 
sensitive measure of the extent of the comet tail), by the formula:
Tail Moment (pm) = % DNA in Tail x d.
Calculation of the degree of crosslinking present in a drug-treated sample is 
determined by comparing the TMs with irradiated and un-irradiated untreated controls 
(Hartley et al, 1999). The reduction in the TM that occurs in relation to the TM of the 
irradiated, untreated control is proportional to the level of interstrand crosslinking 
present, and is calculated by the following formula:
% decrease in TM 1 -
r  ~\
TMdi -  TMcu
TMci -  TMcu y
x 100
Where: TMdi = tail moment of drug-treated irradiated sample
TMcu = tail moment of untreated, un-irradiated control 
TMci = tail moment of untreated, irradiated control
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2.10 In vivo animal experiments
The animals used in the in vivo experiments were MFI nude mice, Sprague Dawley 
rats and Rowett nude rats supplied by the CBU unit, Royal Free Hospital (RFH). All 
procedures were carried out according to Home Office regulations and were covered 
by the Home Office Licence No. PPL 70/4517. These procedures were carried out at 
the CBU unit, Royal Free Hospital. Cell suspensions were prepared by trypsinisation 
of adherent cell lines from tissue culture flasks and washing with sterile PBS. Cells 
were counted and resuspended in the appropriate volume of cold-sterile PBS. The full 
details of the in vivo animal protocols are described in Chapters VII and VIII.
2.11 Immunohistochemistrv
To study the effect of hypoxia, cell proliferation, P-gp expression and vascularity on 
the intratumoural topographic distribution of cisplatin-DNA adducts in intrahepatic 
xenografts of mice, immunohistochemistry was performed on parallel sections 
prepared from the same tumour in each relevant experiment. Point counting using two 
independent observers quantitated the staining reactions.
2.11.1 NCL-Ki67-MM1
Cell proliferation was visualised with the monoclonal antibody NCL-Ki67-MM1 
(Novocastra Laboratories Ltd, Newcastle upon Tyne, UK), that recognises the Ki-67 
antigen, which is expressed during Gi phase, increases during the cell cycle and 
declines after mitosis. After the relevant experiment the tumours were rapidly 
removed and snap frozen in liquid nitrogen and stored at -70°C until they were 
sectioned. Frozen sections were cut at 4 pm thickness and stored at -70°C until 
required. All slides were stained in the same batch. Before staining, frozen sections
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were air-dried and fixed with acetone at 4°C for 10 min. Endogenous peroxidase was 
blocked by incubating samples for 15 min at room temperature in PBS containing 
0.03% hydrogen peroxide and sodium azide (15 mmol dm'3). Non-specific staining 
was blocked by pre-incubating sections with PBS (0.5% Tween 20, 0.1% normal 
horse serum) for 1 h. Following this the fluid was drained off and a 0.1% monoclonal 
mouse anti-serum against the Ki-67 antigen (Novocastra Laboratories Ltd, Newcastle 
upon Tyne, UK) was applied and the sections incubated overnight. The fluid was then 
drained off and sections washed twice with PBS (0.5% Tween 20, 0.1% normal horse 
serum). Immunoperoxidase detection was achieved by using a standard Vector ABC 
kit with a peroxidase-conjugated second antibody to mouse IgG and a Vector DAB 
substrate kit (Vector Laboritories, California, USA) with Harris’s haematoxylin 
counterstain (Raymond A Lamb Ltd, Eastbourne, UK).
2.11.2 7-(4’-(2-nitroimidazol-l-yl)-theophylline (NITP)
Tumour hypoxia has been shown to influence the efficacy of many chemotherapeutic 
agents. Numerous methods have been proposed for measuring tumour hypoxia in the 
hope that this would allow treatment to be optimised for individual patients on the 
basis of the oxygen status of their tumours. Hypoxia can be measured using 
bioreductive binding of the novel compound NITP, which consists of a 2- 
nitroimidazole with an immunologically recognisable theophylline sidechain. The 2- 
nitroimidazole component binds to cellular macromolecules under low-oxygen 
conditions, and the bound adducts of the probe, in hypoxic cells, can then be 
identified and quantified by antibodies raised against theophylline (Hodgkiss et al, 
1991). NITP (0.5 pMg'1) was administered by intra-peritoneal injection in peanut oil 
containing 10% DMSO to mice or added to perfusate during rat liver perfusion. After
123
Chapter II: Materials and Methods
the relevant experiment the tumours were rapidly removed and snap frozen in liquid 
nitrogen and stored at -70°C until they were sectioned. Frozen sections were cut at 4 
pm thickness and stored at -70°C until required. All slides in each experiment were 
stained in the same batch, to avoid the methodologic error due to inter batch variation. 
Before staining, frozen sections were air-dried and fixed with acetone at 4°C for 10 
min. Endogenous peroxidase was blocked by incubating samples for 15 min at room 
temperature in PBS containing 0.03% hydrogen peroxide and sodium azide (15 mmol 
dm'3). Non-specific staining was blocked by pre-incubating sections with PBS (0.5% 
Tween 20, 0.1% normal goat serum) for 1 h. Following this the fluid was drained off 
and a 0.1% polyclonal rabbit anti-serum against theophylline (Biogenesis Ltd, Poole, 
UK) was applied and the sections incubated overnight. The fluid was then drained off 
and sections washed twice with PBS (0.5% Tween 20, 0.1% normal goat serum). 
Immunoperoxidase detection was achieved by using a standard Vector ABC kit with a 
peroxidase-conjugated second antibody to rabbit IgG and a Vector DAB substrate kit 
(Vector Laboritories, California, USA) with Harris’s haematoxylin counterstain 
(Raymond A Lamb Ltd, Eastbourne, UK).
2.11.3 von Willebrand factor (factor VIII)
Blood vessels were identified by an immunohistochemical staining against the von 
Willebrand factor (factor VIII), which recognises endothelial cells. Before staining, 
The 4 pm frozen sections were air-dried and fixed with acetone at 4°C for 10 min. 
Endogenous peroxidase was blocked by incubating samples for 15 min at room 
temperature in PBS containing 0.03% hydrogen peroxide and sodium azide (15 mmol 
dm '). Non-specific staining was blocked by pre-incubating sections with PBS (0.5% 
Tween 20, 0.1% normal horse serum) for 1 h. Following this the fluid was drained off
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and the slides were treated with MCA 127 (mouse monoclonal anti-human von 
Willebrand factor) (Serotec Ltd, Oxford, UK) diluted 1:100 in PBS at 4°C overnight. 
The fluid was then drained off and sections washed twice with PBS (0.5% Tween 20, 
0.1% normal horse serum) followed by treatment using a standard Vector ABC kit 
with a peroxidase-conjugated second antibody to mouse IgG and a Vector DAB 
substrate kit (Vector Laboritories, California, USA) with Harris’s haematoxylin 
counterstain (Raymond A Lamb Ltd, Eastbourne, UK).
2.11.4 P-gp expression on tumour tissue sections
Frozen sections were cut using the same tumours used for NITP and NCL-Ki67-MM1 
at 4 jam thickness and stored at -70°C until required. Before staining, frozen sections 
were air-dried and fixed with acetone at 4°C for 10 min. Endogenous peroxidase was 
blocked by incubating samples for 15 min at room temperature in PBS containing 
0.03% hydrogen peroxide and sodium azide (15 mmol dm'3). Non-specific staining 
was blocked by pre-incubating sections with PBS (0.5% Tween 20, 0.1% normal 
horse serum) for 1 h. Following this the fluid was drained off and treated with JSB-1 
(mouse monoclonal anti-human P-gp antibody) (Chemicon International Inc., 
Temecula CA) diluted 1:20 overnight. The fluid was then drained off and sections 
washed twice with PBS (0.5% Tween 20, 0.1% normal horse serum). 
Immunoperoxidase detection was achieved by using a standard Vector ABC kit with a 
peroxidase-conjugated second antibody to mouse IgG and a Vector DAB substrate kit 
(Vector Laboritories, California, USA) with Harris’s haematoxylin counterstain 
(Raymond A Lamb Ltd, Eastbourne, UK).
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2.12 Ex vivo perfused human liver
Patients undergoing hepatic resection for either primary hepatocellular carcinoma or 
secondary colorectal metastases were selected. The Royal Free Hospital ethics 
committee approved the study and patients were consented for the use of resected 
specimens in research. The details of the ex vivo perfused human liver protocol are 
described in Chapter IX.
2.12.1 Laser Doppler Flowmetry
The hepatic microcirculation (HM) was assessed using a commercially available laser 
doppler flowmeter (LDF, DRT4, Moor Instruments Limited, Axminster, UK). It gives 
a continuous measure of red cell motion in the outermost layer of the tissue under 
study.
Principle
Laser Doppler is based on the principle of recording Doppler shifts in backscattered 
light caused by movements of red blood cells in the incident path of the 
monochromatic light of a laser beam. The device consists of a helium-neon laser and 
an optic fibre which transmits this light to the surface of the tissue to be studied. Light 
that is scattered by red blood cells undergoes a frequency shift and a portion of this 
spectrally broadened light is transmitted back by a fibre light-guide to two 
photodetectors. This signal is analyzed and the relative portion of light which has 
undergone a Doppler shift is proportional to the velocity of the blood flow. The 
micro vascular bed consists of an intricate network of small blood vessels and hence 
the angle between the red cell velocity vectors and beam propagation vectors of the 
scattered light can be regarded as random.
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Instrument
The operating principle of this instrument is a light guide which transmits a low- 
energy laser beam (2 mW He-Ne laser of 780 nm wavelength) to the tissue surface 
under examination via 8 emitting fibres and 8 collecting fibres. The bundle of 
collecting fibres returns light to the photodetectors where it is converted into an 
electrical signal. Further processing of this signal finally produces the actual Doppler 
signal that varies linearly with the product of the total number of moving red blood 
cells in the measured volume of few mm multiplied by the mean velocity of these red 
blood cells (Seifalian et al, 1997). The numerical product is termed a perfusion unit or 
blood cell flux unit. The optical fibre probe was applied to the experimental tumour/s 
in the perfused hemiliver. HM expressed in units of flux was averaged over a period 
of 2 min. The light enters the tissue where it is repeatedly reflected, refracted, and 
absorbed increasingly. This produces a region of virtually isotropic illumination. All 
red blood cells passing through this region reflect some of the light and produce a 
shift in wavelength. Laser Doppler flowmetry (LDF) is a non-invasive technique that 
allows for continuous evaluation of microvascular perfusion (Seifalian et al, 1991). Its 
use for measurement of the hepatic microcirculation has been validated in animal 
models (Seifalian et al, 1991; Wheatley et al, 1993). Parenchymal perfusion measured 
by LDF correlates well with total liver blood flow and surface LDF measurements are 
representative of deep parenchymal perfusion (Kotzampassi et al, 1992). In human 
liver transplantation a significant correlation between the microcirculation of the liver 
graft at the time of transplantation using surface LDF and total liver blood flow 
measured by electromagnetic flowmeter (EMF) has been demonstrated. The perfusion 
measurements were reproducible with a coefficient of variation of 4% (Seifalian et al, 
1997).
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2.12.2 Transonic Flowmetry
The flow rate was measured with a dual Transonic Medical Flowmeter system 
(HT207, Transonic Medical System Inc, Ithaca NY, USA).
Principle
Transonic flowmetry uses an ultrasonic transit-time principle to sense liquid volume 
flow in vessels or tubing largely independent of flow velocity profile, turbulence and 
haematocrit. One ray of the ultrasonic beam undergoes a phase shift in transit time 
proportional to the average velocity of the liquid times the path length over which this 
velocity is encountered. With wide-beam ultrasonic illumination, the receiving 
transducer sums these velocities: averages the velocity times and the vessels cross 
sectional area. Since the transit time is sampled at all points across the vessel 
diameter, volume flow measurement is independent of the flow velocity profile. 
Ultrasonic beam rays which cross the acoustic window without intersecting the vessel 
do not contribute to the volume flow integral.
A Transonic flowprobe consists of a probe body which houses low ultrasonic 
transducers and a fixed acoustic reflector. The transducers are positioned on one side 
of the vessel and the reflector is positioned midway between the two transducers on 
the opposite site of the vessel. The flowmeter’s electronic ultrasonic circuitry directs a 
flowprobe through the following cycles: an electrical excitation causes the 
downstream transducer to emit a plane wave of ultrasound. This ultrasonic wave 
intersects the vessel in the upstream direction, then bounces off the "acoustic 
reflector", again intersects the vessel and is received by the upstream transducer 
where it is converted into electrical signals. From these signals, the flowmeter then
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derives an accurate measure of the "transit time" it took for the wave of ultrasound to 
travel from one transducer to the other. The same transit-receive sequence of the 
upstream cycle is repeated, but with the transmitting and receiving functions of the 
transducers reversed so that the liquid flow under study is bisected by an ultrasonic 
wave in the downstream direction.
The transit-time of ultrasound passing through a vessel is affected by the motion of 
liquid flowing through that vessel. During the upstream cycle, the sound wave travels 
against flow and total transit time is increased by a flow dependent amount. During 
the downstream cycle, the sound wave travels with flow and total transit time is 
decreased by a flow dependent amount. During the downstream cycle, the sound wave 
travels with flow and total transit time is decreased by the same flow-dependent 
amount. The Transonic flowmeter subtracts the downstream transit time from the 
upstream transit time utilizing wide-beam ultrasonic illumination.
Instrument
A dual Transonic Medical Flowmeter system (HT207, Transonic Medical System Inc, 
Ithaca NY, USA) consists of a bench-top electronic flow detection unit and volume 
flowsensing probes ranging from 1 to 8 mm in diameter.
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III. GROWTH CHARACTERISTICS AND CYTOTOXICITY 
DETERMINATION OF HCC AND CRC CELL LINES
3.1 Introduction
In vitro (cell culture) studies have been considered a valuable tool for assessing the 
toxicity of cytotoxic agents for decades, and have been useful in determining their in 
vivo application (Eagle and Foley, 1956). Although they fail to take into account the 
microenvironment of malignant cells, as they cannot mimic the complexities of drug 
delivery, metabolism and excretion found clinically, cell culture studies are 
straightforward to perform, inexpensive, use small amounts of reagents and can be 
performed relatively quickly. Prior to investigating the various mechanisms involved 
in drug resistance of the chosen panel of cell lines, their growth characteristics and 
relative drug sensitivities were determined.
3.2 Materials and Methods
3.2.1 Growth characteristics
The doubling time of each cell line was determined to act as an aid in cytotoxicity 
experiments, the SRB assay ideally requires 2-3 doubling times, and to examine the 
potential role of growth rate in drug resistance in subsequent selected sub-lines. A 
single experiment was performed utilising 4 replicates of each cell line. Cell growth 
was followed over 5 days by staining 24-well plates seeded with equal numbers of 
cells on successive days with SRB, allowing quantification of total cellular protein in 
each well. Plotting the increase in cell protein against time allowed growth of each 
cell line to be determined over the 5-day period. Briefly, a fixed number of cells of 
each cell line (5 x 104 in 2 ml of the appropriate culture medium) were plated into
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four \yells of 24-well plates. Each plate was incubated under standard conditions for a 
period of 1, 2, 3, 4 and 5 days. On each of these days a single plate was assayed by 
staining with SRB (1 ml rather than 100 pi used in 96-well plates, of 30% (w/v) 
trichloroacetic acid and 0.4% (w/v) SRB in 1% acetic acid ). Once dry, the stained 
monolayer was re-suspended by adding 150 pi 10 mM Tris base and placing on a 
plate agitator for 20 min. Absorbance was determined by transferring 125 pi of each 
well’s contents into the well of a 96-well plate and reading at 540 nm with a Titertek 
Multiskan MCC/340 colorimeter (Labsystems, Finland). The doubling times for each 
cell line were then calculated from the exponential portion of each line using 
GraphPad Prism 3 Software (GraphPad Software, San Diego, California, USA).
Before cytotoxicity determination of the cell lines, cell growth in the 96-well 
microculture plates was characterised at a variety of cell densities (5000, 10,000, 
20,000, 40,000 and 50,000 cells per well) over a 5-day period of growth in order to 
select a suitable inoculation density. From these data, the specific inoculation density 
selected for each cell line was that which produced an optical density signal above the 
noise level of the assay and within the linear range of the SRB signal (ie, within the 
range of 0.2 - 2.0 OD units), for both the To and control optical density measurements. 
The T0 and control optical densities generated from SRB-stained cells are a function 
of cell mass and growth rate. Thus, cells with a small mass are inoculated at relatively 
high densities of 30 - 40,000 cells per well. Furthermore, cells that divide relatively 
slowly are inoculated at 20,000 per well, while more rapidly dividing cells are 
inoculated at 5000 per well.
132
Chapter III: Growth characteristics and cytotoxicity determination o f  HCC & CRC cell lines
3.2.2 Cytotoxicity determination
The cytotoxic agents cisplatin, etoposide, melphalan and 5FU were used in the initial 
screening of the cell lines, these were chosen for their different mechanisms of action 
(see Introduction). The cytotoxicity of drugs was assessed by the SRB colorimetric 
assay. The SRB assay measures the degree of growth inhibition of an established cell 
culture after drug treatment, by allowing quantification of total cellular protein. This 
assay measures cytotoxicity taking into account the negative metabolic effects and 
rate of cell death after drug exposure, in addition to impaired reproductive function of 
the cell. Exponentially growing cells were harvested as already described, inoculated 
into 96-well tissue culture plates in a volume of 100 pi at densities between 5000 and 
20,000 cells per well and allowed to attach for 24 h at 37°C, 5% CO2, in a humidified 
atmosphere. After overnight incubation, the plates were removed and all medium 
aspirated from the wells. For initial screening of drugs, each agent was routinely 
tested at five 10-fold dilutions, starting from a maximum concentration of 1 x 10'4 M 
(data not shown). The active concentration range for each drug on each cell line was 
thus determined and alternative concentrations chosen for re-testing. Drug solutions 
were prepared at the required concentrations (0.01-1000 pM) by diluting the stock 
solution with serum-free MEM, 100 pi was added to each well followed by a further 
100 pi of the appropriate medium containing 10% FCS. Control wells received drug 
free medium alone. All wells were then cultured for a further 4-5 days, until the 
control wells were seen to have grown to an almost confluent state when examined by 
microscopy. At this stage the plates were stained and analysed. The cells were fixed, 
stained with SRB and read in a colorimeter. Full details of the protocol are given in 
Chapter II, Section 2.5. Mean absorbance values for control and drug treated wells
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were determined, and values as a proportion of control calculated for each drug 
concentration using the following equation:
Cell survival (%) = OD (treated cells) x 100
OD (control cells)
A survival curve was subsequently constructed for each cell line. The IC50 value 
(concentration of drug required to inhibit growth by 50%) was determined from the 
survival curve, which is a measure of cytotoxicity of the drug in that cell line. All 
experiments were performed in triplicate.
3.3 Results
3.3.1 Growth characteristics
The means of the absorbance values obtained for each cell line over a 5 day period of 
growth are plotted in Figures 3.1 A and B (Appendix 3.1). The doubling times for 
each cell line, calculated from the exponential portion of each line are shown in 
Tables 3.1 A and B. The majority of the cell lines studied shared similar growth 
characteristics, each having doubling times within the range 47-58 hours. Three of 
the cell lines, HepG2, SW620 and CAC02, however, had substantially shorter 
doubling times (27, 33 and 39 h respectively), whilst PLC/PRF/5 had a much longer 
doubling time at 81 h.
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Growth characteristics CRC cell 
Growth characteristics HCC cell ljnes /2 x-jq4)
lines (2x104)
HepG2
SkHep-1
C3A
PLC/PRF/5
Hep3B
Time (h)
Figure 3.1. Growth characteristics of the HCC A. and CRC B. cell line panels.
Cell Line Doubling Time/h r2
HepG2 27 0.99
SkHep-1 58 0.924
C3A 49 0.986
PLC/PRF/5 81 0.976
Hep3B 57 0.997
A
Cell Line Doubling Time/h r2
WIDR 47 0.99
CAC02 39 0.993
HT29 49 0.953
SW620 33 0.995
B
Table 3.1. Doubling times for each HCC A. and CRC B. cell line.
WIDR
CAC02
HT29
SW 620
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The means of the absorbance values obtained for each cell line at different inoculation 
densities with time are plotted in Figures 3.2 and 3.3 (Appendix 3.2), whilst the 
chosen optimal inoculation densities are shown in Tables 3.2 and 3.3. Most of the cell 
lines were thus inoculated at 1 x 104. Although they had low growth rates, SkHep-1 
and PLC/PRF/5 had a large cell mass requiring the lower inoculation density of 5 x 
103. HepG2 and SW620 had a small cell mass so needed the higher inoculation 
density of 2 x 104.
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Figure 3.2. Bar graphs demonstrating HCC cell line growth in 96-well plates at 
different inoculation densities.
Cell Line Inoculation Density
HepG2 2 x 104
SKHep-1 5x 103
C3A 1 x 104
PLC/PRF/5 5 x 103
Hep3B 1 x I04
Table 3.2. Inoculation densities used in HCC cell lines.
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Figure 3.3. Bar graphs demonstrating CRC cell line growth in 96-well plates at 
different inoculation densities.
Cell Line Inoculation Density
WIDR 1 x 104
CAC02 1 x 10“
HT29 1 x 104
SW620 2 x 104
Table 3.3. Inoculation densities used in CRC cell lines.
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3.3.2 Cytotoxicity determination
The dose response curves of both the HCC and CRC cell lines to the selected 
cytotoxic drugs are shown in Figures 3.4 and 3.5, whilst their IC50S are shown in 
Tables 3.4 and 3.5 (Appendices 3.3 & 3.4).
C isplatin E to p o sid e
SKHep-1
SKHep-1
PLC/PRF/5
PLC/PRF/5
[Cisplatin]/pM
i.oxio-® 0.1 1 10 100
[E toposide]/p  M
5FU M elphalan
HepG2 
- SKHep-1
C3A 
-  PLC/PRF/5 
Hep3B
O  50- 
S? 40-
0.01 0.1 1 10 100 1000
• SKHep-1
PLC/PRF/5
Urn. IF
[5FU]/pM
10 100
[M elphalan]/p M
Figure 3.4. Dose response curves for HCC cell lines incubated with cisplatin, 
etoposide, 5-FU and melphalan for 120 h continuous exposure. Values represent 
the mean ± SEM of four independent experiments.
Drug Cell Line
HepG2 SkHep-1 C3A PLC/PRF/5 Hep3B
Cisplatin 25 20 2.5 34.3 9
Etoposide 45 9 18 100 10
5-FU >1000 100 8 150 60
Melphalan 40 35 30 150 55
Table 3.4. Drug cross-resistance of HCC cell lines to multidrug resistant phenotype 
(MDR) and non-MDR drugs. Values given as IC50 (pM). The IC50 value was 
determined as the concentration of drug inhibiting cell growth to 50% of that in drug- 
free control.
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Figure 3.5. Dose response curves for CRC cell lines incubated with cisplatin, 
etoposide, 5-FU and melphalan for 120 h continuous exposure. Values represent the 
mean ± SEM of four independent experiments.
Drug Cell Line
WIDR CAC02 HT-29 SW620
Cisplatin 15 15 7 50
Etoposide 7 24 4.6 35
5-FU 159 650 65 240
Melphalan 87 90 44 122
Table 3.5. Drug cross-resistance of CRC cell lines to multidrug resistant phenotype 
(MDR) and non-MDR drugs. Values given as IC 50 (pM). The IC 50 value was 
determined as the concentration of drug inhibiting cell growth to 50% of that in 
drug-free control.
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3.4 Discussion
The range of IC50 values observed in the panel of HCC and CRC cell lines appears 
quite broad. Of the HCC cell lines, C3A is extremely sensitive to all drugs except 
etoposide, whereas PLC/PRF/5 is strongly cross-resistant. Similarly, of the CRC cell 
lines, HT-29 is consistently sensitive to all drugs whilst SW620 is cross-resistant. Of 
note is PLC/PRF/5 s prolonged doubling time, this cell cycle prolongation could 
theoretically allow increased time for repair of adduct-induced DNA damage, a theme 
which will be explored in Chapter VI. The range of relative resistance for the selected 
multidrug resistant phenotype (MDR) and non-MDR drugs is shown in Tables 3.6 and 
3.7. For the HCC cell lines, the range of relative resistance varies for each drug with a 
> 125 and 13-fold difference in relative resistance levels observed for 5-FU and 
cisplatin, respectively, whereas both melphalan and etoposide exhibit a 5-fold 
difference in relative resistance levels. The range of relative resistance in the CRC 
cell lines, however, is less varied with a 7-fold difference for both cisplatin and 
etoposide, and 10- and 3-fold difference for 5-FU and melphalan respectively.
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Cell Line1
Relative Resistance2
MDR Non-MDR
Etoposide Cisplatin 5-FU Melphalan
SkHep-1 0.5 8 12.5 1.16
Hep3B 0.55 3.6 7.5 1.8
C3A 1 1 1 1
HepG2 2.5 10 >125 1.33
PLC/PRF/5 5.55 13.72 18.75 5
Table 3.6. Relative resistance of HCC cell lines to selected cytotoxic drugs, 'Cell 
lines are listed in increasing rank order of resistance to etoposide (MDR associated 
drug). 2Relative resistance (mean IC50 cell line/mean IC 50 C3A).
MDR = multidrug resistant phenotype.
Cell Line1
Relative Resistance2
MDR Non-MDR
Etoposide Cisplatin 5-FU Melphalan
HT-29 1 1 1 1
WIDR 1.52 2.14 2.44 1.97
CAC02 5.21 2.14 10 2.045
SW620 7.6 7.14 3.69 2.7
Table 3.7. Relative resistance of CRC cell lines to selected cytotoxic drugs. 'Cell 
lines are listed in increasing rank order of resistance to etoposide (MDR associated 
drug). 2Relative resistance (mean IC 50 cell line/mean IC 50 HT-29).
MDR = multidrug resistant phenotype.
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IV. MULTIDRUG RESISTANCE TRANSPORT PROTEIN ANALYSIS IN 
HCC AND CRC CELL LINES
4.1 Introduction
HCC and CRC are often regarded as intrinsically resistant to multiple 
chemotherapeutic agents(Lai et al, 1991; Mathurin et al, 1998; Simonetti et al, 1997). 
Although unresectable CRC liver metastases can be downstaged to resectable lesions 
(Bismuth et al, 1996; Giacchetti et al, 1999), frequently, when response to 
chemotherapy does occur, it is followed by acquired drug resistance and clinical 
relapse (Nerenstone et al, 1988). Tumour cells often show broad cross-resistance 
between unrelated classes of cytotoxic drugs, a phenomenon known as multidrug 
resistance (MDR). To date, at least two multidrug resistance mechanisms have been 
described, involving members of the ATP binding cassette transporter superfamily, 
namely P-gp and MRP1. P-gp and MRP1 function as transmembrane drug efflux 
pumps, decreasing intracellular accumulation, thereby confering resistance to various 
natural product drugs. LRP is another multidrug resistance related protein identified 
as the major vault protein (Scheffer et al, 1995). Although different from ATP binding 
cassette molecules, vaults have been implicated in transport of various substrates, 
including cytotoxic drugs (Chugani et al, 1993; Kickhoefer et al, 1998).
These MDR related proteins are broadly distributed in normal cells. P-gp is expressed 
on the bile canalicular surface of hepatocytes and the luminal surface of epithelial 
cells of biliary ductules in normal liver (Itsubo and Toda, 1996), and high levels of P- 
gp have also been localised to the apical surfaces of colonic epithelium (Meijer et al, 
1999). MRP1 and LRP expression has also been found in normal liver and colon. An
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increase in the expression of P-gp, MRP-1 and LRP has been observed in numerous 
clinical cancer specimens as well as cancer cell lines displaying the MDR phenotype 
in vitro (Izquierdo et al, 1996). Several reports suggest these MDR related proteins are 
clinically relevant in haematological malignancies (Guerci et al, 1995; Samdani et al, 
1996; Senent et al, 1998; Wood et al, 1994), in particular elevated levels of LRP have 
been shown to be a strong and independent predictor of unfavourable outcome (Hart 
et al, 1997). Their contribution to clinical drug resistance in solid tumours, however, 
is less clear.
Expression of P-gp has previously been investigated in HCC, where levels in human 
HCC tissue has been shown to be inversely correlated with chemotherapeutic 
response (Chou et al, 1997; Ng et al, 2000), and in CRC where it has been linked to 
increased metastatic potential (Weinstein et al, 1991). Few studies, however, have 
assessed the expression of MRP 1 and LRP in HCC and CRC. The MRP1 protein has 
been found to be highly expressed in HepG2 hepatoma cells (Roelofsen et al, 1997). 
Its gene expression was decreased by combined treatment with IFNa and cisplatin 
whilst the hepatoma cell lines HuH7 and SK-Hep-1 were not affected (Takeuchi et al, 
1999). MRP I gene expression in ten childhood hepatoblastomas was higher than that 
observed in normal liver and nine HCCs from adult patients (Matsunaga et al, 1998). 
MRP1 has been found to be expressed in HT-29 colon adenocarcinoma cells, where 
the cytotoxic effect of camtothecin was increased by the specific modulators 
probenecid and MK571 (Chauvier et al, 2002). The expression of the LRP gene was 
not altered in three childhood hepatoblastoma xenografts incorporated into mice 
following treatment with adriamycin or cisplatin, indicating it is not involved in
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resistance to these cytotoxic agents (Bader et al, 1998). LRP protein expression has 
not previously been investigated in CRC.
The aim of this section of the study was to analyse the expression of P-gp, MRP1 and 
LRP in the chosen panel of HCC and CRC cell lines, and to establish whether P-gp 
was functioning when present. The expression of MDR transport proteins was then 
related to the chemosensitivity of the cell lines. Correlations between MDR protein 
expression and the IC50 values of the HCC cells were determined by Spearman’s rank 
correlation test, the correlation coefficients (r-values) and the P-values (two sided) 
were calculated. Only correlations with P-values of 0.05 or below were considered to 
be significant. The potentiating effect of inhibition of P-gp with vpm and PSC833 on 
chemosensitivity was also analysed to confirm the results of P-gp function on flow 
cytometry.
4.2 Materials and methods
4.2.1 Expression of MDR-related proteins
P-gp, MRP1 and LRP protein expression was determined by FACScan analysis using 
the monoclonal antibodies MRK16 MRPm6 and LRP56. Full details of the protocol 
are given in Chapter II, Section 2.6.1. Expression of P-gp was confirmed by Western 
blot analysis using the monoclonal antibody C219. Full details of the protocol are 
given in Chapter II, Section 2.7.
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4.2.2 P-gp function
P-gp function w as determ ined by FA CScan analysis using  D iO C 2 , a fluorescent 
substrate for P-gp. Full details o f  the protocol are given in C hap ter II, Section 2.6.2.
4.2.3 Expression of transport proteins related to cytotoxicity
To test the findings o f  the P-gp flow  cytom etry functional assay, and to determ ine 
w hether P-gp contributed to resistance to etoposide and a further cytotoxic P-gp 
substrate v incristine, cytotoxic assays w ere carried  out in the p resence o f  PSC 833 and 
vpm , both know n m odifiers o f  P-gp m ediated  M D R  (B oesch  et al, 1991). 
Exponentially  grow ing cells w ere harvested  as already described, inoculated  into 96- 
well tissue culture p lates in a volum e o f  100 p i at densities betw een 5000 and 20,000 
cells per w ell and allow ed to attach for 24 h at 37°C, 5%  C O 2 , in a hum idified 
atm osphere. A fter overnight incubation, the p lates w ere rem oved and all m edium  
aspirated from  the w ells. The P-gp inhibitors w ere p repared  at the required 
concentrations (1 or 6 pM ) by  dilu ting the stock solution w ith  serum -free M EM , 50 pi 
was added to each w ell 30 m in p rio r to each test drug. D rug solutions w ere then 
prepared at the required  concentrations (0.01-500 pM ) by dilu ting  the stock solution 
w ith serum -free M EM , 50 p i w as added to each w ell fo llow ed by  a further 100 p i o f  
the appropriate m edium  containing 10% FCS. C ontrol w ells received  drug free 
m edium  alone. All w ells w ere then cultured for a further 4-5 days, until the control 
wells w ere seen to have grow n to an alm ost confluent state w hen exam ined by 
m icroscopy. A t this stage the p lates w ere stained and analysed  using  the SRB assay. 
Full details o f  the protocol are given in C hapter II, Section 2.5.
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4.3 Results
4.3.1 Expression of MDR-related proteins
P-gp expression, determined by FACScan analysis using the anti-P-gp monoclonal 
antibody, MRK16, was demonstrated in 2 of the 5 HCC cell lines (HepG2 and C3A), 
with ratios of 4.07 and 3.92 respectively, relative to the control mouse antibody IgG2a 
(Figure 4.1 A, Table 4.1 A). Two of the 4 CRC cell lines (SW620 and CAC02) 
expressed P-gp with ratios of 4.88 and 1.55 respectively (Figure 4.IB, Table 4.IB). 
The P-gp positive control, CEM/VLBioo, was strongly positive with a ratio of 19.12 (a 
ratio of > 1.5 was considered a positive result) (Figure 4.2, Tables 4.1 A & B). MRP1, 
measured with MRPm6, was expressed in all HCC cell lines with ratios ranging from 
1.9 (SKHep-1) to 7.5 (Hep3B) and two CRC cell lines (SW620 and WIDR) with 
ratios of 4.07 and 2.29 respectively (Figures 4.1 A & B, Tables 4.1 A & B). The 
immunofluorescence detection of LRP-56, a measure of the presence of LRP, was 
detected in all HCC cell lines except Hep3B cells, with ratios ranging from 2.64 
(C3A) to 12.4 (SKHep-1), and all CRC cell lines except CAC02, with ratios ranging 
from 2.6 (SW620) to 11.13 (HT-29) (Figures 4.1A & B, Tables 4.1A & B).
The immunoblot data on P-gp expression were in agreement with FACScan analysis. 
HepG2, C3A, SW620 and CAC02 cell line protein lysates produced weak bands at 
molecular weight 170 KDa. Similar band signals were not visible with SK-Hep-1, 
PLC/PRF/5, Hep3B, WIDR and HT-29 cell lines (Figure 4.3).
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Cell Line HepG2 SKHep-1 C3A PLC/PRF/5 Hep3B CEM/VLBioo
I’-gP 4.07 1.07 3.92 1.0 1.0 19.12
MRP1 2.37 1.9 2.13 3.16 7.5 3.4
LRP 2.74 12.4 2.64 6.98 1.0 1.98
Cell line W IDR CAC02 HT-29 SW620 CEM/VLBioo
p-gP 0.94 1.55 1.03 4.88 19.12
MRP1 2.29 0.93 1.04 4.07 3.4
LRP 10.01 1.38 11.13 2.64 1.98
B
Figure 4.1 & Table 4.1. Immunocytochemical MDR phenotype in A. human HCC 
and B. human CRC cell lines. P-gp, MRP and LRP expression was measured by 
FACScan, using the monoclonal antibodies MRK-16, MRPm6 and LRP56 
respectively. Values were expressed as median fluorescence index (MFI).
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Figure 4.2. Immunocytochemical MDR phenotype of CEM/VLBioo demonstrating 
strongly positive P-gp ratio of 19.12, and SKHep-1 which failed to demonstrate P-gp. 
P-gp, MRP1 and LRP expression was measured by FACScan analysis using 
monoclonal antibodies MRK16, MRPm6 and LRP56 and compared with control 
mouse antibodies IgG2a, IgG2b and IgG 1 respectively.
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A
p200
pl70
MM SKHep-1 HepG2 C3A PLC/PRF5 Hep3B
B
p200
pl70
MM WIDR SW620 CAC02 HT-29
Figure 4.3. Western Blot analysis of A. human HCC cell lines and B. human CRC 
cell lines using the P-gp specific antibody C-219 confirming immunocytochemical 
results.
MM = Molecular Marker (MW 200 kDa)
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4.3.2 P-gp function
The fluorescent dye DiOC2 is a specific substrate for P-gp and provides a sensitive 
functional assay in addition to immunostaining approaches for the detection of P-gp. 
DiOC2 uptake was significantly reduced in the strongly P-gp positive control 
CEM /VLBioo cells relative to the HCC cells. Conversely after treatment with the P-gp 
drug efflux inhibitors vpm (1 pM) and PSC833 (1 and 2 pM) for both 30 and 90 min, 
a strong enhancement of intracellular accumulation of DiOC2 fluorescence was 
observed indicating functional P-gp in CEM /VLBioo cells (Figure 4.4). On the other 
hand the moderately P-gp positive HCC cell lines HepG2 and C3A, and CRC cell 
lines SW620 and CAC02, demonstrated no DiOC2 efflux at 90 min and consequently 
no further DiOC2 accumulation with vpm or PSC833 (Figure 4.4). Hep3B, expressing 
M R P1 only, demonstrated weak efflux of DiOC2 at 90 min with associated inhibition 
of efflux with PSC833 but not vpm (Figure 4.5).
The addition of vpm (initially 1 pM, data not shown, then increased to 6 pM) or 
PSC833 showed no significant lowering of IC50 values except in HepG2 cells with 
vincristine and vpm (Table 4.2 and Figure 4.6) (Appendix 4 . 1). The modulation ratios 
(MR), defined as the ratio of the IC50 value obtained with and without the addition of 
reversing agents, ranged between 0.92 and 8.6.
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Figure 4.4. Flow cytometry using DiOC2 on P-gp expressing cell lines CEM /VLBioo and 
C3A. CEM /VLBioo has functional P-gp as demonstrated by the effect of 1 pM  vpm and 1 
& 2 pM  PSC833 on DiOC2 uptake and retention. No function is shown with C3A as 
demonstrated by the lack of effect of 1 pM  vpm and 1 & 2 pM  PSC833 on DiOC2 uptake 
and retention.
ICE = baseline; DiOC2 = uptake of DiOC2; VPM/1 pM and PSC 1 & 2 pM = effect on 
efflux.
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p-gp
MRPl
IS*
LRP
Figure 4.5. Flow cytom etry using D iOC 2 on MRPl expressing cell line Hep3B, 
dem onstrates weak efflux o f  D iO C 2 at 90 m in w ith associated inhibition o f  efflux with 
PSC833 but not vpm.
ICE =  baseline; D iO C 2 = uptake o f  D iOC 2; VPM/1 pM  and PSC 1 & 2 pM  = effect on 
efflux.
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Figure 4.6. The effect of pre-treatment with the MDR antagonist vpm (6 pM) on 
chemosensitivity of P-gp positive cell lines HepG2 and SW620 to etoposide and 
vincristine (both substrates for P-gp) was determined to confirm results of flow 
cytometry functional assay of P-gp. Vpm demonstrated an increase in 
chemosensitivity only with the cell line HepG2 and vincristine B. No effect on 
chemosensitivity was observed in the other experiments.
Drug Cell Line
Hep-G2 C3A SW620
IC50 Etoposide (pM) 45 18 27
+ vpm (MR) 42(1.07) 19(0.947) 19(1.42)
+ PSC (MR) 40(1.125) 17(1.05) ND
IC50 Vincristine (pM) 6.5 1 85
+ vpm (MR) 0.75 (8.6) K D 82(1.03)
+ PSC (MR) 7 (0.92) K D  . ND
vpm = verapamil (6 pM); PSC = PSC833 (1 pM).
MR = modulation ratio. The ratio of the IC50 values without versus with addition 
of reversing reagent.
ND = not done.
Values are the mean of three experiments.
Table 4.2. Effect of reversing agents on the IC50 values of etoposide and vincristine 
for the two HCC and one CRC P-gp positive cell lines.
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4.3.3 Expression of transport proteins related to cytotoxicity
The in vitro chemosensitivity of the HCC and CRC cell lines to four 
chemotherapeutic agents was determined in the previous chapter by the SRB assay 
(Chapter III, Figures 3.4 and 3.5). Etoposide is a drug known to be transported by the 
P-gp efflux pump. The two HCC P-gp positive cell lines, HepG2 and C3A, showed 
similar sensitivity to this drug in comparison to the P-gp negative cell lines. The most 
resistant HCC cell line to etoposide, PLC/PRF/5, expressed only MRPl and LRP. The 
chemosensitivities of anticancer agents that are poor substrates for P-gp (cisplatin, 
melphalan and 5FU) were also examined. C3A cells, expressing all 3 MDR proteins, 
were the most sensitive to all chemotherapeutic agents used, except etoposide, whilst 
PLC/PRF/5 cells, expressing MRPl and LRP were the most resistant to all agents 
except 5FU (Table 4.3.A). Of the CRC cell lines, SW620, which expressed all three 
MDR proteins, was consistently resistant to all chemotherapeutic reagents, whilst HT- 
29, expressing LRP only, was consistently sensitive to all reagents (Table 4.4.A).
The expression of P-gp, MRPl and LRP proteins and their relationship to 
chemosensitivity was also investigated using Spearman’s rank correlation test, no 
statistically significant correlation was observed (Tables 4.3.B & 4.4.B).
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Cell Lines IC50 Etoposide 
(UM)
IC50 Cisplatin 
(pM)
IC50 5-FU 
(pM)
IC50Melphalan
(pM)
P-gP MRPl LRP
HepG2 45 25 1000 40 4.07 2.37 2.74
SK-Hep-1 9 20 100 35 1.07 1.9 12.4
C3A 18 2.5 8 30 3.92 2.13 2.64
PLC/PRF/5 100 50 150 150 1 3.16 6.98
Hep3B 10 9 60 55 1 7.5 1
Table 4.3.A. IC50 values and expression of MDR related proteins of HCC cell lines.
Transport
protein
Cisplatin Etoposide 5-FU Melphalan
r-value P - value r-value P - value r-value P - value r-value P - value
■ IQ •a -0.154 0.783 0.0513 0.95 0.2 0.783 0.667 0.233
MRP 0.2 0.783 0.4 0.517 0.1 0.95 0.8 0.133
LRP 0.6 0.35 0.000 1.05 0.5 0.45 0.00 1.05
Table 4.3.B. Correlation between IC50 values of HCC cell lines and the expression of 
MDR related proteins. The Spearman rank correlation coefficient (r - values) and 
significancies (P - values) are given. Only correlations with P-values of 0.05 or below 
were considered significant.
Cell
Lines
ICSo Etoposide 
(pM)
IC50 Cisplatin 
(pM)
IC50 5-FU 
(PM)
IC50 Melphalan 
(PM)
P-gP MRPl LRP
WIDR 7 15 159 87 0.94 2.29 10.01
CAC02 24 15 650 90 1.55 0.93 1.38
HT-29 4.6 7 65 44 1.03 1.04 11.13
SW620 35 50 240 122 4.88 4.07 2.64
Table 4.4.A. IC50 values and expression of MDR related proteins of CRC cell lines.
Transport
protein
Cisplatin Etoposide 5-FU Melphalan
r-value P - value r-value P - value r-value P - value r-value P - value
*0 ■ IQ ■o 0.63 0.417 0.8 0.33 0.6 0.416 0.8 0.33
MRP 0.632 0.417 0.4 0.75 -0.2 0.916 0.4 0.75
LRP -0.63 0.417 -0.8 0.33 No correlation -0.8 0.33
Table 4.4.B. Correlation between IC50 values of CRC cell lines and the expression of 
MDR related proteins. The Spearman rank correlation coefficient (r - values) and 
significancies (P - values) are given. Only correlations with P-values of 0.05 or below 
were considered significant.
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4.4 Discussion
Despite advances in diagnostic imaging techniques leading to the earlier detection of 
smaller HCCs, only 5-15% of HCC patients are suitable for surgical resection 
(Bismuth et al, 1999), whilst only 20-25% of CRC liver metastases are candidates for 
surgery. Chemotherapy is therefore an important treatment modality for HCC and 
CRC. They are, however, only moderately sensitive to systemically administered 
chemotherapeutic agents. To investigate the poor response rates of HCC and CRC to 
chemotherapy the intrinsic expression of MDR-related proteins, a factor known to be 
associated with drug resistance, has been evaluated in the chosen panel of HCC and 
CRC cell lines.
P-gp was found in low levels or was absent in the HCC and CRC cell lines studied. 
For the HCC cell lines, this is in agreement with most other studies (Isshiki et al, 
1993; Lin et al, 1999; Prokipcak et al, 1999). Koike et al, however, failed to 
demonstrate any P-gp expression in HepG2 cells when transfecting them with 
cMOAT antisense cDNA (Koike et al, 1996) and low levels of P-gp have been 
demonstrated in Hep3B (Park et al, 1994 ; Tong et al, 1996), PLC/PRF/5 (Leveille- 
Webster and Arias, 1996; Marucci et al, 1997; Tong et al, 1996) and SKHep-1 cells 
(Ihnat et al, 1997). For the CRC cell lines similar observations to the current results 
have been found in the majority of previous studies (Barnes et al, 1996; Bates et al, 
1992; Beaumont et al, 1998; Chauvier et al, 2002a; Kramer et al, 1993; Kunzelmann 
et al, 1994; Lai et al, 1991; Lalloo et al, 2004; Laska et al, 2002; Luo et al, 2002; 
Peters and Roelofs, 1992; Vredenburg et al, 2001). Beaumont et al, however, failed to 
demonstrate P-gp expression in CAC02 cells as did Kramer et al with SW620 cells 
(Beaumont et al, 1998; Kramer et al, 1993).
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An important issue is whether P-gp, once detected in a tumour cell, is also 
functionally active. P-gp function in HCC cell lines has previously been studied with 
HepG2 and Hep3B cells using the fluorescent P-gp substrate Rhodamine 123 (Rh 
123), with minimal function being demonstrated in HepG2 cells (Lin et al, 1999). In 
CRC cell lines only CAC02 and SW620 have been examined, neither of which 
demonstrated any function (Kramer et al, 1993). The current experiments fail to 
demonstrate any P-gp function using either DiOC2 or Rh 123 (data not shown) in the 4 
P-gp positive cell lines. In several studies, the expression of P-gp does not correlate 
with its drug efflux function (Bailly et al, 1995) and therefore determining the 
functional role appears to be more informative than quantification of the MDR 
protein. Kramer et al, investigated P-gp biosynthesis in 19 wild type human CRC cell 
lines and concluded that only the mature 170 kDa P-gp molecule, but not the 140 kDa 
precursor, can be phosphoralated and located at the cell surface. Furthermore, they 
observed a correlation between the phosphorylation status and membrane association 
of P-gp with the MDR phenotype, emphasising that both of these factors are 
important in establishing cellular drug resistance (Kramer et al, 1993). The increase in 
cell associated DiOC2 accumulation produced by vpm and PSC833 treatment in 
CEM/VLBioo, a cell that has been shown to express high levels of P-gp, demonstrates 
that the DiOC2 uptake assay employed is appropriate for examining P-gp functional 
activity. The accumulation of DiOC2 was similar in both control and vpm/PSC833 
treated HCC and CRC cells. The absence of an effect on DiOC2 uptake with the P-gp 
modifying agent’s vpm and PSC833, suggests that either there is no functional P-gp 
present in these cells or the activity is too low to be measured. A controversial point is 
how specific an accumulation defect of DiOC2 is for the action of the pump. The dye 
has been used in flow cytometry as a mitochondrial dye, thus potentially fluorescence
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intensity per cell may vary, not only by virtue of a dye efflux pump, but also with 
proliferative and/or metabolic activity.
Resistance in P-gp over-expressing cell lines can be reversed by a wide variety of 
compounds, although the mechanisms underlying chemosensitisation are poorly 
understood. The most extensively studied reversing agents are the calcium channel 
blocker vpm and the immunosuppressive compound cyclosporin A. It has been 
suggested that these compounds reverse resistance by directly binding to P-gp and 
inhibiting its drug efflux activity. In this study, vpm and PSC833 produced no reversal 
of resistance except when vpm was used with vincristine on the P-gp positive but drug 
efflux negative HepG2 cells. The reason for this result is unclear, though an 
explanation could be the presence of an undescribed non-P-gp, non-MRP 1, non-LRP 
transporter. A recent study on cells from acute myeloid leukaemia (AML) patients 
reported a cyclosporine-resistant efflux not associated with P-gp, MRPl, or LRP 
expression in 18% of cases, implying the presence of as yet undefined efflux 
mechanisms (Leith et al, 1999). The ABC transporter termed breast cancer resistance 
protein (BCRP) has subsequently been identified in human breast carcinoma cells 
selected for resistance to doxorubicin in the presence of vpm (Chen et al, 1990; Doyle 
et al, 1998).
In the current study, MRPl was demonstrated in all HCC cell lines and the CRC cell 
lines SW620 and WIDR. This is in agreement with previous studies on HepG2 cells 
(Roelofsen et al, 1997; Takeuchi et al, 1999) but not with SKHep-1 cells (Takeuchi et 
al, 1999) or with HT-29 cells (Chauvier et al, 2002a; Chauvier et al, 2002b). No 
correlation was found between MRPl expression and the IC50 values of the
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chemotherapeutic drugs studied, therefore, MRPl is probably not important in the 
chemosensitivity of these cell lines. Overexpression of MRPl, which confers 
resistance to danorubicin, vincristine and other drugs, has been demonstrated to 
reduce ATP-dependent accumulation of drugs and to enhance drug efflux (Cole et al,
1994). MRP-1 transport has been shown to be dependent on the presence of GSH 
(Lautier et al, 1996), this is examined in greater detail in Chapter V.
High expression of the LRP protein in AML and ovarian carcinomas has been 
associated with a poor response to chemotherapy, in particular cisplatin treatment 
(Izquierdo et al, 1995). In the HCC cell lines, LRP was detectable in all except the 
Hep3B cells, and present in all the CRC cell lines. No correlation was found between 
LRP expression and the IC50 values of the chemotherapeutic drugs studied. Although 
their study did not include HCC or CRC cell lines, Izquierdo et al demonstrated a 
predictive value of LRP expression for in vitro sensitivity to several types of drugs, 
including cisplatin, in a number of different types of cancer cells (such as ovarian and 
small cell lung cancers) (Izquierdo et al, 1996). The results in these cell lines in the 
current study indicate that mechanisms other than LRP may control their response to 
cisplatin. These may include DNA damage recognition proteins in DNA repair and 
the nucleotide excision repair system in repairing cisplatin DNA damage (Barret and 
Hill, 1998).
The lack of either functional or significant biochemical evidence for the expression of 
P-gp in the cell lines examined in this present study would suggest that P-gp has little 
role in the intrinsic resistance found in HCC and CRC. Similarly, the lack of 
correlation of MRPl and LRP with chemosensitivity also suggests that this has a
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limited role in MDR resistance in the HCC and CRC cell lines. It is likely that 
additional drug resistance mechanisms contribute to the overall level of intrinsic 
tumour drug resistance.
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V. INTRACELLULAR GSH LEVELS IN HCC AND CRC CELL LINES
5.1 Introduction
A form of drug resistance that can affect several classes of drugs is associated with 
increased cellular levels of glutathione (GSH) and/or glutathione S-transferase (GST). 
GSH has been firmly established in resistance to cisplatin where conjugation of 
cisplatin and GSH can occur either nonenzymatically under physiological conditions, 
or be catalysed by GST. The conjugate is then eliminated from the cell by an ATP- 
dependent glutathione S-conjugate export pump (Goto et al, 1995; Ishikawa and Ali- 
Osman, 1993). Although cisplatin is not known to induce MDR itself, MDR induced 
cells can become cross-resistant to cisplatin (Loe et al, 1996a). The possible 
involvement of MDR in the response to platinum based treatments has also been 
reported in a panel of 61 human cell lines of eight different tumour types (Izquierdo et 
al, 1996).
MRPl confers resistance to heavy metals that interact with GSH (Cole et al, 1994) 
and to anthracyclines, epipodophyllotoxins, and vinca alkaloids (Grant et al, 1994). 
Buthionine sulfoxamine (BSO) is a potent irreversible inhibitor of y-glutamylcysteine 
synthesis, the enzyme that catalyses the first, rate-limiting step in the synthesis of 
GSH (Chapter I, Figure 1.9). Treatment of cells with BSO results in the reduction of 
intracellular GSH levels by up to 90% within 24 h, depending on the cell line 
examined. A number of studies have shown that BSO-treatment is capable of 
enhancing drug accumulation and toxicity in MRPl-overexpressing cell lines (Lautier 
et al, 1996). The mechanism by which BSO inhibits drug transport by MRPl is 
believed to be as a direct result of depletion of GSH, and not an interaction between
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BSO and MRPl. Evidence supporting this includes the finding that acute exposure to 
BSO had no effect on drug accumulation (Schneider et al, 1995), and treatment with 
GSH ethyl ester increased cytoplasmic GSH and decreased daunorubicin 
accumulation in two BSO-treated MRPl-overexpressing cell lines (Versantvoort et al.
1995).
In this section of the study the total GSH content was determined in the chosen panel 
of HCC and CRC cell lines, the cell lines were then treated with BSO for 24 h to 
establish the extent of reduction of intracellular GSH levels and its effect on 
chemosensitivity to cisplatin. This was then related to each cell lines expression of 
MRPl to determine whether it contributed to its intrinsic resistance. Cisplatin was 
chosen to investigate the effect of GSH on resistance because it is known to conjugate 
with GSH and the resulting cisplatin-GSH complex has been proposed to be ejected 
from the cell in an ATP-dependent fashion by the MRP/GS-X pump (Ishikawa, 1992). 
Cisplatin is also the main drug used in the experiments in the following Chapters.
5.2 Materials and methods
5.2.1 Determination of GSH levels
Intracellular total GSH was determined in 1 x 106 cells, both untreated and after 
exposure to 50 pM BSO for 24 h, by an enzymatic recycling assay based on the 
glutathione reductase method. Full details of the protocol are given in Chapter II, 
Section 2.8.
5.2.2 Reversal of drug resistance with BSO
The chemosensitivity of the HCC and CRC cell lines to cisplatin was repeated with 
and without prior exposure to BSO for 24 h. Briefly, exponentially growing cells were
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harvested as already described, inoculated into 96-well tissue culture plates in a 
volume of 100 pi at densities between 5,000 and 20,000 cells per well and allowed to 
attach for 24 h at 37°C, 5% CO2, in a humidified atmosphere. After overnight 
incubation, the plates were removed and all medium aspirated from the wells. Fifty 
pM of BSO was prepared by diluting the stock solution with serum-free MEM, 100 pi 
was then added to each well and the cells incubated for a further 24 h. After overnight 
incubation, the plates were removed and all medium aspirated from the wells. 
Cisplatin solutions were then prepared at the required concentrations (0.01-200 pM) 
by diluting the stock solution with serum-free MEM, 100 pi was added to each well 
followed by a further 100 pi of the appropriate medium containing 10% FCS. Control 
wells received drug free medium alone. All wells were then cultured for a further 4-5 
days, until the control wells were seen to have grown to an almost confluent state 
when examined by microscopy. At this stage the plates were stained and analysed 
using the SRB assay. Full details of the protocol are given in Chapter II, Section 2.5.
5.3 Results
5.3.1 Determination of GSH levels
The total levels of GSH in the HCC cell lines ranged between 3.53 and 7.13 nM/106 
cells (Figure 5.1.A and Table 5.1). The highest levels were seen in the relatively 
cisplatin resistant cell lines HepG2 (IC50 24.67 pM) and SkHepl (IC50 23.39 pM) 
(7.13 and 6.11 nM/106 cells respectively). PLC/PRF/5 (IC50 35.35 pM), the cell line 
most resistant to cisplatin, however, had the lowest level of GSH (3.53 nM/106 cells). 
The addition of BSO led to a decrease in GSH in the range of 1.52 to 3.34 fold, the 
highest fold difference being seen in HepG2 (3.34 fold) and SkHepl and Hep3B (both 
2.17 fold). The total levels of GSH in the CRC cell lines ranged between 4.67 and
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6.52 nM/106 cells. The addition of BSO lead to a decrease in GSH in the range of 1.67 
to 2.31 fold (Figure 5.1.B and Table 5.2).
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Figure 5.1. Intracellular GSH content measured in untreated A. HCC and B. CRC 
cells, and cells exposed to BSO. Cells (1 x 106), after a 24 h attachment period, had 
their medium replaced with either normal culture medium or medium containing 50 
pM BSO for 24 h prior to harvesting and measurement of their total GSH content by 
an enzymatic recycling procedure. Values represent the mean ±SEM of three 
independent experiments.
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Cell Lines GSH level (nM/l<f cells f i c 50 ( m b
Untreated +BSO -fold Untreated +BSO -fold
HepG2 7.13 ±2.51 2.13 ±0.48 3.34 24.67 ± 0.67 15.86 ± 1.33 1.55
SkHep-1 6.11 ±0.89 2.81 ± 1.04 2.17 23.39 ± 1.87 17.02 ± 1.8 1.37
C3A 4.58 ±1.1 3.0 ± 0.87 1.52 7.16 ±0.93 7.15 ± 0.4 1 . 0
PLC/PRF/5 3.53 ±0.57 2.15 ±0.92 1.64 35.35 ± 1.57 22.27 ± 1.35 1.58
Hep3B 4.78 ±1.64 2.2 ± 0.77 2.17 17.34 ±0.71 8.31 ±0.933 2.08
a Values are the means +SEM of three independent experiments. 
b Values are the means +SEM of four independent experiments.
Table 5.1. Effect of 24 h incubation of 50 pM BSO on GSH levels and IC50S with 
cisplatin on HCC cell lines.
Cell Lines GSH level (nM/101 cells f 1C so (fjM)b
Untreated +BSO -fold Untreated +BSO -fold
WIDR 4.67 ± 0.98 2.02 ± 0.92 2.31 14.52 ±2.98 9.68 ± 1.77 1.5
CAC02 6.52 ± 2.73 3.6 ±0.66 1.81 11.95 ±2.34 10.87 ±0.99 1.09
HT-29 4.75 ± 1.75 2.85 ±0.38 1.67 9.21 ±0.95 8.73 ±2.3 1.05
SW620 4.03 ± 1.26 2.07 ± 0.26 1.94 48.25 ± 1.52 25.5 ± 1.64 1.89
a Values are the means +SEM of three independent experiments. 
b Values are the means +SEM of four independent experiments.
Table 5.2. Effect of 24 h incubation of 50 pM BSO on GSH levels and IC50S with 
cisplatin on CRC cell lines.
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5.3.2 Reversal of drug resistance with BSO
The effect on IC50S in the HCC cell lines ranged between 1 and 2.08 fold, the highest 
fold difference being seen in Hep3B (2.08 fold) (Figure 5.2 and Table 5.1). The effect 
on IC50S in the CRC cell lines ranged between 1.05 and 1.89 fold, the highest fold 
difference being seen in SW620 (1.89 fold) (Figure 5.3 and Table 5.2).
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Figure 5.2. The effect of reduction of GSH using BSO on inhibition of cell growth by 
cisplatin in human HCC cell lines. Cells (5 x 103 - 2 x 104), after a 24 h attachment 
period, had their medium replaced with medium containing 50 pM BSO for 24 h prior 
to exposure to 0.01-100 pM cisplatin or no drug for 120 h. Percentage cell growth 
was then assessed by the SRB assay.
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Figure 5.3. The effect of reduction of GSH using BSO on inhibition of cell growth by 
cisplatin in human CRC cell lines. Cells (lxlO4 - 2 x 104), after a 24 h attachment 
period, had their medium replaced with medium containing 50 pM BSO for 24 h prior 
to exposure to 0.01-100 pM cisplatin or no drug for 120 h. Percentage cell growth 
was then assessed by the SRB assay.
5.4 Discussion
In the current section, BSO treatment was generally associated with a decrease in 
GSH and a resultant increase in chemosensitivity. As demonstrated in Chapter IV, of 
the HCC cell lines, only Hep3B cells expressed a significant amount of MRPl (7.5 
MFI) (Chapter IV, Figure 4.1 A, Table 4.1 A). This has now shown to be associated 
with modest levels of intracellular GSH (4.78 nM/106cells), but a 2.17 fold reduction 
with BSO and an associated 2.08 fold increase in sensitivity to cisplatin. Of the CRC 
cell lines, SW620 cells expressed the largest amount of MRPl (4.07 MFI) (Chapter
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IV, Figure 4.IB, Table 4.IB), this was again associated with modest levels of 
intracellular GSH (4.03 nM/106cells), but a 1.94 fold reduction with BSO and an 
associated 1.89 fold increase in sensitivity to cisplatin. This suggests that the 
combination of MRPl and GSH contributes to cisplatin resistance in these cell lines. 
Of the other MRPl expressing cell lines (HepG2, SkHepl, C3A, PLC/PRF/5 and 
WIDR), even though they demonstrated similar or higher levels of GSH, and had 
significant reduction of GSH levels this led to minimal fold differences in 
chemosensitivity.
Of the numerous mechanisms involved in drug resistance, a decrease in drug 
accumulation is believed to play a major role in resistance to cisplatin (Tew, 1994). 
Cisplatin rapidly interacts with GSH thus MRPl may be a GSX pump that promotes 
the ATP dependent efflux of GSH conjugated cisplatin (Ishikawa et al, 1996). 
However, cells transfected with the sense MRPl cDNA and drug selected MRPl 
overproducing cells did not show any altered sensitivity to cisplatin (Cole et al, 1994; 
Koike et al, 1996).
Observations that the GSH-conjugated chemotherapeutic drugs doxorubicin and 
daunorubicin, but not the unconjugated drugs were capable of competitively inhibiting 
the MRP-mediated transport of leukotriene C4 (LTC4) in vitro (Priebe et al, 1998) 
have led to speculation that MRP-mediated drug resistance occurs by the transport of 
drug conjugates from cells. As mentioned above MRPs have previously been called 
MRP/GS-X pumps (Ishikawa, 1992). This, however, has turned out to be 
inappropriate as MRPl and MRP2 have been shown to be capable of transporting 
compounds not conjugated to GSH such as bilirubin mono- and diglucuronides.
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Although many substrates for MRPs are conjugated compounds, the conjugation is 
thought not to be critical for transport. There has been some evidence that reduced 
GSH can also act as either a co-substrate or possess the ability to activate MRPs. 
Evidence for this comes from the observation that unconjugated chemotherapeutic 
agents, such as doxorubicin and daunorubicin, fail to inhibit LTC4 transport in isolated 
vesicles even at very high doses (Loe et al, 1996b). The addition of reduced GSH, 
however, increases the inhibitory effect of some of these drugs. Vincristine uptake 
into membrane vesicles from MRP 1 -transfected HeLa cells has been shown to be both 
ATP and GSH dependent and can be inhibited by the MRPl-specific mouse antibody 
QCRL-3 (Loe et al, 1998). In this study, vincristine transport in the absence of GSH 
was extremely low and showed no ATP dependence, whereas active vincristine 
transport increased with increasing concentrations of GSH. As GSH appears not to be 
a substrate for MRP-1, there is evidence for the co-substrate theory provided by a 
study showing that the ATP-dependent uptake of [3H]GSH into membrane vesicles 
from MRP 1-transfected cells could be stimulated by vincristine in a dose-dependent 
manner (Loe et al, 1996b).
In summary, the evidence so far collected on the transport of compounds by MRPl 
suggests that GSH is required and may act as a co-substrate during transport of 
compounds. The mechanism by which this occurs is not clear, but GSH may act as a 
co-substrate with unconjugated compounds, or if the compound is already conjugated, 
the conjugate attached to the compound acts as a co-substrate.
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VI. CISPLATIN SENSITIVITY AND DNA REPAIR OF CROSSLINKS IN 
HCC AND CRC CELL LINES
6.1 Introduction
Cisplatin is one of the most important anticancer drugs in the treatment of a wide 
variety of solid tumours including ovarian, testicular, bladder and small-cell lung 
carcinomas. Its success in the treatment of HCC and CRC, however, has been limited. 
In HCC, cisplatin has been administered systemically as both a single agent with 
response rates (RR) of 17% and median survival (MS) of 3.5 months (Falkson et al, 
1987), and in combination with doxorubicin, 5-fluorouracil (5-FU) and interferon a  
(IFNa) (RR 26%, MS 8.9 months) (Leung et al, 1999); via hepatic arterial infusion 
combined with 5-FU (RR 71%, 5-year survival 45.7%) (Okuda et al, 1999), and 
using transcatheter arterial chemoembolisation (TACE) combined with doxorubicin 
and mitomycin C (RR 23%, MS 6.8 months) (Ueno et al, 2000). It has also been 
combined with radiotherapy giving an overall RR of 43% (Abrams et al, 1997). In 
metastatic CRC, a randomized phase II clinical trial demonstrated a RR of 29% to 
cisplatin in patients pre-treated with 5-FU, and 56% in chemotherapy naive patients 
with cisplatin administered as a single agent, MS was 12 and 16 months respectively 
(Falcone et al, 2001). Combining continuous 5-FU and bolus doses of cisplatin have 
achieved RRs of 40% and 1 and 2 year survivals of 56 and 29% respectively (Tsuji et 
al, 2000). Cisplatin is thus potentially effective in the treatment of HCC and CRC. A 
major limitation of cisplatin therapy, however, is that many tumours are intrinsically 
resistant or develop resistance over the course of treatment.
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It is generally accepted that the cytotoxic activity of cisplatin results from its 
interactions with DNA (Chapter I, Figure 1.2). Platinum-DNA (pt) covalent adducts 
inhibit fundamental cellular processes, including replication, transcription, translation 
and DNA repair (Suo et al, 1999). As previously discussed interstrand crosslinks 
(ICL) represent a small amount of the total cisplatin lesions but several studies have 
suggested that they could also be responsible for the cytotoxicity of the drug. The 
distortions induced by these crosslinks exhibit specific features such as location of the 
platinum residue in the minor groove, extrusion of the cytosines of the crosslinked 
d(GpC) d(GpC) site, bending of the helix axis towards the minor groove and large 
DNA unwinding (Malinge et al, 1999).
HCC and CRC often show intrinsic resistance to cisplatin or develop resistance after 
initially responding to treatment (Falkson et al, 1987). The problem is complicated by 
the multitude of molecular mechanisms that have been associated with cisplatin 
resistance. These mechanisms include 1) reduced intracellular accumulation of the 
drug (Kuppen et al, 1988). When decreases in cisplatin accumulation are observed 
they are usually modest, and often do not correlate with the level of resistance. To 
date, the search for a specific cisplatin membrane transport system has been 
inconclusive (Andrews and Howell, 1990). 2) Increased pt-DNA damage tolerance as 
manifested by defects in mismatch repair and enhanced replicative bypass (Vaisman 
et al, 1998). 3) Increased drug inactivation by intracellular thiols. The role of 
glutathione (GSH) in cisplatin resistance seems to be important as cells with in vitro 
acquired resistance often show elevated levels of GSH compared with parental cells 
(Meijer et al, 1992). Glutathione S-transferase (GST) catalyses the conjugation of 
cisplatin to GSH, the cisplatin-GSH complex has been proposed to be ejected from
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the cell in an ATP-dependent fashion by the glutathione S-conjugate export pump 
(Goto et al, 1995). 4) Enhanced pt-DNA repair. Prior studies have demonstrated 
increased sensitivity of cells deficient in excision repair of cisplatin (Fraval et al, 
1978). Many pt-resistant cell lines appear to have enhanced repair activity based on 
the rate of disappearance of intrastrand adducts from unreplicated DNA (Lai et al, 
1988; Parker et al, 1991), and the rate of disappearance of ICLs (Johnson et al, 1994a; 
Johnson et al, 1994b).
Previous studies on the rate of repair of ICLs have been predominately on cisplatin- 
resistant human ovarian cancer cell lines in view of its effectiveness clinically 
(Johnson et al, 1994a; Johnson et al, 1994b; Lai et al, 1988; Parker et al, 1991; Zhen 
et al, 1992). Further studies have also been performed using murine leukaemia L1210 
cells (Eastman and Schulte, 1988) and human BE colon carcinoma cells (Fram et al, 
1990). In most, enhanced cisplatin ICL repair has been observed in cisplatin-resistant 
cells, however some have demonstrated no differences in the kinetics of excision 
(Fram et al, 1990). The contribution of DNA repair to resistance to cisplatin in HCC 
has not been previously investigated. Genomic ICL formation and repair in cells has 
been measured most frequently using the alkaline elution technique (Fram et al, 1990; 
Zhen et al, 1992). An equally sensitive, but simpler and quicker method is the single 
cell gel electrophoresis (comet) assay. Although established for measuring DNA 
strand breaks, the technique can be easily modified to allow the sensitive detection 
and quantification of DNA ICLs at the single cell level (Blasiak et al, 2000).
In this section of the study, the induction and excision of cisplatin DNA ICLs in 
human HCC and CRC cell lines were determined at the level of the overall genome by 
the comet assay, and related to pt chemosensitivity. The objective was to evaluate the
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extent of initial ICL formation and the contribution of DNA repair to pt resistance 
with HCC and CRC cell lines.
6.2 Materials and methods
6.2.1 One hour cytotoxicity determination
When cisplatin is given intravenously (i.v.) in a clinical situation it is rapidly 
sequestered by protein binding, such that 1 h after administration no free drug remains 
in the plasma. The IC50S of HCC and CRC cell lines to cisplatin exposure for 1 or 120 
h were therefore determined by the SRB assay to assess cisplatin cytotoxicity and 
allow comparison with ICL formation and repair rates. Full details of cytotoxicity 
determination are given in Chapter III, Section 3.2.2, and the protocol for the SRB 
assay is given in Chapter II, Section 2.5.
6.2.2 Interstrand cross-linking and repair
6.2.2.1 Extent of ICL formation
Since DNA ICLs are critical lesions for cisplatin cytotoxicity, the comet assay was 
used to quantify these lesions in the overall genome. Cells were initially treated with 
10-100 pM cisplatin for 1 h, washed, and incubated in drug free medium for 12 h. The 
treated samples, plus one control, were subjected to 10 Gy X-irradiation. The second 
control remained un-irradiated, the comet assay was then performed as described in 
Chapter II, Section 2.9. A 12 h incubation was chosen since peak levels of ICLs have 
been shown to be formed during this time interval over a wide range of doses 
(Zwelling et al. 1978).
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6.2.2.2 Rates of formation and repair of ICLs
The relative rates of formation and removal of DNA ICLs were determined at 
equimolar concentrations of cisplatin. Cells were exposed to 10-100 pM of cisplatin 
for 1 h, washed, and ICLs measured over the course of 72 h using the comet assay.
6.3 Results
6.3.1 One hour cytotoxicity determination
The HCC cell lines 1 h IC50S were 1.6-4.5-fold higher relative to the 120 h values, the 
relative resistance, however, remained similar regardless of the duration of drug 
exposure (Table 6.1 A and Figure 6.1). Three of the cell lines tested (HepG2, SKHep-1 
and PLC/PRF/5) were resistant to cisplatin with IC50S of 20.66, 21.84 and 36.7 pM at 
120 h and 91.18, 93.32 and 88.44 pM at 1 h respectively. The other cell lines (C3A 
and Hep3B) were sensitive with IC50S of 5.2 and 14.63 pM at 120 h, and 10.96 and 
24.54 pM at 1 h. One resistant (SW620) and 1 sensitive (HT-29) CRC cell line was 
examined, the 1 h IC50S were 3.55 and 6 -fold higher relative to the 120 h values 
respectively, again the relative resistance remained similar (Table 6 .IB and Figure 
6 .2).
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HCC Cell 
lines
ICS0 ( l h ) f j M IC5o(120 h) fjM
HepG2 91.18 ± 6.8 20.66 ± 1.88a
SKHep-1 93.32 ± 4.4 21.84 ± 1.66a
C3A 10.96 + 7.5 5.2 ± 1.82a
PLC/PRF/5 88.44 ± 5.4 36.7 ±2.8
Hep3B 24.54 ± 5 14.63 ±3.28
A
CRC Cell ICS0 (1 h) /iM ICS0 (120 h) jjM
lines
HT-29 40.2 ±3.21 6.5 ±3.4
SW620 160.46 ±4.7 45 ± 2.93a
B
Values are the means ± SEM of three independent experiments. 
aValues are the means ± SEM of four independent experiments.
Table 6.1. Sensitivity of A. HCC and B. CRC cell lines to cisplatin at 1 h and 120 h 
drug exposure times.
179
Chapter VI: Cisplatin sensitivity and DNA repair o f  crosslinks in HCC & CRC cell lines
Cisplatin  1 h
HepG2
—  SKHep-1
—  C3A
—  PLC/PRF/5 
\  —  Hep3B
A 0-----■ ' ■ '■■■■!....      1 T l .ll.l
0.01 0.1 1 10 100
[Cisplatin]/pM
C isp la t in  120 h
100-1
HepG2
—  SKHep-1
—  C3A
—  PLC/PRF/5
—  HUPT4
80-
ohCoO
20 -
0.01 0.1 1 10 100
[Cisplatin]/pM
•C50
SKHep-1 HepG2 C3A PLC/PRF/ Hep3B 
Cell line
Figure 6.1. Inhibition of cell growth by cisplatin in human HCC cell lines. Cells (1 x 
104) were exposed to 0.01-100 pM cisplatin or no drug for either A. 1 h or B. 120 h. 
Percentage cell growth was then assessed. C. Comparisons of the drug concentration 
that causes a 50% inhibition of control cell growth (IC50) after 1 and 120 h exposure. 
Values represent the mean ± SEM of three (1 h) and four (120 h) independent 
experiments.
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Figure 6.2. Inhibition of cell growth by cisplatin in human CRC cell lines. Cells (1 x 
104) were exposed to 0.01-100 pM cisplatin or no drug for either A. 1 h or B. 120 h. 
Percentage cell growth was then assessed. (C) Comparisons of the drug 
concentration that causes a 50% inhibition of control cell growth (IC50) after 1 and 
120 h exposure. Values represent the mean ± SEM of three (1 h) and four (120 h) 
independent experiments.
181
Chapter VI: Cisplatin sensitivity and DNA repair o f  crosslinks in HCC & CRC cell lines
6.3.2 Interstrand cross-linking and repair 
6.3.2.1 Extent of ICL formation
As shown in Figure 6.3A, at 12 h ICL formation increased with cisplatin 
concentration in all cell lines studied. The resistant HCC cell line PLC/PRF/5 had 
between 1.5 and 3-fold lower levels of ICLs in total cellular DNA compared to the 
sensitive cell line C3A over the range of drug concentrations measured. This trend 
was also observed in the resistant and sensitive CRC cell lines, although the 
magnitude of difference was less marked (1.3 to 2.5-fold), at 100 pM cisplatin SW620 
and HT-29 had equivalent ICLs (Figure 6.3B).
6.3.2.2 Rates of formation and repair of ICLs
Two of the HCC cell lines resistant to cisplatin (HepG2 and SKHep-1) began to repair 
ICLs with all cisplatin concentrations at 18-24 h. At lower concentrations of cisplatin 
(10 and 25 pM), ICLs were fully repaired at 72 h, whilst at higher concentrations 
repair was incomplete (Figure 6.4). The resistant cell line PLC/PRF/5 in contrast, only 
began to repair ICLs after 24 h at a slower rate and incompletely at all concentrations 
(Figure 6.4). The sensitive HCC cell lines, Hep3B and C3A, had a similar initial rates 
of removal of ICLs with 10-45 pM at 18-24 h as HepG2 and SKHep-1, the repair rate 
then decreased with failure to fully repair at any concentration. Essentially no repair 
was noted at 100 pM (Figure 6.5). The CRC cell lines demonstrated similar initial 
rates of repair with 10-45 pM at 18-24 h, neither was effective at removing ICLs with 
100 pM, SW620 cells completely repaired with 10 pM at 72 h (Figure 6.6).
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Figure 6.3. Dose response for cisplatin ICL form ation in the overall genom e in hum an 
A. HCC and B. CRC cell lines. Cells w ere exposed to 10-100 pM  cisplatin  for 1 h, 
washed and then incubated for 12 h at 37°C, 5% C 0 2 . Cells w ere trypsinised and the 
comet assay perform ed.
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Figure 6.4. Rate of formation and excision of cisplatin ICL in the overall genome of 
relatively resistant HCC cell lines. Cells were incubated with 10, 25, 45 and 100 pM 
cisplatin for 1 h at 37°C and then allowed to repair in fresh medium. ICLs were 
quantified by the comet assay at 6-72 h after cisplatin treatment.
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Figure 6.5. Rate of formation and excision of cisplatin ICL in the overall genome of 
relatively sensitive HCC cell lines. Cells were incubated with 10, 25, 45 and 100 pM 
cisplatin for 1 h at 37°C and then allowed to repair in fresh medium. ICLs were 
quantified by the comet assay at 6-72 h after cisplatin treatment.
0 20 40  60
T im e  (h )
185
Chapter VI: Cisplatin sensitivity and DNA repair o f  crosslinks in HCC & CRC cell lines
SW620
100-,
8 0 -
6 0 -
o
4 0 -
20 -
40 60 800 20
10pM 
25pM 
45pM 
10OpM
T im e  (h)
HT -29
100-1
C0
0> ~■ £ 
( o  a>® £|  o
a )  5Q
10pM 
25pM 
45pM 
10OpM
B
“i
800 20 40  60
T im e  (h )
Figure 6.6. Rate of formation and excision of cisplatin ICL in the overall genome of 
relatively A. resistant and B. sensitive CRC cell lines. Cells were incubated with 10, 
25, 45 and 100 pM cisplatin for 1 h at 37°C and then allowed to repair in fresh 
medium. ICLs were quantified by the comet assay at 6-72 h after cisplatin treatment.
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The role of formation and excision of DNA ICLs in mediating resistance to cisplatin 
is further emphasised by comparing these lesions at the same high concentration of 
cisplatin. When resistant and sensitive HCC cell lines are both exposed to 100 pM 
cisplatin for 1 h and ICL formation measured 12 h after drug removal, a 1.5-fold 
difference is noted. Seventy-two h after drug removal, however, more than a 3-fold 
difference in ICL formation is present suggesting these resistant HCC cell lines have 
enhanced DNA repair (Figure 6.7). The CRC cell lines failed to show any significant 
difference in repair rates at this concentration.
HepG2
SKHep-1
C3A
PLC/PRF/5
Hep3B
HT-29
SW620
T im e  (h)
Figure 6.7. Comparison of the formation and excision of DNA ICLs in A. HCC and 
B. CRC cell lines treated with 100 pM cisplatin. Cells were incubated with 100 pM 
cisplatin for 1 h at 37°C and allowed to repair in fresh medium. ICLs were quantified 
by the comet assay at 6-72 h after cisplatin treatment.
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6.4 Discussion
The objective of this section of study was to examine mechanistically important 
features underlying resistance to cisplatin in the chosen panel of human HCC cell 
lines and two CRC cell lines. The results would support previous studies highlighting 
the importance of ICL formation to cisplatin resistance. At the level of the overall 
genome, between 1.5 and 3-fold fewer ICLs were formed in the most resistant HCC 
cell line compared to the most sensitive cell line over the range of drug concentrations 
measured. These results are consistent with previously published data for resistant 
human ovarian (Behrens et al, 1987; Zhen et al, 1992) and colon (Fram et al, 1990) 
cancer cells. There have been no previous reports on ICL formation and repair in 
human HCC cell lines. The quantitative decrease in ICLing could be explained by 
mechanisms of cisplatin resistance which prevent active drug from damaging DNA, 
such as decreased cellular drug accumulation (Andrews et al, 1988) and inactivation 
via protein (Kasahara et al, 1991) and non-protein sulfhydryls.
ICL repair was also demonstrated in the overall genome of the cisplatin-resistant cells. 
In comparison the sensitive HCC cell lines C3A and Hep3B, and sensitive CRC cell 
line HT-29, were unable to fully repair ICLs at even the lowest concentration of 
cisplatin used. This would suggest that ICL repair is important in resistance in both 
the HCC and CRC cell lines studied. Several previous studies have examined the rate 
of repair of the overall genome in cisplatin-resistant cell lines. In most, enhanced 
cisplatin ICL repair has been observed (Johnson et al, 1994b; Masuda et al, 1988; 
Parker et al, 1991), however some have demonstrated no differences in the rate of 
repair (Fram et al, 1990).
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There is good evidence that actively transcribed genes are repaired at a faster rate than 
background genomic DNA lesions (Sancar, 1996). It is conceivable that the survival 
of cisplatin-resistant cells may depend more on the speed or efficiency of repair in 
essential regions of their genomes than in bulk DNA. If this is the case, differences in 
gene-specific repair may be more dramatic and correlate more closely to relative 
cisplatin resistance than does repair in the overall genome. It has been reported that 
the gene-specific repair of cisplatin ICLs may be associated with cellular resistance to 
cisplatin in human ovarian cancer cell lines (Zhen et al, 1992). Studying repair at the 
gene-specific level in this cell panel would help clarify the role of the cisplatin ICLs 
in cytotoxicity, and the mechanism of repair.
The mechanism used by cells to repair ICLs is not clearly understood. However, 
several studies have suggested that excision repair cross-complementing group 1 
(ERCC1) and XPF, probably formed by a complex containing ERCC4 and ERCC11, 
may be involved in this mechanism (Larminat and Bohr, 1994). As shown for 
classical nucleotide excision repair (NER), the ERCC1/XPF complex might also 
interact with XPA to facilitate the repair of ICLs. The mechanism might involve co­
operation between NER and recombination, certainly outside the normal context of 
NER (Sijbers et al, 1996). An increased expression of the human NER repair genes 
XPA and ERCC1 has been reported in tumour tissue of patients with ovarian cancer 
who did not respond to pt-based chemotherapy (Li et al, 2000). It has also been shown 
that ERCC1 mRNA levels correlate with clinical resistance to cisplatin-based 
chemotherapy in human gastric cancer (Metzger et al, 1998). While transfection of an 
XPA-expressing vector into XPA-deficient cell lines can restore NER activity, 
overexpression of the same plasmid in repair-proficient cell lines do not appear to
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have any effect on the activity levels (Cleaver et al, 1995). To date there is no clear 
evidence of overexpression of NER genes in resistant cell lines or in resistant 
tumours.
The lh IC50 for the resistant cell lines in this study was approximately 100 pM. It has 
been demonstrated that at this concentration the cytotoxicity is related to their 
inability to fully repair the ICL formed. However, the cell lines were also unable to 
fully repair the ICLs formed at 45 pM. These findings suggest that DNA damage 
tolerance pathways are also present in the resistant cells, in particular PLC/PRF/5, 
which demonstrated high resistance but low repair rates. One mechanism by which a 
cell can exhibit damage tolerance is through increased replicative bypass of pt-DNA 
adducts and defects in mismatch repair. This has been reported to occur in human 
ovarian carcinoma cells (Vaisman et al, 1998) in which mismatch repair defects 
resulted in 1.5-4.8 fold increased cisplatin resistance and 2.5-6 fold increased 
replicative bypass of cisplatin adducts.
If enhanced repair activity does contribute to resistance, it is theoretically possible to 
enhance the efficacy of alkylating chemotherapeutic agents by altering the repair of 
the adducts they form. There are, however, a number of barriers to adopting this 
strategy. The most important being the multifactorial nature of resistance. Decreased 
accumulation, efflux increased by GSH and GST or by metallothionene, altered 
metabolism and increased tolerance of unrepaired damage all contribute to resistance 
to chemotherapeutic drugs (Kuppen et al, 1988; Meijer et al, 1992). Repair activity is 
usually only enhanced 1.5 to 2.0-fold, even in cell lines that are 20 to 100-fold 
resistant to chemotherapeutic drugs. However, even a 1.5-fold to 2.0-fold decrease in
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repair activity may be enough to elicit a response in some resistant tumours especially 
if inhibitors of repair could be combined with agents that block mechanisms of 
resistance.
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VII. ORTHOTOPIC MODEL OF LIVER CANCER IN NUDE MICE IN 
WHICH TO EVALUATE CISPLATIN CYTOTOXICITY BY THE 
COMET ASSAY
7.1 Introduction
The translation of molecular mechanisms of action of cytotoxic agents from in vitro 
tissue culture models to tumours in vivo remains challenging. In vitro tissue culture 
models are extremely useful for examining the response of cancer cells to cisplatin 
and play a role in dissecting molecular events following exposure. Comparison of 
ovarian tumours treated in vivo and in vitro with cisplatin have demonstrated that their 
relative sensitivity observed in vitro is preserved in vivo (Kelland et al, 1992b). 
However, use of tumour cells that have been adapted to growth in culture may have 
limitations as it is frequently necessary to employ concentrations higher than those 
achieved in patients to detect measurable effects in vitro (Potapova et al, 1997). 
Moreover, in vitro cancer cells often generate degrees of resistance to cytotoxic agents 
that are higher than those observed in patients (Teicher et al, 1991). Several studies 
have also noted that cisplatin-resistant tumours established by in vivo treatment with 
cisplatin show acquired resistance in three-dimensional spheroid in vitro cultures, but 
not when cultured as monolayers in vitro (Kobayashi et al, 1993).
Many methods have been developed and applied to measure DNA damage produced 
by a wide variety of cytotoxic agents (Iliakis, 1991). With few exceptions, these are 
population-based assays and it must be assumed that all cells within a population will 
respond identically to a DNA-damaging agent. While, generally, a reasonable 
assumption for cells in tissue culture incubated with an agent in a well-controlled
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environment, a global measure of DNA damage is unlikely to be adequate to describe 
damage produced in cells exposed in solid tumours. Drug uptake and accumulation is 
an important determinant for tumour cell sensitivity and subsequent response to 
cisplatin therapy in vivo. Little is known about the distribution patterns of cisplatin 
within tumours in vivo. A number of physiological barriers can lead to heterogeneous 
accumulation of therapeutic agents in solid tumours including variations in 
angiogenesis and blood flow, heterogeneous permeability of tumour vessels, the 
physico-chemical properties of the interstitium, and interstitial hypertension (Jain, 
1998). At a cellular level many cells have intrinsic resistance due to the presence of 
energy dependent efflux pumps (eg. P-gp and MRP1) which can decrease the net 
intracellular accumulation of cytotoxic agents. The chemotherapeutic agent must also 
be effective in the in vivo microenvironment. The diverse microenvironments within 
solid tumours often include areas of low pH, hypoxia, and are deficient in nutrients 
and growth factors. Hypoxia is known to aid cytotoxicity of alkylating agents 
(Skarsgard et al, 1995), and inhibit effectiveness of bleomycin (Teicher et al, 1981). 
The level of cell proliferation may also play a role in tumour sensitivity. Proliferating 
cells are more susceptible to damage by cisplatin (Shalinsky et al, 1996), but whether 
the drug accumulation is higher in proliferating cells is unknown.
Present murine models involve growth of human tumour xenografts at ectopic sites 
where the local environment would be different from their natural (orthotopic) sites, 
thus limiting extrapolation of results to solid tumours. Intraperitoneal (i.p.) ascitic 
tumour models, which are often treated by i.p. drug injections, fail to consider the 
efficiency of vascular drug delivery to the tumour site and the need for drug 
penetration through multiple cell layers, which are critical determinants of successful
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clinical therapy of solid tumours. In mice bearing subcutaneous (s.c.) tumour 
xenografts, tumour size can be directly measured using calipers and response to 
therapeutic intervention monitored quantitatively. However, when some cell lines are 
injected subcutaneously, resultant tumours grow as well-encapsulated, poorly 
vascularised masses so that early tissue necrosis and haemorrhage may complicate 
evaluation of tumour volume. Both ascitic and s.c. models fail to consider the concept 
that the microenvironment in which the tumour cells grow can profoundly influence 
their response to cytotoxic therapy (Dong et al, 1994). It is generally accepted that the 
host microenvironment influences tumour biology. There are discrepancies in growth 
rate, angiogenesis, metastatic potential and related gene expression (Takahashi et al, 
1996), and the efficacy of systemic treatments between ectopic and orthotopic 
tumours (Fidler, 1995). The liver is the most common and critical site of distant 
metastasis of CRC. Tumourigenicity and efficacy of chemotherapeutic agents in CRC 
tumours are different in liver and subcutaneous sites (Fidler et al, 1994). Such 
limitations may explain, in part, the discrepancy between successes reported with in 
vivo chemosensitisation protocols in murine models and failure of these protocols in 
clinical trials with solid tumours.
The purpose of this section of the study is to describe the intratumoural topographic 
distribution of cisplatin induced DNA damage in intrahepatic xenografts of human 
HCC and CRC in nude mice in terms of cisplatin-DNA adducts assessed by the comet 
assay. As only a few thousand cells are required for this assay, samples can be taken 
by fine needle aspirate (FNA) biopsies from a variety of sites within each tumour. 
This allows the residual tumour to be utilised for immunohistochemical staining of
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parallel tissue sections to investigate the potential influence of cell proliferation, 
hypoxia, vascularity and P-gp expression on intratumoral adduct distribution.
7.2 Materials and Methods
7.2.1 Orthotopic model of liver cancer in nude mice in which to evaluate 
cisplatin cytotoxicity by the comet assay
To study the effect of cell proliferation, hypoxia, vascularity and P-gp expression on
the intratumoural topographic distribution of cisplatin-DNA adducts in intrahepatic
xenografts, a cisplatin sensitive and resistant HCC and CRC cell line was initially
selected from in vitro data (Table 7.1). The animals were supplied by, and the in vivo
experiments were carried out at the Comparative Biology Unit (CBU), Royal Free
Hospital (RFH). All procedures were within national ethical guidelines, were in
compliance with the United Kingdom Coordinating Committee on Cancer Research
Guidelines for the welfare of Animals in Experimental Neoplasia, and covered by the
Home Office Licence No. PPL 70/4517. Tumour volume was determined by external
measurement in two dimensions according to the published method using the equation
V = (L x W2)/2, where V = volume, L = length, and W = width (Johnsson and
Cavallin-Stahl, 1996).
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HCC Cell IC50 (1 h) fjM ICS() (120  h) fjM
lines
C3A 10.96 ±7.5 5.2 ± 1.82a
PLC/PRF/5 88.44 ± 5.4 36.7 + 2.8
A
CRC Cell IC50( l h ) f j M ICso(120h) fjM
lines
HT-29 40.2 ±3.21 6.5 ±3.4
SW620 160.46 ±4.7 45 ± 2.93a
B
Values are the means ±SEM of three independent experiments. 
“Values are the means ±SEM of four independent experiments.
Table 7.1. In vitro data on chemosensitivity of A. HCC and B. CRC cell lines to 
cisplatin at 1 h and 120 h drug exposure times.
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Experiment series I: Direct injection of tumour cell suspension (in PBS) into
mouse liver parenchyma
MFI nude mice (3-4 weeks old) weighing between 20-25 g were housed in cages and 
fed a standard laboratory diet and tap water. The strict use of surgical asepsis was 
performed in order to prevent infective complications. A million C3A or PLC/PRF/5 
HCC, or HT-29 or SW620 CRC cells were prepared by trypsinisation of adherent 
cells from tissue culture flasks. Cells were washed once with sterile PBS, counted and 
resuspended in 100 pi cold-sterile PBS. Anaesthesia was induced and maintained with 
halothane and a 2:1 mixture of nitrous oxide:oxygen. The skin was cleansed with 
antiseptic solution, laparotomies were performed through a midline abdominal 
incision and the bowel retracted to the left to reveal the liver. Cells were injected 
subcapsularly into the right lobe of the liver. After applying pressure for a few 
minutes to stop bleeding at the injected site, the abdominal wall was closed using 4/0 
vicryl. Mice recovered within minutes of discontinuing the halothane. Analgesia 
(Temgesic) was provided for the first 24 h. The animals were inspected on a daily 
basis for any adverse effects. Animals were killed at 45 days by a schedule 1 method. 
The liver, lung and peritoneal cavity were examined for evidence of tumour.
Results
A total of 12 mice (3 mice with each cell line) were implanted with cells. After 45 
days, all the animals were sacrificed. No evidence of macroscopic tumour was found 
in liver, lung or peritoneal cavity.
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Experiment series II: Direct injection of tumour cell suspension (in Matrigel)
into mouse liver parenchyma
All procedures were performed as described in experimental series I except the cells 
were suspended in Matrigel (Collaborative Biochemical Products, Becton Dickson, 
Bedford (MA), USA). Matrigel is stored at -20°C and thawed at 4°C at the time of 
use. A dilution of 1:2 of Matrigel in serum-free RPMI-1640 was prepared. One 
hundred microlitres of cell suspension containing 1 x 106 cells in a 1-ml syringe was 
carried in ice and warmed in a 37°C incubator before injection. Mice were divided 
into groups as in experimental series I. Animals were killed at 45 days by a schedule 1 
method.
Results
Cell suspensions in Matrigel were viscous but not difficult to inject into the liver 
paranchyma. The cell suspension was also separately grown in a 25-cm2 culture flask 
to test the viability of cells. The results showed that cells resuspended in Matrigel 
survived and grew normally in vitro. A total of 12 mice (3 mice with each cell line) 
were implanted with cells. During inoculation of the cell suspension, 2 mice suddenly 
arrested intraoperatively. The complication was not related to cell type. The other 10 
mice survived without complication until terminated at 45 days. Again, no evidence 
of macroscopic tumour was found in liver, lung or peritoneal cavity.
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Experiment series III: Injection of tumour cell suspension (in PBS or
Matrigel) into subcutaneous tissues of nude mice
Nude mice were injected subcutaneously into their flanks using 25-gauge needles. 
Three million cells were prepared from tissue culture flasks and resuspended in 500 pi 
of either cold-sterile PBS or Matrigel. Mice were divided into the same groups as in 
experiment series I. A successful s.c. injection resulted in the formation of a bleb 
during discharge of the cell suspension. Mice were then left to recover and were 
intermittently assessed for weight loss and other signs of discomfort. The size of 
tumour was recorded and animals anaesthetised at 30 days to perform experiment 
series IV.
Results
Eight mice (2 mice with each cell line) were implanted with cells resuspended in cold- 
sterile PBS and 8 mice (2 mice with each cell line) were implanted with cells 
resuspended in Matrigel. After 30 days, none of the cells resuspended in cold-sterile 
PBS resulted in subcutaneous tumour nodules, the mean tumour volumes of C3A, 
PLC/PRF/5, HT-29 and SW620 cells resuspended in Matrigel were 489, 344, 264 and 
566 mm3, respectively (Figure 7.1). The presence of tumours was confirmed 
histologically.
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A
B
Figure 7.1. Examples of tumour nodules generated in subcutaneous tissues of nude mice. 
A. SW620 and B. C3A xenografts.
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Experiment series IV: Implantation of the tumour tissue generated in
subcutaneous tissues of nude mice into mouse liver 
parenchyma
The same mice and groups with s.c. tumours generated with Matrigel were used as in 
-experiment series III. General experimental procedures were similar to those 
described in experiment series I. On the 30th day the nude mice were anaesthetised, 
subcutaneous tumours were measured, excised, and cut into small cubes of 
approximately 2 mm . After disinfection, the mice underwent a midline abdominal 
incision. The bowel was retracted to the left to expose the liver. A small superficial 
incision on the liver was made using the tip of a No.l 1 surgical blade with the knife at 
a 15° angle to the liver surface. A small piece of Gelfoam (Pharmacia & Upjohn, 
London, England) was inserted into the incision for approximately 1 min and the 
incision compressed with a piece of gauze. When the bleeding had stopped, the 
Gelfoam was removed and a tumour fragment gently placed into the incision. The 
procedure was performed in both the right and left lobe of the liver. After the bleeding 
had ceased, 2 ml of balanced salt solution was placed into the peritoneal cavity and 
the abdominal incision closed as previously described. Animals were killed at 45 days 
by a schedule 1 method.
Results
The same 8 mice (2 mice with each cell line) with s.c. tumours generated with 
Matrigel from experiment series III were studied. The procedure was uncomplicated. 
The bleeding from the incision in the liver parenchyma was easily controlled by 
Gelfoam and packing for a few minutes. There was no intraoperative or postoperative 
mortality. All implantation’s resulted in intrahepatic tumours. The mean tumour
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volumes of C3A, PLC/PRF/5, HT-29 and SW620 cells were 750, 421.8, 351.6, and 
1171.9 mm3, respectively (Figure 7.2). The presence of tumours was confirmed 
histologically.
B
Figure 7.2. Subcutaneous tumour nodules from nude mice implanted into liver 
parenchyma of nude mice, A. SW620 and B. PLC/PRF/5 xenografts.
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7.2.2 Analysis of spatial and temporal tumour cisplatin induced DNA damage
The human HCC cell line C3A and CRC cell line SW620 were chosen for this part of 
the study. This was based on both in vitro data of cisplatin chemosensitivity 
demonstrating them to be sensitive and resistant respectively with different rates of 
.formation and removal of DNA interstrand crosslinks (ICLs), and in vivo data 
confirming adequate intrahepatic solid tumour growth. Subcutaneous xenografts were 
established in the flanks of a total of 6 nude mice (3 mice for each cell line) as 
detailed in experiment series III. Animals were killed at 30 days by a schedule 1 
method. Subcutaneous tumours were measured, excised, and cut into small cubes of
'i
approximately 2 mm then transplanted under anaesthesia into both the right and left 
lobe of the liver parenchyma of other mice (18 mice for each cell line) as detailed in 
experiment series IV. Drug treatment did not start until day 45, whereupon mice were 
randomised into groups. There were 3 animals in each control or treatment group. The 
mice in the treatment groups were treated intravenously (i.v.) (via the tail vein) with a 
single dose of 4 mg/kg cisplatin in 0.9% NaCl (time = 0). The route and dose was 
selected on the basis of maximum-tolerated dose determination experiments in non- 
tumour-bearing mice before drug testing in tumour-bearing mice. Tumours were 
sampled before dosing (control group) and in groups of animals at 6, 12, 24, 48 and 
72 h post treatment. The mice in each control and treatment group were killed by a 
schedule 1 method. Fine needle aspiration (FNA) biopsies were taken from two sites 
(A & B) and depths (0.25 & 0.5 cm) in each tumour and frozen immediately in 1 ml 
RPMI, 10% foetal calf serum and 10% DMSO at -70°C until analysed by the comet 
assay as described in Chapter II, Section 2.9. As cisplatin is an alkylating agent cells 
were irradiated immediately prior to analysis to deliver a fixed level of random strand
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breakage and crosslinks were quantitated as the decrease in the comet tail moment 
(TM) compared to unirradiated controls.
Statistical Analysis
Values are expressed as mean ± SEM. For comparison between depths and sites, the 
two-tailed unpaired t-test was used. One-way ANOVA followed by the Bonferroni 
multiple t-test was used to compare DNA-adduct formation between tumours. P < 
0.05 was considered statistically significant.
Results
Assays performed on FNAs of tumours from untreated animals showed no evidence 
of ICLs. Peak levels of ICLs were observed at 12 h in both xenografts (Figure 7.3). 
The resistant cell line SW620 had 1.5-fold fewer ICLs compared to the sensitive cell 
line C3A at both superficial and deep levels (at 0.25 cm and 12 h, 42 vs 63 % 
decrease in TM [P < 0.001]) (Table 7.2). Both cell lines demonstrated fewer ICLs 
when grown as xenografted tumours when compared with in vitro data with 100 pM 
of cisplatin (Table 7.2).
%  Decrease in Tail Moment
Cell line In vivo In vitro
0.25 cm 0.5 cm 100 pM
SW620 42 30.3 60
C3A 63 50.9 89
Table 7.2. Percentage decrease in Tail Moment of SW620 and C3A at 12 hours in 
vivo and in vitro.
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Figure 7.3. Rate of formation and excision of cisplatin ICLs in the overall genome of 
in-vivo A. SW620 and B. C3A intrahepatic xenografts of nude mice. Mice were 
treated i.v. via the tail vein with a single dose of 4 mg/kg cisplatin in 0.9% NaCl at 
time = 0. Values are the mean ±SEM of three mice (each with 2 tumours and 2 sample 
sites), * indicates P < 0.05 with two-tailed unpaired t-test.
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Rates of repair of ICLs were both quantitatively and qualitatively different from in 
vitro data with growth of cells in xenografts. In vitro there was little repair in either 
cell line with 100 pM of cisplatin, in vivo, however, percentage decrease in TM was 
reduced to approximately 13 and 35% in SW620 and C3A xenografts at 72 h 
respectively (Figure 7.3).
Differences in ICLs were noted at different depths in xenografts, with superficial cells 
having higher levels of ICLs. With SW620 these were statistically significant at 12, 
24 and 72 h, with C3A statistical significance was only noted at 12 h (Figure 7.3) 
(Appendix 7.1). Superficial cells were more efficient at repair of ICLs, by 72 h 
superficial SW620 cells had statistically significant less ICLs than deep cells (P =
0.0086) (Figure 7.3) (Appendix 7.1). Differences between sites in the same tumour, 
and tumours in the same mouse were minimal and generally not statistically 
significant (Appendix 7.2).
7.2.3 Correlation of tumour cell proliferation, hypoxia, vascularity and P-gp 
expression to cisplatin induced DNA damage
As peak levels of ICLs were observed at 12 h, the animals in the 12 h post-treatment
group were used to study the effect of cell proliferation, hypoxia, vascularity and P-gp
expression and on the intratumoural topographic distribution of cisplatin-DNA
adducts in intrahepatic xenografts (3 mice with six tumours). Eleven hours after i.v.
cisplatin administration, 7-(4’-(2-nitroimidazol-l-yl)-theophylline (NITP) was
injected i.p into each mouse: 70 mg NITP in 0.5 ml 10% DMSO with 4.5 ml peanut
oil, 0.3 ml per animal (155 mg/kg) (For full details see Chapter II, Section 2.11.2.).
One hour after the administration of NITP the animals were killed by a schedule 1
method. Fine needle aspiration biopsies were taken for analysis by the comet assay.
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The tumours were measured to calculate their volumes and then frozen immediately
in liquid nitrogen and stored at -70°C until they were sectioned. From each of the 12
tumours four parallel 4 pm cryostat sections were prepared on poly-L-lysine coated
slides from both the superficial and deep parts (0.25 & 0.5 cm respectively) for
immunohistochemical analysis of MIB-1, NITP, Factor VIII and P-gp. Details of the
immunohistochemical staining techniques of each are given in Chapter II, Sections
2.11.1-4. All slides in each immunohistochemical experiment were stained in the
same batch, to avoid the methodological error due to inter-batch variation.
Quantitative and statistical analysis
Point counting using two independent observers quantitated the staining reactions. 
Cell proliferation, hypoxia and P-gp expression were assessed using 10 high power 
fields (x 40 objective lens, field size 150 x 80 pm) in each section. Each high powered 
field consisted of 50-100 cells, and the average labelling index (LI) was calculated as 
the total number of labelled cells vs the total tumour cells counted and expressed as a 
percentage. As a measure of vascularity, the numbers of vascular structures per mm2 
(vascular density, VD) were calculated from 10 low powered fields (x 10 objective 
lens, field size 1.22 mm ) in each section. The heterogeneity between measured fields 
was calculated as standard deviations (SD) and relative standard deviations 
(coefficients of variation, CV). Only areas with morphologically intact tumour cells 
were analysed. Stromal cells and necrotic cells were not measured. Comparisons of 
parameters between depths and tumours were made using the two-tailed unpaired t- 
test. Correlations were calculated as Pearson’s correlation coefficients (r).
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Results 
I. Proliferation
The MIB-1 staining was strong in all tumours (Figure 7.4, A & B). On each slide 10 
fields representing 500-1000 cells per section were analysed. The staining was 
distributed fairly evenly on each section, with CV values for both xenographs ranging 
from 8 to 34% at 0.25 cm and 20 to 40% at 0.5 cm (Table 7.3). Proliferation was 
generally higher in superficial cells with statistically significant intra-tumour 
differences between peripheral and central cells noted in 3 SW620 and 2 C3A 
xenografts (Appendix 7.7). Strong statistical differences in proliferation between 
depths were observed for both xenografts, however, when all results were pooled 
(SW620, 12.37 vs 9.48% [P < 0.0001] and C3A, 16.25 vs 13.41% [P < 0.0001] at 0.25 
and 0.5 cm respectively) (Table 7.3, Figure 7.5, A & B). C3A xenografts 
demonstrated higher proliferation levels at both depths when compared with SW620 
xenografts (Figure 7.5 C).
II. Hypoxia
Bound metabolites of NITP occurred mainly at the edges of tumour cords. Little 
staining was found within the tumour cords or in the surrounding necrotic material. A 
wide intra- and inter-tumour variation of hypoxia was noted as reflected by high CV 
values (33 to 70% at 0.25 cm and 25 to 50% at 0.5 cm) (Table 7.3). Overall hypoxic 
staining was higher in deep cells. Although statistically significant intra-tumour 
differences between superficial and deep cells were noted in only 2 of each cell line 
xenografts (Appendix 7.8), strong statistical differences for both were observed when 
all results were pooled (SW620, 7.5 vs 10.29% [P = 0.0007] and C3A, 7.71 vs 13.16% 
[P < 0.0001] at 0.25 and 0.5 cm respectively) (Table 7.3, Figure 7.5 D & E). C3A
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xenografts demonstrated higher levels of hypoxia at 0.5 cm only when compared with
SW620 xenografts (Figure 7.5 F).
C D
Figure 7.4. Microscopic images (40 x magnification) of sections from xenografted 
tumours from nude mice at 12 h after injection of 4 mg cisplatin/kg i.v. MIB-1 
staining in A. SW620 xenograft and B. C3A  xenograft indicating cell proliferation. C. 
NITP staining in SW620 xenograft indicating hypoxia. D. P-gp staining in SW620 
xenograft.
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Parameter Cell Line Depth
(cm)
Mean (%) 
(n=60)
SD
range
CV (%) 
range
t-test
(Total)
Proliferation SW620 0.25 12.37 2.11-3.55 18.09-25.78 P0.0001
0.5 9.48 1.85-3.19 20.06-33.57
C3A 0.25 16.25 1.38-5.87 8.35-34.5 P0.0001
0.5 13.41 2.8-5.48 22-39.67
SW620 vs C3A 0.25 P0.0001
0.5 P0.0001
Hypoxia SW620 0.25 7.5 2.81-7.44 42.33-70.2 P=0.0007
0.5 10.29 2.18-5.47 25.89-46.79
C3A 0.25 7.71 2.35-4.56 33.11-54.64 P0.0001
0.5 13.16 4.42-6.15 38.22-50.37
SW620 vs C3A 0.25 P=0.7677
0.5 P=0.0152
Vascularity SW620 0.25 26.33 4.9-10.81 16.8-44.49 P=0.0004
0.5 21.57 4.6-7.51 20.52-37.93
C3A 0.25 28.2 4.8-8.2 15.88-29.95 P<0.0001
0.5 20.87 5.1-6.88 24.77-33.01
SW620 vs C3A 0.25 P=0.1645
0.5 P=0.5269
P-gp expression SW620 0.25 17.25 6.48-8.66 40.67-48.57 P=0.01
0.5 14.13 4.24-6.5 27.21-51.1
C3A 0.25 13.73 3.57-6.46 31.51-48.09 P=0.33
0.5 12.88 2.05-5.33 20.93-38.25
SW620 vs C3A 0.25 P=0.003
0.5 P=0.157
Table 7.3. Summary of immunohistochemical results of in vivo tumour cell 
proliferation, hypoxia, vascularity and P-gp expression (total of 6 tumours in 3 mice).
SD, standard deviation; CV, coefficient of variation.
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Figure 7.5. Parallel tissue sections of nude mice intrahepatic SW620 and C3A 
xenografts were stained with MIB-1 to analyse cell proliferation A-C. and anti­
theophylline antibody to detect hypoxia D-F. at 0.25 & 0.5 cm. Three mice with a total 
of 6 tumours were studied, on each section 10 fields were analysed. Each bar indicates 
the mean LI of 60 or 6 values. Comparisons between depths were made using the two- 
tailed t-test.
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III. Vascularity
All tumours were well vascularised. Factor VUI-positive endothelial cells indicating 
capillaries, were seen mainly in stromal parts of tumours. Scattered endothelial cells 
were also seen within tumour nodules. There was little intra- and inter-tumour 
variation (CV values 16 to 44% at 0.25 cm and 20 to 37% at 0.5 cm) (Table 7.3). In 
general vascularity was greater superficially. Significant intra-tumour differences 
between superficial and deep areas were noted in only 2 of each cell line xenografts 
(Appendix 7.9), statistical differences were apparent when all results were pooled 
(SW620, 26.33 vs 21.57 [P = 0.0004] and C3A 28.2 vs 20.87 [P < 0.0001] at 0.25 and 
0.5 cm respectively) (Table 7.3, Figure 7.6 A & B). No statistical difference was 
noted between tumours at either depth (Figure 7.6 C).
IV. P-gp expression
P-gp expression in xenografts of SW620 and C3A was confirmed 
immunohistochemically with Mdr/-reactive mouse monoclonal anti-human antibody 
JSB-1. Expression was heterogeneous as reflected in the high intra- and inter-tumour 
CV values (Appendix 7.10). None of the individual tumours demonstrated any 
significant intratumoural difference in expression between superficial and deep cells. 
When values were pooled, however, SW620 xenografts expressed statistically higher 
levels of P-gp superficially (P = 0.01) (Table 7.3 and Figure 7.6 D). SW620 
xenografts also demonstrated higher levels of P-gp expression when compared with 
C3A xenografts at 0.25 cm (Table 7.3, Figure 7.6 F).
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Figure 7.6. Parallel tissue sections of nude mice intrahepatic SW620 and C3A 
xenografts were stained with Factor VIII to detect vessels A-C. and JSB-1 to detect P- 
gp D-F. at 0.25 & 0.5 cm. Three mice with a total of 6 tumours were studied, on each 
section 10 fields were analysed. Each bar indicates the mean LI of 60 or 6 values. 
Comparisons between depths were made using the two-tailed t-test.
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SW620 xenografts had statistically significant inverse correlations at 0.5 cm between 
tumour volume and proliferation, and vascularity (Appendix 7.11, Figure 7.7 A & B), 
and a positive correlation with hypoxia (Figure 7.7 C). A similar inverse correlation 
was observed between vascularity and hypoxia in both superficial and deep cells 
Figure 7.7 D & E).
C3A xenografts had a statistically significant inverse correlation at 0.5 cm between 
tumour volume and proliferation, and a positive correlation with hypoxia (Figure 7.8 
A & B). There was no correlation between tumour volume and vascularity, and 
vascularity inversely correlated with hypoxia at 0.25 cm only (Figure 7.8 C). Tumour 
volume correlated with heterogeneity of adducts at 0.25 cm in terms of CV values (r = 
0.8254, P =0.043), and at 0.5 cm in terms of both SD values (r = 0.877, P = 0.0218) 
and CV values (r = 0.8832, P = 0.0197) (Appendix 7.11) (Figure 7.8 D-F). C3A 
adduct formation correlated positively with proliferation and negatively with hypoxia 
when both superficial and deep values were combined (Appendix 7.12) (Figure 7.9).
Intratumour adduct heterogeneity within samples at 12 h, expressed as variations in 
SD and CV, was greater in deep cells with SDs ranging from 3.5 to 13.43 and 1.41 to 
12.7 and CVs ranging from 29.11-67.14% and 22.36-58.93% in SW620 and C3A 
xenografts respectively (Appendix 7.11).
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Figure 7.7. Correlation between tumour volume and A. proliferation, B. vascular 
density and C. hypoxia at 0.5 cm. Correlation between vascular density and 
hypoxia at D. 0.25 and E. 0.5 cm. Ten sections were analysed in 6 intrahepatic 
xenografted SW620 tumours at 12 h after injection of 4 mg/kg cisplatin i.v.
Correlations are calculated as Pearson’s correlation coefficients O).
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Figure 7.8. Correlation between tumour volume and A. proliferation and B. 
hypoxia at 0.5 cm. C. Correlation between vascular density and hypoxia at 0.25 
cm. D-F. Correlations between tumour volume and heterogeneity. Ten sections 
were analysed in 6 intrahepatic xenografted C3A tumours at 12 h after injection of 
4 mg/kg. cisplatin i.v.
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Figure 7.9. Correlation between cisplatin DNA-adducts and A. cell proliferation, 
and B. hypoxia, at 0.25 & 0.5 cm in 6 C3A xenografted tumours from nude mice at 
12 h after injection of 4 mg cisplatin/kg i.v.
Correlations are calculated as Pearson’s correlation coefficients (r).
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7.3 Discussion
This section of the study describes the topographic distribution of cisplatin DNA- 
adducts within tumours, using an in vivo model with intrahepatic xenografted HCC 
and CRC in nude mice. Potential mechanisms for drug heterogeneities have also been 
explored by using different immunohistochemical stainings on parallel tissue sections. 
Factors influencing the cytotoxicity of cisplatin at a cellular level have been examined 
in vitro in previous chapters, including reduced uptake or increased drug efflux, 
inactivation by glutathione, DNA repair, and tolerance of DNA damage. Thus, 
although drug uptake into the tumour cell is not the only determinant for cytotoxicity 
of cisplatin, it is certainly a prerequisite for antitumour activity. In vitro studies often 
show correlations between cisplatin sensitivity and accumulation (Andrews and 
Howell, 1990). One potential reason for treatment failure with cisplatin is 
heterogeneities in drug distribution within the tumour, with some cells receiving 
sublethal intracellular concentrations.
It is increasingly important to directly analyse tumour material to determine if 
proposed mechanisms of action are operative. The investigation of material obtained 
following treatment with DNA-damaging agents has been revolutionised by the use of 
the comet assay. This allows quantitative estimation of DNA damage and repair in 
individual cells following drug exposure, thus heterogeneity in response can be 
evaluated, and has recently been applied to monitor ICLs in the clinical setting 
(Hartley et al, 1999; Webley et al, 2001).
In the present section, DNA ICLs were detected in samples taken by FNAs from 
human HCC and CRC intrahepatic xenografts after administration of a therapeutic
219
Chapter VII: Orthotopic model o f  liver cancer in nude m ice in which to evaluate cisplatin cytotoxicity
by the comet assay_______________________________________________________________________________
dose of cisplatin. After a single administration ICLs were detected at 6 h, with peak 
levels being observed at 12 h which correlates well with previous reports on the time 
of DNA damage with cisplatin administration. The resistant xenografts had 1.5-fold 
fewer ICLs at the level of the overall genome compared to the sensitive xenografts in 
both superficial and deep cells, reflecting in vitro observations. Quantitatively fewer 
ICLs were noted, however, in cells grown as xenografted tumours when compared 
with in vitro cells. The dose of cisplatin used in these experiments was 4mg/kg i.v. 
Assuming a mouse has a blood volume of 72 ml/kg this is equivalent to 185 pM or 12
'•y sy
mg/m (where dose in mg/m = km x dose in mg/kg [km = 3 for nude mice with a 
body weight of 20 g]) (Freireich et al, 1966). This is higher than the highest in vitro 
dose used in previous chapters (100 pM) and slightly lower than human clinical doses 
(15-20 mg/m2). When cisplatin is given i.v. to nude mice it is rapidly sequestered by 
protein binding, such that 1 h after administration no free drug remains in the plasma 
(Siddik et al, 1987). Therefore, with a single i.v. dose of 4mg/kg we are measuring the 
response to a brief genotoxic insult induced by cisplatin treatment at a dose close to 
that used in vitro and clinically. In addition, once the cisplatin molecule is injected 
into the blood stream, it encounters the following “resistances” before reaching the 
intracellular space: (i) distribution through the vascular space; (ii) transport across the 
microvascular wall; (iii) transport through the interstitial space; and (iv) transport 
across the cell membrane. The combination of these factors would explain the 
quantitative differences between in vivo and in vitro findings.
Interstrand crosslinks were noted to be quantitively higher in superficial cells of 
xenografts, and these cells were more efficient at repair than central cells. Rates of 
repair of ICLs in superficial cells were generally greater than those observed in in
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vitro cells. Intratumour adduct heterogeneity within samples at 12 h, expressed as 
variations in CV, was greater in deep cells with CVs ranging from 29.11-67.14% and 
22.36-58.93% in SW620 and C3A xenografts respectively. Although a number of 
studies have examined the distribution of platinum within tumours (Deurloo et al, 
1991; Richmond et al, 1992), few have examined the topographic distribution of 
cisplatin-DNA adducts and none have used the comet assay. Johnsson et al studied the 
intratumoural distribution of cisplatin-DNA adducts in squamous cell carcinoma 
xenografted tumours in nude mice immunohistochemically using NKI-A59 antiserum 
elicited against cisplatin-DNA interaction products and reported CV values between 
75 and 115% (Johnsson and Cavallin-Stahl, 1996). A three-dimensional image of 
adduct distribution was produced which showed a 2-fold difference between high and 
low adduct levels. No specific mention was made on differences between superficial 
and deep areas.
Potential reasons for heterogeneity in cisplatin-DNA adduct distribution were also 
investigated in this study. Larger tumours were found to have greater intratumoural 
variation in adducts in C3A xenografts. Although Johnsson et al demonstrated 
positive correlation coefficients between tumour size and heterogeneity of cisplatin- 
DNA adducts, these were not statistically significant (Johnsson and Cavallin-Stahl, 
1996).
An adequate vascular system is required for sufficient drug delivery to tumour cells. 
The three-dimensional growth of solid tumours requires a vascular network of new 
capillaries. These new capillaries lack a supporting architecture and are thin-walled 
and leaky. The lack of a smooth muscle wall also renders them less responsive to
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vasoactive stimuli and more prone to compression, especially in larger tumours in 
which the interstitial pressure is raised. Thus, a tumour often has oxygen diffusion 
gradients and a relatively poor nutrient supply, which may result in necrosis (Trotter 
et al, 1989). Immunohistochemical staining for Factor VIII related antigen (von 
Willebrand factor) is considered a valuable method of demonstrating endothelial cells 
giving a distinct picture of the vascular pattern in normal and malignant tissue 
(Sehested and Hou-Jensen, 1981). The tumours used in this section were well 
vascularised and in general vascularity was greater superficially. Theoretically 
cisplatin-DNA adduct levels should be higher in areas that are well vascularised 
reflecting better drug delivery, and higher in tumour cells close to capillaries. 
Johnsson et al, however, analysed cisplatin-DNA adduct levels at different distances 
from large capillaries, and found there was a tendency for lower adduct levels close to 
capillaries (Johnsson and Cavallin-Stahl, 1996). It was suggested that cisplatin, being 
a small molecule, diffuses so easily into surrounding tissue that distance from the 
delivering capillary is of minor importance. Alternatively the lack of correlation could 
have been due to the fact that the tumours studied were extremely well vascularised.
Cell proliferation is an important determinant for cytotoxicity of cisplatin and most 
other cytotoxic agents. Cells in active cell cycle are more susceptible to damage by 
cisplatin than quiescent cells in Go phase (Shalinsky et al, 1996). Whether 
proliferating cells also accumulate more drug and form more adducts is as yet 
unknown. The MIB-1 staining was strong in all tumours indicating a high 
proliferating activity. Labeling index values were within the same range noted in other 
human CRC mouse xenografts (Sharma et al, 1997). Proliferation was generally 
higher in superficial cells in both xenografts, and significantly higher values were
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noted in superficial C3A cells in comparison with SW620 xenografts. Tumour volume 
was inversely correlated with proliferation in cells aspirated from deep areas of both 
xenografts. There was a positive correlation between proliferation and adduct 
formation in C3A xenografts. This suggests that the higher uptake and adduct 
formation noted in C3 A xenografts is a result of their higher proliferating activity and 
could in part account for adduct heterogeneity. A weak correlation between 
proliferation and adducts in human squamous cell carcinoma xenografted tumours in 
nude mice has previously been noted, but was not statistically significant (Johnsson 
and Cavallin-Stahl, 1996).
Central necrosis is a common feature of larger tumours. Cells close to the areas of 
necrosis may sustain hypoxia due to oxygen diffusion limitations. Transient, acute 
hypoxia has also been demonstrated in tumours (Trotter et al, 1989). This is a 
perfusion-limited hypoxia that is caused by a temporary interruption of blood flow 
within the vasculature as the vessels undergo spontaneous opening and closing. Both 
chronic and acute mechanisms are responsible for the presence of hypoxic cells in 
tumours (Chaplin et al, 1987). The LI for NITP ranged from 6.58 to 13.04%, there 
was a wide inter- and intratumour variation. This large variation was also observed in 
immunohistochemical studies with NITP staining in human squamous cell carcinoma 
xenografts in nude mice (Bussink et al, 1999). An inverse correlation between 
hypoxia and adduct formation was seen in the C3A xenografts, suggesting aerobic 
conditions favour cisplatin-DNA adducts. There is conflicting evidence regarding the 
effect of hypoxia on the cytotoxicity of cisplatin. Several studies have indicated that 
hypoxia enhances the cytotoxicity of cisplatin (Douple and Richmond, 1979; Skov et 
al, 1998; Stratford et al, 1980), while others have found that cisplatin is more
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cytotoxic under aerobic conditions (Donnelly et al, 2004; Grau and Overgaard, 1988; 
Melvik and Pettersen, 1988). It has also been reported that the cytotoxicity of cisplatin 
is not influenced by the cellular oxygenation state (Korbelik and Skov, 1989; Teicher 
et al, 1981). The majority of these studies have been in vitro studies culturing 
mammalian cells with cisplatin under aerobic and hypoxic conditions (Korbelik and 
Skov, 1989; Melvik and Pettersen, 1988; Skov et al, 1998; Stratford et al, 1980; 
Teicher et al, 1981), whilst two studies have used in vivo s.c. murine tumour models 
(Donnelly et al, 2004; Grau and Overgaard, 1988), all have used clonogenic assays to 
determine cytotoxicity. Although two studies have specifically examined cisplatin- 
DNA crosslinking using alkaline elution (Skov et al, 1998; Teicher et al, 1981), and 
another has indirectly determined the hypoxic fraction within solid tumours (Grau 
and Overgaard, 1988), no previous study, however, has correlated the extent of 
cisplatin-DNA crosslinking directly with local hypoxia.
In summary, this section confirms the use of FNAs to obtain individual cells from 
human HCC and CRC xenografts in nude mice in their orthotopic sites for analysis by 
the comet assay. It has demonstrated the feasibility of characterising and quantitating 
DNA damage and repair in an animal model that could be transferred to a clinical 
setting. Differences have been demonstrated in both the topographic distribution of 
cisplatin-DNA adducts, and in the quantitative and qualitative rates of repair of ICLs 
in comparison to in vitro data. The findings from this series of experiments are 
consistent with those of previous studies suggesting a correlation between 
proliferation and adduct formation (Johnsson and Cavallin-Stahl, 1996), and also 
provide support to the observation that cisplatin is more cytotoxic to well-oxygenated 
tumour cells than to hypoxic tumour cells (Donnelly et al, 2004).
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VIII. ORTHOTOPIC MODEL OF CRC LIVER METASTASES IN NUDE 
RATS IN WHICH TO EVALUATE DRUG CYTOTOXICITY BY THE 
COMET ASSAY USING THE ISOLATED DUAL-PERFUSED RAT 
LIVER
8.1 Introduction
For any therapeutic agent to be effective, it must accumulate in target cells in optimal 
concentrations for a required duration of time. Unfortunately, physico-chemical and 
physiological barriers can lead to heterogeneous accumulation of therapeutic 
molecules, particles and cells in solid tumours (Jain, 1998). In cancer, failure to treat a 
small fraction of cells can result in tumour regrowth. Thus, it is crucial to know which 
cells have been successfully treated and which have not. To determine this, 
simultaneous and continuous high-resolution imaging of drug distribution and its 
physiological determinants is required. Only with this knowledge can drug delivery be 
improved to all regions of a tumour. Invasive methods such as immunohistochemistry 
used in Chapter VII can provide the desired spatial resolution, but require tumour 
removal, so the temporal dynamics are missed.
Not only is the comet assay sensitive to low levels of DNA damage, but more 
important it provides sufficient resolution to detect subpopulations of cells that differ 
in damage by as little as a factor of 2 (Olive et al, 1993). The fact that the method can 
be applied to tumour samples obtained by FNA biopsy means there is the potential to 
examine both spatial resolution, by taking samples from different sites of a tumour, 
and temporal dynamics, by taking samples at different times from the same tumour.
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The ability to perform sequential or multiple samples has the additional advantage of
using the given tumour as its own control.
Although it has been over 100 years since the first reported use of the isolated 
perfused rat liver (IPRL) (Miller, 1972), this model is still a valuable and commonly 
used tool for exploring the physiology and pathophysiology of the liver, and 
pharmacological investigations. The IPRL remains an important experimental model 
despite the availability of newer techniques (such as liver slices, isolated and cultured 
cells, and isolated organelles) for evaluating hepatic function. This popularity is due 
to the fact that, in contrast to in vivo models, the IPRL allows repeated sampling of 
the perfusate and liver, permits easy exposure of the liver to different concentrations 
of test substances and is amenable to alterations in temperature that would not be 
tolerated in vivo. Furthermore, experiments can be done independent of the influence 
of other organ systems, plasma constituents and neural-hormonal effects. In contrast 
to the other in vitro models, such as isolated and cultured hepatocytes and isolated 
organelles, hepatic architecture, cell polarity and bile flow are preserved in the IPRL.
Typical experiments with the IPRL are performed under conditions that differ 
markedly from the in vivo situation such as lack of perfusion via the hepatic artery 
(HA) and the composition of the perfusate. Although perfusion solely through the 
portal vein (PV) with an oxygen-rich medium is sufficient to maintain the viability of 
the liver (Meijer et al, 1981; Ross, 1972), this model is still clearly unphysiological as 
it excludes the possible contribution that arises from input via the HA. Furthermore, 
anatomical studies show that metastasising tumour cells entering the liver via the 
portal vein develop into liver tumours, which are mainly vascularised by the HA
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(Sigurdson et al, 1987). Studies of the blood supply of liver tumours show that the HA 
provides up to 95% of their total blood flow (Wang et al, 1994). In contrast to normal 
liver tissue the PV plays a minor role in the blood supply of liver tumours (Taylor et 
al, 1978).
The ideal perfusate for continuous perfusion of the IPRL has not yet been defined. 
However, the perfusate should deliver oxygen to the liver by using an oxygen carrier 
for the full benefit of perfusion to be realised (Kamada et al, 1980), (Gores et al, 
1986). Simple oxygenated buffer solutions require higher flows for adequate oxygen 
delivery and create degenerative changes in the perfused tissues that are not seen 
when red blood cells are used as the oxygen carrier (Riedel et al, 1983; Starnes et al, 
1991). In addition to tissue damage, high flows can decrease first-pass hepatic 
clearance (Pries et al, 1981). Similarly, high pressures cause hepatic barotrauma and 
enlarge sinusoidal fenestrations (Fraser et al, 1980). A Haematocrit of 20% has been 
suggested to provide the optimum combination of haemodynamics and oxygen- 
carrying capacity (Pegg et al, 1984). Also, red cells can attenuate sinusoidal damage 
by scavenging xanthine-oxidase-dependent radicals (which cause respiratory burst 
leading to lipid peroxidation and cellular destruction) in IPRLs.
The prime aim of this section of the study was to establish an intrahepatic xenograft of 
human CRC in rats, and to use the isolated dual-perfused rat liver (IDPRL) thus 
mimicking physiological delivery of chemotherapeutic agents, to assess the spatial 
and temporal pattern of chemotherapy related cancer DNA damage using the comet 
assay.
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8.2 Materials and methods
8.2.1 Orthotopic model of liver cancer in nude rats in which to evaluate drug 
cytotoxicity by the comet assay
To study the spatial and temporal pattern of drug induced DNA damage in rat
intrahepatic xenografts using IDPRLs, the HCC cell line C3A and CRC cell line
SW620 used in the study of intrahepatic xenografts in nude mice (Chapter VII) were
initially selected. All animals were supplied by, and the in vivo experiments were
carried out at the Comparative Biology Unit (CBU), Royal Free Hospital. All
procedures were within national ethical guidelines, were in compliance with the
United Kingdom Coordinating Committee on Cancer Research Guidelines for the
welfare of Animals in Experimental Neoplasia, and covered by the Home Office
Licence No. PPL 70/4517. Tumour volume was determined by external measurement
in two dimensions according to the published method using the equation V = (L x
W2)/2, where V = volume, L = length, and W = width (Johnsson and Cavallin-Stahl,
1996).
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Experiment series I: Implantation of tumour tissue generated in subcutaneous
tissues of nude mice into rat liver parenchyma
Three million cells were prepared from tissue culture flasks and resuspended in 500 pi 
of Matrigel. Mice were divided into two groups (2 mice for each cell line) and the 
cells injected subcutaneously into their flanks using 25-gauge needles. Mice were then 
recovered and were intermittently assessed for weight loss and other signs of 
discomfort. The mice were killed at 30 days by a schedule 1 method, the size of 
subcutaneous (s.c.) tumours were recorded, excised, and cut into small cubes of 
approximately 2 mm . Sprague-Dawley rats weighing 200-250 g were anaesthetised 
with halothane and a 2:1 mixture of nitrous oxide:oxygen. Removal of hair was 
carried out with electrical clippers and the skin cleansed with antiseptic solution. 
Laparotomies were performed through a midline abdominal incision and the bowel 
retracted to the left to expose the liver. A small superficial incision on the liver was 
made using the tip of a No.l 1 surgical blade with the knife at a 15° angle to the liver 
surface. A small piece of Gelfoam was inserted into the incision for approximately 1 
minute and the incision compressed with a piece of gauze. When the bleeding had 
stopped, the Gelfoam was removed and a tumour fragment gently placed into the 
incision. The procedure was performed in both the right and left lobe of the liver. 
After the bleeding had ceased, 20 ml of balanced salt solution was placed into the 
peritoneal cavity and the abdominal incision closed using 4/0 vicryl. Rats recovered 
within minutes of discontinuing the halothane. Analgesia (Temgesic) was provided 
postoperatively for the first 24 h. The animals were inspected on a daily basis for any 
adverse effects. Animals were killed at 45 days by a schedule 1 method. The liver, 
lung and peritoneal cavity were examined for evidence of tumour.
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Results
A total of 12 rats (6 rats in each group) were implanted with the human HCC cell line 
C3A and human CRC cell line SW620. After 45 days, all animals were sacrificed. No 
evidence of tumour was found in liver, lung or peritoneal cavity. In four of the 
animals evidence was found of intrahepatic abscesses at the site of solid tumour 
insertion (Figure 8.1.B).
Experiment series II: Implantation of tumour tissue generated in subcutaneous 
tissues of nude mice into nude rat liver parenchyma
All procedures were performed as described in experiment series I except Rowett 
{rnu/rnu) nude rats were used as the experimental animals. These rats have a 
congenital absence of the thymus resulting in a severely deficient cell-mediated 
branch of the immune system. When maintained under specific pathogen-free (SPF) 
conditions, wasting and infections do not occur as frequently as in the nude mouse 
counterpart. The lack of T lymphocyte cells, combined with the size and robustness of 
the rnu/rnu rat and the absence of major endocrinological abnormalities observed in 
some strains, make it an attractive experimental model for biomedical research. In 
particular, the nude rat allows human tumour cells to grow without a mechanism for 
immunological rejection allowing potential use of the animal in xenografting human 
tumours (Fossum et al, 1980; Vos et al, 1980). Subcutaneous tumours were generated 
in nude mice and implanted intrahepatically into nude rats as described in experiment 
series I. Animals were killed at 45 days by a schedule 1 method. The liver, lung and 
peritoneal cavity were examined for evidence of tumour.
231
Chapter VIII: Orthotopic model o f  CRC liver metastases in nude rats in which to evaluate drug
cytotoxicity using the isolated dual-perfused rat liver________________________________________________
Results
A total of 4 Rowett nude rats (2 rats in each group) were implanted with the human 
HCC cell line C3A and human CRC cell line SW620. After 45 days, all animals were 
sacrificed. All implantation’s resulted in intrahepatic tumours (Figure 8.1.C). The 
mean tumour volumes of C3A and SW620 cells were 265 and 452 mm3, respectively. 
In view of the larger size of SW620 intrahepatic xenografts, this cell line was selected 
for further experiments.
Figure 8.1. A. Subcutaneous SW620 tumour nodules from nude mice implanted 
into rat liver parenchyma, B. examples of intrahepatic abscesses observed 
implantation into in Sprague Dawley rats, C. examples of intrahepatic xenografts of 
in Rowett nude rats.
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8.2.2 In vitro studies to determine drugs producing rapid DNA damage
As the life-span of the IPRL is generally considered to be approximately 3 to 4 hours 
under usual conditions (Gores et al, 1986), it was important to ensure that the 
cytotoxic drugs used in the perfusion experiments produced significant DNA damage 
within this time-span. Four drugs were initially chosen to examine the speed of onset 
of DNA damage on SW620 cells in vitro. First, cisplatin, which is known to cause 
peak interstrand crosslinks (ICLs) between 6 and 12 h over a wide range of doses 
(Chapter VI and [Zwelling et al, 1978]). Second, etoposide, which acts as an efficient 
DNA double strand (ds) breaker in proliferating cells with effects noted between 1 
and 2 h (Huang et al, 1998). Third, mechlorethamine hydrochloride (nitrogen mustard, 
HN2), whose primary mode of action is through alkylation of DNA, is known to 
exhibit increased ICLs for 1 to 2 h following which they are repaired (Ross et al, 
1978), and finally chlorambucil, which demonstrates ICLs within 3 h (Hartley et al, 
1999). SW620 cells were exposed to either 50 or 100 pM of each of the drugs for 1 h, 
washed, and either ICLs (cisplatin, HN2 and chlorambucil) or DNA strand breaks 
(etoposide) measured at 1, 2, 3 and 4 h using the comet assay.
Statistical analysis
Results were expressed as mean ±SEM. Comparison between percentage decrease in 
tail moment (TM) or TM with time for each chemotherapeutic agent was calculated 
by one-way analysis of variance (ANOVA) followed by a post test for linear trend, 
differences between doses were examined with the one-tailed unpaired t-test. 
Statistical significance was defined at P < 0.05.
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Results
Differences were observed in the timing of maximal DNA damage between drugs. 
Cisplatin and chlorambucil demonstrated a gradual increase in ICLs over 4 h, with a 
maximum percentage decrease in TM of over 30 and 50 % with 100 pM at 4 h 
respectively (Figure 8.2 A & D, Appendix 8.1). Both HN2 and etoposide demonstrated 
maximal DNA damage after 1 h (Figure 8.2 B & C, Appendix 8.1). DNA damage 
increased linearly with time with 100 pM cisplatin and with both concentrations of 
HN2 and chlorambucil (Figure 8.2 A, C & D, Appendix 8.2). After 1 h, DNA damage 
decreased linearly with time with 100 pM etoposide indicating repair (Figure 8.2 B, 
Appendix 8.2). Greater DNA damage was noted as the chemotherapeutic dose 
increased. This was statistically significant between 50 and 100 pM at all time points 
with cisplatin and HN2 , and at only 1 and 4 h with etoposide. There was no 
statistically significant difference in DNA damage between doses with chlorambucil 
(Figure 8.2, Appendix 8.3).
Nitrogen mustard and etoposide were selected for the following perfusion 
experiments because of their speed of action. Although chlorambucil caused more 
ICLs within 4 h than cisplatin, it did not demonstrate statistically significant 
differences in DNA damage between doses. Thus cisplatin was chosen in preference, 
cisplatin also provided continuity with the in vitro and in vivo work performed in 
Chapters VI and VII.
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Figure 8.2. Rate of formation of ICLs in vitro in SW620 cells with A. cisplatin, C. 
HN2 and D. chlorambucil, and B. rate of formation of ds DNA breaks with 
etoposide. Cells were incubated with 50 and 100 pM of each cytotoxic agent for 1 
h at 37°C, the cytotoxic agents were then removed and replaced by fresh medium. 
The comet assay was then used to quantify DNA damage at 1, 2, 3 and 4 h. Cells 
treated with alkylating agents (A., C. and D.) were irradiated immediately prior to 
analysis to deliver a fixed level of random strand breakage.
Values are the mean of three individual experiments ±SEM.
* one-way ANOVA with post test for linear trend.
• P < 0.05 between 50 & 100 pM (one-tailed unpaired t-test).
HN2, nitrogen mustard; ds, double strand breaks
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8.2.3 Isolated dual-perfused rat liver -  perfusion via portal vein and hepatic 
artery
SW620 tumours generated subcutaneously in nude mice, were implanted into the right 
and left lobes of livers of 10 Rowett (rnu/rnu) nude rats as described in experiment 
series I and II. On day 45 anaesthesia was induced with halothane and a 2:1 mixture 
of nitrous oxide:oxygen.
Surgical procedure
The abdomen was opened through a midline incision and the abdominal contents 
displaced to the left to expose the liver and common bile duct. The bile duct was 
cannulated with tubing obtained from a 22 GA catheter (Beckton Dickinson Infusion 
Therapy, Helsingborg, Sweden, 0.8 mm) and then tied securely in place. For smaller 
animals it was necessary to draw out the tubing to approximately one-half its starting 
diameter to successfully cannulate the duct. The abdominal contents were then 
displaced to the animal’s right and the thin strands of connective tissue between the 
left liver lobes and the stomach were cut. The lower oesophagus was cut between 
ligatures and then gently displaced inferiorly to expose the aorta and coeliac artery. 
The superior mesenteric artery, left and right renal arteries, and ileolumbar arteries 
were ligated. The left gastric and splenic arteries, branches of the coeliac artery and 
gastroduodenal artery were also ligated. Two loose ligatures were placed around the 
aorta, one above the coeliac artery and the other at the level of the left renal artery. 
Following these procedures, only the hepatic artery was left patent.
The abdominal contents were again displaced to the animals left, the strands of 
connective tissue between the right lobe of the liver and vena cava above the right 
kidney were cut, and a loose ligature passed around the abdominal vena cava. After
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heparinisation (0.2 IU/g/iv), the PV was cannulated using an 18 GA catheter (Beckton
Dickinson Infusion Therapy, Helsingborg, Sweden, 1.2 mm) and flushed with 20 ml
oxygenated perfusate. The inferior vena cava above the kidneys was tied to ensure
unidirectional flow, whereas the lower abdominal vena cava was severed to allow
immediate drainage. The diaphragm was then opened and the suprahepatic inferior
vena cava cannulated with an 18 GA catheter (Beckton Dickinson Infusion Therapy,
Helsingborg, Sweden, 1.2 mm) to collect outflow from the hepatic veins.
The aorta was tied below the level of the left renal artery and above the coeliac artery, 
then cannulated with an 18 GA catheter (Beckton Dickinson Infusion Therapy, 
Helsingborg, Sweden, 1.2 mm) and flushed with 2 ml heparinised saline. Finally, all 
loose ligatures were secured, the livers were excised, weighed, and placed on the 
perfusion circuit. All operative procedures were completed within 40-50 min.
Liver perfusion
The liver was placed on a removable petri dish and connected to the liver perfusion 
circuit in a closed recirculating system. The perfusion circuit consisted of two 
independent low-flow roller pumps (Watson-Marlow Limited, Falmouth, Cornwall, 
England, UK), and used polyvinylchloride tubing (Medtronic, Watford, UK) with an 
internal diameter of 3/16 inches. Grooves at the edge of the dishes stabilised the 
cannulae. The HA and PV cannulae were perfused at constant flow rates of 0.3 and 
1.5 ml/min/g liver, respectively. The instantaneous flow rate was measured by a 6 mm 
tubular flow probe connected to a Transonic Medical Flowmeter system (HT207, 
Transonic Medical System, NY, USA). Serial intraluminal pressure measurements 
were made by a Millar Mikro-tip catheter transducer (Millar Instruments, Houston,
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TX, USA) introduced via a Y-connection port. All outputs were fed into a commercial 
analogue-to-digital data acquisition recording system (ADC/MacLab, AD Instrument, 
Hastings, UK). The perfusate was collected from the suprahepatic inferior vena cava 
and returned to a shared reservoir by gravity. Circulating perfusate was oxygenated 
through a Maxima hollow-fibre oxygenator (Johnson & Johnson Cardiovascular, 
Division of McNeilab, Anaheim, CA, USA) with a mixture of 95% oxygen and 5% 
carbon dioxide. The pH, pC>2 and pCC>2 of the circulating perfusate were monitored at 
regular time intervals with an automatic blood gas, electrolyte and haematocrit 
analyser (BG Electrolytes System, Instrumentation Laboratory, Lexington, MA, 
USA), and corrections made accordingly to ensure constant physiological values. The 
temperature was kept constant at 37°C by keeping the reservoir within a heated water 
bath (Figure 8.3).
Portal vein
Liver K
Hepatic artery
Suprahepatic inferior Pha~81m m H g
Bile
Reservoir Pump Pump
Water Bath,
37°C
Oxygenator
Figure 8.3. Rat liver perfusion circuit. 
P, pressure; q, flow,
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The perfusate consisted of a modified Krebs’ solution (NaCl 150 mM, Hepes 10 mM, 
NaHCC>3 10 mM, Glucose 5 mM, MgCl2 1.18 mM, KH2PO4 5 mM in 100 ml 
Gelofusine [Vifor Medical, Sempach, Switzerland], a colloid solution of 4% 
succinylated gelatin in 0.9% NaCl, and 100 ml H20) containing 20% (vol./vol.) of 
outdated human Type O RBC’s (obtained from Blood Transfusion Services) and 1 IU 
heparin/ml (Ellis et al, 1996; Rothbarth et al, 2002).
Liver viability was assessed by gross liver appearance, stable HA and PV pressures, 
alanine aminotransferase (ALT) levels of the perfusate (measured using a standard 
clinical biochemistry autoanalyser [Hitachi 747 Autoanalyser, Boehringer Mannheim, 
Germany]), and bile production (measured directly with a calibrated collection 
vessel). At the end of each experiment, after FNA biopsies had been taken for analysis 
by the comet assay, the tumours were measured to calculate their volumes and then 
immediately frozen in liquid nitrogen and stored at -70°C until they were used for 
histological examination. The specimens were later sectioned and stained with 
haemotoxylin and eosin (H & E), and examined by light microscopy by an 
experienced histopathologist.
Figure 8.4. Examples of SW620 intrahepatic rat xenografts post perfusion.
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8.2.4 Analysis of spatial and temporal tumour drug induced DNA damage
One of the Rowett {rnu/rnu) nude rat livers was perfused with drug free perfusate as a 
control. As well as observing gross liver appearance, post perfusion histology, HA 
and PV pressures, ALT levels of the perfusate and bile production; FNA biopsies of 
tumour and wedge biopsies of normal liver were taken hourly to examine DNA 
integrity, and oxygen consumption (pM/min/g of liver) was calculated by (Mischinger 
et al, 1992):
PV O? content -  IVC O? content x flow (ml/min) x 44.6 
100 xW  (liver)
The normal liver wedge biopsies were reduced to a single cell suspension by finely 
mincing and filtering through a 30 pm nylon mesh, and then along with the procured 
FNA’s frozen immediately in 1 ml RPMI, 10% foetal calf serum and 10% DMSO at 
-80°C.
The other livers were initially perfused with drug free perfusate for 20 min to allow 
stabilisation. Prior to initiation of cytotoxic perfusion (i.e. Time = 0 h), tumour FNA 
biopsies were obtained. The cytotoxic agent was then added to the recirculating 
perfusate. Three cytotoxics were used in total; cisplatin, etoposide, and HN2 (see 
Section 8.2.2), a single agent was used in each experiment. Tumour FNA biopsies 
were taken at 60 min intervals at accessible sites and depths depending on the size of 
the tumour studied. FNA biopsies were frozen immediately in 1 ml RPMI, 10% foetal 
calf serum and 10% DMSO at -80°C. All samples were analysed using the comet 
assay (for details see Chapter II, Section 2.9). For the samples treated with alkylating 
agents one group was irradiated with 10 Gy using an X-ray source (dose rate 2.35
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Gy/min) and the other group remained unirradiated. For the samples treated with 
etoposide this step was omitted and thus only one group analysed.
Statistical analysis
Results were expressed as mean ±SEM. Statistical analysis of differences in perfusion 
characteristics with time were calculated using the two-tailed paired t-test. 
Comparison between percentage decrease in TM or TM with time and dose of each 
chemotherapeutic agent was calculated by one-way ANOVA followed by a post test 
for linear trend or the one-tailed unpaired t-test. Intra- and intertumour variability in 
percentage decrease in TM or TM with depth and site was calculated with either the 
two-tailed unpaired t-test or one-way ANOVA followed by the Bonferroni multiple t- 
test when three or more groups were compared. Statistical significance was defined at 
P < 0.05.
Results
A total of 10 Rowett (rnu/rnu) nude rats were implanted with SW620 tumours. One of 
the rats died 7 days post-implantation, the cause was unknown as it was ingested by 
the other animals within the cage. Table 8.1 summarises the pathological 
characteristics of the remaining 9 rats. Two rats generated only 1 intrahepatic 
xenograft, all the others produced a tumour in each lobe of the liver, giving a total of 
16 tumours with a median volume of 269.5 (range 22.5-1152) mm3.
Table 8.2 summarises the perfusion characteristics. All livers were perfused for 4 h, 
and median total perfusion flow was 20 (range 15-23) ml/min, the HA contributing 
17% (3.3 [range 2.5- 3.83] ml/min) and PV 83% (16 [range 13-19] ml/min).
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Experiment Tumour
implant
No.tumours Tumour
No.
Size
(mm)
Tumour
volume
(mm3)
Cytotoxic
perfused
1 SW620 lx 1 5 x 3 22.5 Cisplatin 50pM
2 SW620 2x 2 10x5 125 Cisplatin lOOpM
3 5 x 4 40
3 SW620 2x 4 15x5 187.5 Cisplatin 100pM
5 10 x 5 125
4 SW620 2x 6 1 6 x 9 648 Etoposide 50pM
7 18 x 8 1152
5 SW620 2x 8 12x 8 768 Etoposide lOOpM
9 1 5 x 7 735
6 SW620 2x 10 16x7.5 450 HN2 50pM
11 7 x 4 56
7 SW620 2x 12 1 6 x 8 512 HN2 lOOpM
13 11 x 7 269.5
8 SW620 2x 14 14 x 7 343 HN2 lOOpM
15 4 x 4 32
9 SW620 lx 16 7 x 6 126 Control
Tumour volume = (length x width2)/2 mm3
Table 8.1. Isolated Perfused Rat Liver characteristics.
Characteristics Median Range
Liver weight (g) 11.08 7.14- 11.84
Hepatic artery flow (ml/min) 3.34 2.5-3.84
Portal vein flow (ml/min) 16.71 12.93-19.24
Hepatic artery pressure (mm Hg) 81.75 67-89
Portal vein pressure (mm Hg) 8.73 6.2-13.3
Bile flow (ml/hr) 0.24 0.15-0.43
ALT (IU/L) 21.5 17-33
ALT, alanine aminotransferase
Table 8.2. Isolated Perfused Rat Livers: Perfusion Characteristics at 1 h (n=9)
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Figure 8.5 summarises the viability parameters of the nude rat liver perfused with
drug free perfusate as a control. It maintained a normal gross appearance, remaining
homogenous in colour without the evidence of white spots caused by air emboli or red
spots due to nonhomogenous perfusion. Although swelling of hepatocytes was noted
on histological examination there was no necrosis and tissue structures of both tumour
and normal liver were preserved. Hepatic arterial pressure, bile production and
oxygen consumption values tended to decrease, whilst PV pressure and ALT levels of
the perfusate tended to increase with time. All values were solitary during a single
experiment, thus statistical significance could not be calculated. The TMs of the
control tumour and wedge biopsies of normal liver remained stable within the
experiment with no statistically significant differences in values between 1 and 4 h (P
= 0.8101 and 0.7879 respectively).
Liver viability whilst on the perfusion circuit of the IDPRLs treated with cytotoxics 
was confirmed by gross appearance, histological examination, stable HA and PV 
pressures, and bile production (Figure 8.6 A-C). Although the overall trend for the 
pressures was to increase and bile production to decrease, they were not statistically 
significant between 1 and 4 h. The increase in mean levels of ALT during perfusion, 
however, were statistically significant between 1 and 4 h (Figure 8.6 D).
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Time on perfusion circuit (h) Time on perfusion circuit (h)
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0 1 2 3 54
Q Time on perfusion circuit (h) Time on perfusion circuit (h)
- Control Tumour
Normal liver
c1
i
0 1 2 3 4 5 0 1 2 3 4 5
Time on perfusion circuit (h) Time on perfusion circuit (h)
G
Figure 8.5. Viability parameters of the control liver and tumour whilst on the 
perfusion circuit. A. HA pressure, B. PV pressure, C. bile production, D. ALT levels 
of the perfusate, E. TM as assessed by the comet assay of the control tumour and 
normal liver, and F. O2 consumption (values are a single measurement except E. 
where values are the mean +SEM of 25 measurements and P > 0.05 between 1 and 4 
h using the two-tailed t-test). G. Histology of control liver post perfusion 
demonstrating swelling of hepatocytes (high power view, x 10 objective lens).
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Time on perfusion circuit (h) Time on perfusion circuit (h)
Time on perfusion circuit (h) Time on perfusion circuit (h)
Figure 8.6. Viability of livers treated with chemotherapeutic agents whilst on the 
perfusion circuit was confirmed by stable A. HA and B. PV pressures, and C. bile 
production (values are the mean [±SEM] of 8 individual experiments, P > 0.05 
between 1 and 4 h using the two-tailed paired t-test). D. Mean ALT levels of the 
perfusate increased significantly between 1 and 4 h using the paired t-test (*, P = 
0.0423).
245
Chapter VIII: Establishment o f  intrahepatic xenograft o f  human CRC in the nude rat and quantification
o f  drug induced D N A  damage in the isolated dual-perfused rat liver__________________________________
Greater DNA damage was noted as the chemotherapeutic dose increased. This was
statistically significant between 50 and 100 juM at all time points with etoposide and
HN2, and from 2 h onwards with cisplatin (Figure 8.7, Appendices 8.4 & 8.5).
Differences were observed in the timing of maximal DNA damage between drugs
during perfusion. Both etoposide and HN2 had maximal effects after 1 h, whilst
cisplatin demonstrated a gradual increase in ICLs over the 4 h experiment (Figure
8.7). DNA damage increased linearly with time at both cisplatin concentrations, and
decreased linearly with time after 1 h with 100 pM etoposide. There was no
statistically significant linear relationship with either dose of HN2 or 50 pM etoposide
(Figure 8.7, Appendix 8.6).
Only 7 of the intrahepatic xenografts were large enough to take samples at different 
depths. There was no statistically significant difference in TM between superficial and 
deep portions of the tumours prior to perfusion with cytotoxic drugs (Figure 8.8, 
Appendix 8.7). Once perfusion with cytotoxics commenced, however, superficial 
cells generally had higher levels of DNA damage in comparison to deep cells, these 
were statistically significant in at least 3 time-points in 4 of the 7 perfused tumours 
large enough to take samples at different depths (Figure 8.9, Appendix 8.8).
When comparing cytotoxic induced DNA damage at different sites at the same depth 
in the same tumour, statistically significant differences were observed in only one 
tumour (Appendix 8.9). No significant differences were observed between different 
tumours in the same liver at the same depth (Appendix 8.10).
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Figure 8.7. Effect of cytotoxic drugs on tumour DNA with time as assessed by the 
comet assay. Values are the mean (±SEM) of 2 (A. 50 pM), 4 (B. 50 & 100 pM; C. 
50 pM), 5 (C, 100 pM) & 8 (A. 100 |aM) measurements. (*), statistically significant 
with one-way ANOVA with post test for linear trend; (•), P < 0.05 between 50 pM 
& 100 pM using the one-tailed unpaired t-test.
HN2 , nitrogen mustard.
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Figure 8.8. Tail M om ent o f  intrahepatic hum an xenografts in nude rat livers at 
different depths prior to perfusion w ith cytotoxic drugs (T im e =  0 h) as assessed by 
the com et assay. Tw enty five individual cells from  each sam ple are represented. 
There were no statistically significant differences betw een sam ples using the two- 
tailed unpaired t-test.
HN 2 , nitrogen mustard.
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Figure 8.9. Percentage decrease of Tail Moment or Tail Moment of the same tumour 
and site but different depths during perfusion with cytotoxic drugs as assessed by the 
comet assay.
P < 0.05, two-tailed unpaired t-test
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8.3 Discussion
Using a closed recycling system, intrahepatic xenografts of human CRC in the nude 
rat have been perfused for 4 h using the IDPRL system and treated with 
chemotherapeutic agents allowing quantification and localisation of drug induced 
DNA damage.
Liver metastases of CRC remains a challenging problem associated with poor 
prognosis. It is generally accepted that the host microenvironment influences tumour 
biology with discrepancies noted in the efficacy of systemic treatments between 
ectopic and orthotopic tumours (Fidler, 1995), thus an appropriate experimental 
model based on orthotopic liver xenografts of human CRC may help to find new 
therapeutic options. Intrahepatic xenograft tumour models for human CRC in nude 
rats have previously been reported for the cell lines LS174T (Stein and Berger, 1999; 
Sundin, 1993; Sundin et al, 1993), HT-29 (Ashraf et al, 1997; Shen et al, 2000; Vogel 
et al, 1998), and LOVO (Zhang et al, 2003a; Zhang et al; 2003b). Of these studies, 
only Zhang et al have used this model to investigate new chemotherapeutic options by 
studying portal venous infusion of enhanced human carcinoembryonic antigen (CEA) 
promoter for yeast cytosine deaminase (yCD), which converts 5-fluorocytosine (5- 
FC) to 5-fluorouracil (5-FU), and subsequent intraperitoneal 5-FC treatment (Zhang et 
al, 2003b). In the current study, by direct implantation of solid tumour 
intrahepatically, successful generation of xenografts was achieved in 88% of cases. 
This compares favourably with previous studies, which report successful colonisation 
in only 50-60% of nude rats following injection of cells either directly into the liver 
(Stein and Berger, 1999; Zhang et al, 2003a; Zhang et al, 2003b), or via mesenteric, 
splenic or portal veins. Tumour growth in this study was found to be extremely
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variable over 45 days as reflected by a median volume of 269.5 with a range of 22.5- 
1152 mm3. The reason for this is unclear. All tumours were originally generated 
subcutaneously in nude mice, all had 2 mm3 of macroscopically similar tissue 
implanted, and all tumours were generated for 45 days. Similar observations have 
been noted with other models, for example LS174T cells showed an exponential but 
somewhat irregular growth in the liver of nude rats within the observation period of 6 
weeks (Stein and Berger, 1999).
Unlike the PV, the HA in the rat cannot be cannulated directly due to its small size 
and strong adhesion to the PV. Therefore, an indirect approach is employed for the 
cannulation of the HA. The major discriminatory feature among the various published 
methods for the IDPRL is the level of cannulation. In most cases, the rat liver is 
perfused by cannulation of the coeliac artery (Ahmad et al, 1984; Pang et al, 1988; 
Reichen, 1988), or aorta (Gardemann et al, 1987; Gascon-Barre et al, 1988; Kassissia 
et al, 1994). Although cannulation of the HA via the gastroduodenal artery (GDA) is a 
more direct method, in pharmokinetic studies, this method is restricted to larger 
animals such as the rabbit (Alexander et al, 1992), cat and dog (Lautt et al, 1993), 
mainly due to the larger size of the vessel. However, the rat has been used 
successfully as an animal model for the study of regional delivery of 
chemotherapeutic agents, such as mitomycin C and 5-FU (de Brauw et al, 1991; 
Hemingway et al, 1991; Marinelli et al, 1990), via the GDA. Among the methods of 
cannulation of the HA, despite the longer operation time, aortic cannulation was 
found to be the most suitable method in this study largely due to the relative ease of 
introducing a cannula. As most authors do not report the problems associated with the 
surgical procedure, it is difficult to make a comparison with the literature. One study,
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however, specifically examining the 3 surgical procedures for HA perfusion, reported 
a low success rate of this method (30-40%) mainly due to extensive leaking, including 
leakage from the surface of the liver (Sahin and Rowland, 1998).
The rate at which substances can diffuse across the hepatic arterial and portal venous 
vasculatures has been shown to be modulated by the magnitude of the arterioportal 
pressure gradient (Browse et al, 1995). Thus constancy of both perfusion pressure and 
flow rate during an experiment is a prerequisite to approximate physiological 
conditions and maintain uniformity between experiments (Gores et al, 1986; Ross, 
1972). Perfusion at lower pressures may result in nonhomogenous perfusate 
distribution within the liver, whilst the use of high perfusion pressures can result in an 
enlargement of sinusoidal fenestrations (Fraser et al, 1980) and barotrauma of the 
liver. The flow rates of 0.3 ml/min/g liver (HA) and 1.5 ml/min/g liver (PV) resulted 
in physiological perfusion pressures. Although it is appreciated that in vivo two thirds 
of the blood supply normally comes from the PV and one third from the HA, attempts 
to increase the HA flow during perfusion led to unacceptably high HA perfusion 
pressures.
The oxygen-carrying capacity of the perfusate was increased by the addition of 
erythrocytes, the haematocrit value of 20% is reported to be the ideal combination of 
blood and perfusate for the optimum oxygen-carrying capacity at physiological 
pressures (Riedel et al, 1983). Because human red blood cells are readily available 
from blood banks, previous investigators have employed them for isolated liver 
studies (Burczynski et al, 1996; Ellis et al, 1996; Rothbarth et al, 2002). Because of 
higher oxygen-carrying capacity higher flow rates were not required. Oxygen
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consumption in the control liver gradually decreased throughout the perfusion (Figure
8.5.F) consistent with a decline in the viability of erythrocytes. Throughout the
perfusion of both the control and livers treated with cytotoxics ALT levels rose, this
may have been a reflection of loss of viability of the livers but could also be explained
by haemolysis of red cells (Mischinger et al, 1992).
Although a number reports exist describing in situ perfusion of cytotoxics via the HA 
and PV of rat livers bearing rat CRC cell lines (Hemingway et al, 1991; Marinelli et 
al, 1990; Radnell et al, 1990), only one report to our knowledge describes an IDPRL 
model with a rat CRC cell line (Rothbarth et al, 2002). There are no reports to date of 
an IDPRL model with human CRC being perfused with cytotoxics.
Experiments using the IDPRL with a human CRC xenograft have confirmed the 
ability of the comet assay to detect DNA damage in FNA biopsies, demonstrating a 
similar time course of DNA damage relative to chemotherapy administration to in 
vitro cells and a similar relationship between dose of either ICLs or ds breaks. Two 
features are of note: firstly with etoposide, maximal ds breaks reflected by TM occur 
at 1 h after which the TM decreases. This response curve reflects the sum of a number 
of factors: damage induction by the circulating drug, pharmacological clearance of the 
etoposide, and repair of the drug induced ds breaks. The maximal damage at 1 h 
correlates with in vivo data in human WIDR carcinomas xenografted in nude mice 
treated with etoposide (Huang et al, 1998), whilst perfusion of the control liver in this 
section failed to demonstrate any significant increase in DNA damage after perfusion 
over a 4 h period. With the perfused rat liver model using 20% rat blood, 90% of drug 
clearance can be accounted for by the direct biliary clearance of etoposide or
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conjugation to glucuronide with a drug half-life of 44 min (Hande et al, 1988). Thus
the decrease in TM observed here would appear to be the result of DNA repair.
Secondly, although there were no significant differences in DNA damage prior to
perfusion with chemotherapeutic agents, a number of tumours displayed differences
once cytotoxics had been added to the perfusate. Autopsy studies of liver metastases
have demonstrated a decrease in the number of tumour vessels in their centre (Lin et
al, 1984). Generally, small molecules with a molecular weight (MW) < 1000 show a
more rapid diffusion into tissues than large molecules, such as antibodies or viral
vectors. Under conditions of extensive intracellular binding and a low plasma
membrane transport rate, penetration from the periphery to the centre of such drugs,
such as cisplatin, etoposide and HN2 (MWs 300, 588.6 and 192.5 respectively), can be
slowed down considerably. The slow penetration of the small molecule drug
doxorubicin has been shown in patients, resulting in gradients in clinical biopsies of
solid tumours (Lankelma et al, 1999). Cells in the centre of tumour islets, which are
the most remote from the microvessels, are exposed to lower drug concentrations in
the surrounding extracellular fluid compared to the cells in the periphery. It could be
argued that when the gradient reverses during drug clearance from the blood, the drug
concentration in the cells at the periphery might become lower when compared to
cells at the center.
This investigation was performed on only one tumour cell line and with a limited 
number of tumours. Studies on other CRC or HCC cell lines with larger variations in 
blood supply and drug sensitivities may lead to different results. Thus, this section of 
the study should primarily be regarded as a presentation of a methodological approach
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for investigating intra- and intertumoural heterogeneities in drug induced DNA 
damage.
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IX. RESPONSE TO CHEMOTHERAPY IN HCC AND CRC METASTASES IN 
THE ISOLATED PERFUSED HUMAN LIVER
9.1 Introduction
The efficacy of chemotherapy in CRC and HCC has been approached to date using 
firstly in vitro cell culture studies (Chapters III-VI), which do not take into account 
the microenvironment of malignant cells, and secondly xenograft models in severe 
combined immunodeficient mice (Chapter VII), which do not behave like naturally 
occurring tumours in humans. In addition the isolated dual-perfused rat liver (IDPRL) 
has been used to assess the spatial and temporal pattern of chemotherapy related 
cancer DNA damage (Chapter VIII).
Normothermic extracorporeal perfusion of porcine livers has previously been used to 
optimise organ preservation protocols (St Peter et al, 2002). Butler et al have shown 
that the porcine liver can be perfused for up to 72 h (Butler et al, 2002), and Schon et 
al have demonstrated that livers preperfused before transplantation functioned well 
even if damaged by 1 h of warm ischaemia (Schon et al, 1993). Human cirrhotic and 
normal livers have also been perfused in isolation to study hepatic microcirculation 
and drug elimination (Villeneuve et al, 1990; Villeneuve et al, 1996a; Villeneuve et 
al, 1996b), and to study augmentation of portal blood flow to improve liver function 
(Cardoso et al, 1994).
Isolated in situ liver perfusion has been used to deliver the chemotherapeutic agent 
melphalan to patients with CRC hepatic metastases to examine its conjugation with 
glutathione (GSH) (Vahrmeijer et al, 1996). Similarly, isolated in situ lung perfusion
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with doxorubicin to patients with pulmonary sarcoma metastases has been used to 
study MDR1 gene expression (Abolhoda et al, 1999). A major limitation of 
conventional clinical studies has been the time lag between administration of 
chemotherapeutic agents and the determination of MDR1 status. Using the isolated 
lung perfusion model the immediate molecular events occurring in tumours in situ in 
response to acute drug exposure could be accurately assessed.
In the current section of this study, liver specimens obtained from patients undergoing 
hemihepatectomy for liver tumours were perfused ex vivo with an oxygenated 
modified Krebs bicarbonate buffer solution containing 20% (vol./vol.) pre-washed 
human red blood cells (RBC) at 37°C for up to six hours, in order to investigate the 
short term effects of chemotherapeutic agents used in the treatment of liver cancer. As 
many chemotherapeutic agents produce DNA damage, the comet assay was used to 
detect DNA double-strand breaks and crosslinks (Fairbaim et al, 1995; Hartley et al, 
1999). As only a few thousand cells are required for this assay, samples can be taken 
by fine needle aspiration (FNA) biopsies from a variety of sites within tumour nodules 
and can be repeated during the perfusion period (Olive et al, 1993).
9.2 Materials and methods
9.2.1 Patients and Tissue procurement
Eight patients undergoing hepatic resection for either HCC or CRC metastases were 
selected. The Royal Free Hospital (RFH) ethics committee approved the study, 
patients completed fully informed consent for the use of resected specimens in 
research.
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9.2.2 Liver Perfusion Technique
At operation, the relevant hepatic duct, hepatic artery (HA) and branch of the portal 
vein (PV) were divided between ligatures. The relevant hepatic vein was also divided 
and the lobe removed to be immediately placed on ice. The branch of the PV was 
cannulated with polyvinylchloride tubing (Medtronic, Watford, UK) with an internal 
diameter of % inch, intravenous cannulae (Beckton Dickinson Infusion Therapy, 
Helsingborg, Sweden) were used for the branch of the HA (14 GA, 2 mm) and the 
hepatic duct (16 GA, 1.7 mm). The liver was flushed with 1 L of ice cold University 
of Wisconsin (UW) solution (Viaspan®; Du Pont, Stevenage, UK), used widely for 
cold liver graft preservation (Kalayoglu et al, 1989), through the PV and HA branches. 
The effluent was then discarded. The specimen was immediately transported on ice to 
the experimental laboratory. The liver was weighed, and to prevent oozing from the 
resection surface was coated with Op Site spray (Smith and Nephew Medical Limited, 
Hull, England, UK).
The liver was placed on a purpose-built Perspex tray and connected to the liver 
perfusion apparatus in a closed recirculating system consisting of independent roller 
pumps (Watson-Marlow Limited, Falmouth, Cornwall, England, UK) for the PV and 
HA using polyvinylchloride tubing (Medtronic, Watford, UK) with an internal 
diameter of V* and 3/16 inches. The instantaneous flow rates were measured by 6 and 
8 mm tubular flow probes connected to a Transonic Medical Flowmeter system 
(HT207, Transonic Medical System, NY, USA). Serial intraluminal pressure 
measurements were made by a Millar Mikro-tip catheter transducer (Millar 
Instruments, Houston, TX, USA) introduced via a Y-connection port. 
Microcirculatory perfusate flow of the tumours was measured using laser doppler
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flowmetry (LDF) (DRT4, Moor Instruments Limited, Axminister, UK). All outputs 
were fed into a commercial analogue-to-digital data acquisition recording system 
(ADC/MacLab, AD Instrument, Hastings, UK). The perfusion fluid was collected 
from the hepatic veins and returned to the reservoir by gravity. Circulating perfusate 
was oxygenated through a Maxima hollow-fibre oxygenator (Johnson & Johnson 
Cardiovascular, Division of McNeilab, Anaheim, CA, USA) with a mixture of 95% 
oxygen and 5% carbon dioxide. The pH, pC>2 and pCC>2 of the circulating perfusate 
were monitored at regular time intervals with an automatic blood gas, electrolyte and 
haematocrit analyser (BG Electrolytes System, Instrumentation Laboratory, 
Lexington, MA, USA), and corrections made accordingly to ensure constant 
physiological values. The temperature was kept constant at 37°C by keeping the 
reservoir within a heated water bath (Figure 9.1). The perfusate consisted of 1.5 L 
Krebs bicarbonate buffer (pH 7.4) containing 20% (vol./vol.) prewashed human Type 
O RBC’s (obtained from Blood Transfusion Services), 20 gm/L BSA, 2 gm/L alpha 
1-acid glycoprotein, 2.1 mmol/L calcium, and 5.5 mmol/L glucose (Villeneuve et al. 
1990). The perfusate was supplemented with 7000 units of heparin. Liver viability 
was assessed by gross liver appearance, measuring HA and PV pressures, measuring 
alanine aminotransferase (ALT) levels of the perfusate using a standard clinical 
biochemistry autoanalyser (autoanalyser Hitachi 747 Autoanalyser, Boehringer 
Mannheim, Germany), and bile production (measured directly with a calibrated 
collection vessel).
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Liver
Hepatic portal vein
Reservoir
Heater
Hepatic vein
L_ I1Bile
Hepatic artery
q-85.5ml/min
Pha~54mmHg
q -2 0 5 m l  min
P ~17mmHg
Oxygenator
Figure 9.1. Extracorporeal perfusion circuit. FP, flow probe; P, pressure; q, 
flow; ivc, inferior vena cava; ha, hepatic artery; pv, portal vein.
At the end of each experiment the liver was perfused with 10% formalin and the 
specimen taken for histological examination. Sections were stained with 
haemotoxylin and eosin (H & E), and examined by light microscopy by an 
experienced histopathologist. Figure 9.2 demonstrates a typical perfused hemiliver.
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A
B
Figure 9.2. Control perfused hemiliver. A. Pre-operative CTScan demonstrating 
CRC metastases in segment VI. B. Hemiliver being perfused on perfusion 
apparatus. C. Macroscopic histological specimen demonstrating CRC metastases.
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9.2.3 Analysis of spatial and temporal tumour drug induced DNA damage
One of the hemilivers was perfused with drug free perfusate as a control. As well as 
observing gross liver appearance, post perfusion histology, HA and PV pressures, 
ALT levels of the perfusate and bile production; FNA biopsies of tumour and wedge 
biopsies of normal liver were taken hourly to examine DNA integrity, and oxygen 
consumption (pM/min/g of liver) was calculated by (Mischinger et al, 1992):
PV O? content - 1 VC O? content x flow (ml/min) x 44.6 
100 x W (liver)
The normal liver wedge biopsies were reduced to a single cell suspension by finely 
mincing and filtering through a 30 pm nylon mesh, and then along with the procured 
FNA’s frozen immediately in 1 ml RPMI, 10% foetal calf serum and 10% DMSO at 
-80°C.
The other livers were initially perfused with drug free perfusate for 20 min to allow 
stabilisation. Prior to initiation of cytotoxic perfusion (i.e. Time = 0 h), tumour FNA 
biopsies were obtained. The cytotoxic agent was then added to the recirculating 
perfusate. Three cytotoxics were used in total; cisplatin, etoposide, and 
mechlorethamine hydrochloride (nitrogen mustard [HN2]), a single agent was used in 
each experiment. Tumour FNA biopsies were taken at 60 min intervals at accessible 
sites and depths depending on the size of the tumour studied. FNA biopsies were 
frozen immediately in 1 ml RPMI, 10% foetal calf serum and 10% DMSO at -80°C.
All samples were analysed using the comet assay (for details see Chapter II, Section 
2.9). For the samples treated with alkylating agents one group was irradiated with 10
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Gy using an X-ray source (dose rate 2.35 Gy/min) and the other group remained 
unirradiated. For the samples treated with etoposide this step was omitted and thus 
only one group analysed.
Statistical analysis
Results were expressed as mean ±SEM or SD. Statistical analysis of differences in 
perfusion characteristics with time were calculated using the two-tailed paired t-test. 
Comparison between percentage decrease in tail moment (TM) or TM with time and 
dose of each chemotherapeutic agent was calculated by one-way analysis of variance 
(ANOVA) followed by a post test for linear trend or the one-tailed unpaired t-test. 
Intra- and intertumour variability in percentage decrease in TM or TM with depth and 
site was calculated with either the unpaired t-test or one-way ANOVA followed by 
the Bonferroni multiple t-test when three or more groups were compared. Statistical 
significance was defined at P < 0.05.
Results
Table 9.1 summarises the clinicopathological characteristics of the 8 patients. Seven 
patients had moderately differentiated CRC metastases and had received between 4 
and 6 cycles of pre-operative systemic chemotherapy with 5-FU and folinic acid. Two 
of those with CRC metastases presented with synchronous tumours, those with 
metachronous tumours had a mean disease free interval of 28.2 months (± SD 18.1). 
One patient had an HCC and had not received any pre-operative chemotherapy. A 
total of 13 tumours (12 CRC, 1 HCC) of median size 30 (range 20-85) mm were 
perfused in 8 hemilivers (1 left and 7 right).
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Table 9.2 summarises the perfusion characteristics. Median perfusion time was 5 
(range 4-6) h and median total perfusion flow 300 (range 110-420) ml/min, the HA 
contributing 35% (85.5 [range 35-190] ml/min) and PV 65% (205 [range 65-250] 
ml/min). Median microcirculatory perfusate flow of surface accessible tumours was 
187 (range 155-207) flux units indicating perfusion and exposure to cytotoxic agents.
Figure 9.3 summarises the viability parameters of the hemiliver perfused with drug 
free perfusate as a control. It maintained a normal gross appearance, remaining 
homogenous in colour without evidence of white spots caused by air emboli or red 
spots due to nonhomogenous perfusion. Histological examination demonstrated 
minimal to no necrosis and preserved tissue structures of both tumour and normal 
liver. Microcirculatory perfusate flow and oxygen consumption values tended to 
decrease, whilst PV pressure, bile production and ALT levels of the perfusate tended 
to increase with time. Hepatic arterial pressures initially decreased then increased to 
values similar to those observed at the onset of perfusion. All values were solitary 
during a single experiment, thus statistical significance could not be calculated. The 
TMs of the control tumour and wedge biopsies of normal liver remained stable within 
the experiment with no statistically significant differences in values between 1 and 4 h 
(P = 0.34 and 0.1145 respectively) (Appendix 9.1).
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Pt Sex Age
( y )
Hepatect
“°my
Diagnosis No.tumours/size
(mm)
Tumour
No.
Previous
Chemotherapy
Liver
metastases
Cytotoxic
perfused
1 F 53 Right CRC
Mod. Diff.
2x (52 x 48 x 65) 
(31x24x30)
1 & 2 5-FU/folinic
acid
Synchronous Cisplatin
23.3pM
2 M 51 Right CRC
Mod. Diff.
2x (20 x 20) 
(25 x 25)
3 & 4 5-FU/folinic
acid
Synchronous Cisplatin
50pM
3 M 64 Right CRC
Mod. Diff.
2x (42 x 37 x 32) 
(80 x 72 x 55)
5 & 6 5-FU/folinic
acid
Metachronous Cisplatin
lOOpM
4 M 58 Right CRC
Mod. Diff.
lx (85 x75 x 75) 7 5-FU/folinic
acid
Metachronous Etoposide
50pM
5 M 55 Right HCC lx (80x75 x50) 8 Nil N/A Etoposide
lOOpM
6 M 56 Right CRC
Mod. Diff.
lx (30x25 x25) 9 5-FU/folinic
acid
Metachronous h n 2
50pM
7 M 57 Left CRC
Mod. Diff.
3x (24 x 24) 
(30 x 15) 
(25 x 25)
10, 11 & 
12
5-FU/folinic
acid
Metachronous h n 2
lOOpM
8 M 51 Right CRC
Mod. Diff.
lx (25 x23) 13 5-FU/folinic
acid
Metachronous Control
CRC, colorectal cancer; Mod. Diff., moderately differentiated adenocarcinoma; 
HN2, nitrogen mustard.
Table 9.1. Patient clinicopathological characteristics.
Characteristics Median Range
Liver specimen weight (g) 749 678-1899
Duration of perfusion (h) 5 4-6
Total hepatic flow (ml/min) 300 110-420
Hepatic artery flow (ml/min) 85.5 35-190
Portal vein flow (ml/min) 205 65-250
Hepatic artery pressure (mmHg) 55 40-81
Portal vein pressure (mmHg) 17 9-24
Bile production (ml/hr) 4 3-6
ALT (IU/L) 250 71-464
Microcirculatory perfusate flow 
(flux)
187 155-207
ALT, alanine aminotransferase.
Table 9.2. Isolated Perfused Hemilivers: Perfusion Characteristics (n=8)
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Time on perfusion circuit (h)Time on perfusion circuit (h)
Time on perfusion circuit (h) Time on perfusion circuit (h)
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Time on perfusion circuit (h)
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0.4-0 1 2 3 4 5 6
Time on perfusion circuit (h)
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Figure 9.3. Viability parameters of the control liver and tumour whilst on the 
perfusion circuit. A. HA pressure, B. PV pressure, C. bile production, D. ALT levels 
of the perfusate, E. microcirculatory perfusate flow, F. O2 consumption and G. TM as 
assessed by the comet assay of the control tumour and normal liver (values are a 
single measurement except G. where values are the mean ±SEM of 25 measurements 
and P > 0.05 between 1 and 4 h using the two-tailed paired t-test). H. Histology of 
control liver following 5 h of perfusion showing the infiltrative edge of the moderately 
differentiated CRC in the control hemiliver. There is some fibrosis and a moderate 
surrounding chronic inflammatory cell infiltrate with minimal to no necrosis and 
nreserved tissue structure thigh nower view, x 10 obiective lensV
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Figure 9.4 summarises the viability parameters of the hemilivers treated with 
cytotoxics. All hemilivers maintained a normal gross appearance and HA and PV 
pressures remained stable. Although the overall trend for bile production was to 
increase and microcirculatory perfusate flow to decrease, there was no statistical 
significance between 1 and 4 h (P = 0.489 and 0.332 respectively) (Appendix 9.1). 
Mean level of alanine aminotransferase (ALT) increased with time and this was 
statistically significant between 1 and 4 h (P = 0.0108) (Appendix 9.1). All the 
hemilivers with CRC tumours showed normal histological architecture of the liver 
except that perfused with 100 pM cisplatin which showed necrosis and collapse of 
peritumoural liver cell plates, a feature often observed histologically with CRC liver 
metastases (Figure 9.5 A & B). The HCC tumour displayed diffuse necrosis and 
architectural destruction centrally. This was reflected in high TMs with the comet 
assay, a normal finding with necrotic cells (Figures 9.5 C & D).
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Figure 9.4. Viability of livers treated with chemotherapeutic agents whilst on the 
perfusion circuit was confirmed by stable A. hepatic artery and B. portal vein 
pressures, C. bile production, and E. microcirculatory perfusate flow (values are 
the mean [±SEM] of 7 [1-4 h] & 5 [5 h] individual experiments). P > 0.05 between 
1 and 4 h using the two-tailed paired t-test. D. Mean ALT levels of the perfusate 
increased significantly between 1 and 4 h using the paired t-test (* P = 0.0108).
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B
C D
Figure 9.5. Abnormal histological findings post perfusion with cytotoxics. A. & B. 
Low and high power views (x 2.5 & x 10 objective lens) following 5 h of perfusion 
of the moderately differentiated CRC perfused with 100 pM cisplatin. Although the 
tumour remains well preserved there is extensive necrosis and collapse of the 
surrounding liver cell plates. C. & D. Low and high power views (x 2.5 & x 10 
objective lens) following 5 h of perfusion of the HCC perfused with 100 pM 
etoposide. Superficially the HCC remained well-preserved (C.). There is both 
trabecular and microacinar architecture with an infiltrative edge and vascular 
invasion. At deeper levels (D.) the HCC tumour mass was necrotic with ghost 
outlines of trabecular structure and bile pigment.
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Greater DNA damage was observed as the chemotherapeutic dose increased. This was 
statistically significant from 3 h onwards with cisplatin, at all timepoints except 3 h 
with etoposide and only 1 and 2 h with HN2 (Figure 9.6, Appendices 9.5, 9.6 & 9.7). 
Differences were observed in the timing of maximal DNA damage of tumour cells 
between drugs during perfusion. Both etoposide and HN2 had maximal effects at 1 h, 
whilst cisplatin demonstrated a gradual increase in DNA damage over 5 h (Figure 
9.6). DNA damage increased linearly with time at all cisplatin concentrations (P < 
0.0001). There was no linear relationship with etoposide and HN2 with time (Figure 
9.6, Appendix 9.8).
All tumours were large enough to take samples at different depths. The majority of 
tumours failed to demonstrate any statistically significant difference in TM between 
superficial and deep portions of tumours during perfusion with drug free perfusate 
prior to the addition of cytotoxic drugs (Figure 9.7, Appendix 9.9). Significant 
differences, however, were noted between 0.5 and 2 cm in Tumour 6 (P < 0.05), 1 and 
4 cm in Tumour 7 (P < 0.05), and between 0.5 and 1.5, 2 and 3 cm in the Tumour 8 (P 
< 0.05, < 0.001 and < 0.001 respectively (Figure 9.7, Appendix 9.9). In these tumours 
central necrosis was observed on histological examination at deeper portions of the 
tumours.
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Cisplatin
100-
si- 80-a>
2  60-
3 5 60 2 41
-23.3pM
50nM
100pM
Time on perfusion circuit (h)
E top osid e
c
1
i
o 2 3 4 5 61
-50pM
100pM
Time on perfusion circuit (h)
HN,
—  50mM
—  100pM
20H
o-
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Time on perfusion  circuit (h)
Figure 9.6. Effect o f  cytotoxic drugs on tum our DNA w ith tim e as assessed by the 
com et assay. V alues are the m ean (±SEM ) o f  6 (A. & B.) and 12 m easurem ents (C .) 
at 0.5 & 1 cm.
* P <  0.001, linear trend w ith tim e w ith 23.3, 50 & 100 (iM cisplatin  (one-w ay 
A N O V A  w ith post test for linear trend).
•  P < 0.001, linear trend w ith concentration w ith 23.3, 50 & 100 pM  cisplatin (one­
way A N O V A  with post test for linear trend).
o P < 0.001, betw een 50 & 100 pM  cisplatin (one-tailed unpaired t-test).
# P < 0.05, betw een 50 & 100 pM  etoposide and H N 2 (one-tailed unpaired t-test).
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Tumour 2 ,1.5cm
*
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Tumour 4 ,1cm
Liver sp e c im en  3
Tumour 5, 0.5cm 
Tumour 5. 2cm 
Tumour 6 ,0.5cm 
Tumour 6,1cm 
TUmour 6 ,2cm
Liver s p e c im en  5
Liver sp e c im en  4
• * 1cm M PO O* PO 001 P 0  001 .  0 5cm
P<0.05 . 2cm * 7 Sn
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|  20- • 3cm
i “T  ^  | 9 0
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; ^
1r J
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Tumour 7. Depth Tumour 8, Depth
L iver sp e c im en  6
Tumour 9, Depth
Liver sp e c im en  7 Liver sp e c im en  7
Liver s p e c im en  7
Figure 9.7. Tail moment of tumour samples at different depths prior to perfusion 
with cytoxic drugs (Time = 0 h) as assessed by the comet assay.
* two-tailed unpaired t-test.
• one-way ANOVA followed by the Bonferroni multiple t-test.
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Once perfusion with cytotoxic drugs was commenced, superficial cells generally had 
higher levels of DNA damage in comparison to deep cells. In 5 of 6 tumours perfused 
with cisplatin percentage decrease in TM was greater in superficial cells than the 
deepest cells sampled at all time points (23.3 pM, tumour 1; 50 pM, tumours 3 & 4; 
100 pM, tumours 5 & 6) (Figure 9.8, Appendix 9.10). In 1 of 2 tumours perfused with 
etoposide TM was greater superficially at all time points (100 pM, tumour 8; 1.5 cm 
was taken as the deepest depth due to the presence of necrotic cells at 2 & 3 cm) 
(Figure 9.8, Appendix 9.11). Tail moments of tumours treated with etoposide were 
generally greater at all depths when compared with the control tumour perfused with 
drug fee perfusate (Figure 9.8, Appendix 9.11). All 4 tumours perfused with HN2 had 
greater decrease in TM superficially at all time points (50 pM, tumour 9; 100 pM, 
tumours 10, 11 & 12) (Figure 9.8, Appendix 9.12).
When comparing cytotoxic induced DNA damage between sites at the same depth 
within a tumour, statistically significant differences were consistently observed 
between at least two sites in all tumours except tumour 3 (Figure 9.9, Appendices 
9.13, 9.14 & 9.15). Similar variability was also noted between tumours within the 
same hemiliver at the same depth. Statistically significant differences were noted 
between tumours 1 and 2 when perfused with 23.3 pM cisplatin, tumours 3 & 4 when 
perfused with 50 pM cisplatin, and tumours 10, 11 and 12 when perfused with 50 pM 
HN2 (Figure 9.10, Appendices 9.16 & 9.17).
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Figure 9.8. Examples of percentage decrease in Tail Moment/Tail Moment of the 
same tumour and site but different depths during perfusion with cytotoxic drugs as 
assessed by the comet assay. All values are from site A of the relevant tumours.
P values are between the most superficial and deepest tumour cells sampled.
• P < 0.001 (unless otherwise stated), one-way ANOVA followed by the Bonferroni 
multiple t-test
* P < 0.0001, two-tailed unpaired t-test.
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Figure 9.9. Examples of differences in percentage decrease in Tail Moment/ Tail 
Moment at the most superficial depth but different sites in the same tumour during 
perfusion with cytoxic drugs as assessed by the comet assay.
• P < 0.05, One-way ANOVA followed by the Bonferroni multiple t-test
* P < 0.05, two-tailed unpaired t-test.
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Figure 9.10. Examples of intertumour variation in percentage decrease in Tail 
Moment at the most superficial depth during perfusion with the same cytoxic drug 
as assessed by the comet assay.
• P < 0.01, One-way ANOVA followed by the Bonferroni multiple t-test.
* P < 0.05, two-tailed unpaired t-test.
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9.3 Discussion
The IDPRL system with intrahepatic xenografts of human CRC has been shown to be 
a valuable tool to assess the spatial and temporal pattern of chemotherapy related 
cancer DNA damage in the previous chapter. The relevance of these results to clinical 
studies on chemotherapy responses is based on the assumption that this animal liver 
xenograft model provides an accurate reflection of human liver cancers. The 
comparability of animal models and human disease, however, remains uncertain 
(Perez, 1983). Thus, using a closed recycling system, human hemilivers with primary 
and secondary liver tumours were perfused in this section of the study for up to 6 
hours and treated with chemotherapeutic agents allowing quantification and 
localisation of drug induced DNA damage. Although isolated in situ human liver 
perfusion has previously been reported to deliver the chemotherapeutic agent 
melphalan to patients with CRC hepatic metastases to examine its conjugation with 
GSH (Vahrmeijer et al, 1996), there have been no previous reports of ex vivo 
perfusion and drug delivery with human liver cancers.
The perfused hemilivers remained viable as assessed by gross appearance and 
histology, stable perfusion flow dynamics and bile production. Studies on organ 
preservation for transplantation have demonstrated that the flow characteristics of 
porcine livers during perfusion indicate the degree of injury sustained, in particular 
total hepatic and portal flow has been shown to inversely correlate with warm 
ischaemia time (Valero et al, 1998). Liver haemodynamic changes following liver 
resection have not been clearly defined. Rabinovici and Wiener demonstrated that 
liver blood flow per gram of liver increases immediately after partial hepatectomy in 
vivo and remains above preoperative levels for 24 h in the rat (Rabinovici and Wiener,
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1963). It is appreciated that the HA perfusion pressures in this section of the study are 
lower than physiological values, this can be explained by the absence of sympathetic 
innervation. Previous studies have demonstrated that the addition of noradrenaline can 
restore perfusion pressures in IDPRLs to physiological levels (Yang et al, 1999). Bile 
production is a sensitive parameter of liver function. It requires an intact architecture 
of the liver sinusoid and hepatocyte (Jamieson et al, 1988; Sumimoto et al, 1988), and 
several dedicated metabolising steps which are energy dependent requiring adenosine- 
triphosphate (ATP). During ischaemia, the cellular ATP levels decrease, leading to 
reduced bile flow allowing the extent of hepatic injury to be assessed (Kamiike et al,
1985). The progressive rise in ALT in the perfusate during this study suggests 
hepatocyte injury. Using the isolated rat liver perfusion model, acid phosphatase, 
ALT, and aspartate aminotransferase (AST) were noted to correlate inversely with 
liver function during perfusion (Smrekova et al, 2000). In a further study high levels 
of AST, ALT, and lactate dehydrogenase in the effluent of cold-stored human liver 
grafts all predicted non-function (Lange et al, 1996). The perfused hemiliver will have 
undergone injury prior to removal during ligation of the hepatic vessels and hepatic 
resection (warm ischaemia); during transport from theatre to the laboratory (cold 
storage ischaemia); during ischaemic rewarming (warm ischaemia) and at reperfusion. 
However, this combined ischaemic injury is unlikely to have produced significant 
functional impairment. Perfusion of isolated porcine livers at 37°C for 3 h has 
demonstrated that basic liver function can be regained on a perfusion circuit after 75 
min of circulatory arrest (Schon et al, 1993), and that 1 h of warm ischaemia followed 
by 24 h of normothermic perfusion can preserve liver function (St Peter et al, 2002).
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The comet assay has been shown to be suitable for measuring DNA damage in cells 
obtained from FNA biopsies of treated tumours (Olive et al, 1993). Problems were 
anticipated as the result of constraints of sample size and mechanical damage to DNA 
on obtaining samples. However, adequate numbers of cells were obtained to perform 
the comet assay and minimal DNA damage was seen as reflected by the low mean 
TMs of tumour and normal liver throughout perfusion of the control hemiliver (Figure 
9.3.G), and in tumours prior to perfusion with cytotoxics (Figure 9.7). There are 
inherent limitations to the use of the comet assay in this system. Only drugs that 
produce measurable quantities of DNA damage within 6 hours can be assessed, and 
such assessement can only be made in accessible tumours. In clinical practice, single 
drug administration is seldom used, this should not be a problem providing that DNA 
damage is produced by the combination chemotherapy.
The comet assays of the isolated perfused liver cancers demonstrated that DNA 
damage increased linearly with time at all cisplatin concentrations with peak levels 
being observed at 4-5 h at the end of each experiment. This correlates well with the 
previous in vitro and in vivo data obtained in this study and previous reports on the 
timing of DNA damage with cisplatin administration (Zwelling et al, 1978). Cell 
proliferation is an important determinant for cytotoxicity of cisplatin, with cells in 
active cell cycle being more susceptible to damage by cisplatin than quiescent cells in 
Go phase (Shalinsky et al, 1996). The assumed presence of proliferation thus provides 
further evidence of viability of the hemilivers whilst on the perfusion circuit.
In contrast, both etoposide, which produces double stranded breaks by interacting 
with DNA and the enzyme topoisomerase-II in proliferating cells (Huang et al, 1998),
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and HN2 , an alkylating agent which forms a variety of adducts in both quiescent and 
proliferating cells (Webley et al, 2001), had maximal effects within an hour with no 
linear trend with time. Again this correlates well with the previous in vitro and in vivo 
data obtained in this study and previous reports on the timing of DNA damage with 
etoposide and HN2 administration (Barret et al, 2000; Ross et al, 1978). Only two 
concentrations of these drugs were used, however, and these were physiologically 
high. Repeating the experiments with lower doses may have revealed a linear trend 
with time.
The majority of tumours demonstrated no statistically significant difference in TM 
between the most superficial and deepest depths studied prior to perfusion with 
cytotoxic drugs. Once perfusion with cytotoxics was commenced, however, tumours 
demonstrated more DNA damage at superficial levels, suggesting DNA damage is 
related to tumour vascularity and delivery of chemotherapeutic drugs rather than 
tumour biology. This correlates with autopsy studies of liver metastases which 
demonstrate a decrease in the number of tumour vessels in the centre of metastases 
(Lin et al, 1984), and the associated microenvironmental changes that are the result of 
inefficient vascular function (Sutherland, 1988). Considerable heterogeneity of DNA 
damage was found following perfusion at the same depth but different sites within the 
same tumour and between different tumours in the same hemiliver. This may reflect 
heterogeneity of drug delivery and distribution, tumour microenvironment or the 
multitude of molecular mechanisms that have been associated with intrinsic drug 
resistance. These observations underscore drug delivery as an important component of 
drug resistance.
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The availability of resected human liver specimens offers an opportunity to study the 
heterogeneity of drug and DNA interaction secondary to differences in delivery and 
microenvironment, and the subsequent identification of populations of resistant 
tumour cells which can lead to treatment failure. A variety of short term ex vivo drug 
sensitivity tests have previously been developed to study cellular drug resistance in 
order to predict individual outcome in various neoplastic diseases. The avoidance of 
cell lines ensures relevance. These ex vivo assays, however, use tumour cell 
suspensions that cannot mimic the complexities of drug delivery, metabolism and 
excretion found clinically, thus affecting their ability to predict individual treatment 
outcome. As the perfusion model used in this section of the study involves solid 
tumours and permits easy exposure of the liver to different concentrations of test 
substances with repeated sampling, it may allow more precise prediction of outcome 
following chemotherapy. In addition, the concept of dynamic and transient changes in 
genetic expression in drug resistance is emerging as an important area for 
investigation. Despite perfusion time limitations, this model potentially allows the 
dynamic and transient changes in genetic expression involved in drug resistance, 
hypoxia, cell growth and apoptosis to be evaluated, contributing to a more detailed 
molecular understanding of acute gene regulation in response to chemotherapy. These 
issues are discussed in more detail in Chapter X.
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X. CONCLUSIONS AND FUTURE DIRECTIONS
Using FACScan analysis the expression of P-gp, MRP1 and LRP, along with the 
function of P-gp when present was studied in the chosen panel of HCC and CRC cell 
lines. The lack of functional P-gp when present, and the observation that there was no 
correlation of the presence of MRP 1 and LRP with chemosensitivity, suggested these 
transport proteins had a limited role in resistance to these chemotherapy agents. It is 
likely that additional drug mechanisms contribute to resistance of these tumours. 
Candidates include other members of the MDR P-gp family which have recently been 
characterised. For example, MDR3, a phospholipid flippase, and a bile salt export 
pump, called sister of P-glycoprotein (SPGP), are expressed in hepatocytes under 
physiological conditions and play an important role in bile formation and excretion of 
various toxic substances, including drugs and their metabolites (Borst and Elferink, 
2002). MDR3 and SPGP expression has been demonstrated in human HCC, although 
they were expressed at low levels with a large variation between individual tumours 
(Zollner et al, 2005).
The current work has only examined expression of the founding member of the MRP 
family, MRP1. Recent work, however, has shown MRP I mRNA expression to be at 
least 10-fold lower than MRP2 or MRP3 mRNA expression in human HCC (Nies et 
al, 2001). Because of the similar substrate specificities of MRP 1 and MRP2 (Konig et 
al, 1999), it has been suggested that MRP2 also confers drug resistance. This 
suggestion is supported by transfection of MRP2 antisense RNA into HepG2 cells, 
which decreases MRP2 protein expression and increases sensitivity to cisplatin 
(Koike et al, 1997). MDR conferred by MRP2 has also been demonstrated in cells
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expressing recombinant MRP2 (Cui et al, 1999). Similarly, resistance to etoposide 
and methotrexate conferred by MRP3 has been demonstrated after expression of 
recombinant MRP3 in human embryonic kidney 293 cells (Zeng et al, 1999). In 
addition, although this study suggests that GSH is an important component of MRP 1- 
mediated MDR and drug transport, we have not specifically examined MRP1 
function. Recently described is the 5-carboxyfluorescein diacetate (CFDA)/5- 
carboxyfluorescein (5-CF) efflux assay which has been used to study the functional 
activity of MRP (Lee and Piquette-Miller, 2001). In this assay, the nonfluorescent 5- 
CFDA passively diffuses into cells where it is converted to the fluorescent anion 5-CF 
by intracellular esterases. 5-CF effluxes from cells by the MRP family of transporters, 
and is not a substrate of P-gp. The identification of specific inhibitors of MRP- 
mediated transport function has been sought since the characterisation of the family. 
The most important inhibitors reported so far are analogues of cysteinyl leukotrienes, 
such as the leukotriene C4 (LTC4) analogue MK571. This analogue has so far been 
shown to inhibit MRP1 transport and to a lesser extent MRP2 transport (Buchler et al, 
1996), MRP2 efflux function has also been shown to be reversibly inhibited by 
sulfinpyrazone and cyclosporin A (Morrow et al, 2000). Further studies to determine 
both the expression of the other members of the P-gp and MRP families, and the 
function of the MRP family would provide more understanding of intrinsic tumour 
drug resistance.
Rather than attempting to inhibit the function of MDR resistance efflux transporters, 
there has been recent interest in modulating their expression. Suppression of mRNA 
and protein expression of P-gp has been observed with subtoxic doses of the DNA 
cross-linking agents Mitomycin C and cisplatin (Ihnat et al, 1997). The pro-
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inflammatory cytokines interleukin-6 (IL-6), interleukin-lp (IL-ip), and tumour 
necrosis factor-alpha (TNF-a), also cause significant down regulation in the 
expression and activity of MRP 1, MRP3, and P-gp in the HCC cell lines HepG2 and 
HuH 7 (Lee and Piquette-Miller, 2003). These results merit further investigation and 
suggest the basis for novel clinical cancer chemotherapy regimens aimed at drug 
resistant tumours, where the MDR phenotype is modulated prior to treatment with 
cytotoxic agents.
In contrast to MDR secondary to increased drug export via P-gps and MRPs, 
insufficient drug uptake may also contribute to chemoresistance of HCC and CRC. 
Organic anion transporting proteins (OATPs) such as OATP2/SCL21A6 play an 
important role in drug absorption and regulation (Hagenbuch and Meier, 2003), 
increased expression of OATP2/SCL21A6 would thus lead to increased drug uptake 
into neoplastic cells. Hepatic uptake systems may represent an attractive target for 
chemotherapeutic agents of HCC and CRC metastases. Cisplatin covalently bound to 
bile acids have been proposed as a novel approach to provide specific drug targeting 
to the liver to overcome insufficient uptake into HCCs (Briz et al; 2002; Dominguez 
et al, 2001). The uptake of drugs bound to bile acids as carrier molecules would 
depend on preserved expression of the Na+/taurocholate co-transporter 
(NTCP/SLC10A1) and OATP2/SCL21A6 (Kullak-Ublick et al, 1997). Residual bile 
acid uptake has been shown to be detectable in HCC cells but at low levels in 
comparison to normal hepatocytes (Kullak-Ublick et al, 1996), this would favour the 
distribution of compound drugs to normal rather than malignant hepatocytes. 
However, there are only limited data on the expression of NTCP and
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OATP2/SCL21A6 in HCCs, thus further studies are required to establish whether they 
would be a useful chemotherapeutic target.
The formation and excision of cisplatin DNA ICLs in the chosen human HCC and 
CRC cell lines were determined at the level of the overall genome by the comet assay, 
and related to platinum chemosensitivity. Resistant cell lines demonstrated 
quantitatively fewer ICLs than sensitive cell lines, and an increased capacity to repair 
those that were formed. The mechanism used by cells to repair ICLs is not clearly 
understood. As shown for classical nucleotide excision repair (NER), the 
ERCC1/XPF complex may interact with XPA to facilitate the repair of ICL. The 
mechanism may involve cooperation between NER and recombination, but outside of 
the classical context of NER. The fact that several types of DNA damage are 
recognised and repaired by NER has led to the search for inhibitors of this 
mechanism. XPA and ERCC1/XPF are potential targets, as these proteins are often 
found to be overexpressed in tumour cells resistant to cisplatin (Dabholkar et al, 1994; 
States and Reed, 1996). Furthermore, it has been suggested that the incision step, 
which involves XPA and ERCC1/XPF, is the rate-limiting step of NER (Barret et al, 
1996). Thus, any inhibition of XPA or ERCC1/XPF should have the most efficient 
impact on NER.
To date the targeted inhibition of XPA by transfection with antisense XPA RNA has 
been shown to decrease XPA mRNA levels and sensitise human lung adenocarcinoma 
cells to cisplatin (Wu et al, 2003), and inhibition of NER by anti-XPA monoclonal 
antibodies has been achieved (Saijo et al, 2004). Detailed mechanistic studies, 
however, need to be performed to confirm any definite validity for this approach.
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The fact that the final step of NER is DNA resynthesis has resulted in attempts to 
inhibit NER with antimetabolic drugs. For example, DNA polymerase inhibitors, such 
as aphidicolin (a selective inhibitor of DNA polymerase a  and 8) and cytarabine have 
been tested in combination with several chemotherapeutic agents. While some of 
these combinations may prove to be clinically useful, such inhibitors cannot be 
considered true repair inhibitors. They are likely to affect DNA synthesis as well as 
DNA repair, and thus may affect normal cells as well as tumour cells. Similarly there 
has been considerable interest in modulating the sensitivity to bifunctional 
chemotherapeutic agents through activation or inactivation of various signal 
transduction cascades. Of the interactions studied to date, activation of the protein 
kinase C (Isonishi et al, 1994), EGF (Nishikawa et al, 1992), and HER-2/neu (Pietras 
et al, 1994) signal transduction pathways has been reported to decrease the repair of 
cisplatin-DNA adducts. However, the effects of these signal transduction pathways on 
DNA repair are relatively modest and are insufficient, by themselves, to explain the 
enhancement of cisplatin toxicity. Thus, while modulation of some signal transduction 
pathways may be useful for increasing tumour sensitivity to bifunctional 
chemotherapeutic agents, it appears that alteration of repair activity makes only a 
minor contribution to these interactions. Finally, replicative bypass appears to make a 
substantial contribution to the tolerance of unrepaired DNA adducts. Once the 
enzymatic mechanisms of replicative bypass are known in more detail, it should be 
possible to design inhibitors of replicative bypass that, along with more selective 
repair inhibitors, could increase the efficacy cisplatin.
The current study has successfully developed both murine and rat intrahepatic 
xenograft models of human HCC and CRC to study the topographic distribution of
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chemotherapeutic agents within tumours. Although the malignant cells grew as solid 
tumours within a microenvironment similar to that seen clinically, tumour 
engraftment could not reliably be monitored. In addition, the animals had to be 
sacrificed after treatment in order to obtain samples. A model in which the human 
tumours contain a quantifiable marker permitting serial noninvasive monitoring of 
tumour burden would be an advantage. PLC/PRF/5 cells, which contain an integrated 
hepatitis B virus genome, secrete large amounts of HBsAg when growing as murine 
hepatic xenografts. HBsAg accumulates in the mouse’s circulation and progressively 
increases over time. Tumour burden, as determined by wet weight, is proportional to 
serum HBsAg titre, and thus provides a noninvasive method for serially quantifying 
tumour burden at initiation of therapy and during chemotherapy (Leveille-Webster 
and Arias, 1996). HBsAg is an ideal circulating marker as it is rapidly secreted by 
tumour cells, is nonpathogenic, has a short half-life, and can be quantified by a highly 
sensitive reproducible RIA (Gupta et al, 1991). Similarly, nude mice with 
intrahepatically implanted human HCCs, have had their tumour size successfully 
evaluated with B-ultrasound from 2 to 9 weeks after implantation (Gao et al, 2004). A 
combination of these two procedures may enable FNAs to be taken from tumours in 
mice and rats, prior to chemotherapy to act as their own control, and sequentially 
thereafter, to avoid sacrificing the animals. Another consideration is that both the 
murine and rat intrahepatic xenograft models were originally derived from cell lines, 
therefore they do not necessarily reflect the original structure and biological 
behaviour of human tissue. Orthotopic implantation using intact human tissue 
obtained surgically has been described (Hoffman, 1994), adopting this technique with 
human HCC and CRC could further increase the relevance of these models.
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This study has examined the topographic distribution of cisplatin DNA-adducts 
within tumours, and the potential mechanisms for drug heterogeneities, using the 
comet assay and by using different immunohistochemical stainings on parallel tissue 
sections. Immunohistochemical analysis by manual counting, however, is laborious 
and limited in scope. A sophisticated multi-step immunofluorescent staining and 
computer-controlled microscope scanning method has been developed, allowing 
simultaneous quanitative analysis of architectural patterns of proliferation, 
vascularisation, blood perfusion and oxygenation (Bussink et al, 1999). This allows 
quantitation of spatial relationships between these parameters in a tumour model, but 
does not provide temporal dynamics. Although useful for functional imaging, positron 
emission tomography, nuclear magnetic resonance, and ultrasound currently do not 
have the desired spatial resolution required to monitor events at a cellular level. 
Nuclear magnetic resonance microscopy can provide high-resolution structural 
information, and limited functional imaging. The only noninvasive method currently 
available that provides both is in vivo microscopy. This approach has been used to 
provide data on red blood cell velocity, vessel diameter, density, permeability, and 
leucocyte-endothelial interactions human CRC hepatic xenografts of mice (Fukumura 
et al, 1997). A major limitation of this method is that the imaging is surface weighted 
(< 40pm). With the availability of multiphoton microscopy and novel probes, it now 
possible to image deeper in tissue (< 40pm) without significant loss of spatial 
resolution. It is also possible to adapt some of these techniques to a clinical setting. 
Until technology for deeper imaging is developed, these techniques should provide 
useful insight into mechanisms that contribute to heterogeneous distribution of drugs 
in tumours.
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Using a closed recycling system, intrahepatic xenografts of human CRC in nude rats 
and human hemilivers with primary and secondary liver tumours, were perfused via 
the HA and PV, and treated with chemotherapeutic agents allowing quantification of 
drug induced DNA damage. Tumours show heterogeneity of genotype and phenotype, 
and such heterogeneity in HCC and CRC tumours almost certainly affects response to 
cytotoxic agents. Since the early 1980s a variety of short term ex vivo drug sensitivity 
tests have been developed to study cellular drug resistance in order to predict 
individual outcome in various neoplastic diseases. These tests aim to mimic the 
situation within the tumour accurately enough to examine issues of dose response, 
sequence and timing. The avoidance of cell lines ensures relevance, and the sensitivity 
of some of these methods allows large numbers of chemotherapeutic permutations to 
be tested with a small amount of material. The colorimetric methyl-thiazol-terazolium 
(MTT) assay has the advantage of its suitability for automation (Sargent and Taylor, 
1989), but contamination of more than 30% of non-neoplastic cells may interfere with 
proper interpretation (Kaspers et al, 1994). The differential staining cytotoxicity 
(DiSC) assay is a dye exclusion test that is based on morphological differentiation 
between living and dead tumour and non-tumour cells by light microscopy (Bird et al,
1986), which enables more reliable detection of contamination by non-neoplastic 
cells. However, assessment of cell kill is labour intensive and subject to individual 
interpretation. Although recent technical advances have led to the introduction of the 
adenosine triphosphate-tumour chemosensitivity assay (ATP-TCA), which has 
relatively high evaluability rates with solid tumours (Andreotti et al, 1995), cellular 
assays have largely been ignored due to their overall low evaluabilty rates and 
technical problems, in particular infection. In addition, these ex vivo assays use 
tumour cell suspensions, which cannot mimic the complexities of drug delivery,
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metabolism and excretion found clinically, thus affecting their ability to predict 
individual treatment outcome. As both perfusion models used in this study involve 
solid tumours and permit easy exposure of the liver to different concentrations of test 
substances with repeated sampling, they may allow more precise prediction of 
outcome following chemotherapy.
The concept of dynamic and transient changes in genetic expression in drug resistance 
is emerging as an important area for investigation. The overexpression of genes 
associated with the development and maintenance of drug resistance phenotypes has 
been attributed to the selection and subsequent clonal expansion of pre-existing drug 
resistant cells. Although several drugs, by virtue of their mutagenic properties, have 
been suggested to increase the frequency with which these subpopulations arise, the 
possibility that chemotherapeutics may actually induce drug-resistant variants has 
remained largely unexplored. A number of studies indicate that the expression of the 
MDR1 gene can be rapidly and transiently induced in cultured cell lines (Hu et al, 
1995; Tomida et al, 1995), and in vivo in human metastatic lung sarcoma (Abolhoda 
et al, 1999), when exposed to a variety of chemotherapeutic agents. Several genes are 
thought to be activated under hypoxic conditions, such as vascular endothelial growth 
factor (VEGF) (Levy et al, 1996), erythropoietin (Jelkmann and Hellwig-Burgel, 
2001), and glycolytic enzymes (Hanahan and Folkman, 1996), which are 
transcriptionally regulated by hypoxia inducible factor la  (HIF-la). As an important 
factor in tumourigenesis and angiogenesis, HIF-la overexpression is associated with 
an increased mortality and treatment failure in various cancers (Unruh et al, 2003). In 
addition, HIF-la can regulate the MDR1 gene (Comerford et al, 2002), and blocking 
the activity of HIF-la can enhance the therapeutic efficacy of cancer immunotherapy
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(Sun et al, 2001). A number of drugs have been developed with the aim of 
counteracting genetic changes leading to cancer. Several oncogenes make cell surface 
receptors through which growth factors exert their effects, these receptors can be 
targeted by antibodies and small-molecule drugs in order to block their activity. 
Other drugs seek to block oncogene products that transmit growth stimulatory signals 
inside cells, such as the protein produced by the ras oncogene. Most cancers have 
inactivating mutations in one or more of tumour-suppressor genes, these normally act 
to control cell growth. For example, the tumour suppressorp \6  normally holds up cell 
division by blocking the activity of cyclin-dependent kinase 4 (CDK4), one of several 
enzymes called CDKs that propel cells through the cell cycle. A small-molecule 
inhibitor of CDK4 would replace the function of p i 6 restoring cell growth control. 
Other mutations of oncogenes and tumour-suppressor genes impair apoptosis, or 
programmed cell death, which serves to remove cells whose DNA has been damaged. 
These mutations not only allow damaged cells to avoid death, but also make cancer 
cells resistant to many chemotherapeutic drugs that work by triggering apoptosis. 
Efforts to repair apoptosis have included gene therapy to replace mutated p53 with 
normal copies of p53, a tumour-suppressor gene that plays a role in apoptosis and is 
defective in approximately 50% of human cancers. The function of the oncogene bcl- 
2, an inhibitor of apoptosis, can also be impaired with antisense nucleotides designed 
to prevent the protein from being made. Despite perfusion time limitations, both 
models used in this study will potentially allow the dynamic and transient changes in 
genetic expression involved in drug resistance, hypoxia, cell growth and apoptosis to 
be evaluated, contributing to a more detailed molecular understanding of acute gene 
regulation.
293
Chapter X: Conclusions and Future Directions
In conclusion, eventually it may be possible to exploit and manipulate tumour 
environments to produce preferential effects of therapeutic agents on tumours. It may 
also be possible to treat tumours with combined therapy modalities that are effective 
against specifically characterised subpopulations and heterogeneous environments, 
and to control or stabilise the heterogeneity in favourable directions, for example, 
differentiation or expression of antigens or receptors that can then be treated with 
specific agents.
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Appendix 2.1: Reagents and solutions
Amersham, Life Sciences, UK: Rainbow coloured protein molecular weight 
markers, ECL western blot detection reagents, nitro-cellulose membrane and Nova 
blot electrode papers.
An Der Grub, Kaumberg, Austria: Permeabilisation reagents A (fixation medium) 
and B (permeabilisation medium).
Collaborative Biochemical Products, Becton Dickson, Bedford (MA), USA: 
Matrigel.
Bio-rad Laboratories Ltd, UK: Biorad Protein Assay Reagent.
Dr R Hodgkiss, Gray Laboratory Cancer Research Trust, Middlesex, UK: 7-(4’- 
(2-nitroimidazol-l -yl)-theophylline (NITP).
Fuji PhotoFilm Ltd (UK): Fuji Film Super RX, Medical X-Ray film.
Novartis Pharma, Basel, Switzerland: cyclosporin D analogue PSC833.
Novex, Groningen, the Netherlands: Nu-PAGE: LDS sample buffer, sample 
reducing reagent (lOx), sample buffer (4x), antioxidant and transfer buffer (20x).
Pharmacia & Upjohn, London, England: Gelfoam.
Sigma-Aldrich, UK: The protein binding dye, sulfohodamine B (SRB); the 
fluorescent substrate 3,3’-diethyloxacarbocyanine (DiOC2); the western blot reagents 
aprotinin, phenylmethylsulfonyl fluoride (PMSF), p mercapto-ethanol and Ponceau’s 
reagent; D L-buthionine-(S,R)-sulfoxamine (BSO); agarose, types IA and VII; 
propidium iodide; Hoechst 33342 and the calcium channel blocker verapamil (vpm).
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Appendix 2.2: Drugs
David Bull Laboratories, Warwick, UK: Cisplatin (c/s-dichlorodiammine platinum 
(II)), vincristine and 5-Fluorouracil (5-FU)
Glaxo Wellcome, Middlesex, UK: Melphalan.
Bristol-Myers Pharmaceuticals, Dublin, Ireland: Etoposide.
Sigma-Aldrich, UK: Mechlorethamine (Nitrogen Mustard).
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Appendix 3.1: Data for SRB Growth Assay
Table 1: Absorbance measurements at 540 nm for HCC & CRC cell lines
(arbitary units)
Time/h Hep
G2
SkHep
-1
C3A PLC/P
RF/5
Hep3B WIDR CAC
02
HT29 SW620
24
0.067 0.662 0.353 0.992 0.819 0.362 0.431 0.555 0.389
0.069 0.676 0.349 1.023 0.843 0.37 0.462 0.511 0.376
0.08 0.683 0.344 0.96 0.836 0.335 0.464 0.583 0.346
0.079 0.689 0.373 0.998 0.829 0.353 0.489 0.584 0.384
48
0.269 1.662 0.926 1.742 1.203 0.964 0.699 1.179 0.524
0.246 1.602 0.93 1.871 1.371 0.908 0.747 1.07 0.568
0.233 1.543 0.927 2.014 1.29 0.928 0.689 1.06 0.552
0.244 1.574 0.953 1.807 1.09 0.899 0.766 1.114 0.548
72
0.551 2.915 1.512 2.447 1.835 1.464 1.133 2.175 0.686
0.536 2.89 1.428 2.496 1.771 1.447 1.108 2.112 0.721
0.523 2.859 1.358 2.407 1.696 1.322 1.296 2.172 0.754
0.492 2.84 1.388 2.351 1.315 1.209 1.215 2.168 0.739
96
1.082 2.858 1.453 3.037 2.451 1.623 1.766 2.782 1.169
1.118 2.875 1.957 3.034 2.512 1.812 1.784 2.796 1.175
1.182 3.086 1.6 3.052 2.279 1.848 2.128 2.718 1.171
1.064 2.96 1.689 3.024 2.163 1.842 2.02 2.767 1.149
120
1.812 2.91 2.243 2.81 2.934 2.351 2.503 2.77 2.124
1.786 2.927 2.392 3.014 2.82 2.389 2.515 2.886 2.112
1.625 3.137 2.326 3.057 2.826 2.393 2.66 3.013 2.123
1.673 3.013 2.265 2.861 2.856 2.345 2.695 2.856 2.156
Table 2: Mean Absorbance Values at 540 nm (arbitary units)
Time/h Hep
G2
SkHep
-1
C3A PLC/P
RF/5
Hep3B WIDR CAC
02
HT29 SW620
24 0.073 0.677 0.354 0.993 0.832 0.355 0.461 0.558 0.373
48 0.248 1.595 0.934 1.858 1.238 0.924 0.725 1.105 0.548
72 0.525 2.876 1.421 2.425 1.654 1.36 1.188 2.156 0.725
96 1.111 2.944 1.674 3.036 2.351 1.781 1.924 2.765 1.166
120 1.724 2.996 2.306 2.935 2.859 2.369 2.593 2.881 2.128
Table 3: Standard deviation of data
Time/h Hep
G2
SkHep
-1
C3A PLC/P
RF/5
Hep3B WIDR CAC
02
HT29 SW620
24 0.007 0.016 0.013 0.026 0.01 0.015 0.024 0.034 0.019
48 0.015 0.0506 0.013 0.116 0.12 0.029 0.037 0.054 0.018
72 0.025 0.0331 0.067 0.061 0.233 0.119 0.085 0.03 0.029
96 0.052 0.104 0.211 0.012 0.159 0.106 0.178 0.034 0.0116
120 0.081 0.103 0.067 0.0118 0.052 0.025 0.098 0.1 0.018
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Appendix 3.2: Data for SRB Inoculation Densities
Table 1: Mean absorbance measurements at 540 nm for HCC cell lines
(arbitary units). (±Standard Deviation)
Cell
Line
Inoculation
Density
24 h 48 h 72 h 96 h 120 h
HepG2 5xl03 - - - - -
lxlO4 0.074 (0.006) 0.248 (0.015) 0.525 (0.025) 1.112(0.052) 1.724 (0.089)
2xl04 0.163 (0.011) 0.517(0.009) 1.156 (0.133) 2.192 (0.022) 2.421 (0.024)
4xl04 0.310(0.02) 0.941 (0.02) 2.059 (0.055) 2.546 (0.071) 2.422 (0.121)
5xl04 0.601 (0.041) 1.729 (0.045) 2.542 (0.043) 2.742 (0.05) 2.607 (0.045)
SKHep
-1
5xl03 0.466 (0.024) 1.057 (0.048) 2.427 (0.135) 2.886 (0.071) 2.941 (0.087)
lxlO4 0.671 (0.025) 1.602 (0.039) 2.856 (0.029) 2.887 (0.129) 3.048 (0.173)
2xl04 1.378 (0.052) 2.331 (0.075) 3.115(0.163) 3.136(0.136) 3.09 (0.156)
4xl04 2.375 (0.031) 2.480 (0.089) 3.326 (0.162) 3.345 (0.16) 3.049 (0.039)
5xl04 2.485 (0.0144) 2.513 (0.04) 3.475 (0.261) 3.297 (0.033) 3.073 (0.066)
C3A 5xl03 0.146 (0.005) 0.390 (0.009) 0.682 (0.01) 1.063 (0.047) 1.407 (0.048)
lxlO4 0.354 (0.013) 0.934 (0.013) 1.421 (0.067) 1.674 (0.211) 2.306 (0.066)
2xl04 0.593 (0.021) 1.735 (0.025) 2.221 (0.02) 2.495 (0.02) 2.649 (0.117)
4xl04 1.212(0.05) 2.319(0.025) 2.521 (0.047) 2.664 (0.052) 2.86 (0.098)
5xl04 1.256 (0.049) 2.359 (0.055) 2.427 (0.086) 2.779 (0.104) 2.66 (0.049)
PLC/P
RF/5
5xl03 0.541 (0.01) 0.971 (0.091) 1.793 (0.058) 2.650(0.0133) 2.741 (0.036)
lxlO4 0.993 (0.026) 1.858 (0.116) 2.425 (0.061) 3.036 (0.011) 2.935 (0.118)
2xl04 1.842 (0.019) 2.438 (0.042) 2.632 (0.031) 3.085 (0.035) 2.971 (0.084)
4xl04 2.596 (0.046) 2.706 (0.099) 2.717(0.063) 2.991 (0.063) 2.5402 (0.144)
5xl04 2.654 (0.04) 2.644 (0.089) 2.472 (0.031) 2.651 (0.099) 2.058 (0.173)
Hep3B 5xl03 0.343 (0.027) 0.656 (0.133) 0.695 (0.107) 2.351 (0.159) 2.412(0.145)
lxlO4 0.832 (0.01) 1.238 (0.12) 1.654 (0.233) 1.497 (0.175) 2.859 (0.052)
2xl04 1.695 (0.1) 2.336(0.154) 2.599 (0.112) 2.858(0.155) 2.982 (0.087)
4xl04 2.636 (0.036) 2.573 (0.077) 3.089 (0.205) 3.145 (0.163) 2.9140.141)
5xl04 2.342 (0.29) 2.643 (0.115) 2.935 (0.033) 2.988 (0.032) 2.305 (0.313)
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Table 2: Absorbance measurements at 540 nm for CRC cell lines
(arbitary units) (±Standard Deviation)
Cell
Line
Inoculation
Density
24 h 48 h 72 h 96 h 120 h
WIDR 5xl03 0.140 (0.024) 0.382 (0.012) 0.696 (0.01) 1.113 (0.054) 1.368 (0.057)
lxlO4 0.355 (0.015) 0.924 (0.029) 1.360 (0.119) 1.781 (0.106) 2.369 (0.025)
2xl04 0.580 (0.032) 1.669 (0.039) 2.172 (0.028) 2.500 (0.062) 2.771 (0.055)
4xl04 1.302 (0.013) 2.345 (0.041) 2.469 (0.048) 2.736 (0.098) 3.072 (0.082)
5xl04 1.265 (0.093) 2.359 (0.023) 2.435 (0.027) 2.812 (0.037) 2.774 (0.141)
CAC02 5xl03 0.317(0.013) 0.496 (0.021) 0.802 (0.006) 1.312(0.106) 2.162 (0.195)
lxlO4 0.462 (0.023) 0.725 (0.037) 1.188 (0.085) 1.924 (0.178) 2.593 (0.098)
2xl04 0.901 (0.06) 1.361 (0.082) 2.382 (0.136) 2.676 (0.077) 2.815 (0.016)
4xl04 1.832 (0.084) 2.202 (0.06) 2.948 (0.092) 2.891 (0.095) 2.932 (0.098)
5xl04 2.099 (0.039) 2.314(0.053) 2.881 (0.102) 2.862 (0.079) 2.949 (0.097)
HT29 5xl03 0.226 (0.026) 0.521 (0.01) 1.165 (0.066) 2.034 (0.12) 2.196 (0.107)
lxlO4 0.558 (0.034) 1.106 (0.054) 2.156(0.029) 2.765 (0.04) 2.881 (0.1)
2xl04 1.302 (0.345) 1.919(0.036) 2.861 (0.03) 3.090 (0.087) 3.089 (0.117)
4xl04 2.250 (0.055) 2.508 (0.036) 3.333 (0.04) 3.441 (0.263) 3.126 (0.1)
5xl04 2.313 (0.081) 2.538 (0.051) 3.335 (0.2) 3.437 (0.176) 3.181 (0.152)
SW620 5x10i 0.222 (0.073) 0.285 (0.027) 0.394 (0.02) 0.573 (0.03) 1.153 (0.06)
lxlO4 0.373 (0.019) 0.548 (0.018) 0.725 (0.029) 1.166 (0.012) 2.128 (0.018)
2xl04 0.752 (0.022) 1.051 (0.056) 1.532 (0.06) 2.225 (0.054) 2.525 (0.105)
4xl04 1.587 (0.161) 2.032 (0.047) 2.397 (0.105) 2.522 (0.043) 2.608 (0.095)
5xl04 1.845 (0.04) 2.221 (0.077) 2.533 (0.111) 2.752 (0.047) 2.824 (0.068)
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Appendix 3.3: Data for SRB HCC Chemosensitivitv Assays
Survival as percentage of control (±SEM)
Table 1: Cisplatin
Cisplatin
(UM)
Hep3
B
Cisplatin
(UM)
PLC/P
RF/5
Cisplatin
(UM)
C3A Cisplatin
(pM)
HepG2 SkHep-1
0.01 100.0
(0.7)
0.01 100.0
(0.98)
0.01 100.0
(1.17)
0.01 100
(1.59)
100.0
(1.87)
0.15 91.9
(0.85)
0.045 92.5
(1-22)
0.045 96.81
(1.06)
1 93.2
(1.05)
92.3
(2.42)
0.19 96.3
(0.86)
0.137 94.29
(0.72)
0.137 95.9
(1.06)
4 92.3
(2.32)
90.7
(2.85)
0.76 95.34
(0.59)
0.411 95.23
(1.34)
0.38 82.81
(3.75)
7 84.3
(3.96)
84.6
(2.69)
1.56 95.09
(0.47)
1.234 93.88
(0.81)
1.2 62.48
(3.60)
10 86.0
(4.02)
89.7
(0.77)
3.12 90.77
(0.57)
3.7 94.7
(1.29)
3.7 40.18
(2.18)
40 14.3
(3.53)
2.2
(0.25)
6.25 72.28
(1.26)
11.1 91.04
(1.57)
11.1 21.32
(1.13)
70 3.9
(0.11)
2.7
(0.308)
12.5 11.27
(0.53)
33.3 62.05
(3.08)
33.3 8.84
(0.50)
100 5.1
(0.31)
6.2
(0.215)
25.0 5.23
(0.27)
40 3.8
(0.3)
100 8.85
(0.26)
50.0 4.2
(0.31)
100 4.29
(0.7)
100 2.8
(0.21)
Table 2: Etoposide
Etoposide
(pM)
Hep3
B
Etoposide
<pM)
PLC/P
RF/5
Etoposide
(pM)
C3A Etoposide
(M-M)
HepG2 SkHep-1
0.01 100.0
(2.66)
0.01 100.0
(1.047)
0.01 100.0
(1.43)
0.01 100.0
(1.64)
100.0
(2.49)
0.45 93.7
(1.66)
0.2 94.91
(2.42)
0.2 98.26
(0.92)
1 86.6
(1.18)
77.3
(1.53)
0.8 96.6
(0.50)
0.5 98.0
(0.935)
0.45 98.46
(0.99)
5 79.9
(1.96)
51.7
(2.087)
1.7 92.7
(0.74)
1.7 93.78
(1.27)
1.37 83.8
(2.69)
10 73.2
(1.82)
47.8
(2.15)
3.45 84.1
(1.05)
5.0 91.85
(1.26)
4.1 64.92
(2.57)
50 49.3
(2.009)
18.6
(3.04)
6.9 61.7
(0.72)
13.8 82.95
(1.839)
12.3 53.7
(3.52)
100 44.2
(2.02)
11.1
(2.46)
13.8 29.4
(1.31)
40.0 62.94
(1.99)
37.0 41.18
(1.37)
500 6.6
(1.73)
0.6
(0.158)
27.7 13.9
(0.59)
166.0 48.02
(2.02)
111.0 44.1
(2.05)
55.5 10.59
(0.43)
400.0 3.98
(3.98)
333.0 9.29
(1.19)
166.0 9.47
(0.99)
333.0 1.56
(0-13)
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Table 3: 5-FU
5-FU
(UM)
Hep3B PLC/P
RF/5
C3A 5-FU
(UM)
HepG2 SkHep
-1
0.01 100.0
(3.20)
100.0
(2.36)
100.0
(1.73)
0.01 100.0
(2.22)
100.0
(1.99)
0.05 102.1
(0.91)
93.11
(3.40)
104.6
(0.62)
1.0 91.1
(1.109)
88.4
(0.98)
0.152 100.1
(1.77)
97.09
(2.18)
105.5
(0.71)
5.0 88.0
(1.68)
90.8
(1.54)
0.45 94.85
(1.14)
96.37
(2-31)
105.2
(0.50)
10.0 82.0
(1.126)
68.6
(1.16)
1.37 87.1
(1.80)
95.21
(1.65)
102.5
(1.83)
50.0 71.6
(1.55)
56.5
(1.92)
4.1 76.4
(2.34)
91.41
(2.247)
66.69
(1.49)
100.0 68.6
(1.18)
50.3
(2.08)
12.3 72.44
(1.70)
80.9
(3.36)
39.66
(1-99)
500.0 69.3
(1.85)
17.4
(1-54)
37.0 64.5
(2.17)
69.48
(2.18)
29.94
(1.06)
1000.0 65.8
(194)
4.7
(0.55)
111.0 38.09
(1.46)
57.68
(1.57)
31.56
(1.09)
333.0 14.48
(0.55)
34.91
(1.40)
18.93
(0.62)
1000.0 11.07
(0.48)
21.7
(0.683)
7.56
(0.40)
Table 4: Melphalan
Melphalan
(pM)
Hep3B PLC/P
RF/5
C3A HepG2 SkHep-1
0.01 100.0
(0.82)
100.0
(4.050)
100.0
(2.82)
100.0
(3.65)
100.0
(1.55)
1 95.6
(0.455)
108.5
(0.530)
99.3
(2.31)
90.2
(6.8)
95.5
(0.37)
4 98.45
(0.88)
110.62
(1.12)
78.66
(2.78)
94.3
(4.53)
92.5
(1.086)
7 97.37
(1-03)
112.87
(2.2)
72.5
(3.84)
88.0
(5.38)
90.9
(1.011)
10 95.77
(0.508)
110.0
(2.15)
67.3
(2.63)
89.0
(4.52)
91.1
(0.72)
40 82.2
(0.52)
95.39
(1.64)
47.4
(1-54)
51.1
(8.81)
47.8
(3.68)
70 21.86
(0-74)
78.89
(1.68)
28.5
(1.68)
22.5
(6.18)
12.9
(1.06)
100 4.847
(0.23)
67.32
(2.1)
26.7
(2.09)
11.9
(2-95)
4.4
(1.41)
400 1.47
(0.066)
3.07
(0.15)
13.23
(0.84)
4.0
(1.08)
0.4
(0.052)
700 1.48
(0.103)
2.15
(0.09)
2.83
(0.14)
0.7
(0.07)
0.3
(0.046)
1000 1.52
(0.138)
1.77
(0-13)
1.66
(0-23)
0.8
(0-17)
0
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Appendix 3.4: Data for SRB CRC Chemosensitivitv Assays
Survival as percentage of control (±SEM)
Table 1: Cisplatin
Cisplatin
(pM)
SW620 Cisplatin
G*M)
CAC02 HT-29 Cisplatin
(pM)
WIDR
0.01 100.0
(0.92)
0.01 100.0
(2.72)
100.0
(3.78)
0.01 100.0
(0.56)
0.15 99.92
(0.75
1 92.8
(2.18)
76.2
(2.19)
0.45 97.0
(1.04)
0.45 101.8
(2.68)
4 85.4
(4.56)
65.2
(2.3)
1.37 93.99
(0.10)
1.37 103.6
(2.33)
7 68.2
(1.17)
48.6
(3.39)
4.11 90.93
(0.97)
4.11 101.3
(2.04)
10 58.1
(5.15)
43.9
(3.15)
12 57.16
(0.68)
12.00 96.47
(2.21)
40 21.7
(2.82)
4.6
(0.677)
37 13.67
(1.04)
37.00 58.95
(1.77)
70 19.4
(1.23)
2.7
(0.23)
111 3.97
(1.50)
111.00 23.77
(2.33)
100 19.9
(0.29)
1.5
(15.4)
333.00 15.23
(0.70)
Table 2: Etoposide
Etoposide
(pM)
SW620 Etoposide
(PM)
HT-29 Etoposide
(pM)
WIDR Etoposide
(PM)
CAC02
0.01 100.0
(1.11)
0.01 100.0
(3.01)
0.1 100.0
(0.151)
0.1 100.0
(8.009)
1.6 93.28
(0.92)
0.7 86.0
(2.71)
0.7 86.69
(1.096)
10 75.1
(6.99)
3.3 85.07
(2.09)
1 89.8
(1.31)
1.6 87.61
(0.79)
40 31.4
(0.98)
6.60 72.17
(2.31)
4 57.7
(9.18)
3.30 78.13
(0.121)
70.00 25.1
(1.53)
13.20 58.59
(2.39)
7 37.4
(10.9)
6.60 55.28
(0.9)
100 27.8
(1.41)
26.40 52.07
(1.64)
10 35.3
(10.2)
13.20 23.22
(1.15)
400 6.6
(2.25)
52.80 44.03
(2.07)
40 7.5
(2.39)
26.40 7.92
(0.39)
105.60 32.68
(1.89)
70 11.0
(3.36)
52.80 6.83
(0.2)
211.00 2.7
(0.17)
100 11.8
(3.76)
105.60 7.017
(0.25)
422.00 3.18
(0.172)
500 0.6
(1.3)
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Table 3: 5-FU
5-FU
(pM)
SW620 WIDR 5-FU
(UM)
HT-29 CAC02
0.1 100.0
(8.5)
100.0
(1.4)
0.1 100.0
(2.87)
100.0
(2.8)
0.15 95.62
(8.8)
96.8
(0.204)
1.0 75.1
(2.007)
89.0
(3.03)
0.45 91.68
(7.56)
92.3
(2.68)
5.0 75.8
(2.82)
87.2
(1.43)
1.37 93.69
(7.02)
88.4
(0.95)
10.0 68.0
(2.066)
84.4
(1.7)
4.10 92.7
(7.077)
83.5
(1.23)
50.0 59.0
(3.46)
83.3
(2.11)
12.30 91.9
(8.07)
76.9
(1.45)
100.0 35.0
(4.35)
78.7
(1.488)
37.00 85.15
(7.99)
79.3
(2.22)
500.0 7.9
(0.85)
65.2
(1.46)
111.0 68.69
(6.327)
55.39
(1.22)
1000.0 5.2
(0.59)
25.4
(10.07)
333.0 42.67
(3.43)
40.11
(2-47)
1000 30.56
(3.25)
22.9
(0.59)
2000 27.77
(2.7)
5.6
(0.66)
Table 4: Melphalan
Melphalan
(UM)
WIDR CAC02 HT-29 SW620
0.01 100.0
(0.49)
100.0
(1.76)
100.0
(1.937)
100.0
(3.65)
1 98.0
(1.115)
96.8
(1.11)
96.4
(1.011)
97.42
(6.8)
4 96.47
(2.5)
97.9
(1.26)
86.7
(2.84)
98.0
(4.53)
7 92.5
(0.68)
95.7
(1.89)
82.6
(3.89)
96.32
(5.38)
10 82.9
(1.65)
96.0
(1.62)
80.2
(3.79)
95.8
(4.52)
40 85.2
(2-9)
84.5
(1.81)
54.4
(3.59)
92.65
(8.81)
70 59.21
(2.107)
63.6
(4.98)
31.5
(1.39)
76.68
(6.18)
100 36.78
(0.17)
43.2
(6.55)
16.4
(2.8)
58.3
(2.95)
400 5.6
(0.39)
1.3
(0.19)
3.4
(0.29)
6.3
(1.08)
700 0.77
(1.4)
0.7
(0.067)
0.8
(0.07)
0.9
(0.07)
1000 2.0
(0.068)
0.8
(0.08)
0.8
(0.208)
1.2
. .0:2).....
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Appendix 4.1: Data for SRB assays for P-2 P reversal in selected P-gp positive 
HCC & CRC cell lines
Survival as percentage of control, ±SEM
Table 1: HCC
Etoposide
(UM)
HepG2 HepG2 & 
vpl (6pM)
Vincristine
(pM)
HepG2 HepG2 & 
vpl (6pM)
0.01 100.0
(1.64)
98.53
(3.29)
0.01 100.0
(3.6)
100.0
(2.22)
1.0 86.6
(1.18)
87.9
(2.97)
0.1 84.0
(4.7)
76.0
(3.4)
5.0 79.9
(1.96)
73.69
(3.5)
0.4 76.0
(2.9)
52.8
(4.22)
10.0 73.2
(1.82)
71.88
(1.66)
1.0 62.0
(3.33)
48.2
(6.0)
50.0 49.3
(2.01)
51.12
(2.65)
4.0 54.0
(6.3)
42.0
(4.33)
100.0 44.2
(2.02)
41.93
(3.26)
10.0 46.0
(2.78)
40.0
(4-0)
500.0 6.6
(1.73)
5.59
(3.07)
40.0 40.0
(5.9)
36.0
(2.77)
100.0 36.0
(4.8)
32.0
(10.0)
Table 2: CRC
Etoposide
(UM)
SW620 SW620& 
vpl (6pM)
Vincristine
(pM)
SW620 SW620& 
vpl (6pM)
0.01 100.0
(2.99)
100.0
(2.68)
0.01 100.0
(1.57)
100.0
(1.14)
1.6 998.0
(1.9)
96.8
(3.3)
0.046 73.42
(0.94)
79.7
(1.69)
3.3 86.4
(1.59)
76.0
(6.4)
0.137 72.59
(2.12)
76.2
(1.71)
6.6 75.95
(3.39)
65.29
(1.03)
0.411 74.5
(1.54)
73.1
(2.69)
13.2 59.92
(1.147)
51.6
(1.11)
1.23 74.17
(2.16)
71.81
(2.82)
26.4 49.7
(1.104)
46.1
(2.88)
3.7 76.01
(2.9)
77.47
(2.33)
52.8 43.3
(5.28)
40.048
(3.12)
11.1 76.7
(3.57)
72.99
(1.59)
105.6 31.22
(1-13)
25.8
(1.24)
33.3 67.9
(2.04)
72.19
(4.5)
211.0 2.847
(0.13)
2.787
(0.12)
100.0 45.3
(1.04)
46.7
(1.29)
422.0 3.2
(0.134)
3.33
(0.12)
225.0 10.77
(0.43)
11.8
(0.5)
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Appendix 5.1: Data for GSH assays in HCC & CRC cell lines
Table 1: HCC
Cell Lines Total GSH 
I
Total GSH 
II
Total GSH 
III
Mean (nM/106 cells) SEM
HepG2 2.1 9.7 9.6 7.13 2.51
SK-Hep-1 4.5 7.6 6.25 6.11 0.89
C3A 1.75 5.2 7.4 4.58 1.097
PLC/PRF/5 2.7 6.5 4.55 3.53 0.57
Hep3B 2.4 4.2 4.0 4.78 1.64
Cell Lines + BSO 
I
+ BSO 
11
+ BSO 
III
Mean (nM/106 cells) SEM
HepG2 1.2 2.8 2.4 2.13 0.48
SK-Hep-1 2.4 4.8 1.25 2.81 1.04
C3A 1.8 3.7 1.1 3.0 0.87
PLC/PRF/5 2.8 4.6 1.6 2.15 0.92
Hep3B 1.25 4.0 1.2 2.2 0.77
Table 2: CRC
Cell Lines Total GSH 
I
Total GSH 
II
Total GSH 
III
Mean (nM/106 cells) SEM
WIDR 2.80 5.10 6.10 4.67 0.98
CAC02 1.80 11.25 6.50 6.52 2.73
HT-29 1.75 7.80 4.70 4.75 1.75
SW620 2.10 4.00 6.00 4.03 1.12
Cell Lines + BSO 
I
+ BSO 
II
+ BSO 
III
Mean (nM/106 cells) SEM
WIDR 1.50 3.80 0.75 2.02 0.92
CAC02 2.30 4.40 4.10 3.6 0.65
HT-29 2.45 2.50 3.60 2.85 0.37
SW620 2.50 1.60 2.10 2.07 0.26
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Appendix 5.2: Data for effect of BSO (50 uM) on ICsnS with cisplatin in HCC & 
CRC cell lines
Survival as percentage of control, ±SEM
Table la: Untreated HCC cells
Cisplatin
(pM)
HepG2 SkHep
-1
Cisplatin
(pM)
Hep3B Cisplatin
(pM)
PLC/PRF/
5
Cisplatin
(PM)
C3A
0.01 100.0 100.0 0.1 100.0 0.01 100.0 1.0 100.0
4.0 98.89
(4.35)
90.48
(4.49)
0.19 100.43
(0.25)
0.045 92.50
(1.22)
1.5 84.48
(2.52)
6.0 94.47
(1.70)
89.38
(1.15)
0.39 101.58
(2.76)
0.137 94.29
(0.72)
3.1 76.22
(2.07)
8.0 94.04
(1.076)
88.53
(2.47)
0.78 99.86
(1.44)
0.41 95.23
(1.34)
6.2 55.79
(6.10)
10.0 92.91
(1.07)
87.61
(2.28)
1.5 98.94
(1.21)
1.23 93.88
(0.81)
12.5 28.97
(6.61)
20.0 78.25
(3.06)
63.15
(6.42)
3.12 100.38
(1.35)
3.7 94.70
(1.29)
25.0 22.74
(2.93)
30.0 24.95
(3.13)
32.33
(5.59)
6.3 97.5
(2.98)
11.1 91.04
(1.57)
50.0 20.81
(6.39)
40.0 20.87
(2.29)
21.27
(9.75)
12.5 76.83
(4.06)
33.3 62.05
(3.08)
100.0 20.53
(7.20)
60.0 16.28
(1.98)
9.40
(3.45)
25.0 15.89
(9.43)
40.0 3.80
(0.30)
80.0 24.0
(2.07)
6.96
(2.51)
50.0 17.56
(6.94)
100.0 4.29
(0.42)
100.0 23.06
(2.56)
6.56
(3.06)
100.0 6.85
(3.48)
Table lb: HCC cells treated with BSO (50 pM)
HepG2 SkHep
-1
Hep3B PLC/PRF/
5
C3A
Cisplatin
(PM)
+ BSO + BSO Cisplatin
(PM)
+ BSO Cisplatin
(pM)
+ BSO Cisplatin
(PM)
0.01 100.0 100.0 0.10 100.0 0.01 100.0 1.0 100.0
4.0 96.20
(2-47)
89.23
(3-21)
0.19 98.40
(3.34)
0.045 90.03
(3.65)
1.5 93.38
(5.38)
6.0 95.84
(1.70)
87.52
(2.18)
0.39 93.06
(3.78)
0.137 91.98
(2.58)
3.1 78.77
(3.59)
8.0 93.07
(1.05)
87.03
(1.95)
0.78 92.49
(0.95)
0.411 88.58
(0.84)
6.2 55.28
(2.20)
10.0 88.89
(1.36)
84.37 
(1 45)
1.5 90.40
(3.14)
1.234 89.54
(0.99)
12.5 24.13
(4.16)
20.0 29.98
(7.96)
38.94
(6.66)
3.12 82.20
(6.33)
3.7 87.36
(3.51)
25.0 12.65
(4.91)
30.0 21.05
(9.0)
16.43
(8.14)
6.3 73.23
(2.15)
11.10 79.36
(2.40)
50.0 9.91
(2.76)
40.0 25.7
(9.68)
12.62
(3.92)
12.5 18.92
(6.98)
33.30 35.55
(2.00)
100.0 8.15
(2.98)
60.0 15.93
(0.64)
5.62
(1.6)
25.0 15.32
(5.73)
40.0 1.55
(1.75)
80.0 8.85
(2.23)
6.10
(2.54)
50.0 9.94
(1.52)
100.0 1.55
(3.90)
100.0 5.12
(0.39)
8.21
(3.22)
100.0 15.77 
(0.36) |
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Table 2a: Untreated CRC cells
Cisplatin
(nM)
CAC02 HT-29 Cisplatin
(pM)
SW620 Cisplatin
(pM)
WIDR
0 100.0 100.0 0.10 100.0 0.10 100.0
1.5 99.32
(5.91)
91.48
(0.85)
0.15 99.92
(0.75)
0.45 97.00
(5.70)
3.1 95.27
(9.14)
90.90
(3.28)
0.45 101.88
(2.68)
1.37 93.99
(3.99)
6.2 76.38
(6.47)
75.09
(2.66)
1.37 103.61
(2.33)
4.11 90.93
(5.70)
12.5 47.57
(0.41)
24.65
(1.72)
4.11 101.32
(2.043)
12.0 57.16
(2.90)
25.0 25.82
(7.59)
1.30
(4.08)
12.0 96.47
(2.21)
37.0 13.67
(8.60)
50.0 16.33
(8.28)
3.10
(2.58)
37.0 58.95
(1.77)
111.0 3.97
(2.43)
100.0 13.67
(7.25)
6.80
(1.69)
111.0 23.77
(2.33)
200.0 14.71
(6.14)
5.30
(1.08)
333.0 15.23
(0.70)
Table 2b: HCC cells treated with BSO (50 jiM)
Cisplatin
(pM)
CAC02 HT-29 Cisplatin
(pM)
SW620 Cisplatin
(pM)
WIDR
+ BSO + BSO + BSO + BSO
0.1 100.0 100.00 0.10 100.0
(3.20)
0.1 100.0
(3.50)
1.5 92.78
(2.18)
101.47
(0.84)
0.15 93.50
(4-70)
0.45 98.99
(7.32)
3.1 96.77
(4-12)
102.58
(5-08)
0.45 99.59
(6.0)
1.37 96.74
(2.80)
6.2 80.72
(0.96)
75.23
(2-26)
1.37 92.56
(2.77)
4.11 79.60
(5.80)
12.5 42.14
(9.03)
14.87
(3.47)
4.11 90.40
(4.78)
12.0 41.70
(1.89)
25.0 23.0
(1.27)
4.611
(2-41)
12.0 69.04
(5.20)
37.0 7.95
(4.90)
50.0 16.09
(2.61)
5.098
(4.56)
37.0 38.49
(3.80)
111.0 2.50
(4.20)
100.0 14.34
(3.57)
6.57
(0.46)
111.0 13.70
(3.11)
200.0 16.73
(8.09)
10.65
(1.26)
333.0 9.11
(1.60)
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Appendix 6.1: Data for ICsos after 1 h exposure to cisplatin in HCC & 
CRC cell lines
Survival as percentage o f control, ±SEM
Table la: HCC cells
Cisplatin
(UM)
HepG2 HSkHep-1 C3A PLC/PR
F/5
Hep3B
0.01 100.0
(0.58)
100.0
(2.38)
100.0
(1.28)
100.0
(3.64)
100.0
(1.02)
0.045 99.21
(2.43)
100.0
(2.33)
76.97
(3.11)
100.0
(3.0)
100.0
(1.7)
0.137 98.30
(2.88)
99.45
(3.85)
68.30
(4.24)
98.34
(2.38)
97.61
(1.69)
0.411 99.30
(3.02)
97.78
(1.70)
66.02
(4.23)
96.91
(4.62)
87.50
(4.23)
1.23 98.86
(3.40)
97.0
(2.27)
68.10
(3.85)
92.53
(2.28)
81.0
(2.47)
3.7 101.65
(3.30)
88.80
(4.37)
71.07
(5.35)
86.39
(2.10)
74.59
(1.47)
11.1 81.12
(4.66)
91.66
(2.11)
50.19
(2.83)
92.22
(2.23)
64.45
(2.88)
33.3 75.30
(9.98)
77.28
(2.37)
42.16
(1.44)
81.37
(2.87)
44.0
(3.47)
60.0 63.70
(3.32)
67.70
(4.32)
34.6
(3.5)
74.9
(2-19)
41.63
(1.66)
80.0 67.70
(3.66)
65.39
(2.56)
29.11
(4.62)
65.0
(3.7)
37.43
(5.35)
100.0 37.30
(4.17)
42.0
(1-17)
22.50
(1.52)
45.83
(2.36)
19.66
(2^7)
Table lb: CRC cells
Cisplatin
(UM)
SW620 Cisplatin
(pM)
HT-29
0.01 100.0
(1.77)
0.01 100.0
(4.5)
0.15 99.82
(4.37)
1.0 96.23
(3.19)
0.45 103.2
(6.30)
4.0 95.45
(3.6)
1.37 104.54
(3.50)
7.0 88.71
(5.21)
4.11 100.47
(2.06)
10.0 73.90
(6.0)
12.0 98.33
(3.90)
40.0 54.60
(5.4)
37.0 82.70
(2.77)
70.0 32.70
(3.88)
111.0 53.84
(3.30)
100.0 31.50
(3.49)
333.0 41.20
(1.24)
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Appendix 6.2: Data for Comet Assays after 1 h exposure to cisplatin in HCC & 
CRC ceil lines
Interstrand Cross Links represented as % decrease in Tail Moment ±SEM
Table la: HCC cells
Cell Line Time (h) Cisplatin (pM)
10 25 45 100
HepG2 6 4.0 ± 5.7 22.4 ±4.7 13.6 ±6.7 47.12 ±2.3
12 17.1 ±3.2 27.47 ± 3.5 40.3 ±4.3 68.0 ±3.4
18 0.0 ± 5.3 16.3 ±6.5 36.9 ±2.8 76.6 ±2.3
24 0.0 ± 5.0 0.0 ± 6.4 17.3 ± 2.1 58.2 ±4.0
48 0.0 ± 1.33 2.0 ±3.6 15.4 ±3.88 49.1 ± 1.77
72 0.0 ± 12.4 0.0 ± 1.22 10.0 ±5.4 33.8 ±3.4
SkHep-1 6 28.66 ±3.8 37.3 ± 1.2 48.9 ±2.4 58.8 ±4.7
12 38.0 ±7.0 33.0 ±4.3 51.65 ±3.4 72.0 ±4.6
18 13.5 ±4.5 19.0 ±4.3 43.47 ± 5.0 59.89 ± 3.99
24 9.8 ±3.22 0.0 ±5.9 19.0 ±6.7 49.3 ± 7.4
48 0.0 ± 4.98 0.0 ±6.55 19.1 ±2.44 49.9 ±3.9
72 0.0 ± 9.0 0.0 ± 12.4 11.22 ±3.2 24.05 ±2.3
C3A 6 25.11 ±3.8 32.6 ± 1.2 59.9 ± 2.4 67.2 ± 4.7
12 39.66 ±7.0 59.0 ±4.3 64.33 ±3.4 89.46 ± 4.6
18 42.8 ±4.5 65.31 ±4.3 69.08 ± 5.0 91.2 ±3.99
24 35.9 ±3.22 42.1 ±5.9 62.45 ± 6.7 82.0 ± 7.4
48 32.3 ±4.98 33.8 ±6.55 32.58 ±2.44 92.87 ±3.9
72 30.0 ± 11.0 35.0 ± 12.0 39.0 ±3.2 86.72 ± 2.3
PLC/PRF/
5
6 0.0 ±0.0 0.56 ±3.0 9.88 ±2.38 19.2 ±4.62
12 15.93 ±2.28 19.23 ±2.1 25.0 ±2.23 56.0 ±2.55
24 23.58 ±4.9 29.7 ± 2.94 35.5 ± 1.86 59.18 ± 2.17
48 8.1 ±3.192 29.0 ± 1.42 32.2 ±2.36 38.56 ±2.1
72 9.48 ± 4.3 18.53 ±3.5 27.11 ±5.8 35.68 ±3.77
Hep3B 6 20.6 ±5.7 37.7 ±4.7 47.6 ±6.77 67.5 ±2.3
12 29.2± 3.2 34.4 ±3.5 60.1 ±4.3 84.8 ± 3.4
18 18.0 ±6.0 29.0 ± 6.5 57.3 ±9.8 82.0 ±2.3
24 10.0 ±5.0 23.5 ±6.4 40.0 ±2.1 84.0 ± 4.0
48 12.0 ±4.6 14.1 ±6.9 42.0 ±3.88 88.42 ± 1.77
72 9.0 ± 15.0 6.0 ±3.2 41.0 ±5.4 84.6 ± 3.4
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Table lb: CRC cells
Cell Line Time (h) Cisplatin (pM)
10 25 45 100
HT-29 6 7.0 ±5.31 7.6 ±4.58 19.7 ±5.06 49.7 ±7.8
12 16.0 ±4.3 25.8 ±4.15 47.2 ± 4.2 63.11 ±4.32
24 12.0 ±3.1 19.0 ±2.98 35.0 ±3.99 65.1 ± 1.4
48 10.21 ±2.32 16.5 ±3.26 33.21 ±3.7 62.35 ±4.6
72 5.88 ±3.87 9.76 ±4.12 27.78 ±3.7 58.35 ±4.82
SW620 6 0.0 ± 0.0 3.0 ±2.33 13.3 ±2.41 33.0 ±2.1
12 12.1 ±2.73 21.1 ±2.6 27.0 ±3.0 60.33 ± 3.54
24 4.58 ±2.75 11.0 ± 2.12 21.36 ± 2.01 58.64 ±3.24
48 1.4 ±3.55 10.2 ±2.8 16.0 ± 1.85 63.77 ± 2.95
72 1.1 ±5.9 8.2 ±2.58 13.0 ±3.06 45.71 ±2.73
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Appendix 7.1: Raw data for formation of ICLs in in-vivo intrahepatic CRC and 
HCC xenografts of nude mice
A: Percentage decrease of Tail Moment of SW620 cells treated with 4 mg/kg 
(i.v.) cisplatin as assessed by the comet assay
Values are the mean of 25 measurements 
(*Two-tailed unpaired t-test, n=12)
Time
(h)
Site & Depth (cm) Mouse & Tumour Number
Mouse 1 Mouse 2 Mouse 3 P
T1 T2 T1 T2 T1 T2
6 A 0.25 25.0 18.0 17.0 27.0 23.0 10.0
0.5 22.0 19.0 9.0 8.0 29.0 12.0
B 0.25 15.0 31.0 10.0 8.0 27.0 15.0
0.5 17.0 22.0 11.0 18.0 18.0 15.0
*Total 0.25 vs 0.5 P=0.451
12 A 0.25 50.0 52.0 33.0 46.0 58.0 17.0
0.5 38.0 46.0 24.0 29.0 52.0 16.0
B 0.25 42.0 45.0 39.0 52.0 43.0 29.0
0.5 19.0 35.0 31.0 16.0 37.0 21.0
*Total 0.25 vs 0.5 P= 0.02
24 A 0.25 48.0 24.0 36.0 29.0 42.0 32.0
0.5 22.0 28.0 32.0 24.0 29.0 27.0
B 0.25 38.0 33.0 56.0 38.0 41.0 29.0
0.5 18.0 32.0 41.0 26.0 32.0 19.0
*Total 0.25 vs 0.5 P= 0.0057
48 A 0.25 16.0 12.0 33.0 21.0 31.0 23.0
0.5 26.0 32.0 26.0 31.0 19.0 27.0
B 0.25 24.0 19.0 18.0 29.0 15.0 26.0
0.5 24.0 27.0 28.0 18.0 24.0 27.0
*Total 0.25 vs 0.5 P= 0.1347
72 A 0.25 6.0 12.0 8.0 23.0 9.0 12.0
0.5 20.0 14.0 16.0 18.0 22.0 18.0
B 0.25 15.0 21.0 10.0 16.0 16.0 9.0
0.5 18.0 17.0 19.0 12.0 26.0 21.0
*Total 0.25 vs 0.5 P= 0.0086
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B: Percentage decrease of Tail Moment of C3A cells treated with 4 mg/kg (iv) 
cisplatin as assessed by the comet assay
Values are the mean of 25 measurements 
(*Two-tailed unpaired t-test, n =12)
Time
(h)
Site & Depth (cm) Mouse & Tumour Number
Mouse 1 Mouse 2 Mouse 3 P
T1 T2 T1 T2 T1 T2
6 A 0.25 42.0 56.0 62.0 33.0 48.0 29.0
0.5 37.0 55.0 42.0 38.0 52.0 32.0
B 0.25 49.0 52.0 48.0 39.0 45.0 18.0
0.5 42.0 47.0 49.0 31.0 56.0 25.0
*Total 0.25 vs 0.5 P= 0.7859
12 A 0.25 67.0 78.0 66.0 55.0 57.0 48.0
0.5 59.0 63.0 52.0 49.0 49.0 35.0
B 0.25 72.0 69.0 58.0 62.0 58.0 69.0
0.5 61.0 48.0 55.0 52.0 35.0 53.0
*Total 0.25 vs 0.5 P= 0.002
24 A 0.25 75.0 78.0 67.0 35.0 56.0 62.0
0.5 53.0 73.0 49.0 38.0 42.0 49.0
B 0.25 69.0 82.0 58.0 42.0 59.0 54.0
0.5 61.0 76.0 52.0 36.0 50.0 46.0
*Total 0.25 vs 0.5 P= 0.0983
48 A 0.25 55.0 56.0 67.0 47.0 38.0 48.0
0.5 48.0 56.0 57.0 38.0 42.0 50.0
B 0.25 49.0 59.0 63.0 56.0 32.0 52.0
0.5 41.0 48.0 65.0 48.0 35.0 42.0
*Total 0.25 vs 0.5 P= 0.2665
72 A 0.25 32.0 48.0 52.0 39.0 17.0 37.0
0.5 39.0 19.0 29.0 38.0 36.0 35.0
B 0.25 27.0 33.0 36.0 32.0 26.0 41.0
0.5 52.0 36.0 34.0 43.0 42.0 39.0
*Total 0.25 vs 0.5 P= 0.6149
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Appendix 7.2: Comparison of percentage decrease in Tail Moment at different 
depths, sites and between tumours, with 4 mg/kg cisplatin (i.v.) on intrahepatic 
human xeno2 rafts in nude mice at 12 h as assessed by the comet assay
A: Depth (Two-tailed unpaired t-test) (n=25, except * n=12)
Xenograft Site Depth
(cm)
Mouse & Tumour Number
Mouse 1 Mouse 2 Mouse 3
T1 T2 T1 T2 T1 T2 Total
SW620 A 0.25 vs 0.5 P = 0.043 P = 0.303 P = 0.029 P = 0.015 P = 0.20 P = 0.869
B 0.25 vs 0.5 P = 0.003 P = 0.048 P - 0.056 P0.0001 P = 0.487 P = 0.069
*A 
& B
0.25 vs 0.5 P =0.02
C3A A 0.25 vs 0.5 P = 0.166 ooIICL, P = 0.073 P = 0.067 P = 0.233 P = 0.001
B 0.25 vs 0.5 P = 0.154 P = 0.013 P = 0.694 P = 0.075 P0.0001 P = 0.002
*A 
& B
0.25 vs 0.5 P=0.002
B: Site (Two-tailed unpaired t-test) (n=25)
Xenograft Depth
(cm)
Site Mouse & Tumour Number
Mouse 1 Mouse 2 Mouse 3
T1 T2 T1 T2 T1 T2
SW620 0.25 A vs B P = 0.355 P = 0.167 P = 0.134 P = 0.383 P = 0.085 P = 0.048
C3A 0.25 A vs B P = 0.396 P = 0.272 P = 0.332 P = 0.031 P = 0.86 P<0.0001
C: Intertumour (One-way ANOVA followed by the Bonferroni multiple t-test) (n=25)
Xenograft Depth
(cm)
Tumour 
Number & Site
Mouse Number
Mouse 1 Mouse 2 Mouse 3
SW620 0.25 T1 A vs T2 A P > 0.05 P > 0.05 P< 0.001
T1 A vs T2 B P > 0.05 P<0.01 P< 0.001
T1 B vs T2 A P > 0.05 P > 0.05 P<0.01
T1 B vs T2 A P > 0.05 P > 0.05 P > 0.05
C3A 0.25 T1 A vs T2 A P > 0.05 P > 0.05 P< 0.001
T1 A vs T2 B P > 0.05 P<0.01 P< 0.001
T1 B vs T2 A P > 0.05 P > 0.05 P<0.01
T1 B vs T2 A P > 0.05 P > 0.05 P > 0.05
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Appendix 7.3: Raw data for proliferation in in-vivo intrahepatic CRC and HCC 
xenografts of nude mice
A: Labelling Index (LI, %) of SW620 intrahepatic xenografts treated with 
4 mg/kg (i.v.) of cisplatin at 12 h, as measured with the monoclonal antibody 
MIB-1 against Ki-67
LI assessed in 10 high power fields (each high powered field consisted of 50-100 cells)
Xenograft Depth
(cm)
Mouse & Tumour Number
Mouse 1 Mouse 2 Mouse 3
T1 T2 T1 T2 T1 T2
SW620 0.25 14.7 17.8 14.8 11.2 8.4 13.4
11.2 17.9 11.2 14.2 10.5 14.3
12.6 12.7 12.4 7.4 12.6 9.1
10.6 18.5 15.0 8.3 9.9 14.2
14.3 12.8 13.5 13.3 11.8 12.6
8.6 9.6 12.1 12.8 11.5 9.2
8.2 12.9 7.9 13.0 9.8 14.4
13.6 14.9 9.6 16.0 15.2 00 00
15.8 12.9 13.2 14.2 14.4 11.1
12.7 7.8 14.3 11.7 12.3 12.2
0.5 11.6 10.3 7.4 9.2 7.5 7.8
8.4 6.7 9.6 13.6 11.7 10.2
6.1 4.7 5.9 8.4 11.0 6.7
12.4 12.1 12.7 6.9 12.6 9.2
9.1 8.2 8.6 14.3 15.0 12.7
7.3 8.7 9.6 12.9 7.8 9.7
8.7 5.6 5.8 6.7 11.6 9.3
9.8 8.9 12.0 4.9 12.8 10.8
9.1 5.1 12.3 10.2 6.7 13.5
9.8 10.6 9.7 7.9 5.6 15.2
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B: Labelling Index (LI, %) of C3A intrahepatic xenografts treated with 4 mg/kg 
(i.v.) of cisplatin at 12 h, as measured with the monoclonal antibody MIB-1 
against Ki-67
LI assessed in 10 high power fields (each high powered field consisted of 50-100 cells)
Xenograft Depth
(cm)
Mouse & Tumour Number
Mouse 1 Mouse 2 Mouse 3
T1 T2 T1 T2 T1 T2
C3A 0.25 13.2 15.4 12.8 12.8 17.4 21.3
24.8 16.5 17.2 15.3 21.2 13.5
12.1 17.2 22.3 14.8 16.3 16.7
14.0 18.0 18.6 19.6 12.8 15.8
14.2 15.7 20.5 29.8 16.0 19.3
25.0 16.8 12.7 12.6 19.1 25.3
7.8 17.2 11.5 9.3 21.9 17.5
19.2 16.8 18.3 22.9 15.1 18.6
17.9 18.2 12.3 17.8 11.0 12.8
15.3 13.5 16.3 16.9 18.4 19.4
0.5 6.1 12.3 12.6 7.2 17.8 9.3
17.4 12.8 13.2 15.7 11.1 15.9
16.7 15.3 14.3 12.7 16.1 14.4
7.6 22.8 9.4 10.0 12.8 15.9
21.3 18.6 8.4 9.5 7.1 12.3
16.5 12.3 13.7 18.5 19.9 9.7
7.4 13.2 16.2 16.5 15.2 16.0
17.5 15.8 9.7 15.0 7.7 12.2
9.8 13.3 8.4 7.0 18.4 13.8
18.0 15.0 9.2 19.6 15.5 6.9
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Appendix 7.4: Raw data for hypoxia in in-vivo intrahepatic CRC and HCC 
xenografts of nude mice
A: Labelling Index (LI, %) of SW620 intrahepatic xenografts treated with 
4 mg/kg (i.v.) of cisplatin at 12 h, as measured with polyclonal rabbit anti­
serum against theophylline (covalently linked to the hypoxic probe NITP)
LI assessed in 10 high power fields (each high powered field consisted of 50-100 cells)
Xenograft Depth
(cm)
Mouse & Tumour Number
Mouse 1 Mouse 2 Mouse 3
T1 T2 T1 T2 T1 T2
SW620 0.25 6.8 13.0 6.8 2.8 0.3 7.8
27.3 6.9 17.3 9.7 4.7 9.2
4.2 4.0 3.2 3.8 9.7 7.6
7.3 1.3 8.1 6.7 7.8 8.3
13.8 6.1 9.3 5.5 2.4 5.6
17.7 4.2 3.4 6.8 3.6 11.8
10.8 9.8 6.1 9.8 4.7 2.4
11.8 11.2 5.1 6.7 16.2 8.6
3.5 2.4 5.4 10.9 11.9 7.3
4.2 6.9 7.6 3.6 6.6 1.9
0.5 16.7 14.2 12.8 17.5 12.6 3.7
2.4 18.3 13.8 7.2 00 bo 7.6
11.8 12.6 8.1 8.6 7.9 8.6
18.3 7.8 4.3 6.3 8.3 6.5
19.3 2.8 15.0 10.6 9.4 8.4
17.8 17.4 11.6 9.8 7.8 12.1
15.4 12.8 9.2 15.6 3.9 11.9
9.6 6.4 7.8 11.3 8.2 15.6
7.3 6.3 12.9 7.4 7.4 7.9
11.8 9.9 4.6 8.7 9.8 8.7
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B: Labelling Index (LI, %) of C3A intrahepatic xenografts treated 4 mg/kg (i.v.) 
of cisplatin at 12 h, as measured with polyclonal rabbit anti-serum against 
theophylline (covalently linked to the hypoxic probe NITP)
LI assessed in 10 high power fields (each high powered field consisted of 50-100 cells)
Xenograft Depth
(cm)
Mouse & Tumour Number
Mouse 1 Mouse 2 Mouse 3
T1 T2 T1 T2 T1 T2
C3A 0.25 7.7 5.8 3.6 8.3 7.4 1.7
17.3 6.7 9.6 7.9 5.3 5.8
6.7 3.6 8.7 16.8 5.6 7.9
10.6 13.4 6.3 4.3 6.3 8.4
7.9 11.8 5.8 7.8 6.6 7.8
3.8 6.6 9.3 3.8 8.5 6.3
9.7 3.8 13.4 4.3 16.4 6.7
11.7 4.9 4.8 6.9 11.5 8.3
0.3 14.8 2.8 12.7 2.8 10.8
7.8 8.7 5.8 11.3 3.9 7.2
0.5 12.2 4.2 12.3 13.7 11.5 16.8
13.0 5.1 15.8 13.5 3.6 23.9
14.5 6.7 9.8 15.3 6.9 6.5
5.3 7.4 7.9 8.7 9.7 8.0
8.4 15.8 18.6 8.6 15.3 6.7
17.2 18.8 15.8 15.8 9.8 16.7
21.3 13.8 7.6 7.3 7.8 12.9
2.8 14.1 16.6 19.8 12.2 3.6
6.7 9.8 19.8 17.8 9.7 14.8
13.3 7.9 5.9 3.6 19.4 12.1
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Appendix 7.5: Raw data for vascularity in in-vivo intrahepatic CRC and HCC 
xenografts of nude mice
Vascular density (VD) (= number of vascular structures/mm2) of SW620 & C3A 
intrahepatic xenografts treated with 4 mg/kg (i.v.) of cisplatin at 12 h, as 
measured with mouse monoclonal anti-human von Willebrand factor
VD assessed in 10 high power fields (each high powered field consisted of 50-100 cells)
Xenograft Depth
(cm)
Mouse & Tumour Number
Mouse 1 Mouse 2 Mouse 3
T1 T2 T1 T2 T1 T2
SW620 0.25 29.0 17.0 14.0 32.0 29.0 28.0
18.0 28.0 27.0 36.0 19.0 22.0
25.0 38.0 24.0 37.0 35.0 33.0
17.0 27.0 9.0 21.0 22.0 27.0
21.0 22.0 34.0 29.0 17.0 25.0
33.0 37.0 11.0 28.0 38.0 36.0
18.0 29.0 29.0 33.0 15.0 29.0
7.0 18.0 36.0 26.0 40.0 21.0
38.0 30.0 40.0 30.0 25.0 28.0
17.0 35.0 19.0 25.0 28.0 19.0
0.5 18.0 16.0 27.0 23.0 27.0 23.0
22.0 23.0 19.0 16.0 34.0 21.0
21.0 31.0 24.0 28.0 31.0 25.0
15.0 11.0 18.0 26.0 23.0 32.0
26.0 17.0 22.0 24.0 20.0 13.0
14.0 27.0 18.0 8.0 27.0 23.0
8.0 25.0 26.0 14.0 28.0 16.0
25.0 6.0 25.0 17.0 17.0 22.0
19.0 21.0 12.0 22.0 21.0 28.0
21.0 21.0 20.0 28.0 28.0 31.0
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Xenograft Depth
(cm)
Mouse & Tumour Number
Mouse 1 Mouse 2 Mouse 3
T1 T2 T1 T2 T1 T2
C3A 0.25 32.0 22.0 40.0 17.0 28.0 36.0
36.0 28.0 31.0 26.0 33.0 35.0
29.0 39.0 35.0 28.0 36.0 32.0
24.0 36.0 28.0 25.0 29.0 28.0
17.0 33.0 33.0 31.0 32.0 26.0
36.0 29.0 29.0 36.0 26.0 28.0
39.0 17.0 27.0 26.0 15.0 30.0
18.0 32.0 23.0 18.0 28.0 16.0
29.0 26.0 33.0 29.0 28.0 28.0
21.0 13.0 27.0 16.0 32.0 32.0
0.5 19.0 24.0 19.0 20.0 30.0 17.0
24.0 27.0 28.0 22.0 27.0 26.0
22.0 31.0 31.0 24.0 29.0 27.0
29.0 26.0 16.0 29.0 18.0 23.0
13.0 12.0 25.0 17.0 32.0 20.0
24.0 8.0 24.0 16.0 15.0 13.0
14.0 19.0 12.0 24.0 17.0 24.0
17.0 22.0 11.0 19.0 26.0 9.0
25.0 20.0 21.0 21.0 23.0 16.0
19.0 22.0 16.0 9.0 19.0 20.0
369
Appendices
Appendix 7.6: Raw data for expression of P-gp in in-vivo intrahepatic CRC and 
HCC xenografts of nude mice
Expression of P-gp (LI, %) in SW620 & C3A intrahepatic xenografts treated 
with 4 mg/kg (i.v.) of cisplatin at 12 h, as measured with mouse monoclonal anti­
human P-gp antibody
LI assessed in 10 high power fields (each high powered field consisted of 50-100 cells)
Xenograft Depth
(cm)
Mouse & Tumour Number
Mouse 1 Mouse 2 Mouse 3
T1 T2 T1 T2 T1 T2
SW620 0.25 10.0 5.0 7.5 21.4 7.77 6.6
11.2 18.0 9.8 14.6 12.6 27.0
25.0 26.0 15.0 4.5 10.0 13.0
16.0 17.4 18.7 19.8 5.8 23.9
32.0 12.5 30.4 36.0 19.0 14.45
9.0 28.8 23.9 17.0 16.0 23.01
17.0 13.2 18.7 13.6 26.6 12.38
28.0 19.8 7.9 22.0 18.5 14.81
8.9 14.9 24.0 8.2 19.8 33.1
19.6 27.0 17.6 21.3 10.0 9.40
0.5 4.6 18.6 11.2 16.2 15.3 7.6
13.2 16.3 6.4 8.4 9.0 11.2
15.0 9.8 3.0 9.2 4.3 5.0
16.59 20.5 22.39 15.0 13.91 12.8
10.77 13.43 9.05 18.42 23.8 9.9
19.22 17.8 10.72 9.8 11.9 15.67
25.62 14.55 17.3 14.19 14.6 21.03
15.0 10.9 14.08 25.6 18.2 13.6
18.33 11.61 22.9 12.9 7.67 16.9
20.3 22.39 10.2 17.11 8.7 18.3
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Xenograft Depth
(cm)
Mouse & Tumour Number
Mouse 1 Mouse 2 Mouse 3
T1 T2 T1 T2 T1 T2
C3A 0.25 5.0 18.2 6.7 9.6 18.7 26.0
29.2 11.3 16.5 7.3 17.2 13.3
14.6 9.8 22.1 15.2 6.3 15.0
12.4 14.54 16.03 16.5 12.8 11.07
8.8 9.74 6.96 23.6 16.2 13.0
13.3 6.5 11.6 16.8 19.6 15.69
12.2 9.2 9.9 9.5 9.5 19.81
13.9 15.3 13.85 14.6 17.3 14.23
8.7 10.67 15.6 17.4 7.8 23.23
16.3 8.35 13.7 7.6 21.5 6.38
0.5 8.5 16.5 13.5 24.6 25.0 5.6
6.4 13.2 10.3 19.6 16.7 9.7
9.5 11.5 19.0 14.5 15.0 16.0
10.82 13.41 11.05 13.76 14.16 9.14
11.33 13.3 11.14 9.43 6.82 13.22
9.05 19.02 10.46 15.83 17.91 14.18
8.023 12.8 9.97 11.68 13.26 18.33
13.01 18.57 14.99 6.98 13.16 16.86
12.38 7.65 17.33 16.7 9.80 15.0
9.08 8.49 11.65 13.6 7.6 6.79
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Appendix 7.7: Proliferation statistics of xenografts of nude mice
(SD = standard deviation; CD = coefficient of variation) (n = 10 fields)
Unpaired t-test (two-tailed) (n = 10), *(n = 60), #(n = 6)
Xenogr
aft
Depth
(cm)
Mouse & Tumour Number (n = 10)
Mouse 1 Mouse 2 Mouse 3 Total
T1 T2 T1 T2 T1 T2
SW620 0.25 Mean 12.23 13.78 12.4 12.21 11.64 11.93
SD 2.55 3.55 2.3 2.67 2.11 2.25
CV (%) 20.85 25.78 18.55 21.87 18.09 18.85
0.5 Mean 9.23 8.09 9.36 9.5 10.23 10.51
SD 1.85 2.51 2.49 3.19 3.107 2.62
CV (%) 20.06 31.07 26.67 33.57 30.37 24.89
0.25 vs 
0.5
Unpaired
t-test
P=0.0075 P=0.0006 P=0.011 P=0.0541 P=0.2502 P=0.2094 *P<0.0001
C3A 0.25 Mean 16.35 16.53 16.25 17.18 16.92 18.02
SD 5.468 1.38 3.771 5.867 3.446 3.686
CV (%) 33.44 8.35 23.2 34.15 20.36 20.45
0.5 Mean 13.83 15.14 11.51 13.17 14.16 12.64
SD 5.487 3.331 2.809 4.571 4.392 3.163
CV (%) 39.67 22.0 24.41 34.71 31.02 25.02
0.25 vs 
0.5
Unpaired
t-test
P=0.3172 P=0.2386 P=0.0051 P=0.1054 P=0.1353 P=0.0025 *P<0.0001
SW620 
vs C3A
0.25 Unpaired
t-test
#P<0.0001
0.5 Unpaired
t-test
#P<0.0001
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Appendix 7.8: Hypoxia statistics of xenografts of nude mice
(SD = standard deviation; CD = coefficient of variation) (n = 10 fields) 
Unpaired t-test (two-tailed) (n = 10), *(n = 60), #(n = 6)
Xenogr
aft
Depth
(cm)
Mouse & Tumour Number (n = 10)
Mouse 1 Mouse 2 Mouse 3 Total
T1 T2 T1 T2 T1 T2
SW620 0.25 Mean 10.74 6.58 7.23 6.63 6.79 7.05
SD 7.44 3.82 4.04 2.81 4.77 3.02
CV (%) 69.29 57.99 55.87 42.33 70.20 42.90
0.5 Mean 13.04 10.85 10.01 10.3 8.41 9.1
SD 5.47 5.08 3.79 3.66 2.18 3.33
CV (%) 41.97 46.79 37.82 35.56 25.89 36.56
0.25 vs 
0.5
Unpaired
t-test
P=0.441 P=0.048 P= 0.129 P= 0.022 P= 0.341 P= 0.166 *P=0.0007
C3A 0.25 Mean 8.35 8.01 7.01 8.41 7.43 7.09
SD 4.56 4.02 3.22 4.15 3.97 2.35
CV (%) 54.64 50.18 45.93 49.36 53.45 33.11
0.5 Mean 11.47 10.36 13.01 12.41 10.59 12.2
SD 5.68 4.953 4.97 5.15 4.42 6.15
CV (%) 49.51 47.81 38.22 41.47 41.72 50.37
0.25 vs 
0.5
Unpaired
t-test
P=0.192 P= 0.259 P= 0.089 P= 0.072 P= 0.109 P= 0.024 *P<0.0001
SW620 
vs C3A
0.25 Unpaired
t-test
#P=0.7677
0.5 Unpaired
t-test
#P=0.0152
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Appendix 7.9: Vascularity statistics of xenografts of nude mice
(SD = standard deviation; CD = coefficient of variation) (n = 10 fields). 
Unpaired t-test (two-tailed) (n = 10), *(n = 60), #(n = 6)
Xenogr
aft
Depth
(cm)
Mouse & Tumour Number (n =10)
Mouse 1 Mouse 2 Mouse 3 Total
T1 T2 T1 T2 T1 T2
SW620 0.25 Mean 22.3 28.1 24.3 29.7 26.8 26.8
SD 9.081 7.4 10.81 4.99 8.791 5.287
CV (%) 40.72 26.34 44.49 16.80 32.80 19.73
0.5 Mean 18.9 19.8 21.1 20.6 25.6 23.4
SD 5.425 7.51 4.606 6.620 5.254 6.022
CV (%) 28.71 37.93 21.83 32.14 20.52 25.74
0.25 vs 
0.5
Unpaired
t-test
P=0.323 P=0.0228 P=0.4005 P=0.0027 P=0.715 P=0.1964 *P=0.0004
C3A 0.25 Mean 28.1 27.5 30.6 25.2 28.7 29.1
SD 7.838 8.236 4.858 6.477 5.677 5.626
CV (%) 27.89 29.95 15.88 25.70 19.78 19.33
0.5 Mean 20.6 21.1 20.3 20.1 23.6 19.5
SD 5.103 6.887 6.701 5.425 6.041 5.798
CV (%) 24.77 32.64 33.01 26.99 25.60 29.73
0.25 vs 
0.5
Unpaired
t-test
P=0.0207 P=0.0757 P=0.001 P=0.0724 P=0.0675 P=0.0014 *P<0.0001
SW620 
vs C3A
0.25 Unpaired
t-test
#P=0.1645
0.5 Unpaired
t-test
#P=0.5269
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Appendix 7.10: P-gp statistics of xenografts of nude mice
(SD = standard deviation; CD = coefficient of variation) (n = 10 fields) 
Unpaired t-test (two-tailed) (n = 10), *(n = 60), #(n = 6)
Xenogr
aft
Depth
(cm)
Mouse & Tumour Number (n =10)
Mouse 1 Mouse 2 Mouse 3 Total
T1 T2 T1 T2 T1 T2
SW620 0.25 Mean 17.67 18.26 17.35 17.84 14.61 17.77
SD 8.337 7.427 7.528 8.664 6.481 8.509
CV (%) 47.18 40.67 43.39 48.57 44.37 47.90
0.5 Mean 15.86 15.59 12.72 14.68 12.74 13.20
SD 5.717 4.241 6.502 5.145 5.691 4.954
CV (%) 36.04 27.21 51.10 35.04 44.68 37.53
0.25 vs 
0.5
Unpaired
t-test
P=0.579 P=0.336 P=0.159 P=0.335 P=0.502 P=0.159 *P=0.0107
C3A 0.25 Mean 13.44 11.36 13.29 13.81 14.69 15.77
SD 6.463 3.579 4.703 5.214 5.274 5.808
CV (%) 48.09 31.51 35.38 37.76 35.90 36.83
0.5 Mean 9.809 13.44 12.94 14.67 13.94 12.48
SD 2.053 3.787 3.179 5.010 5.333 4.399
CV (%) 20.93 28.17 24.57 34.16 38.25 35.24
0.25 vs 
0.5
Unpaired
t-test
P=0.108 P=0.222 P=0.845 P=0.712 P=0.756 P=0.171 *P=0.3301
SW620 
vs C3A
0.25 Unpaired
t-test
#P=0.0038
0.5 Unpaired
t-test
#P=0.1578
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Appendix 7.11: Volume correlations of xenografts of nude mice
Correlation’s are calculated as Pearson’s correlation coefficients (V) (Two-tailed)
SW620
- Parameter Depth
(cm)
Mouse & Tumour Number
Mouse 1 Mouse 2 Mouse 3
T1 T2 T1 T2 T1 T2 Pearson
r
P
VOLUME
(mm3)
1968.7 1687.5 1367.2 1366.9 381.15 486.0
vs
proliferatio 
n (LI%)
0.25 Mean 12.23 13.78 12.4 12.21 11.64 11.93 0.5311 P=0.2783
SD 2.55 3.55 2.30 2.67 2.10 2.24 0.6263 P=0.1834
CV 20.85 25.78 18.55 21.87 18.09 18.85 0.6320 P=0.1782
0.5 Mean 9.23 8.09 9.35 9.49 10.23 10.51 -0.8167 P=0.0473
SD 1.85 2.51 2.50 3.19 3.10 2.62 -0.6192 P=0.1899
CV 20.06 31.07 26.67 33.57 30.37 24.89 -0.2290 P=0.6626
vs
hypoxia
(LI%)
0.25 Mean 10.74 6.58 7.23 6.63 6.79 7.05 0.5342 P= 0.275
SD 7.44 3.82 4.04 2.81 4.76 3.02 0.4473 P=0.3737
CV 69.29 57.99 55.87 42.33 70.20 42.9 0.1685 P=0.7496
0.5 Mean 13.04 10.85 10.01 10.3 8.41 9.1 0.9167 P=0.0101
SD 5.47 5.08 3.79 3.66 2.18 3.33 0.9172 P=0.01
CV 41.97 46.79 37.82 35.56 25.89 36.56 0.7936 P=0.0595
vs
vascularity
(VD,
no.mm2)
0.25 Mean 22.3 28.1 24.3 29.7 26.8 26.8 -0.3202 P=0.536
SD 9.081 7.4 10.81 4.99 8.791 5.287 0.2471 P=0.6369
CV 40.72 26.34 44.49 16.8 32.80 19.73 0.3258 P= 0.528
0.5 Mean 18.9 19.8 21.1 20.6 25.6 23.4 -0.9702 P=0.0013
SD 5.425 7.51 4.606 6.62 5.254 6.022 0.2283 P= 0.663
CV 28.71 37.93 21.83 32.14 20.52 25.74 0.6072 P= 0.201
vs
adducts
(%
Decrease
TM)
0.25 Mean 46.0 48.5 36.0 49.0 50.5 23.0 0.3770 P=0.4612
SD 5.68 4.95 4.24 4.24 10.61 8.49 -0.8255 P-0.043
CV 52.3 40.21 31.79 48.66 31.0 36.89 0.6822 P=0.1355
0.5 Mean 28.5 40.5 27.5 22.5 44.5 18.5 -0.04241 P=0.9364
SD 13.43 7.77 4.95 9.19 10.6 3.5 0.4102 P=0.4192
CV 67.14 39.21 38.0 60.86 43.84 29.11 0.5943 P=0.2135
vascularity 
vs hypoxia
0.25 -0.8262 P=0.0427
0.5 -0.8980 P= 0.015
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C3A
Parameter Depth
(cm)
Mouse & Tumour Number
Mouse 1 Mouse 2 Mouse 3
T1 T2 T1 T2 T1 T2 Pearson
r
P
VOLUME
(mm3)
1000.0 306.25 1968.8 1171.9 400.0 2679.7
vs
proliferation
(Ll%)
0.25 Mean 16.35 16.53 16.25 17.18 16.92 18.02 0.5190 P=0.2914
SD 5.46 1.38 3.77 5.86 3.44 3.69 0.2477 P=0.6361
CV 33.44 8.35 23.2 34.15 20.36 20.45 0.2053 P=0.6963
0.5 Mean 13.83 15.14 11.51 13.17 14.16 12.64 -0.8283 P=0.0417
SD 5.48 3.33 2.8 4.57 4.39 •3.16 -0.4611 P=0.3574
CV 39.67 22.0 24.41 34.71 31.02 25.0 -0.2296 P=0.6616
vs
hypoxia
(LI%)
0.25 Mean 8.35 8.01 7.01 8.41 7.43 7.09 -0.5747 P=0.2329
SD 4.56 4.02 3.22 4.15 3.97 2.34 -0.8340 P=0.039
CV 54.64 50.18 45.93 49.36 53.45 33.11 -0.8665 P=0.0255
0.5 Mean 12.47 11.36 13.91 13.41 11.59 16.20 0.9783 P=0.0007
SD 5.68 4.95 4.97 5.15 4.42 6.15 0.7038 P=0.1186
CV 49.51 47.81 38.22 41.47 41.72 50.37 0.09047 P=0.8647
vs
vascularity 
(VD, no.mm2)
0.25 Mean 28.1 27.5 30.6 25.2 28.7 29.1 0.4214 P=0.4053
SD 7.838 8.236 4.858 6.477 5.677 5.626 -0.6012 P= 0.207
CV 27.89 29.95 15.88 25.70 19.78 19.33 -0.6112 P= 0.197
0.5 Mean 20.6 21.1 20.3 20.1 23.6 19.5 -0.7203 P=0.1064
SD 5.103 6.887 6.701 5.425 6.041 5.798 -0.1201 P= 0.82
CV 24.77 32.64 33.01 26.99 25.60 29.73 0.2812 P= 0.589
vs
adducts 
(% Decrease 
TM)
0.25 Mean 69.5 73.5 62.0 58.5 57.5 58.5 -0.4435 P=0.3784
SD 3.53 6.36 5.66 4.95 0.70 14.84 0.7859 P=0.0639
CV 25.09 28.66 29.12 28.46 21.23 45.38 0.8254 P-0.0430
0.5 Mean 60.0 55.5 53.5 50.5 42.0 44.0 -0.2210 P=0.6740
SD 1.41 2.12 10.60 9.89 2.12 12.7 0.877 P=0.0218
CV 22.36 23.97 39.11 43.57 24.27 58.93 0.8832 P=0.0197
vascularity vs 
hypoxia
0.25 -0.8441 P= 0.035
0.5 -0.7207 P= 0.106
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Appendix 7.12: Adduct correlations of xenografts of nude mice
Correlation’s are calculated as Pearson’s correlation coefficients (r) (Two-tailed) (n=6)
SW620
Parameter Depth
(cm)
Mouse & Tumour Number
Mouse 1 Mouse 2 Mouse 3
T1 T2 T1 T2 T1 T2 Pearson
r
P
ADDUCTS 
(% Decrease 
TM)
0.25 46.0 48.5 36.0 49.0 50.5 23.0
0.5 28.5 40.5 27.5 22.5 44.5 18.5
vs
proliferation
(LI%)
0.25 12.23 13.78 12.4 12.21 11.64 11.93 -0.8630 P=0.0269
0.5 9.23 8.09 9.359 9.499 10.23 10.51 0.07921 P=0.8814
0.25&0.5 0.4442 P=0.1480
vs
hypoxia
(LI%)
0.25 10.74 6.58 7.23 6.63 6.79 7.05 0.05828 P=0.9127
0.5 13.04 10.85 10.01 10.30 8.41 9.10 -0.1370 P=0.7958
0.25&0.5 -0.3853 P=0.2162
vs
vascularity 
(VD, no.mm2)
0.25 22.3 28.1 24.3 29.7 26.8 26.8 -0.3446 P=0.5036
0.5 18.9 19.8 21.1 20.6 25.6 23.4 0.03941 P= 0.941
0.25&0.5 -0.1549 P=0.6308
C3A
Parameter Depth
(cm)
Mouse & Tumour Number
Mouse 1 Mouse 2 Mouse 3
T1 T2 T1 T2 T1 T2 Pearson
r
P
ADDUCTS 
(% Decrease 
TM)
0.25 69.5 73.5 62.0 58.5 57.5 58.5
0.5 60.0 55.5 53.5 50.5 42.0 44.0
vs
proliferation
(LI%)
0.25 16.35 16.53 16.25 17.18 16.92 18.02 -0.4183 P=0.4092
0.5 13.83 15.14 11.51 13.17 14.16 12.64 0.6262 P=0.1835
0.25&0.5 0.5857 P=0.0454
vs
hypoxia
(LI%)
0.25 8.35 8.01 7.01 8.41 7.43 7.09 0.4403 P=0.3823
0.5 12.47 11.36 13.91 13.41 11.59 16.20 -0.3192 P=0.5375
0.25&0.5 -0.6766 P=0.0157
vs
vascularity 
(VD, no.mm2)
0.25 28.1 27.5 30.6 25.2 28.7 29.1 -0.4110 P= 0.418
0.5 20.6 21.1 20.3 20.1 23.6 19.5 -0.08972 P= 0.866
0.25&0.5 -0.04169 P=0.8976
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Appendix 8.1: Raw Data for in-vitro SW620 Comet Assays
Percentage decrease of Tail Moment of SW620 cells treated with cisplatin, HN2 
& chlorambucil as assessed by the comet assay.
Values are the mean (+SEM) of 3 experiments
*Tail Moment of SW620 cells treated with etoposide as assessed by the comet 
assay.
Values are the mean (±SEM) of 3 experiments
Cytotoxic Dose Time (h)
1 2 3 4
Cisplatin 50pM 12.1 (±1.23) 15.4 (±0.72) 16.95 (±1.99) 17.3 (±4.03)
lOOpM 22.3 (±2.51) 25.0 (±1.90) 28.0 (±2.77) 30.9 (±1.82)
*Etoposide 50 pM 10.13 (±1.02) 9.3 (±0.44) 9.34 (±0.52) 8.07 (±0.43)
lOOpM 14.41 (±1.04) 11.54 (±1.41) 10.38 (±0.82) 10.46 (±0.73)
HN2 50 pM 66.6 (±2.57) 75.0 (±2.46) 80.51 (±2.42) 79.83 (±1.9)
lOOpM 84.6 (±3.7) 86.0 (±2.51) 91.59 (±1.55) 95.97 (±2.55)
Chlorambucil 50 pM 11.0 (±2.53) 28.0 (±5.94) 36.0 (±3.59) 44.0 (±4.87)
lOOpM 17.0 (±5.48) 42.0 (±5.46) 42.0 (±4.64) 52.3 (±3.95)
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Appendix 8.2: Linear trend of increase in in vitro SW620 DNA damage with time 
as assessed by the comet assay
One-way ANOVA with post test for linear trend
Drug Dose Time (h) P
1 2 3 4
Cisplatin 50pM 12.1
(±1.23)
15.4
(±0.727)
16.952
(±1.99)
17.3
(±4.03)
0.1427
lOOpM 22.3
(±2.51)
25.0
(±1.90)
28.0
(±2.77)
30.9
(±1.82)
0.0226
*Etoposide 50pM 10.14
(±1.024)
9.301
(±0.438)
9.341
(±0.52)
8.07
(±0.43)
0.0672
lOOpM 14.41
(±1.045)
11.54
(±1.42)
10.38
(±0.82)
10.46
(±0.74)
0.0232
h n 2 50pM 66.6
(±2.57)
75.0
(±1.47)
80.51
(±2.42)
79.83
(±1.29)
0.0010
lOOpM 84.6
(±3.7)
86.0
(±2.51)
91.59
(±1.55)
95.97
(±2.55)
0.0108
Chlorambucil 50pM 11.0
(±2.53)
28.0
(±5.94)
36.0
(±3.58)
44.0
(±4.87)
0.0006
lOOpM 17.0
(±5.0)
42.0
(±5.0)
42.0
(±4.0)
52.3
(±3.0)
0.0006
Values are the mean ±SEM of % decrease in TM of 3 individual experiments 
* Values are the mean ±SEM of TM of 3 individual experiments
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Appendix 8.3; Linear trend of in vitro SW620 DNA damage with dose of 
cytotoxic as assessed by the comet assay
One-tailed unpaired t-test
Cisplatin
Time (h) Cisplatin P
50pM lOOpM
1 12.1 (±1.23) 22.3 (±2.51) 0.0109
2 15.4 (±0.727) 25.0 (±1.90) 0.0046
3 16.952 (±1.99) 28.0 (±2.77) 0.0160
4 17.3 (±4.03) 30.9 (±1.82) 0.0185
Values are the mean ±SEM of % decrease in TM of 3 individual experiments
Etoposide
Time (h) Etoposide P
50pM lOOpM
1 10.14 (±1.024) 14.41 (±1.045) 0.0215
2 9.301 (±0.438) 11.54 (±1.42) 0.1029
3 9.341 (±0.52) 10.38 (±0.82) 0.1710
4 8.07 (±0.43) 10.46 (±0.74) 0.0247
Values are the mean ±SEM of TM of 3 individual experiments
Nitrogen Mustard
Time (h^ h n 2 P
50pM lOOpM
1 66.6 (±2.57) 84.6 (±3.7) 0.0081
2 75.0 (±1.47) 86.0 (±2.51) 0.0097
3 80.51 (±2.42) 91.59 (±1.55) 0.0091
4 79.83 (±1.29) 95.97 (±2.55) 0.0048
Values are the mean ±SEM of % decrease in TM of 3 individual experiments
Chlorambucil
Time (h) Chlorambucil P
50 pM lOOpM
1 11.0 (±2.53) 17.0 (±5.0) 0.1882
2 28.0 (±5.94) 42.0 (±5.0) 0.0788
3 36.0 (±3.58) 42.0 (±4.0) 0.1820
4 44.0 (±4.87) 52.3 (±3.0) 0.1283
Values are the mean ±SEM of % decrease in TM of 3 individual experiments
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Appendix 8.4: Raw data for isolated dual-perfused rat liver xenografts (SW620)
Percentage decrease of Tail Moment of xenografts treated with cisplatin as 
assessed by the comet assay
Values are the mean (±SEM) of 25 measurements
Cytotoxic
perfused
Tumour
Number
Site & 
Depth 
(cm)
Time (h)
1 2 3 4
Cisplatin
50pM
1 A 2.0 (±3.99) 9.0 (±3.2) 17.0 (±2.73) 18 (±2.44)
B 7.0 (±2.31) 13.0 (±2.81) 21.0 (±3.63) 23 (±2.57
Cisplatin
lOOpM
2 A 16.0 (±3.31) 21.0 (±3.3) 21.0 (±3.15) 25 (±3.5)
B 9.0 (±3.63) 22.0 (±3.39) 26.0 (±2.71) 26 (±3.18)
3 A 24.0 (±3.49) 26.0 (±3.08) 28.0 (±2.88) 29 (±2.99)
B 20.0 (±4.0) 24.0 (±1.93) 25.0 (±4.0) 28 (±3.62)
4 A, 0.25 12.0 (±2.36) 15.0 (±3.5) 21.0 (±2.45) 24 (±2.007)
A, 0.5 3.0 (±2.84) 9.0 (±2.76) 11.0 (±2.55) 14 (±2.66)
B, 0.25 7.0 (±2.93) 19.0 (±3.09) 26.0 (±2.98) 26 (±2.62)
B, 0.5 0.0 (±2.98) 8.0 (±2.46) 14.0 (±2.56) 19 (±2.49)
5 A 8.00 (±3.87) 18.00 (±3.39) 23.00 (±2.46) 25 (±3.07)
B 5.00 (±6.10) 10.00 (±3.67) 19.00 (±3.18) 21 (±3.75)
Tail Moment of xenografts treated with etoposide as assessed bv the comet assay
Values are the mean (±SEM) of 25 measurements
Cytotoxic
perfused
Tumour
Number
Site & 
Depth 
(cm)
Time (h)
1 2 3 4
Etoposide
50pM
6 A, 0.25 10.79 (±0.4) 9.81 (±0.56) 8.07 (±0.78) 8.77 (±0.64)
A, 0.5 8.27 (±0.59) 7.56 (±0.57) 6.34 (±0.49) 6.52 (±0.5)
B, 0.25 9.84 (±0.69) 9.22 (±0.75) 11.69 (±1.08) 7.77 (±0.69)
B, 0.5 8.77 (±0.64) 8.65 (±0.70) 7.15 (±0.62) 7.23 (±0.39)
7 A, 0.25 10.99 (±0.51) 10.17 (±0.65) 8.77 (±0.64) 8.37 (±0.56)
A, 0.5 9.52 (±0.51) 8.15 (±0.59) 7.33 (±0.60) 7.33 (±0.92)
B, 0.25 11.83 (±0.41) 9.7 (±0.74) 9.01 (±0.66) 9.53 (±0.68)
B, 0.5 10.04 (±0.52) 8.75 (±0.62) 8.19 (±0.64) 8.09 (±0.48)
Etoposide
lOOpM
8 A, 0.25 15.12 (±0.65) 12.22 (±0.57) 10.99 (±0.63) 10.79 (±0.78)
A, 0.5 10.63 (±0.87) 10.17 (±0.4) 9.18 (±0.9) 10.12 (±0.63)
B, 0.25 14.26 (±0.84) 16.46 (±1.60) 10.85 (±0.54) 10.69 (±0.82)
B, 0.5 11.41 (±0.65) 11.36 (±0.59) 9.38 (±0.43) 9.21 (±0.44)
9 A, 0.25 14.12 (±0.67) 13.73 (±1.02) 12.36 (±0.53) 12.44 (±0.9)
A, 0.5 12.58 (±0.53) 11.65 (±0.59) 10.79 (±0.78) 10.65 (±0.5)
B, 0.25 14.23 (±0.75) 13.53 (±0.79) 13.11 (±1.08) 12.24 (±0.5)
B, 0.5 12.04 (±0.58) 12.24 (±0.51) 10.79 (±0.78) 10.37 (±0.4)
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Percentage decrease of Tail Moment of xenografts treated with nitrogen mustard 
as assessed by the comet assay
Values are the mean (±SEM) of 25 measurements
Cytotoxic
perfused
Tumour
Number
Site & 
Depth 
(cm)
Time (h)
1 2 3 4
h n 2
50pM
10 A, 0.25 63.0 (±4.37) 67.0 (±3.98) 71.0 (±3.63) 69 (±3.5)
A, 0.5 56.0 (±3.85) 54.0 (±3.86) 57.0 (±4.13) 55 (±3.7)
B, 0.25 60.0 (±4.0) 61.0 (±3.57) 62.0 (±4.27) 65 (±2.9)
B, 0.5 50.0 (±5.5) 52.0 (±4.2) 54.0 (±3.6) 51 (±4.1)
11 A 66.0 (±4.99) 68.0 (±4.51) 72.0 (±3.71) 71 (±2.97)
B 53.0 (±3.74) 57.0 (±4.28) 57.0 (±4.52) 60 (±3.41)
h n 2
lOOpM
12 A, 0.25 68.0 (±3.42) 72.0 (±3.7) 76.0 (±2.7) 78 (±3.48)
A, 0.5 52.0 (±3.25) 52.0 (±5.45) 58.0 (±3.49) 60 (±4.6)
B, 0.25 67.0 (±3.35) 67.0 (±3.48) 68.0 (±4.36) 66 (±3.5)
B, 0.5 58.0 (±3.79) 56.0 (±3.34) 59.0 (±2.8) 63 (±3.7)
13 A 77.0 (±4.49) 78.0 (±4.88) 81.0 (±4.5) 79 (±4.34)
B 72.0 (±4.21) 72.0 (±3.7) 71.0 (±3.9) 74 (±4.31)
14 A 77.0 (±4.32) 84.0 (±3.87) 90.0 (±4.16) 88 (±2.67)
B 78.0 (±4.75) 83.0 (±3.94) 85.0 (±4.06) 87 (±2.14)
15 A 81.0 (±4.36) 84.0 (±4.13) 87.0 (±3.92) 89 (±2.18)
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Appendix 8.5: Comparison of rat liver xenograft (SW620) DNA damage between 
doses of cytotoxic as assessed bv the comet assay
One-tailed unpaired t-test
Cisplatin
Time (h) Cisplatin P
50pM (n=2) lOOpM (n=8)
1 4.5 (±2.5) 12.63 (±2.39) 0.0746
2 11.00 (±2.0) 19.38 (±1.81) 0.0312
3 19.0 (±2.0) 23.63 (±1.10) 0.0468
4 20.5 (±2.5) 25.5 (±0.86) 0.0204
Values are the mean ±SEM of % decrease in TM of combined measurements at 
0.25cm
Etoposide
Time (h) Etoposide P
50 pM (n=4) 100 pM (n=4)
1 10.86 (±0.41) 14.43 (±0.23) 0.0001
2 9.73 (±0.28) 12.99 (±0.37) 0.0019
3 8.38 (±0.3) 11.83 (±0.54) 0.0217
4 8.61 (±0.37) 11.54 (±0.46) 0.0013
Values are the mean ±SEM of TM of combined measurements at 0.25cm.
Nitrogen Mustard
Time (h) h n 2 P
50 pM (n=4) 100 pM (n=5)
1 60.50 (±2.78) 74.29 (±2.75) 0.0057
2 63.25 (±2.59) 77.0 (±3.34) 0.0085
3 65.5 (±3.62) 80.4 (±3.93) 0.0148
4 66.25 (±2.42) 80.00 (±4.15) 0.0162
Values are the mean ±SEM of % decrease in TM of combined measurements at 
0.25cm
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Appendix 8.6: Linear trend of increase in rat liver xenograft (SW620) DNA 
damage with time as assessed bv the comet assay
One-way ANOVA with post test for linear trend
Drug Dose Time (h) P
1 2 3 4
Cisplatin 50(iM
(n=2)
4.5
(±2.5)
11.0
(±2.0)
19.0
(±2.0)
20.5
(±2.5)
0.0217
lOOpM
(n-8)
12.63
(±2.39)
19.38
(±1.81)
23.63
(±1.1)
25.5
(±0.86)
<0.0001
*Etoposide 50pM
(n=4)
10.86
(±0.41)
9.73
(±0.28)
9.38
(±0.79)
8.61
(±0.37)
0.453
lOOpM
(n=4)
14.43
(±0.23)
13.99
(±0.89)
11.83
(±0.54)
11.54
(±0.46)
0.0078
h n 2 50pM
(n=4)
60.5
(±2.78)
63.25
(±2.59)
65.5
(±3.62)
66.25
(±2.24)
0.5176
lOOpM
(n=5)
74.00
(±2.75)
77.14
(±3.34)
80.4
(±3.93)
80.0
(±4.15)
0.5715
Values are the mean ±SEM of % decrease in TM of combined measurements at 
0.25cm 
* Values are the mean ±SEM of TM of combined measurements at 0.25cm
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Appendix 8.7: Tail moment of rat liver xenografts (SW620) at different depths 
prior to perfusion with cvtoxic drugs (Time = 0 h) as assessed bv the comet assay
Two-tailed unpaired t-test
Cytotoxic
perfused
Tumour
Number
Depth (cm) TM (+SEM) 
(n=25)
P
Cisplatin
lOOpM
4 0.25 vs 0.5 3.33 (±0.38) vs 4.11 (±0.37) 0.1536
Etoposide
50pM
6 0.25 vs 0.5 4.29 (±0.34) vs 3.66 (±0.37) 0.2190
7 0.25 vs 0.5 4.48 (±0.32) vs 3.66 (±0.67) 0.2754
Etoposide
lOOpM
8 0.25 vs 0.5 3.3 (±0.42) vs 4.65 (±0.54) 0.0530
9 0.25 vs 0.5 3.86 (±0.43) vs 4.02 (±0.44) 0.7948
h n 2
50pM
10 0.25 vs 0.5 3.38 (±0.34) vs 3.94 (±0.55) 0.3893
h n 2
lOOpM
12 0.25 vs 0.5 4.0 (±0.47) vs 4.1 (±0.51) 0.8910
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Appendix 8.8: Comparison of percentage decrease in Tail Moment and Tail 
Moment (*) at different depths of rat liver xenografts (SW620) during perfusion 
with cvtotoxics as assessed bv the comet assay
Two-tailed unpaired t-test (n=25)
Cytotoxic
perfused
Tumour
Number
Site Depth
(cm)
Time (h)
1 2 3 4
Cisplatin
lOOpM
4 A 0.25 vs 
0.5
P = 0.0186 P = 0.1563 P = 0.0067 P<0.0001
B 0.25 vs 
0.5
P = 0.1004 P = 0.0076 P = 0.0037 P = 0.0587
*Etoposide
50pM
6 A 0.25 vs 
0.5
P = 0.0009 P = 0.0066 P = 0.0664 P = 0.0079
B 0.25 vs 
0.5
P = 0.243 P = 0.582 P = 0.0007 P = 0.4989
7 A 0.25 vs 
0.5
P = 0.0475 P = 0.0261 P = 0.1072 P = 0.3391
B 0.25 vs 
0.5
P = 0.0095 P = 0.0201 P = 0.3818 P = 0.09
*Etoposide
lOOpM
8 A 0.25 vs 
0.5
P = 0.0004 P = 0.0887 P = 0.1076 P = 0.5072
B 0.25 vs 
0.5
P -  0.0035 P = 0.9059 P = 0.0396 P = 0.1176
9 A 0.25 vs 
0.5
P = 0.0783 P = 0.0849 P = 0.1048 P = 0.0896
B 0.25 vs 
0.5
P = 0.0251 P = 0.1772 P = 0.0888 P = 0.0073
h n 2
50pM
10 A 0.25 vs 
0.5
P = 0.2353 P = 0.0232 P = 0.0142 P = 0.0084
B 0.25 vs 
0.5
P = 0.1480 P = 0.1091 P = 0.1585 P = 0.0077
h n 2
lOOpM
12 A 0.25 vs 
0.5
P = 0.0014 P = 0.0039 P = 0.0002 P = 0.0031
B 0.25 vs 
0.5
P = 0.0815 P = 0.0271 P = 0.0888 P = 0.5586
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Appendix 8.9: Comparison of percentage decrease in Tail Moment and Tail 
Moment (*) at different sites in the same rat liver xenograft (SW620) during 
perfusion with cvtotoxics as assessed bv the comet assay
Two-tailed unpaired t-test (n=25)
Cytotoxic
perfused
Tumour
Number
Depth
(cm)
Site Time (h)
1 2 3 4
Cisplatin
50pM
1 0.25 A vs B P = 0.2836 P = 0.3523 P = 0.3829 P = 0.1647
Cisplatin
lOOpM
2 0.25 A vs B P = 0.1606 P = 0.8335 P = 0.2348 P = 0.8342
3 0.25 A vs B P = 0.4548 P = 0.5847 P = 0.5456 P = 0.8322
4 0.25 A vs B P = 0.1901 P = 0.3669 P = 0.2004 p = 0.5474
5 0.25 A vs B P = 0.6798 P = 0.1159 P = 0.3248 P = 0.4133
*Etoposide
50pM
6 0.25 A vs B P = 0.234 P = 0.5358 P = 0.0091 P = 0.2933
7 0.25 A vs B P = 0.2054 P = 0.6460 P = 0.7935 P = 0.1942
*Etoposide
lOOpM
8 0.25 A vs B P = 0.4221 P = 0.0162 P = 0.8684 P = 0.5072
9 0.25 A vs B P = 0.9088 P = 0.8776 P = 0.5364 P = 0.8500
h n 2
50pM
10 0.25 A vs B P = 0.6149 P = 0.2673 P = 0.1149 P = 0.3832
11 0.25 A vs B P = 0.0424 P = 0.0832 P = 0.0135 P = 0.0188
h n 2
lOOpM
12 0.25 A vs B P = 0.8354 P = 0.3299 P = 0.1253 P = 0.0192
13 0.25 A vs B P = 0.4206 P = 0.3321 P = 0.0996 P = 0.4177
14 0.25 A vs B P = 0.8769 P = 0.8571 P = 0.3940 P = 0.7714
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Appendix 8.10; Comparison of percentage decrease in Tail Moment and Tail 
Moment (*) in different rat liver xenografts (SW620) in the same liver during 
perfusion with cvtotoxics as assessed bv the comet assay
One-way ANOVA followed by the Bonferroni multiple t-test
Cytotoxic
perfused
Depth
(cm)
Tumour Number 
& Site
Time (h)
1 2 3 4
Cisplatin
lOOpM
0.25 2A vs 3A P > 0.05 P > 0.05 P > 0.05 P > 0.05
2A vs 3B P > 0.05 P > 0.05 P > 0.05 P > 0.05
2B vs 3A P < 0.05 P > 0.05 P > 0.05 P > 0.05
2B vs 3B P > 0.05 P > 0.05 P > 0.05 P > 0.05
0.25 4A vs 5A P > 0.05 P > 0.05 P > 0.05 P > 0.05
4A vs 5B P > 0.05 P > 0.05 P > 0.05 P > 0.05
4B vs 5A P > 0.05 P > 0.05 P > 0.05 P > 0.05
4B vs 5B P > 0.05 P > 0.05 P > 0.05 P > 0.05
Etoposide
50pM
0.25 6A vs 7A P > 0.05 P > 0.05 P > 0.05 P > 0.05
6A vs 7B P > 0.05 P > 0.05 P > 0.05 P > 0.05
6B vs 7A P < 0.05 P > 0.05 P > 0.05 P > 0.05
6B vs 7B P>0.01 P > 0.05 P > 0.05 P > 0.05
Etoposide
lOOpM
0.25 8A vs 9A P > 0.05 P > 0.05 P > 0.05 P > 0.05
8A vs 9B P > 0.05 P > 0.05 P > 0.05 P > 0.05
8B vs 9A P > 0.05 P > 0.05 P > 0.05 P > 0.05
8B vs 9B P > 0.05 P > 0.05 P < 0.05 P > 0.05
h n 2
50pM
0.25 10A vs 11A P > 0.05 P > 0.05 P > 0.05 P > 0.05
10A vs 1 IB P > 0.05 P > 0.05 P > 0.05 P > 0.05
10B vs 11A P > 0.05 P > 0.05 P > 0.05 P > 0.05
10B vs 1 IB P > 0.05 P > 0.05 P > 0.05 P > 0.05
h n 2
lOOpM
0.25 12A vs 13 A P > 0.05 P > 0.05 P > 0.05 P > 0.05
12A vs 13B P > 0.05 P > 0.05 P > 0.05 P > 0.05
12B vs 13A P > 0.05 P > 0.05 P > 0.05 P > 0.05
12B vs 13B P > 0.05 P > 0.05 P > 0.05 P > 0.05
0.25 14A vs 15 P > 0.05 P > 0.05 P > 0.05 P > 0.05
14B vs 15 P > 0.05 P > 0.05 P > 0.05 P > 0.05
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Appendix 9.1: Viability parameters of human hemilivers whilst on perfusion 
circuit
Paired t-test (n=8, except * where n=4)
Viability Parameters 1 h
Mean (± SEM)
4 h
Mean (± SEM)
P
Portal Vein Pressure (mm/Hg) 14.88 (±1.19) 16.97 (±2.53) 0.265
Hepatic Artery Pressure 
(mm/Hg)
55.32 (±4.69) 51.91 (±5.35) 0.146
Bile Production (ml/h) 4.301 (±0.37) 4.5 (±0.47) 0.489
Microcirculatory Perfusate 
Flow (flux units)
190.6 (±3.44) 184.9 (±3.99) 0.332
ALT (IU/L) 191.0 (±55.68) 267.28 (±69.37) 0.0108
*TM of control tumour 4.33 (±0.64) 4.915 (±0.84) 0.34
*TM of control normal liver 5.273 (±0.365) 5.785 (±0.151) 0.1145
ALT, alanine aminotransferase.
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Appendix 9.2: Raw data of % decrease of TM of human tumours treated with 
cisplatin as assessed bv the comet assay
Values are the mean (±SD) of 6 measurements
Cytotoxic
perfused
Tumour
Number
Site & 
Depth 
(cm)
Time (h)
1 2 3 4 5
Cisplatin
23.3pM
1 A, 0.5 16.01 (±3.3) 30.6 (±5.01) 45.3 (±4.17) 49.6 (±6.58)
A, 1 12.3 (±3.19) 28.3 (±4.11) 38.86 (±4.29) 45.4 (±3.47)
A, 1.5 10.4 (±2.54) 22.7 (±3.30) 34.5 (±4.42) 42.4 (±3.99)
2 A, 0.5 20.0 (±4.80) 32.9 (±2.45) 39.2 (±3.68) 42.0 (±2.1)
A, 1 18.1 (±3.93) 29.85 (±2.63) 33.6 (±3.9) 36.0 (±1.99)
A, 1.5 17.4 (±4.22) 24.7 (±3.43) 30.2 (±4.19) 36.4 (±3.6)
Cisplatin
50pM
3 A, 0.5 37.0 (±2.85) 38.6 (±2.66) 47.5 (±2.88) 53.3 (±3.85) 55.4 (±2.29)
A, 1 31.8 (±3.61) 34.2 (±3.28) 38.4 (±2.84) 48.2 (±2.77) 48.1 (±2.69)
B, 0.5 32.7 (±2.67) 37.6 (±2.71) 44.9 (±3.9) 51.7 (±3.43) 49.9 (±2.77)
B, 1 29.0 (±3.43) 31.0 (±3.93) 41.1 (±2.8) 46.4 (±2.64) 41.6 (±2.23)
4 A, 0.5 20.6 (±3.73) 39.8 (±3.59) 40.71 (±3.08) 42.7 (±2.86) 53.7 (±2.11)
A, 1 13.4 (±3.169) 37.8 (±5.54) 38.4 (±2.98) 40.5 (±2.507) 44.1 (±1.63)
B, 0.5 24.7 (±3.44) 36.4 (±3.26) 38.8 (±2.5) 45.8 (±2.96) 54.3 (±2.22)
B, 1 23.26 (±3.69) 33.5 (±2.83) 35.4 (±3.56) 44.1 (±3.099) 46.1 (±2.41)
Cisplatin
lOOpM
5 A, 0.5 32.9 (±4.028) 39.7 (±3.277) 61.5 (±4.822) 77.1 (±2.83) 85.9 (±2.65)
A, 1 28.6 (±2.722) 25.4 (±4.36) 59.24 (±4.92) 74.5 (±3.22) 79.53 (±1.7)
A, 2 8.5 (±3.51) 14.7 (±4.23) 46.8 (±4.52) 65.2 (±2.03) 82.33 (±3.05)
B, 0.5 26.9 (±4.3) 35.0 (±3.42) 67.0 (±4.62) 70.0 (±2.76) 78.28 (±1.85)
B, 1 19.5 (±5.2) 27.4 (±4.05) 58.4 (±4.54) 64.7 (±2.04) 77.3 (±1.27)
B, 2 11.5 (±2.87) 16.1 (±4.39) 54.5 (±3.56) 62.4 (±2.63) 73.7 (±3.24)
C, 0.5 34.1 (±4.39) 46.0 (±2.309) 72.42 (±3.68) 86.0 (±2.45) 89.0 (±1.41)
C, 1 30.9 (±3.933) 44.4 (±2.59) 63.7 (±3.77) 80.0 (±2.21) 86.55 (±2.17)
C, 2 21.3 (±3.51) 27.6 (±3.26) 57.4 (±3.61) 68.0 (±2.31) 72.2 (±2.01)
6 A, 0.5 40.2 (±2.37) 49.86 (±3.35) 79.05 (±3.15) 91.18 (±1.542) 94.87 (±2.468)
A, 1 30.5 (±2.18) 34.7 (±4.6) 78.6 (±4.0) 93.45 (±2.8) 95.41 (±1.208)
A, 2 8.8 (±3.31) 18.0 (±4.36) 74.7 (±3.91) 81.3 (±2.23) 87.75 (±2.21)
B, 0.5 11.0 (±9.2) 42.5 (±5.8) 69.67 (±2.39) 81.62 (±1.98) 85.42 (±2.11)
B, 1 9.0 (±3.87) 32.2 (±7.048) 62.8 (±2.98) 75.28 (±2.1) 78.9 (±2.4)
B, 2 10.0 (±5.4) 25.5 (±6.107) 53.4 (±3.65) 57.5 (±2.599) 69.21 (±3.44)
C, 0.5 30.5 (±3.94) 67.8 (±3.58) 77.0 (±3.42) 80.005 (±2.95) 84.5 (±3.044)
C, 1 19.1 (±6.31) 57.8 (±3.23) 66.1 (±2.79) 74.0 (±1.71) 71.0 (±3.09)
C, 2 11.2 (±4.04) | 40.0 (±1.344) 61.6 (±3.19) 65.7 (±2.61) 71.2 (±2.69)
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Appendix 9.3: Raw data of TM of human tumours treated with etoposide as 
assessed by the comet assay
Values are the mean (±SEM) of 25 measurements
Cytotoxic
perfused
Tumour
Number
Site & 
Depth 
(cm)
Time (h)
1 2 3 4 5 6
Etoposide 
50 pM
7 A, 1 8.93
(±0.61)
10.0
(±0.554)
12.0
(±0.579)
11.0
(±0.63)
13.0
(±0.478)
14.0
(±0.508)
A, 2 8.5
(±0.601)
9.9
(±0.43)
9.76
(±0.46)
8.255
(±0.679)
8.0
(±0.459)
8.2
(±0.438)
A, 3 8.27
(±0.535)
8.79
(±0.54)
8.44
(±0.457)
8.67
(±0.675)
7.62
(±0.463)
7.36
(±0.54)
A, 4 7.12
(±0.59)
9.208
(±0.47)
8.539
(±0.58)
7.87
(±0.47)
7.41
(±0.45)
8.67
(±0.589)
B, 1 10.039
(±0.695)
10.83
(±0.69)
9.67
(±0.514)
9.234
(±0.563)
7.5
(±0.606)
7.831
(±0.516)
B, 2 10.52
(±0.648)
9.76
(±0.52)
8.94
(±0.552)
7.457
(±0.486)
8.23
(±0.43)
7.74
(±0.39)
B, 3 10.229
(±0.48)
9.54
(±0.95)
7.88
(±0.53)
7.735
(±0.62)
8.06
(±0.466)
5.503
(±0.278)
B, 4 9.12
(±0.59)
9.167
(±0.665)
6.72
(±0.691)
5.62
(±0.617)
6.41
(±0.714)
6.162
(±0.548)
C, 1 13.01
(±0.657)
12.48
(±0.723)
13.48
(±0.679)
12.87
(±0.541)
15.66
(±0.484)
16.38
(±0.619)
C, 2 12.417
(±0.610)
11.61
(±0.483)
11.651
(±0.56)
13.14
(±0.52)
13.018
(±0.434)
12.406
(±0.714)
C, 3 9.55
(±0.55)
10.27
(±0.72)
8.708
(±0.48)
9.1
(±0.65)
8.536
(±0.517)
9.0198
(±0.639)
C, 4 7.22
(±0.579)
9.66
(±0.708)
8.27
(±0.53)
7.77
(±0.399)
6.889
(±0.413)
8.4
(±0.623)
0.5 1 2 3 4 5
Etoposide
lOOpM
8 A, 0.5 16.26
(±1.079)
16.86
(±0.57)
19.054
(±0.533)
18.5
(±0.534)
20.0
(±0.63)
18.0
(±0.469)
A, 1 14.87
(±1.42)
17.914
(±0.657)
14.81
(±0.648)
15.0
(±0.457)
13.0
(±0.55)
12.5
(±0.396)
A, 1.5 9.666
(±1.232)
12.009
(±0.72)
10.75
(±0.44)
9.247
(±0.39)
9.55
(±0.502)
9.17
(±0.487)
A, 2 22.0
(±1.11)
25.0
(±1.47)
27.0
(±0.504)
22.0
(±0.512)
23.0
(±1.132)
22.0
(±0.927)
B, 0.5 19.1
(±0.75)
22.0
(±0.707)
21.0
(±0.54)
20.5
(±0.5)
22.0
(±0.456)
19.0
(±0.79)
B, 1 16.0
(±0.77)
15.0
(±0.549)
10.47
(±0.56)
9.68
(±0.46)
9.25
(±0.51)
9.12
(±0.54)
B, 1.5 9.065
(±0.872)
10.68
(±0.46)
8.898
(±0.522)
8.17
(±0.44)
8.85
(±0.643)
9.0
(±0.58)
B, 2 9.76
(±0.695)
10.99
(±0.51)
8.86
(±0.402)
11.34
(±1.1)
9.567
(±1.47)
8.86
(±1.2)
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Appendix 9.4: Raw data of % decrease of TM of human tumours treated with 
HN2 as assessed bv the comet assay
Values are the mean (±SD) of 6 measurements
Cytotoxic
perfused
Tumour
Number
Site & 
Depth 
(cm)
Time (h)
1 2 3 4 5 6
h n 2
50pM
9 A, 0.5 51.0
(±3.89)
54.0
(±3.84)
57.2 
_ (±5-71)
62.3
(±4.25)
62.2
(±4.27)
63.3
(±2.08)
A, 1 38.0
(±4.27)
48.3
(±2.56)
52.0
(±3.18)
62.0
(±3.63)
62.1
(±3.36)
60.6
(±1.91)
A, 2 30.4
(±4.42)
34.1
(±2.6)
36.1
(±4.33)
49.3
(±2.24)
51.8
(±3.31)
47.3
(±3.21)
B, 0.5 56.0
(±3.36)
55.8
(±3.68)
54.4
(±4.34)
48.9
(±4.28)
54.5
(±5.51)
49.4
(±1.55)
B, 1 36.7
(±2.52)
44.01
(±3.19)
40.3
(±4.91)
40.8
(±5.13)
45.1
(±2.65)
49.4
(±2.42)
B, 2 23.1
(±2.96)
31.5
(±3.66)
30.0
(±3.61)
33.2
(±2.83)
35.41
(±4.84)
33.4
(±3.39)
C, 0.5 58.6
(±3.75)
58.1
(±2.95)
56.0
(±2.19)
59.5
(±3.93)
59.3
(±2.96)
56.2
(±1.85)
c, 1 44.9
(±3.86)
46.4
(±2.92)
44.0 
.... (±5-67)
46.0
(±3.71)
47.6
(±3.38)
44.5
(±2.26)
C, 2 26.3
(±5.01)
27.8
(±3.61)
31.3
(±3.71)
37.6
(±3.74)
30.2
(±2.35)
42.8
(±3.44)
D, 0.5 68.8
(±3.96)
76.4
(±3.36)
62.61
(±3.53)
62.3
(±3.37)
58.43
(±3.1)
60.0
(±3.03)
D, 1 36.0
(±5.66)
40.4
(±3.5)
35.0
(±3.47)
52.0
(±3.49)
41.4
(±3.02)
38.8
(±2.55)
D, 2 20.0
(±4.76)
20.8
(±2.73)
27.0
(±3.75)
39.3
(±5.05)
34.83
(±3.27)
34.6
(±2.4)
0.5 1 2 3 4
h n 2
lOOpM
10 A, 0.5 34.8
(±3.66)
41.5
(±3.65)
47.1
(±3.19)
43.4
(±3.63)
42.6
(±3.99)
A, 1 19.0
(±3.86)
36.3
(±2.54)
38.6
(±2.94)
38.3
(±2.81)
31.4
(±4.0)
A, 2 18.3
(±3.48)
22.5
(±3.38)
32.3
(±3.44)
25.0
(±2.41)
25.9
(±3.45)
B, 0.5 27.8
(±3.91)
47.0
(±3.26)
42.0
(±2.187)
38.4
(±3.64)
40.8
(±3.63)
B, 1 21.9
(±3.8)
37.7
(±3.05)
35.0
(±2.41)
31.7
(±2.98)
23.7
(±2.13)
B, 2 18.2
(±4.25)
17.7
(±3.5)
25.0
(±5.19)
19.6
(±4.73)
18.9
(±2.96)
11 A, 0.5 63.4
(±3.041
)
63.3
(±3.19)
64.8
(±2.49)
61.0
(±2.93)
62.8
(±2.387)
A, 1 49.85
(±3.56)
51.5
(±4.27)
54.6
(±2.81)
55.29
(±4.36)
56.9
(±1.41)
B, 0.5 70.5
(±3.35)
64.4
(±3.2)
61.6
(±3.2)
66.3
(±3.38)
69.1
(±1-4)
B, 1 42.6
(±3.8)
61.9
(±3.49)
62.0
(±3.12)
57.1
(±3.055)
59.78
(±2.31)
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Cytotoxic
perfused
Tumour
Number
Site & 
Depth 
(cm)
Time (h)
0.5 1 2 3 4
h n 2
lOOpM
12 A, 0.5 49.4
(±3.23)
84.3
(±3.45)
80.7
(±2.62)
78.7
(±3.32)
77.9
(±2.67)
A, 1 54.2
(±3.35)
74.92
(±3.08)
76.2
(±2.52)
75.9
(±2.5)
76.9
(±2.49)
A, 2 62.3
(±3.16)
71.9
(±3.316)
69.8
(±2.52)
68.9
(±2.65)
74.1
(±2.45)
B, 0.5 28.8
(±2.91)
67.3
(±3.59)
70.7
(±3.46)
66.1
(±3.66)
64.5
(±2.43)
B, 1 25.42
(±3.845)
58.0
(±3.68)
55.2
(±1.93)
52.0
(±5.36)
57.1
(±3.4)
B, 2 19.1
(±2.86)
49.28
(±4.37)
43.1
(±3.219)
45.0
(±8.07)
40.0
(±3.6)
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Appendix 9.5: Linear trend of human tumour DNA damage with concentration 
of cisplatin as assessed by the comet assay
One-way ANOVA with post test for linear trend; except * = one-tailed unpaired t-test
Time (h) Cisplatin P
23.3pM (n=6) 50pM (n=6) lOOpM (n=6)
1 15.7 (±1.493) 26.7 (±3.587) 21.8 (±4.249) 0.214
2 28.17 (±1.561) 37.4 (±0.788 40.9 (±8.037) 0.0776
3 36.94 (±2.169) 41.45 (±1.578) 62.04 (±4.004) <0.0001
4 41.96 (±2.135) 47.03 (±2.044) 72.75 (±2.469) <0.0001
5 ND 50.91 (±1.777) 79.08 (±2.671) <0.0001*
Values are the mean ±SEM of % decrease in TM of combined measurements of 0.5 & 
1 cm
ND, not done
Appendix 9.6: Linear trend of human tumour DNA damage with concentration 
of etoposide as assessed by the comet assay
One-tailed unpaired t-test
Time (h) Etoposide P
50pM (n=6) lOOpM (n=6)
1 8.89 (±0.504) 15.74 (±1.685) 0.0015
2 9.74 (±0.286) 14.16 (±2.034) 0.0285
3 9.55 (±0.538) 13.52 (±2.139) 0.0515
4 8.75 (±0.516) 13.77 (±2.377) 0.0328
5 8.63 (±0.884) 12.79 (±1.886) 0.0365
Values are the mean ±SEM of TM of combined measurements of 0.5 & 1 cm.
Appendix 9.7: Linear trend of human tumour DNA damage with concentration 
of HNi as assessed by the comet assay
One-tailed unpaired t-test
Time (h) h n 2 P
50 pM (n=12) lOOpM (n=12)
0.5 40.82 (±4.408) 40.64 (±4.884) 0.489
1 44.80 (±4.414) 57.34 (±4.318) 0.0273
2 43.83 (±3.524) 57.37 (±4.244) 0.0112
3 49.43 (±3.002) 55.35 (±4.377) 0.138
4 47.74 (±3.214) 55.29 (±4.981) 0.108
Values are the mean +SEM of % decrease in TM of combined measurements of 0.5 & 
l c m .
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Appendix 9.8: Linear trend of increase in human tumour DNA damage with 
time as assessed by the comet assay
One-way ANOVA with post test for linear trend
Drug Dose Time (h) P
0.5 1 2 3 4 5
Cisplatin
(n=6)
23.3pM 15.7
(±1.493)
28.17
(±1.56)
36.94
(±2.169)
41.96
(±2.135)
<0.0001
50pM 26.7
(±3.588)
37.4
(±0.788)
41.45
(±1.578)
47.03
(±2.044)
50.92
(±1.776)
< 0.0001
lOOpM 21.8
(±4.249)
40.9
(±8.037)
62.04
(±4.003)
72.75
(±2.469)
79.08
(±2.671)
<0.0001
*Etoposide
(n=6)
50pM 8.89
(±0.505)
9.75
(±0.287)
9.56
(±0.538)
8.75
(±0.516)
8.63
(±0.884)
0.408
lOOpM 15.74
(±1.685)
14.16
(±2.03)
13.51
(±2.139)
13.77
(±2.377)
12.79
(±1.886)
0.3392
h n 2
(n=12)
50pM 40.82
(±4.408)
44.80
(±4.414)
43.82
(±3.524)
49.43
(±3.002)
47.74
(±3.214)
0.1259
lOOpM 40.64
(±4.884)
57.34
(±4.318)
57.37
(±4.244)
55.35
(±4.377)
55.29
(±4.982)
0.0642
Values are the mean ±SEM of % decrease in TM of combined measurements of 0.5 & 
1 cm.
* Values are the mean ±SEM of TM of combined measurements of 0.5 & 1 cm.
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Appendix 9.9; TM of human tumours at different depths prior to perfusion with 
cvtoxic drugs (Time = 0 h) as assessed by the comet assay
One-way ANOVA followed by the Bonferroni multiple t-test; except * = two-tailed unpaired t-test
Cytotoxic perfused Tumour
Number
Depth (cm) TM (±SEM) 
(n=25)
P
Cisplatin 23.3pM 1 0.5 vs 1.5 2.45 (±0.26) vs 2.64 (±0.25) 0.6044*
2 0.5 vs 1.5 1.74 (±0.25) vs 1.89 (±0.22) 0.6535*
Cisplatin 50pM 3 0.5 vs 1 2.23 (±0.49) vs 2.41 (±0.31) 0.752*
4 0.5 vs 1 2.85 (±0.412) vs 3.78 (±0.66) 0.237*
Cisplatin lOOpM 5 0.5 vs 2 2.72 (±0.4) vs 2.048 (±0.25) 0.1629*
6 0.5 vs 1 2.34 (±0.26) vs 2.447 (±0.36) >0.05
0.5 vs 2 2.34 (±0.26) vs 3.59 (±0.3) <0.05
Etoposide 50pM 7 1 vs 2 3.34 (±0.38) vs 3.759 (±0.35) >0.05
1 vs 3 3.34 (±0.38) vs 3.013 (±0.37) >0.05
1 vs 4 3.34 (±0.38) vs 5.903 (±1.0) <0.05
Etoposide lOOpM 8 0.5 vs 1 1.67 (±0.25) vs 1.63 (±0.26) >0.05
0.5 vs 1.5 1.67 (±0.25) vs 4.82 (±0.76) <0.05
0.5 vs 2 1.67 (±0.25) vs 17.54 (±1.19) <0.001
0.5 vs 3 1.67 (±0.25) vs 17.33 (±0.76) <0.001
HN2 50pM 9 0.5 vs 1 (±)vs(±) >0.05
0.5 vs 2 (±)vs(±) >0.05
HN2 lOOpM 10 0.5 vs 1 2.15 (±0.3) vs 2.56 (±0.44) >0.05
0.5 vs 2 2.15 (±0.3) vs 2.05 (±0.35) >0.05
11 0.5 vs 1 1.29 (±0.2) vs 1.33 (±0.23) 0.9102*
12 0.5 vs 1 2.76 (±0.57) vs 2.43 (±0.42) >0.05
0.5 vs 2 2.76 (±0.57) vs 2.13 (±0.39) >0.05
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Appendix 9.10: Comparison of % decrease in TM of human tumours at different 
depths during perfusion with cispiatin as assessed by the comet assay
One-way ANOVA followed by the Bonferroni multiple t-test 
except * = two-tailed unpaired t-test
Cytotoxic
perfused
Tumour
Number
Site Depth
(cm)
Time (h)
1 2 3 4 5
Cispiatin
23.3pM
1 A 0.5 vs 1 P0.001 P >0.05 P0.001 PO.01
0.5 vs 1.5 P0.001 P0.001 P0.001 P0.001
1 vs 1.5 P >0.05 P0.001 PO.05 P >0.05
2 A 0.5 vs 1 P>0.05 P0.001 P0.001 P0.001
0.5 vs 1.5 P>0.05 P0.001 P0.001 P0.001
1 vs 1.5 P>0.05 P0.001 PO.05 P>0.05
Cispiatin
50pM
3 *A 0.5 vs 1 PO.OOOl PO.OOOl PO.OOOl PO.OOOl PO.OOOl
*B 0.5 vs 1 PO.OOOl PO.OOOl P0.0002 PO.1941 PO.OOOl
4 *A 0.5 vs 1 PO.OOOl P=0.0391 P=0.0027 P=0.0009 PO.OOOl
*B 0.5 vs 1 PO.0985 P=0.0003 PO.OOOl P=0.041 PO.OOOl
Cispiatin
lOOpM
5 A 0.5 vs 1 P0.001 P0.001 P>0.05 PO.01 P0.001
0.5 vs 2 P0.001 P0.001 P0.001 P0.001 P0.001
1 vs 2 P0.001 P0.001 P0.001 P0.001 P0.001
B 0.5 vs 1 P0.001 P0.001 P0.001 P0.001 P>0.05
0.5 vs 2 P0.001 P0.001 P0.001 P0.001 P0.001
1 vs 2 P0.001 P0.001 P0.001 PO.01 P0.001
C 0.5 vs 1 PO.05 P>0.05 P0.001 P0.001 P0.001
0.5 vs 2 P0.001 P0.001 P0.001 P0.001 P0.001
1 vs 2 P0.001 P0.001 P0.001 P0.001 P0.001
6 A 0.5 vs 1 P0.001 P0.001 P>0.05 PO.01 P>0.05
0.5 vs 2 P0.001 P0.001 P0.001 P0.001 P0.001
1 vs 2 P0.001 P0.001 PO.01 P0.001 P0.001
B 0.5 vs 1 P>0.05 P0.001 P0.001 P0.001 P0.001
0.5 vs 2 P>0.05 P0.001 P0.001 P0.001 P0.001
1 vs 2 P>0.05 PO.01 P0.001 P0.001 P0.001
C 0.5 vs 1 P0.001 P0.001 P0.001 P0.001 P0.001
0.5 vs 2 P0.001 P0.001 P0.001 P0.001 P0.001
1 vs 2 P0.001 P0.001 P0.001 P0.001 P>0.05
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Appendix 9.11: Comparison of TM at different depths of human tumours during 
perfusion with etoposide as assessed bv the comet assay
One-way ANOVA followed by the Bonferroni multiple t-test
Cytotoxic
perfused
Tumour
Number
Site Depth (cm) Time (h)
1 2 3 4 5 6
Etoposide
50pM
7 A 1 vs 2 P>0.05 P>0.05 PO.05 PO.05 PO.OOl PO.OOl
1 vs 3 P>0.05 P>0.05 PO.OOl P>0.05 PO.OOl PO.OOl
1 vs 4 P>0.05 P>0.05 PO.OOl PO.01 PO.OOl PO.OOl
1 vs Control P0.001 PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl
2 vs 3 P>0.05 P>0.05 P>0.05 P>0.05 P>0.05 P>0.05
2 vs 4 P>0.05 P>0.05 P>0.05 P>0.05 P>0.05 P>0.05
2 vs Control PO.OOl PO.OOl PO.OOl PO.OOl PO.05 PO.05
3 vs 4 P>0.05 P>0.05 P>0.05 P>0.05 P>0.05 P>0.05
3 vs Control PO.OOl PO.OOl PO.OOl PO.OOl P>0.05 P>0.05
4 vs Control PO.01 PO.OOl PO.OOl PO.01 P>0.05 PO.01
B 1 vs 2 P>0.05 P>0.05 P>0.05 P>0.05 P>0.05 P>0.05
1 vs 3 P>0.05 P>0.05 P>0.05 P>0.05 P>0.05 PO.01
1 vs 4 P>0.05 P>0.05 PO.01 PO.OOl P>0.05 P>0.05
1 vs Control PO.OOl PO.OOl PO.OOl PO.OOl P>0.05 P>0.05
2 vs 3 P>0.05 P>0.05 P>0.05 P>0.05 P>0.05 PO.01
2 vs 4 P>0.05 P>0.05 PO.05 P>0.05 P>0.05 P>0.05
2 vs Control PO.OOl PO.OOl PO.OOl PO.05 PO.05 P>0.05
3 vs 4 P>0.05 P>0.05 P>0.05 P>0.05 P>0.05 P>0.05
3 vs Control PO.OOl PO.OOl PO.01 PO.01 P>0.05 P>0.05
4 vs Control PO.OOl PO.OOl P>0.05 P>0.05 P>0.05 P>0.05
C 1 vs 2 P>0.05 P>0.05 P>0.05 P>0.05 PO.OOl PO.OOl
1 vs 3 PO.OOl P>0.05 PO.OOl PO.OOl PO.OOl PO.OOl
1 vs 4 PO.OOl PO.05 PO.OOl PO.OOl PO.OOl PO.OOl
1 vs Control PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl
2 vs 3 PO.01 P>0.05 PO.01 PO.OOl PO.OOl PO.01
2 vs 4 PO.OOl P>0.05 PO.OOl PO.OOl PO.OOl PO.OOl
2 vs Control PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl
3 vs 4 PO.05 P>0.05 P>0.05 P>0.05 P>0.05 P>0.05
3 vs Control PO.OOl PO.OOl PO.OOl PO.OOl PO.01 PO.05
4 vs Control PO.01 PO.OOl PO.OOl PO.01 P>0.05 P>0.05
0.5 1 2 3 4 5
Etoposide
lOOpM
8 A 0.5 vs 1 P>0.05 P>0.05 PO.OOl PO.OOl PO.OOl PO.OOl
0.5 vs 1.5 PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl
0.5 vs Control PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl
1 vs 1.5 PO.01 PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl
1 vs Control PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl
1.5 vs Control P< 0.01 PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl
B 0.5 vs 1 PO.05 PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl
0.5 vs 1.5 PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl
0.5 vs Control PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl
1 vs 1.5 PO.OOl PO.OOl P>0.05 P>0.05 P>0.05 P>0.05
1 vs Control PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl PO.01
1.5 vs Control PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl PO.01
Control, TMs of tumour of control liver perfused without cytotoxics
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Appendix 9.12: Comparison of % decrease in TM of human tumours at different 
depths during perfusion with HN? as assessed by the comet assay
One-way ANOVA followed by the Bonferroni multiple t-test 
except * = two-tailed unpaired t-test
Cytotoxic
perfused
Tumour
Number
Site Depth
(cm)
Time (h)
1 2 3 4 5 6
h n 2
50|iM
9 A 0.5 vs 1 P< 0.001 P< 0.001 P< 0.001 P > 0.05 P > 0.05 P < 0.001
0.5 vs 2 P < 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001
1 vs 2 P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001
B 0.5 vs 1 P < 0.001 P< 0.001 P < 0.001 P < 0.001 P< 0.001 P > 0.05
0.5 vs 2 P< 0.001 P< 0.001 P< 0.001 P< 0.001 P < 0.001 P< 0.001
1 vs 2 P< 0.001 P< 0.001 P< 0.001 P < 0.001 P< 0.001 P < 0.001
C 0.5 vs 1 P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001
0.5 vs 2 P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001
1 vs 2 P < 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001 P > 0.05
D 0.5 vs 1 P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001
0.5 vs 2 P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001
1 vs 2 P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001
0.5 1 2 3 4
h n 2
lOOpM
10 A 0.5 vs 1 P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001
0.5 vs 2 P< 0.001 P < 0.001 P< 0.001 P< 0.001 P< 0.001
1 vs 2 P > 0.05 P< 0.001 P< 0.001 P< 0.001 P< 0.001
B 0.5 vs 1 P< 0.001 P < 0.001 P< 0.001 P< 0.001 P< 0.001
0.5 vs 2 P< 0.001 P< 0.001 P< 0.001 P< 0.001 P < 0.001
1 vs 2 P<0.01 P< 0.001 P< 0.001 P< 0.001 P < 0.001
11 *A 0.5 vs 1 PO.OOOl PO.OOOl PO.OOOl PO.OOOl P<0.0001
*B 0.5 vs 1 PO.OOOl P=0.0112 PO.6565 PO.OOOl PO.OOOl
12 A 0.5 vs 1 P< 0.001 P< 0.001 P< 0.001 P<0.01 P > 0.05
0.5 vs 2 P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001
1 vs 2 P< 0.001 P<0.01 P< 0.001 P< 0.001 P< 0.001
B 0.5 vs 1 P<0.01 P< 0.001 P< 0.001 P< 0.001 P< 0.001
0.5 vs 2 P< 0.001 P < 0.001 P< 0.001 P< 0.001 P< 0.001
1 vs 2 P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001
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Appendix 9.13: Comparison of % decrease in TM at different sites in the same 
human tumour during perfusion with cispiatin as assessed bv the comet assay
One-way ANOVA followed by the Bonferroni multiple t-test 
except * = two-tailed unpaired t-test
Cytotoxic
perfused
Tumour
Number
Depth
(cm)
Site Time (h)
1 2 3 4 5
Cispiatin
50pM
3 *0.5 AvsB PO.OOOl P=0.1942 P=0.01 PO.1274 PO.OOOl
*1 AvsB P=0.0071 P=0.003 PO.OOl 4 PO.0228 PO.OOOl
4 *0.5 AvsB P=0.0002 PO.OOl PO.02 P0.0005 PO.3322
*1 AvsB PO.OOOl PO.OOl 2 P0.0022 PO.OOOl PO.OOl 2
Cispiatin
lOOpM
5 0.5 AvsB P>0.05 P>0.05 P>0.05 PO.01 PO.OOl
AvsC P>0.05 PO.01 PO.01 PO.OOl P>0.05
BvsC PO.05 PO.OOl P>0.05 PO.OOl PO.OOl
1 AvsB PO.01 P>0.05 P>0.05 PO.OOl P>0.05
AvsC P>0.05 PO.OOl P>0.05 PO.01 PO.OOl
BvsC PO.OOl PO.OOl P>0.05 PO.OOl PO.OOl
2 AvsB P>0.05 P>0.05 PO.05 P>0.05 PO.OOl
AvsC PO.OOl PO.OOl PO.OOl P>0.05 PO.OOl
BvsC PO.OOl PO.OOl P>0.05 PO.01 P>0.05
6 0.5 AvsB PO.OOl PO.05 PO.OOl PO.OOl PO.OOl
AvsC PO.05 PO.OOl P>0.05 PO.OOl PO.OOl
BvsC PO.OOl PO.OOl PO.01 P>0.05 P>0.05
1 AvsB PO.OOl P>0.05 PO.OOl PO.OOl PO.OOl
AvsC PO.OOl P>0.05 PO.OOl PO.OOl PO.OOl
BvsC P>0.05 PO.05 P>0.05 PO.OOl PO.OOl
2 AvsB P>0.05 PO.05 PO.OOl PO.OOl PO.OOl
AvsC P>0.05 PO.OOl PO.OOl PO.OOl PO.OOl
BvsC P>0.05 PO.OOl PO.01 PO.OOl P>0.05
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Appendix 9.14: Comparison of TM at different sites in the same human tumour 
during perfusion with etoposide as assessed by the comet assay
One-way ANOVA followed by the Bonferroni multiple t-test 
except * = two-tailed unpaired t-test
Cytotoxic
perfused
Tumour
Number
Depth
(cm)
Site Time (h)
1 2 3 4 5 6
Etoposide
50pM
7 1 AvsB P>0.05 P>0.05 PO.05 P>0.05 PO.OOl PO.OOl
AvsC PO.OOl PO.05 P>0.05 P>0.05 PO.01 PO.01
BvsC PO.01 P>0.05 PO.OOl PO.OOl PO.OOl PO.OOl
2 AvsB P>0.05 P>0.05 P>0.05 P>0.05 P>0.05 P>0.05
AvsC PO.OOl PO.05 PO.05 PO.OOl PO.OOl PO.OOl
BvsC P>0.05 PO.05 PO.01 PO.OOl PO.OOl PO.OOl
3 AvsB PO.05 P>0.05 P>0.05 P>0.05 P>0.05 PO.05
AvsC P>0.05 P>0.05 P>0.05 P>0.05 P>0.05 P>0.05
BvsC P>0.05 P>0.05 P>0.05 P>0.05 P>0.05 PO.OOl
4 AvsB P>0.05 P>0.05 P>0.05 PO.01 P>0.05 PO.05
AvsC P>0.05 P>0.05 P>0.05 P>0.05 P>0.05 P>0.05
BvsC P>0.05 P>0.05 P>0.05 PO.05 P>0.05 PO.05
0.5 1 2 3 4 5
Etoposide
lOOpM
8 *0.5 AvsB PO.0327 PO.OOOl PO.0135 P0.0087 PO.0133 P=0.2818
*1 AvsB P=0.4876 PO.OOl 4 PO.OOOl PO.OOOl PO.OOOl PO.OOOl
*1.5 AvsB P=0.6923 PO.1263 P0.0092 PO.0732 PO.3951 P=0.8233
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Appendix 9.15; Comparison of % decrease in TM at different sites in the same 
human tumour during perfusion with HN? as assessed by the comet assay
One-way ANOVA followed by the Bonferroni multiple t-test 
except * = two-tailed unpaired t-test
Cytotoxic
perfused
Tumour
Number
Depth
(cm)
Site Time (h)
1 2 3 4 5 6
h n 2
50pM
9 0.5 AvsB PO.OOl P>0.05 P>0.05 PO.OOl PO.OOl PO.OOl
AvsC PO.OOl PO.OOl P>0.05 P>0.05 P>0.05 PO.OOl
AvsD PO.OOl PO.OOl PO.OOl P>0.05 PO.01 PO.OOl
BvsC P>0.05 P>0.05 P>0.05 PO.OOl PO.OOl PO.OOl
BvsD PO.OOl PO.OOl PO.OOl PO.OOl PO.01 PO.OOl
CvsD PO.OOl PO.OOl PO.OOl P>0.05 P>0.05 PO.OOl
1 AvsB P>0.05 PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl
AvsC PO.OOl P>0.05 PO.OOl PO.OOl PO.OOl PO.OOl
AvsD P>0.05 PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl
BvsC PO.OOl PO.05 PO.05 PO.OOl PO.05 PO.OOl
BvsD P>0.05 PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl
CvsD PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl
2 AvsB PO.OOl PO.05 PO.OOl PO.OOl PO.OOl PO.OOl
AvsC PO.01 PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl
AvsD PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl PO.OOl
BvsC P>0.05 PO.OOl P>0.05 PO.OOl PO.OOl PO.OOl
BvsD P>0.05 PO.OOl PO.05 PO.OOl P>0.05 P>0.05
CvsD PO.OOl PO.OOl PO.OOl P>0.05 PO.OOl PO.OOl
0.5 1 2 3 4
h n 2
lOOpM
10 *0.5 AvsB PO.OOOl PO.OOOl PO.OOOl PO.OOOl PO.1017
*1 AvsB P0.0101 PO.0842 PO.OOOl PO.OOOl PO.OOOl
*2 AvsB P=0.9279 PO.OOOl PO.OOOl PO.OOOl PO.OOOl
11 *0.5 AvsB PO.OOOl PO.2295 P0.0003 PO.OOOl PO.OOOl
*1 AvsB PO.OOOl PO.OOOl PO.OOOl P=0.0956 PO.OOOl
12 *0.5 AvsB PO.OOOl PO.OOOl PO.OOOl PO.OOOl PO.OOOl
*1 AvsB PO.OOOl PO.OOOl PO.OOOl PO.OOOl PO.OOOl
*2 AvsB PO.OOOl PO.OOOl PO.OOOl PO.OOOl PO.OOOl
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Appendix 9.16: Comparison of % decrease in TM in different human tumours in 
the same hemiliver during perfusion with cispiatin as assessed bv the comet 
assay One-way ANOVA followed by the Bonferroni multiple t-test 
except * = two-tailed unpaired t-test
Cytotoxic
perfused
Depth
(cm)
Tumour 
Number & Site
Time (h)
1 2 3 4 5
Cispiatin
23.3pM
0.5 *1 vs 2 PO.OOl 3 P=0.0446 PO.OOOl PO.OOOl
1 *1 vs 2 PO.OOOl PO.1188 PO.OOOl PO.OOOl
1.5 *1 vs 2 PO.OOOl P=0.0409 P0.0009 PO.OOOl
Cispiatin
50pM
0.5 3A vs 4A PO.OOl P>0.05 PO.OOl PO.OOl P>0.05
3A vs 4B PO.OOl P>0.05 PO.OOl PO.OOl P>0.05
3B vs 4A PO.OOl P>0.05 PO.OOl PO.OOl PO.OOl
3B vs 4B PO.OOl P>0.05 PO.OOl PO.OOl PO.OOl
1 3A vs 4A PO.OOl PO.05 P>0.05 PO.OOl PO.OOl
3A vs 4B PO.OOl P>0.05 PO.01 PO.OOl PO.05
3B vs 4A PO.OOl PO.OOl PO.05 PO.OOl PO.01
3B vs 4B PO.OOl P>0.05 PO.OOl PO.05 PO.OOl
Cispiatin
lOOpM
0.5 *5ABC vs 
6ABC
P=0.6704 P=0.1823 P=0.1235 P=0.3204 P=0.4472
1 *5 ABC vs 
6ABC
P=0.3936 P=0.4169 P=0.1615 P=0.3666 P=0.9375
1.5 *5ABC vs 
6ABC
PO.3917 P=0.3351 P=0.2119 P=0.7001 P=0.9974
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Appendix 9.17; Comparison of % decrease in TM in different human tumours in 
the same hemiiiver during perfusion with HNi as assessed by the comet assay
One-way ANOVA followed by the Bonferroni multiple t-test
Cytotoxic
perfused
Depth
(cm)
Tumour 
Number & 
Site
Time (h)
0.5 1 2 3 4
h n 2
lOOpM
0.5 10A vs 11A P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001
10A vs 1 IB P< 0.001 P< 0.001 P< 0.001 P < 0.001 P< 0.001
10A vs 12A P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001
10A vs 12B P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001
10B vs 11A P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001
10B vs 1 IB P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001
10B vs 12A P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001
10B vs 12B P > 0.05 P < 0.001 P< 0.001 P< 0.001 P< 0.001
11A vs 12A P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001
11A vs 12B P< 0.001 P< 0.001 P< 0.001 P< 0.001 P > 0.05
1 IB vs 12A P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001
1 IB vs 12B P< 0.001 P < 0.05 P< 0.001 P > 0.05 P< 0.001
1 10A vs 11A P< 0.001 P< 0.001 P< 0.001 P < 0.001 P< 0.001
10A vs 1 IB P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001
10A vs 12A P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001
10A vs 12B P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001
10B vs 11A P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001
10B vs 1 IB P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001
10B vs 12A P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001
10B vs 12B P < 0.05 P< 0.001 P< 0.001 P< 0.001 P< 0.001
11A vs 12A P< 0.001 P< 0.001 P < 0.001 P< 0.001 P< 0.001
11A vs 12B P< 0.001 P< 0.001 P > 0.05 P < 0.05 P > 0.05
1 IB vs 12A P< 0.001 P< 0.001 P< 0.001 P< 0.001 P < 0.001
1 IB vs 12B P< 0.001 P<0.01 P< 0.001 P < 0.001 P < 0.05
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